background
aim
pneumonia
infect
lung
alveoli
alveolar
wall
bag
diagnosi
pneumonia
quit
obviou
howev
mani
organ
caus
pneumonia
determin
caus
specif
case
difficult
almost
imposs
outpati
present
time
necessari
appli
appropri
diagnost
method
proper
treatment
heal
method
monitor
done
basi
fall
crp
valu
initi
therapi
main
object
master
degre
determin
correl
crp
initi
control
h
hour
antibiot
therapi
possibl
percentag
declin
determin
success
particular
antibiot
therapi
studi
includ
children
pneumonia
area
sarajevo
canton
sex
age
month
less
year
research
undertaken
pediatr
health
center
sarajevo
relat
colderyear
period
time
begin
octob
end
april
result
expect
valu
vari
depend
child
age
gender
initi
increas
valu
crp
season
type
antibiot
thu
result
plu
minu
one
standard
deviat
outpati
condit
rang
less
extrem
low
valu
unsuccess
therapi
fall
crp
conclus
use
monitor
crp
first
control
day
pneumonia
children
condit
gold
standard
diagnosi
unavoid
physic
examin
pediatr
monitor
pneumonia
success
antibiot
treatment
europ
includ
bosnia
herzegovina
significantli
reduc
due
effici
prompt
treatment
dormanc
leviti
seriou
consequ
background
aim
commun
pneumonia
commun
acquir
pneumonia
common
seen
diseas
clinic
practic
especi
children
elderli
caus
great
mortal
hospit
set
pneumonia
easili
overus
term
clinic
practic
sometim
pneumonia
diagnosi
initi
present
respiratori
infect
symptom
moist
rale
lung
pure
vagu
radiographi
lung
posit
result
microbiolog
test
respiratori
track
secret
commonli
inappropri
manag
commun
pneumonia
misus
antibiot
estim
unnecessari
hospit
result
overload
hospit
increas
treatment
cost
drug
resist
decreas
treatment
effect
purpos
work
perform
practic
approach
relat
etiolog
clinic
present
manag
treatment
commun
pneumonia
adult
patient
method
expert
opinion
evidencebas
guidanc
result
patient
commun
pneumonia
often
present
fever
chill
fatigu
dyspnea
rigor
chest
pain
physician
understand
etiolog
diseas
assess
need
hospit
use
predict
tool
mortal
sever
score
score
pneumonia
sever
index
combin
clinic
judgment
patient
commun
acquir
pneumonia
background
aim
videoassist
thoracoscop
surgic
decort
vatsd
report
minim
invas
effect
treatment
acut
thorac
empyema
howev
report
influenc
preoper
clinic
featur
postop
hospit
stay
recurr
patient
underw
vatsd
acut
thorac
empyema
method
retrospect
review
patient
acut
thorac
empyema
underw
vatsd
april
march
analyz
clinic
featur
serolog
bacteriolog
studi
radiolog
find
treatment
outcom
broadspectrum
antibiot
initi
diagnosi
continu
normal
inflamm
paramet
bodi
temperatur
result
total
patient
men
women
underw
vatsd
mean
age
year
comorbid
hypertens
case
diabet
mellitu
mental
ill
neoplasm
median
durat
symptom
oper
day
averag
oper
time
minut
cultur
pleural
effus
certifi
caus
organ
case
isol
organ
sensit
administr
antibiot
durat
preand
postantibiot
day
day
durat
preand
postchest
drainag
day
day
postop
surgic
site
infect
seen
case
recurr
seen
case
extern
fistula
multilocul
septal
format
concomit
ga
median
postop
hospit
stay
day
howev
two
case
show
prolong
hospit
stay
conclus
multilocul
septal
format
concomit
ga
might
prolong
durat
postop
hospit
stay
increas
risk
recurr
acut
thorac
empyema
addit
case
extern
fistula
also
risk
recurr
background
aim
commun
acquir
pneumonia
cap
lead
caus
infect
relat
morbid
mortal
inappropri
antibiot
treatment
associ
increas
risk
antibiot
resist
advers
clinic
outcom
aim
studi
evalu
empir
antibiot
prescript
cap
comparison
current
australian
antibiot
guidelin
assess
impact
antimicrobi
stewardship
am
program
method
retrospect
studi
compar
patient
admit
cap
mayjuli
pream
mayjuli
postam
complianc
empir
antibiot
treatment
determin
current
guidelin
base
pneumonia
sever
calcul
smartcop
score
impact
am
implement
antibiot
prescript
evalu
compar
antibiot
complianc
rate
inpati
mortal
readmiss
rate
length
stay
two
period
result
consecut
patient
includ
period
pream
n
postam
n
overal
antibiot
complianc
rate
significantli
higher
am
implement
vs
p
seen
antibiot
choic
cover
typic
organ
vs
p
atyp
organ
vs
p
proport
nonsever
cap
case
treat
ceftriaxon
azithromycin
significantli
lower
postam
vs
p
vs
p
respect
inpati
mortal
vs
p
ns
readmiss
rate
vs
p
ns
two
period
similar
mean
length
stay
lower
postam
ae
vs
ae
day
p
conclus
antimicrobi
stewardship
significantli
improv
empir
antibiot
guidelin
complianc
cap
reduc
use
broad
spectrum
antibiot
nonsever
cap
appear
reduct
length
stay
without
impact
inpati
mortal
readmiss
rate
postam
implement
prospect
studi
need
confirm
result
studi
background
aim
pulmonari
mycetoma
consid
result
saprophyt
growth
mycelia
within
preexist
caviti
case
aspergillu
spp
caus
develop
multipl
cyst
caviti
lesion
allerg
bronchopulmonari
aspergillosi
abpa
method
result
male
past
histori
asthma
year
admit
hospit
complain
dri
cough
slight
fever
month
left
pneumothorax
multipl
cyst
caviti
found
partial
cystectomi
left
upper
lung
perform
yshape
mycelium
resect
tissu
detect
final
diagnos
pulmonari
mycetoma
histopatholog
find
furthermor
diagnos
possibl
abpa
mycetoma
may
pulmonari
aspergillosi
administr
antifung
agent
one
month
continu
oral
agent
month
final
multipl
cyst
caviti
disappear
conclus
aspergillu
infect
usual
result
saprophyt
growth
within
preexist
caviti
controversi
case
multipl
cyst
caviti
may
caus
aspergillu
infect
extrem
rare
suppos
cyst
caviti
might
form
check
valv
mechan
background
aim
histoplasmosi
chronic
granulomat
system
fungal
diseas
endem
region
global
although
caus
sever
infect
immunocompromis
rel
small
case
report
immunocompet
result
report
previous
fit
well
male
present
symptom
chest
xray
find
suggest
tuberculosi
tb
prolong
cough
weight
loss
dysphagia
hoars
voic
henc
commenc
antitb
clinic
examin
reveal
cachet
individu
otherwis
normal
system
examin
despit
complet
intens
phase
improv
oesophagoduodenoscopi
show
gastric
ulcer
neg
malign
comput
tomographi
ct
scan
show
incident
find
pulmonari
embol
pe
splenomegali
microabscess
also
bilater
adren
mass
septic
work
tumour
marker
hiv
test
serial
sputum
acid
fast
bacilli
afb
neg
sputum
cultur
reveal
atyp
mycobacterium
bone
marrow
aspir
neg
malign
adren
biopsi
inconclus
laryngoscopi
suggest
granulomat
lesion
anticoagul
pe
commenc
view
persist
symptom
despit
treatment
neg
microbiolog
antitb
withheld
repeat
biopsi
vocal
cord
upper
oesophag
sphincter
plasma
antigen
test
posit
histoplasmosi
oral
itraconazol
start
chang
intraven
amphotericin
b
improv
oral
itraconazol
resum
follow
year
good
responseweight
gain
dysphagia
hoars
voic
improv
unfortun
develop
hypocorticol
adren
involv
requir
longterm
oral
steroid
conclus
conclud
patient
poor
respons
antitb
medic
thorough
investig
perform
look
caus
mimic
appear
case
particularli
reinforc
statement
treat
promptli
empir
antibiot
protocol
antibiot
initi
base
sever
evalu
mild
pneumonia
treat
betalactam
macrolid
fluoroquinolon
moder
pneumonia
start
parenter
cephalosporin
plu
fluoroquinolon
carbapenem
plu
fluoroquinolon
recommend
sever
pneumonia
betalactam
plu
betalactamas
inhibitor
select
pneumonia
drugresist
pathogen
patient
also
evalu
pseudomon
risk
factor
patient
switch
parenter
antibiot
oral
antibiot
symptom
improv
afebril
abl
use
oral
medic
patient
receiv
pneumococc
vaccin
influenza
vaccin
tobacco
cessat
counsel
elig
background
aim
rsv
common
caus
respiratori
tract
infect
rti
children
induc
reactiv
airway
diseas
epidemiolog
evid
support
caus
rti
adult
howev
data
limit
thai
patient
method
cohort
studi
conduct
determin
clinic
manifest
rsv
infect
adult
hospit
patient
spirometri
methacholin
challeng
test
also
perform
recoveri
rsv
infect
week
patient
preexist
airway
diseas
result
patient
includ
studi
mean
age
year
except
one
underli
diseas
pulmonari
diseas
cardiovascular
diseas
diabet
immumocompromis
host
common
comorbid
asthma
common
preexist
pulmonari
diseas
asthma
copd
previou
tuberculosi
treatment
bronchiectasi
common
present
symptom
rsv
infect
cough
dyspnea
fever
median
durat
ill
day
rhonchi
andor
wheez
common
physic
find
fever
found
patient
thirti
one
patient
diagnos
pneumonia
common
abnorm
radiograph
bilater
interstiti
opac
twenti
four
patient
develop
respiratori
failur
patient
respiratori
failur
higher
mortal
rate
longer
hospit
without
respiratori
failur
thirteen
patient
underw
spirometri
obstruct
eight
patient
normal
spirometri
underw
methacholin
challeng
test
borderlin
bronchial
hyperrespons
conclus
cough
dyspnea
fever
common
present
symptom
rsv
infect
adult
hospit
patient
wheez
rhonchi
commonli
found
patient
rsv
infect
caus
airway
obstruct
bronchial
hyperrespons
background
aim
myriad
etiolog
link
adult
cervic
lymphadenopathi
report
case
hivneg
adult
present
recurr
cervic
aden
despit
extens
workup
antitubercul
treatment
resolut
cervic
aden
eventu
achiev
commenc
treatment
nontubercul
mycobacterium
ntm
base
singl
posit
sputum
cultur
result
man
smoker
present
initi
cervic
lymphadenopathi
onemonth
durat
repeat
inconclus
lymph
node
fine
needl
aspir
cytolog
excis
biopsi
result
neg
tuberculosi
workup
initi
antitubercul
therapydespit
compliant
antitubercul
medic
suffer
frequent
recurr
new
old
cervic
aden
secondari
bacteri
infect
occas
patient
initi
intraven
amikacin
clarithromycin
ciprofloxacin
nontubercul
mycobacteria
base
singl
posit
sputum
cultur
exclus
possibl
caus
possibl
histori
treatment
respons
carbapenem
anoth
medic
institut
subsequ
review
next
twelv
month
show
recurr
conclus
diagnos
cervic
lymphadenopathi
secondari
nontubercul
mycobacteri
infect
challeng
poor
respons
antitubercul
therapi
alarm
clinician
exclud
possibl
consid
rare
infect
explor
risk
factor
prognost
factor
invas
pulmonari
aspergillosi
ipa
patient
chronic
obstruct
pulmonari
diseas
copd
method
conduct
singlecent
retrospect
casecontrol
studi
copd
patient
ipa
copd
control
patient
without
ipa
carri
depart
respiratori
critic
care
medicin
first
affili
hospit
wenzhou
medic
univers
china
januari
august
diagnost
criteria
ipa
adapt
bulpa
et
al
result
aecopd
admiss
isol
aspergillu
lrt
sampl
case
diagnos
colon
confirm
ipa
enrol
case
group
mortal
rate
ipa
copd
multivari
analysi
five
variabl
independ
risk
factor
associ
ipa
copd
statist
signific
durat
antibiot
longer
day
admiss
ci
p
system
use
steroid
admiss
p
lymphocyt
lower
l
p
temperatur
higher
c
ci
p
worsen
radiolog
find
ci
p
prognost
factor
independ
associ
ipa
patient
copd
includ
mechan
ventil
p
consolid
chest
imag
p
durat
antifung
treatment
ci
p
conclus
system
use
steroid
month
prior
admiss
antibiot
treatment
longer
day
lymphocyt
lower
l
temperatur
higher
c
worsen
radiolog
find
strong
predict
risk
factor
associ
ipa
copd
consolid
chest
imag
mechan
ventil
short
durat
antifung
treatment
associ
poor
outcom
ipa
copd
background
aim
williamscampbel
syndrom
wc
rare
disord
character
congenit
defici
cartilag
subsegment
bronchi
lead
cystic
bronchiectasi
airway
collaps
expir
caus
repeat
airway
infect
first
year
life
mani
patient
die
respiratori
failur
childhood
howev
prognosi
patient
surviv
childhood
improv
age
result
case
present
woman
admit
hospit
histori
worsen
dyspnea
product
cough
short
breath
wheez
infanc
dyspnea
could
hardli
play
outdoor
childhood
year
old
exert
dyspnea
allevi
got
weld
job
iron
factori
later
marri
gave
birth
histori
tuberculosi
sinus
smoke
mother
exhibit
similar
symptom
oxygen
satur
room
air
white
blood
cell
count
creactiv
protein
level
markedli
elev
immunoglobulin
aspergillu
antigen
level
within
normal
rang
pseudomona
aeruginosa
detect
sputum
cultur
ct
reveal
widespread
cystic
bronchiectasi
subsegment
bronchi
collaps
cystic
area
expir
diagnos
wc
administr
antibiot
start
conclus
difficult
obtain
patholog
specimen
bronchoscopi
show
defici
cartilag
bronchial
wall
diagnosi
base
characterist
ct
find
exclus
possibl
caus
includ
cystic
fibrosi
ciliari
dyskinesia
immunoglobulin
defici
allerg
bronchopulmonari
aspergillosi
treatment
aim
control
respiratori
infect
suppress
respiratori
failur
main
bacteria
caus
adult
respiratori
infect
pseudomona
aeruginosa
mycobacterium
avium
haemophilu
influenza
longterm
claritheromycin
therapi
often
perform
chronic
infect
japan
earli
introduct
home
oxygen
therapi
recommend
background
aim
pulmonari
cryptococcosi
pc
refer
acut
subacut
infect
lung
caus
cryptococcu
occur
immunocompromis
nonimmunocompromis
host
clinic
manifest
pc
variabl
untyp
cough
fever
chest
pain
symptom
ct
find
pc
may
easili
confus
tumor
tuberculosi
lead
misdiagnosi
cryptococcu
latex
agglutin
test
commonli
use
clinic
practic
serolog
detect
method
pc
show
high
sensit
specif
howev
pc
patient
neg
la
test
result
studi
aim
analyz
clinic
manifest
ct
find
host
immun
statu
pulmonari
cryptococcosi
patient
accord
differ
latex
agglutin
test
la
result
method
retrospect
review
clinic
data
patient
diagnosi
pulmonari
cryptococcosi
shanghai
pulmonari
hospit
period
patient
categor
accord
latex
agglutin
test
result
differ
clinic
characterist
analyz
result
patient
posit
la
result
patient
neg
la
result
averag
age
la
posit
group
younger
immunecompromis
host
patient
basic
diseas
risk
factor
like
present
posit
la
result
patient
neg
la
result
often
symptom
sign
ct
find
present
solitari
nodul
mass
la
posit
patient
variabl
symptom
cough
fever
dyspnea
etc
great
divers
chest
ct
manifest
shown
la
posit
patient
multipl
nodul
mass
patchi
shadow
interstiti
infiltr
diffus
granular
shadow
patient
solitari
nodul
mass
lower
titer
type
conclus
differ
clinic
characterist
la
posit
neg
patient
la
test
result
associ
clinic
manifest
ct
find
host
immun
statu
pulmonari
cryptococcosi
patient
background
aim
nocardiosi
uncommon
caus
pneumonia
primarili
occur
immunocompromis
patient
gener
impli
poor
prognosi
past
report
describ
comput
tomographi
ct
featur
pulmonari
nocardiosi
usual
variou
combin
nodulemass
groundglass
opac
interlobular
septal
thicken
bronchial
wall
thicken
consolid
cavit
find
often
multipl
nonspecif
report
case
caus
rare
strain
nocardia
speci
atyp
radiolog
present
method
case
report
yearold
caucasian
male
travel
northern
australia
known
diabet
mellitu
chronic
obstruct
pulmonari
diseas
congest
heart
failur
transfer
hospit
gradual
onset
dyspnea
cruis
tour
septic
arriv
respiratori
failur
suppur
skin
lesion
arm
ct
scan
show
randomli
distribut
miliari
shadow
upper
lobe
predomin
multipl
nodul
variou
size
lung
wound
cultur
grew
nocardia
speci
later
identifi
nocardia
terpenica
rrna
sequenc
known
resist
cotrimoxazol
treatment
select
consist
intraven
meropenem
minocyclin
linezolid
follow
improv
chang
oral
clarithromycin
minocyclin
result
discuss
limit
inform
concern
nocardia
terpenica
infect
patient
case
isol
nonjapanes
individu
sinc
first
descript
miliari
pattern
lung
shadow
often
suggest
infect
miliari
tuberculosi
invas
fungal
diseas
dissemin
nocardiosi
diagnos
basi
wound
cultur
respons
treatment
miliari
diffus
granular
pattern
nocardiosi
scarc
report
upon
literatur
search
conclus
nocardiosi
import
differenti
diagnosi
pneumonia
present
miliari
lung
shadow
especi
conjunct
preexist
lung
diseas
immunocompromis
prompt
recognit
would
enabl
laboratori
awar
lead
earli
optim
manag
chungang
univers
intern
medicin
seoul
republ
korea
gimpo
woori
hospit
intern
medicin
seoul
republ
korea
background
aim
although
mycobacterium
avium
complex
mac
lung
diseas
need
immedi
treatment
long
term
natur
cours
mac
lung
diseas
without
treatment
well
establish
therefor
want
identifi
long
term
natur
cours
nodular
bronchiectat
form
mac
lung
diseas
without
treatment
analyz
serial
chest
comput
tomograph
ct
find
method
patient
mac
lung
diseas
select
untreat
nodular
bronchiectat
form
mac
lung
diseas
patient
serial
ct
least
month
interv
mean
year
chest
radiologist
review
retrospect
initi
last
ct
scan
ct
studi
assess
presenc
extent
bronchiectasi
cellular
bronchiol
consolid
caviti
nodul
maximum
score
result
patient
patient
progress
overal
total
score
show
statist
signific
overal
differ
p
bronchiectasi
patient
increas
number
lung
segment
involv
followup
mean
initi
followup
number
lung
segment
involv
ct
scan
respect
p
cellular
bronchiol
patient
increas
number
lung
segment
involv
mean
initi
followup
number
respect
p
conclus
without
treatment
patient
demonstr
progress
diseas
serial
ct
mean
followup
period
year
background
aim
invas
pulmonari
aspergillosi
opportunist
mycosi
difficult
diagnos
furthermor
invas
pulmonari
aspergillosi
aspergillu
empyema
exist
one
man
rare
sever
aspergillu
infect
earli
detect
treatment
may
reduc
rate
mortal
method
eastern
asian
man
develop
invas
pulmonari
aspergillosi
bronchopleur
fistula
empyema
suffer
year
hemoptysi
bronchiectasi
oper
lobectomi
year
ago
oper
biopsi
examin
reveal
pulmonari
aspergillosi
sadli
receiv
antifungu
therapi
time
year
lobectomi
patient
complain
cough
expector
weight
loss
admiss
bronchopleur
fistula
right
main
stem
bronchu
pleural
caviti
bilater
pulmonari
consolid
seen
comput
tomographi
ct
scan
bronchoscopi
biopsi
taken
wall
pleural
caviti
reveal
larg
pleural
aspergillosi
lesion
result
despit
combin
system
antifung
treatment
voriconazol
open
window
thoracostomi
patient
condit
rapid
exacerb
die
conclus
present
rare
case
invas
aspergillosi
infect
lobectomi
year
ago
antifungu
therapi
may
necessari
patient
remov
lesion
aspergillosi
otherwis
fumigatu
might
exist
bodi
long
period
method
eight
case
diagnos
kansasii
izumi
municip
hospit
year
diagnos
basi
result
sputum
cultur
andor
bronchial
wash
retrospect
analyz
total
patient
femal
male
mean
age
year
clinic
radiolog
featur
result
cough
sputum
includ
hemoptysi
common
n
patient
infect
kansasii
previou
lung
tuberculosi
lung
diseas
emphysema
pulmonari
aspergillosi
mac
infect
seen
major
except
one
femal
patient
smoker
mean
brickman
index
chest
ct
scan
reveal
locat
main
abnorm
follow
lt
two
lt
rt
one
rt
three
rt
one
rt
one
caviti
format
observ
case
mean
maximum
diamet
caviti
wall
thick
mm
mm
respect
lesion
classifi
type
follow
larg
caviti
irregular
form
mm
two
small
oval
form
mm
two
tubular
caviti
one
nodul
bronchiectasi
two
micronodul
one
conclus
demonstr
case
diagnos
kansasii
includ
two
femal
patient
might
connect
kansasii
infect
smoke
ct
find
reveal
caviti
format
upper
lobe
predominantli
wall
thick
kansasii
thinner
one
tuberculosi
ct
scan
also
show
nodul
bronchiectasi
micronodul
lesion
kansaii
atyp
studi
indic
kansasii
infect
similar
clinic
featur
mac
infect
background
aim
actinomycosi
rare
infect
mimic
diseas
often
pose
challang
diagnosi
treatabl
high
cure
rate
good
prognosi
report
case
lung
actinomycosi
differ
present
case
year
old
ladi
refer
incident
find
cystic
mass
left
upper
lobe
asymptomat
unremark
clinic
examin
ct
thorax
show
left
upper
lobe
fibrosi
bronchiectasi
cystic
lesion
x
x
cm
bronchoscopi
show
cauliflow
like
mass
biopsi
bal
cytolog
histopatholog
lesion
confirm
actinomycosi
subsequ
commenc
oral
augmentin
case
year
old
housewif
present
signific
loss
weight
lethargi
clinic
examin
reveal
palpabl
mass
suprapub
area
ct
scan
show
heterogen
pelvic
mass
multipl
lung
nodul
suggest
metastasi
examin
gynaecologist
reveal
retain
intrauterin
contracept
devic
subsequ
cervic
biopsi
confirm
actinomycosi
start
augmentin
month
repeat
ct
scan
show
resolut
lung
nodul
mark
clinic
improv
case
man
initi
treat
commun
acquir
pneumonia
follow
product
cough
loss
weight
loss
appetit
howev
month
discharg
hospit
present
worsen
respiratori
symptom
radiolog
evid
lung
cavit
intracavitari
lesion
resembl
aspergilloma
associ
surround
consolid
unfortun
remain
symptomat
despit
antifung
therapyth
repeat
ct
demonstr
persist
cavit
lesion
develop
necrot
pneumoniah
underw
lobectomi
histopatholog
analysi
resect
specimen
howev
reveal
diagnosi
actinomycosi
conclus
actinomycosi
mani
present
biopsi
area
involv
vital
give
right
diagnosi
invas
zygomycosi
fatal
due
complic
poor
respons
medic
therapi
pulmonari
zygomycosi
without
affect
organ
rare
describ
herein
report
man
diagnos
isol
pulmonari
zygomycosi
present
concomitantli
diabet
ketoacidosi
dka
chronic
nonproduct
cough
without
dyspnea
lowgrad
fever
weight
loss
month
becam
deterior
develop
diabet
crisi
refer
investig
past
histori
reveal
myocardi
infarct
hypertens
deni
smoke
consumpt
alcohol
illicit
drug
examin
afebril
respiratori
rate
puls
rate
blood
pressur
mmhg
lung
auscult
normal
complet
blood
count
reveal
wbc
pmn
l
hb
g
dl
chemistri
show
creatinin
mgdl
fast
plasma
glucos
mgdl
liver
function
test
normal
antihiv
result
neg
chest
radiograph
comput
tomographi
ct
chest
demonstr
masslik
consolid
apic
segment
left
upper
lobe
lul
bronchoscopi
transbronchi
biopsi
perform
bronchoalveolar
lavag
fluid
reveal
numer
pmn
without
organ
acidfast
gm
stain
histopatholog
show
acut
necrot
granulomat
inflamm
fragment
fungal
hypha
morpholog
consist
zygomycosi
refus
symptom
sinus
headach
ent
examin
show
evid
sinus
ct
brain
paranas
sinus
normal
liposom
amphotericin
b
mgkgday
given
two
week
withhold
worsen
renal
failur
underw
lul
resect
liposom
amphotericin
resum
improv
discharg
posaconazol
conclus
report
patient
isol
pulmonari
zygomycosi
coincid
dka
high
suspicion
obtain
tissu
histopatholog
make
earli
diagnosi
earli
surgic
erad
highdos
antifung
therapi
effect
conclus
merscov
transmit
via
minim
contact
healthcar
facil
therefor
recommend
earli
extend
contact
manag
may
success
reduc
infect
prevent
interhospit
transmiss
background
aim
mucormycosi
opportunist
fungal
infect
occur
immunocompromis
host
rhinocerebr
infect
common
form
usual
occur
poorli
control
diabet
patient
especi
diabet
ketoacidosi
pulmonari
mucormycosi
howev
rare
clinic
present
method
result
studi
report
male
teacher
live
chaiyaphum
provinc
present
subacut
fever
kg
weightloss
nonmass
hemoptysi
symptom
sinus
underli
diseas
wellcontrol
diabet
mellitu
recent
diagnos
month
histori
diabet
ketoacidosi
physic
examin
reveal
highgrad
fever
bronchial
breath
sound
increas
vocal
reson
left
upper
lung
chest
radiograph
show
dens
consolid
left
upper
lung
initi
investig
leukocytosi
normal
blood
sugar
organ
sputum
gram
stain
afb
smear
melioid
titer
ct
chest
reveal
area
consolid
anterior
segment
left
upper
lung
roundshap
hypodens
lesion
within
consolid
underw
bronchoscopi
transbronchi
lung
biopsi
specimen
show
broad
nonsept
hypha
perpendicular
branch
pulmonari
mucormycosi
diagnos
treat
amphotericin
b
follow
posaconazol
month
antifung
therapi
patient
symptom
improv
left
upper
lung
lesion
still
persist
left
upper
lobe
lobectomi
done
conclus
pulmonari
mucormycosi
concern
diabet
patient
even
though
well
control
blood
sugar
patient
diabet
cours
may
subacut
hematolog
malign
organ
transplant
patient
treatment
combin
antifung
therapi
surgic
remov
background
aim
detect
viru
use
ploymeras
chain
reaction
pcr
technolog
hospit
patient
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
investig
preval
viral
infect
risk
factor
aecopd
method
retrospect
investig
patient
aecopd
may
may
collect
patient
basic
inform
clinic
data
length
hospit
stay
analysi
viru
epidemiolog
use
pcr
logist
regress
analysi
perform
investig
risk
factor
result
patient
aecopd
includ
studi
episod
yield
posit
viral
pcr
result
one
viru
infect
episod
mix
infect
episod
aecopd
patient
viral
infect
associ
longer
hospit
stay
ae
vs
ae
p
multipl
regress
analysi
show
smoke
p
diabet
p
respiratori
failur
p
frequenc
exacerb
previou
year
p
risk
factor
conclus
preval
respiratori
viral
infect
high
hospit
patient
aecopd
length
hospit
stay
longer
aecopd
patient
viru
isol
smoke
diabet
respiratori
failur
frequenc
exacerb
previou
year
risk
factor
viral
infect
earli
identif
risk
factor
may
help
reduc
incid
aecopd
background
aim
introduct
respiratori
virus
recognis
abil
caus
flu
like
symptom
exacerb
asthma
copd
howev
possibl
abil
virus
exist
symbiot
within
lung
yet
explor
aim
determin
incid
asymptomat
viral
carriag
clinic
stabl
asthma
copd
patient
undergo
bronchoscopi
method
asymptomat
patient
recent
current
viral
symptom
undergo
bronchoscopi
recruit
exhal
breath
three
forc
expiratori
maneuv
collect
via
spirometri
filter
ml
bronchoalveolar
lavag
bal
collect
panel
respiratori
virus
human
rhinoviru
hrv
respiratori
syncyti
viru
influenza
influenza
b
parainfluenza
viru
human
metapneumoviru
hmpv
assay
use
sensit
rtpcr
match
sampl
viru
detect
classifi
posit
follow
visualis
weak
strong
band
result
pair
bal
exhal
breath
sampl
collect
patient
underli
respiratori
condit
patient
respiratori
secret
posit
viru
panel
rtpcr
patient
report
symptom
viral
infect
use
common
cold
questionnair
patient
virus
detect
concurr
hrv
hmpv
patient
virus
detect
hrv
influenza
b
hmpv
use
nest
real
time
pcr
exhal
breath
sampl
bal
sampl
show
human
rhinoviru
posit
low
viral
load
conclus
preliminari
analysi
suggest
asymptomat
carriag
virus
may
common
previous
recogn
respiratori
virus
probabl
contribut
microbiom
lung
especi
patient
asthma
copd
import
lung
virom
yet
establish
thu
research
hope
investig
interact
resid
bacteria
viral
speci
background
aim
tuberculosi
tb
risk
might
increas
diabet
factor
hyperglycemia
dyslipidemia
host
lipid
essenti
energi
sourc
use
mycobacteria
persist
latent
tb
state
potenti
therapi
target
cholesterol
catabol
mycobacteria
propos
effect
cholesterollow
drug
antitb
still
remain
unclear
purpos
studi
determin
effect
ezetimib
cholesterol
absorpt
inhibitor
intracellular
mycobacteria
surviv
dormanc
method
intracellular
mycobacteria
surviv
determin
measur
atp
activ
colonyform
unit
gene
express
profil
hypoxiainduc
dormant
mycobacterium
tuberculosi
mtb
analyz
realtim
pcr
flow
cytometri
microscopi
analysi
use
measur
lipid
load
human
macrophag
without
ezetimib
treatment
quantiferontb
gold
intub
qftgit
assay
perform
diagnos
latent
tuberculosi
infect
level
intracellular
cholesterol
triglycerid
measur
enzymat
fluorometr
method
result
ezetimib
capabl
effect
lower
intracellular
growth
mtb
hypoxiainduc
dormant
mtb
signific
decreas
mtb
growth
leukocyt
ezetimibetr
patient
diabet
term
atp
level
intracellular
mycobacteria
cfu
format
also
patient
receiv
ezetimib
therapi
associ
lower
preval
latent
tuberculosi
lower
intracellular
lipid
content
conclus
ezetimib
current
market
drug
hold
promis
adjunct
hostdirect
therapi
tb
background
aim
oropharyng
tuberculosi
usual
secondari
pulmonari
tuberculosi
rare
manifest
report
case
oropharyng
tuberculosi
old
man
tuberculosi
depart
male
pham
ngoc
thach
hospit
method
man
patient
transfer
oncolog
hospit
diagnosi
oropharyng
tuberculosi
biopsi
present
tuberculosi
depart
chief
complaint
sorethroat
loss
appetit
odynophagia
malais
unabl
swallow
liquid
solid
food
lost
kg
bodi
weight
within
last
two
month
right
cervic
lymph
node
detect
oral
oropharyng
examin
show
posterior
oropharyng
wall
mucosa
hyperem
cover
multipl
larg
graywhit
plagu
vari
size
chest
radiograph
show
nonhomogen
opac
right
lung
infiltr
left
lung
blood
test
within
normal
limit
hiv
test
neg
sputum
afb
posit
biopsi
lymph
node
show
tuberculosi
patient
start
antitb
treatment
drug
h
e
result
nearli
month
treatment
recov
symptom
normal
appear
oropharyng
mucosa
transfer
local
tb
unit
continu
treatment
followup
conclus
possibl
tuberculosi
keep
mind
especi
develop
countri
incid
tuberculosi
high
case
ulcer
lesion
oropharynx
oral
caviti
respond
antibiot
therapi
biopsi
necessari
tool
diagnosi
aga
khan
univers
hospit
pulmonari
medicin
karachi
pakistan
aga
khan
univers
hospit
intern
medicin
karachi
pakistan
background
aim
tuberculosi
tb
remain
one
lead
infecti
caus
morbid
mortal
worldwid
diagnosi
reli
sputum
smear
whose
sensit
low
sputum
cultur
afb
time
consum
past
decad
diagnost
techniqu
base
nucleic
acid
amplif
develop
studi
done
see
diagnost
accuraci
xpert
mtbrif
bronchoalveolar
lavag
sampl
popul
method
retrospect
studi
patient
underw
bronchoscopi
evalu
tuberculosi
pulmonari
section
aga
khan
univers
hospit
karachi
june
dec
includ
file
review
ethic
approv
total
file
review
patient
met
inclus
criteria
sensit
specif
xpert
mtbrif
cultur
refer
method
determin
result
total
patient
confirm
pulmonari
tb
cultur
male
mean
age
ae
year
known
histori
tb
contact
diabet
common
present
complaint
fever
cough
mean
durat
symptom
ae
month
common
chest
xray
find
infiltr
cavit
miliari
pattern
patient
mdr
tb
cultur
patient
xdr
tb
afb
smear
posit
patient
sensit
ci
specif
ci
xpert
mtbrif
posit
patient
sensit
ci
specif
ci
sensit
xpert
mtbrif
rifampin
resist
detect
assay
specif
conclus
xpert
mtbrif
detect
tb
case
accur
rapidli
bal
smear
earli
detect
mdr
tb
use
xpert
mtbrif
bal
tb
diagnosi
lead
earli
appropri
treatment
case
set
background
aim
standard
antituberculosi
drug
regimen
sometim
caus
sever
renal
dysfunct
howev
detail
remain
unknown
aim
establish
standard
manag
renal
dysfunct
due
antitb
drug
base
retrospect
data
method
retrospect
analyz
clinic
featur
activ
tb
patient
develop
renal
dysfunct
start
standard
antituberculosi
drug
singl
tb
hospit
result
activ
tb
patient
develop
sever
renal
dysfunct
start
tb
treatment
mean
age
ae
year
old
patient
femal
median
onset
time
renal
dysfunct
rang
day
mean
serum
creatinin
level
ae
mgdl
start
antitb
treatment
peak
serum
creatinin
level
show
renal
dysfunct
ae
mgdl
acut
interstiti
nephriti
confirm
renal
biopsi
patient
patient
clinic
diagnos
acut
interstiti
nephriti
base
urin
find
abnorm
result
steroid
administ
case
presum
acut
interstiti
nephriti
renal
function
fulli
recov
patient
patient
show
renal
dysfunct
despit
stop
antitb
treatment
administ
steroid
rifampicin
presum
drug
caus
renal
dysfunct
case
conclus
result
suggest
renal
dysfunct
mostli
occur
intens
phase
standard
antitb
treatment
rifampicin
lead
candid
found
avoid
rifampicin
gener
effect
complet
antitb
treatment
without
relaps
renal
dysfunct
temporarili
discontinu
antitb
therapi
although
controversi
thought
administr
steroid
short
period
accept
suspect
confirm
acut
interstiti
nephriti
case
discontinu
antitb
drug
suffici
improv
renal
function
introduct
pulmonari
pleural
ectop
thyroid
tissu
rare
never
describ
curiou
case
highlight
approach
diagnosi
pleural
effus
includ
imag
invas
techniqu
arriv
correct
diagnosi
guid
proper
manag
case
present
previous
diagnos
multinodular
toxic
goiter
underw
total
thyroidectomi
year
ago
postop
asymptomat
biochem
euthyroid
mainten
medic
well
year
prior
experienc
recurr
pleural
effus
left
reliev
repeat
thoracentesi
workup
reveal
equivoc
find
subsequ
underw
tube
thoracostomi
chest
ct
scan
reveal
multipl
pleuralbas
mass
ultrasoundguid
biopsi
immunohistochem
stain
reveal
benign
ectop
thyroid
tissu
neck
ultrasound
also
reveal
left
thyroid
nodul
follicular
adenoma
biopsi
tbpcr
pleural
fluid
posit
antitb
medic
start
eventu
underw
talc
pleurodesi
chest
tube
remov
howev
week
admiss
hematochezia
colonoscopi
show
larg
tubular
adenoma
obstruct
distal
colon
colectomi
resect
plan
howev
succumb
acut
myocardi
infarct
week
admiss
discuss
present
ectop
thyroid
tissu
rang
asymptomat
devast
dyspnea
hemoptysi
postul
aris
aberr
embryogenesi
thyroid
develop
predict
common
site
involv
thyroid
tract
ascend
primit
foregut
case
inde
rare
case
sinc
pleura
thyroid
gland
relat
embryolog
pleural
effus
ectop
thyroid
tissu
report
recent
literatur
manag
case
involv
surgic
resect
pleural
implant
togeth
radioiodin
therapi
control
symptom
isol
suscept
ciprofloxacin
amikacin
first
thorax
ct
scan
show
extens
bronchiectasi
diffus
nodular
lung
treein
bud
appear
method
base
initi
find
clarithromycin
grday
amoxicillinclavulan
acid
grday
administ
seven
day
result
increas
complaint
clinic
improv
parenter
antibiot
treatment
hospit
admiss
recommend
couldt
therefor
ciprofloxacin
amikacin
could
nt
administ
prefer
gemifloxasin
mgrday
sinc
gemifloxasin
could
taken
daili
oral
therapi
could
continu
week
howev
feel
better
refus
therapi
final
gemifloxasin
intak
week
result
treatment
outcom
favor
symptom
mostli
resolv
week
radiography
find
improv
slowlier
week
thorax
ct
scan
reveal
signific
chang
conclus
mabscessu
lung
diseas
may
progress
slowli
therefor
treatment
complex
therapi
aim
improv
symptom
radiograph
regress
sputum
convers
neg
amikacin
clarithromycin
cefoxitin
test
suscept
mabscessu
variant
antibiot
bacteriostat
effect
mabscessu
within
macrophag
refractori
invas
pulmonari
infect
antibiot
therapi
explain
sinc
fluoroquinolon
administ
daili
oral
long
period
time
highli
attract
therapi
mabscessu
sever
patient
treat
mabscessu
combin
fluoroquinolon
clarithromycin
howev
activ
still
unclear
mabscessu
therapi
yet
could
nt
optim
regimen
combin
amikacin
cefoxitin
imipenem
clarithromycin
fluoroquinolon
still
plenti
problem
solv
background
aim
tuberculosi
mtb
remain
one
common
caus
death
among
infecti
pathogen
rapid
diagnosi
treatment
pulmonari
tuberculosi
still
great
challeng
genexpert
mtbrif
assay
novel
integr
diagnost
system
rapid
detect
mtb
pathogen
rifampicin
resist
strain
object
studi
evalu
diagnost
perform
sputum
genexpert
mtbrif
smear
neg
pulmonari
tb
high
burden
countri
thailand
method
diagnost
test
studi
suspect
tb
patient
neg
two
smear
afbresult
srinagarind
hospit
result
least
neg
sputum
afb
stain
result
patient
diagnos
smear
neg
pulmonari
tb
case
pulmonari
tb
sputum
cultur
grew
tuberculosi
pulmonari
tb
patient
sensit
genexpert
mtbrif
assay
ci
specif
ci
posit
predict
valu
ppv
neg
predict
valu
npv
ci
ci
respect
likelihood
ratio
posit
lr
likelihood
ratio
neg
lr
ci
ci
respect
case
suspect
pulmonari
tb
concord
two
test
mtuberculosi
cultur
growth
genexpert
mtbrif
result
genexpert
mtbrif
assay
detect
rifresist
mtb
sputum
sampl
confirm
drug
suscept
test
dst
conclus
conclus
genexpert
mtbrif
assay
high
sensit
specif
diagnosi
smear
neg
pulmonari
tb
genexpert
mtbrif
assay
recommend
suspici
pulmonari
tb
case
two
sputum
afb
stain
result
neg
benefit
assay
could
report
quicker
cultur
result
yield
cultur
detect
rifampicin
resist
strain
background
aim
past
intrapleur
administr
fibrinolyt
agent
shown
good
outcom
complic
pleural
infect
although
contrari
evid
shown
variou
small
studi
nowaday
surgic
intervent
includ
thoracotomi
decort
advoc
fibrothorax
present
case
tubercul
fibrothorax
obviat
need
surgic
referr
treat
effect
via
medic
therapi
case
histori
male
present
us
short
breath
left
side
pleurit
chest
pain
kg
weight
loss
two
month
histori
fever
pleuroscopi
perform
larg
symptomat
left
pleural
effus
pleural
drainag
hamper
presenc
multipl
locul
separ
thick
fibrin
wall
intrapleur
fibrinolyt
streptokinas
given
administ
broadspectrum
intraven
antibiot
antitubercul
agent
continu
chest
tube
drainag
nearli
month
subsequ
pleuroscopi
show
resolut
fibrothorax
conclus
streptokinas
may
consid
reason
option
case
pleural
infect
complic
fibrothorax
medic
facil
limit
resourc
background
aim
tuberculosi
tb
remain
one
major
concern
peopl
live
poverti
one
therapeut
challeng
patient
nonadher
antituberculosi
treatment
antituberculosi
drug
resist
occur
due
newli
acquir
mutat
nonadher
antituberculosi
treatment
aim
studi
assess
determin
nonadher
antituberculosi
treatment
includ
drop
lost
follow
pulmonari
tb
patient
live
poverti
east
java
indonesia
method
crosssect
studi
among
tb
patient
age
year
conduct
julydecemb
primari
outcom
socioeconom
variabl
lack
money
lack
social
support
famili
commun
distanc
treatment
centr
secondari
outcom
individu
behaviour
variabl
fear
stigma
feel
better
week
treatment
knowledg
tb
treatment
durat
curabl
side
effect
alcohol
tobacco
use
result
total
tb
patient
experienc
nonadher
treatment
includ
case
loss
followup
patient
took
drug
strict
direct
observ
supervis
health
care
worker
factor
analys
suggest
patient
live
km
treatment
centr
pr
ci
less
incom
rp
us
month
pr
ci
like
nonadher
pulmonari
tuberculosi
treatment
social
support
supervis
famili
pr
higher
educ
level
pr
protect
factor
conclus
found
risk
popul
nonadher
pulmonari
tb
treatment
character
east
java
indonesia
sociodemograph
clinic
characterist
determin
antituberculosi
treatment
nonadher
lost
follow
need
done
enhanc
treatment
supervis
polici
financi
support
health
care
worker
pulmonari
tuberculosi
patient
background
aim
mycobacterium
tuberculosi
mycobacterium
lepra
emerg
epidem
centuri
especi
last
ten
decad
malaysia
sinc
erad
leprosi
declin
tubercul
case
toward
end
last
centuri
increas
report
either
case
local
leprosi
incid
rose
case
everi
popul
case
everi
popul
time
local
tubercul
incid
report
around
case
per
peopl
nevertheless
rate
coinfect
hardli
report
best
knowledg
second
report
case
dual
infect
southeast
asian
region
sinc
last
report
year
ago
case
descript
year
old
man
diabet
histori
diagnos
lepromat
leprosi
first
present
intermitt
gener
rash
diagnosi
confirm
follow
skin
biopsi
commenc
rifampicin
clofazimin
dapson
three
month
later
came
us
weight
loss
kg
past
one
month
associ
dysphagia
chronic
cough
chest
radiograph
reveal
right
upper
zone
infiltr
subsequ
bronchoscopi
establish
diagnosi
mycobacterium
tuberculosi
antitubercular
drug
start
symptom
improv
thereaft
conclus
around
globe
case
tbleprosi
coinfect
report
coinfect
crossimmun
describ
past
exact
mechan
yet
elucid
similar
case
report
first
interv
two
fall
within
expect
durat
rang
earli
two
month
fifteen
year
secondli
tuberculosi
follow
leprosi
infect
summari
case
alert
us
recognis
coexist
two
entiti
allow
us
start
formul
strategi
earli
detect
deliveri
better
care
patient
background
aim
interferongamma
releas
assay
igra
use
detect
activ
tuberculosi
tb
infect
presum
latent
tb
infect
ltbi
igra
tspottb
test
superior
earlier
tb
test
sensit
specif
howev
also
prone
fals
neg
activ
tb
infect
method
retrospect
review
medic
record
patient
suspect
tb
test
use
tspottb
sputum
bronchial
lavag
fluid
cultur
polymeras
chain
reaction
pcr
decemb
februari
assess
diagnost
accuraci
tspottb
case
result
twentyfour
patient
tspottbposit
patient
tspottbneg
sputum
bronchial
lavag
fluid
cultur
pcr
assay
reveal
seven
true
tspottbposit
result
four
fals
tspottbneg
result
activ
tb
cultur
pcr
result
neg
activ
tb
remain
case
indic
tspottb
result
fals
posit
tspottb
result
truli
neg
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
tspottb
activ
tb
infect
respect
four
patient
fals
neg
tspottb
result
discuss
case
present
conclus
fals
neg
tspottb
result
may
result
complic
factor
common
among
igra
immunosuppress
reaction
blood
sampl
issu
abnorm
transport
time
nonstandard
test
method
judgment
error
anoth
possibl
caus
fals
neg
tb
cell
produc
consist
life
cycl
tspottb
exhibit
good
perform
detect
activ
prior
tb
infect
howev
sometim
yield
fals
neg
result
activ
tb
background
aim
introduct
incid
pulmonari
nontubercul
mycobacteri
ntm
diseas
increas
global
first
quarter
nationwid
survey
japan
found
incid
pulmonari
tuberculosi
tb
ntm
diseas
case
case
per
personyear
present
studi
examin
period
incid
pulmonari
ntm
diseas
among
patient
showa
univers
hospit
method
subject
method
januari
march
case
acidfast
bacilli
mycobacteriosi
examin
case
pulmonari
ntm
diseas
diagnos
accord
statement
american
thorac
societyinfecti
diseas
societi
america
incid
pulmonari
ntm
diseas
estim
refer
patient
pulmonari
tb
result
antiacid
bacteria
identifi
tb
activ
pulmonari
tb
extrapulmonari
tb
remain
pulmonari
ntm
diseas
due
follow
bacteria
mycobacterium
avium
mycobacterium
intracerul
case
mycobacterium
abscessu
mycobacterium
gordona
group
mycobacterium
kansasii
mycobacterium
szulgai
diagnosi
definit
ntm
diagnos
studi
start
regist
survey
investig
anoth
diagnos
definit
diagnosi
obtain
definit
diagnos
case
follow
avium
case
intracerul
abscessu
ntm
group
incid
pulmonari
ntm
diseas
showa
univers
case
per
personyear
time
nationwid
survey
conclus
high
incid
pulmonari
ntm
diseas
hospit
suggest
epidemiolog
properti
consid
statu
investig
pulmonari
ntm
diseas
facil
taken
account
dress
would
nt
want
wear
background
aim
antitubercul
agent
associ
mild
sever
cutan
advers
reaction
major
case
mild
cutan
reaction
easili
manag
cessat
offend
agent
dress
rare
potenti
life
threaten
drug
induc
hypersensit
reaction
skin
erupt
system
symptom
involv
organ
method
highlight
case
smear
neg
cultur
posit
tubercul
lymphaden
yearold
man
develop
dress
syndrom
follow
treatment
first
line
antitubercul
medic
subsequ
drug
desensitis
treatment
util
second
line
antitubercul
agent
proof
futil
patient
either
develop
recurr
dress
advers
reaction
follow
conserv
approach
employ
view
signific
improv
patient
clinic
radiolog
featur
remain
symptom
free
subsequ
review
conclus
although
consid
rare
dress
syndrom
secondari
antitubercul
agent
remain
challeng
treatment
tuberculosi
fundament
initi
termin
treatment
select
medic
drug
desensit
approach
crucial
prevent
increas
morbid
mortal
background
aim
standard
treatment
pulmonari
tuberculosi
tb
requir
least
six
month
patient
receiv
incomplet
treatment
may
cure
drug
resist
may
develop
directli
observ
therapi
dot
specif
strategi
endors
world
health
organ
improv
adher
howev
dot
strategi
requir
high
cost
huge
manpow
requir
treatment
smartphon
medic
applic
remind
take
medicin
regularli
may
improv
adher
standard
treatment
determin
effect
use
smartphon
medic
applic
remind
improv
treatment
outcom
complet
rate
sputum
afb
convers
method
blind
random
control
trial
conduct
octob
decemb
tb
clinic
phramongkutklao
hospit
bangkok
patient
older
year
new
case
pulmonari
tuberculosi
smear
posit
randomli
assign
intervent
group
control
group
control
group
treat
standard
regimen
intervent
group
treat
regimen
control
group
use
tb
remind
applic
patient
mobil
phone
primari
outcom
success
complet
cours
treatment
sputum
convers
rate
month
treatment
result
sixtyfour
patient
enrol
studi
thirtynin
patient
male
mean
age
patient
ae
year
treatment
complet
patient
intervent
group
patient
control
group
p
sputum
convers
rate
month
patient
intervent
group
patient
control
group
p
conclus
use
tb
remind
applic
mobil
phone
improv
complet
rate
standard
regimen
treatment
sputum
convers
rate
month
treatment
may
new
method
improv
adher
standard
treatment
chong
hua
hospit
depart
pediatricssect
pediatr
pulmonolog
cebu
citi
philippin
chong
hua
hospit
depart
pediatricssect
pediatr
pulmonolog
cebi
citi
philippin
background
aim
progress
primari
tuberculosi
tb
less
common
cours
tb
infect
among
infant
lesion
progress
area
advanc
penumonia
advent
therapi
children
progress
primari
tb
diseas
die
howev
prompt
diagnosi
appropri
therapi
prognosi
excel
result
old
male
infant
present
persist
cough
month
fever
month
suspect
exposur
nanni
chronic
cough
chest
xray
show
complet
opacif
left
hemithorax
cardiomediastin
structur
slightli
shift
right
suggest
massiv
left
pleural
effus
versu
tumor
cbc
show
leukocytosi
thrombocytosi
monocytosi
erythrocyt
sediment
rate
elev
thoracentesi
yield
dri
tap
percutan
needl
lung
biopsi
done
histopatholog
studi
tuberculin
skin
test
mm
hour
gastric
aspir
acid
fast
bacilli
afb
done
thrice
neg
ct
scan
chest
show
consolid
left
lung
area
necrosi
suggest
chronic
granulomat
infect
malign
metastas
cytolog
report
indic
chronic
granulomat
process
togeth
ceftriaxon
oxacillin
patient
start
quadrupl
antitb
therapi
isoniazid
rifampicin
pyrazinamid
ethambutol
patient
discharg
symptom
control
outpati
followup
month
treatment
show
minim
improv
left
lung
consolid
begin
atelectasi
conclus
case
highlight
difficulti
diagnosi
infantil
tb
absenc
gold
standard
cultur
valu
complet
histori
emphasi
close
contact
adult
activ
pulmonari
tb
prompt
diagnosi
help
clinic
practic
guidelin
avail
diagnost
test
procedur
critic
institut
appropri
therapi
prevent
patient
deterior
demis
background
aim
global
estim
peopl
develop
multidrug
resist
tuberculosi
mdrtb
peopl
die
diseas
indonesia
estim
new
case
mdrtb
everi
year
new
case
previous
treat
global
succes
treatment
outcom
die
treatment
outcom
document
interrupt
treatment
treatment
fail
aim
studi
determin
predictor
factor
treament
fail
mdrtb
patient
mdrtb
unit
hasan
sadikin
gener
hospit
bandung
westjava
indonesia
method
studi
match
casecontrol
studi
patient
treament
fail
case
group
patient
succes
outcom
control
group
match
sex
age
background
aim
sputum
smear
microscopi
remain
cornerston
case
detect
howev
util
limit
poor
sensit
world
health
organ
reduc
minimum
number
sputum
smear
specimen
examin
owe
low
increment
yield
sputum
smear
specimen
howev
differ
yield
pattern
sputum
smear
across
studi
differ
countri
note
signific
diagnost
yield
sputum
smear
note
high
burden
diseas
area
util
third
sputum
smear
underestim
high
burden
diseas
set
increas
risk
popul
philippin
method
studi
hospitalbas
retrospect
crosssect
chart
review
design
includ
presumpt
pulmonari
tuberculosi
patient
age
year
prior
histori
pulmonari
tuberculosi
subject
sputum
smear
microscopi
percentag
posit
smear
increment
yield
sputum
smear
posit
rate
combin
analyz
result
studi
show
sputum
smear
detect
major
case
n
smear
ad
minim
diagnost
yield
n
howev
note
smear
posit
rate
increas
succeed
sputum
smear
specimen
compar
posit
rate
smear
among
posit
combin
significantli
higher
rate
smear
posit
higher
increment
increas
posit
rate
note
specimen
combin
conclus
smear
specimen
case
detect
pulmonari
tuberculosi
nonneglig
diagnost
yield
succeed
specimen
significantli
higher
rate
smear
posit
observ
specimen
less
get
vaccin
tst
mm
subject
subject
receiv
vaccin
posit
igra
subject
get
vaccin
tst
mm
subject
subject
get
vaccin
neg
igra
subject
get
vaccin
tst
result
mm
subject
agreement
igra
tst
suffici
kappa
characterist
subject
male
subject
femal
subject
mean
age
year
risk
factor
statist
signific
length
employ
bcg
vaccin
age
highest
sensit
specif
igra
respect
conclus
studi
show
comparison
igra
tst
healthcar
worker
bbkpm
bandung
agreement
tst
igra
suffici
signific
correl
posit
test
result
risk
factor
length
employ
bcg
vaccin
age
studi
recommend
igra
good
use
screen
test
replac
tst
philippin
heart
center
pulmonari
depart
quezon
citi
philippin
philippin
heart
center
adult
pulmonari
quezon
citi
philippin
introduct
pseudoaneurysm
dilat
branch
pulmonari
arteri
call
rasmussen
aneurysm
rare
sequala
pulmonari
tuberculosi
life
threaten
massiv
hemoptysi
ruptur
aneurysm
uncommon
complic
cavitari
tuberculosi
case
present
year
old
woman
complain
massiv
hemoptysi
start
hour
prior
admiss
nonsmok
examin
pale
diaphoret
normotens
tachycard
normal
respiratori
rate
fine
crackl
lung
field
note
chest
lung
examin
chest
xray
reveal
pulmonari
congest
antifibrinolyt
agent
given
intraven
condit
patient
resolv
temporarili
hospit
day
ctpa
reveal
saccular
aneurysm
rasmussen
segment
branch
right
pulmonari
arteri
measur
x
cm
suppli
medial
segment
right
middl
lobe
multipl
pulmonari
nodul
due
infecti
process
hospit
day
massiv
hemoptysi
recur
approxim
amount
cc
blood
pressur
drop
palpatori
mmhg
went
cardiac
arrest
subsequ
patient
expir
discuss
pulmonari
tuberculosi
result
eros
adjac
structur
lung
tubercul
process
occur
near
vessel
wall
lead
thicken
intima
protrus
aneurysm
result
medic
manag
employ
hemoptysi
minim
howev
recommend
surgeri
perform
patient
episod
massiv
hemoptysi
conclus
rasmussen
aneurysm
rare
tubercul
sequela
literatur
report
hemoptysi
usual
massiv
entail
need
earli
aggress
manag
background
aim
latent
tuberculosi
ltbi
defin
state
persist
immun
respons
stimul
mycobacterium
tuberculosi
antigen
without
evid
clinic
manifest
activ
tuberculosi
tb
infect
control
high
risk
place
dormitori
import
control
tb
transmiss
factor
like
household
surveil
contact
trace
tb
regard
essenti
measur
prevent
tb
dissemin
commun
preliminari
cross
section
studi
contact
investig
pulmonari
tb
patient
colleg
dormitori
jakarta
indonesia
approv
ethic
committ
faculti
medicin
universita
indonesia
method
fifti
seven
femal
student
age
year
old
whose
live
dormitori
index
case
tb
patient
acid
fast
bacilli
posit
three
month
diagnos
subject
interview
regard
past
present
tb
histori
follow
chest
x
ray
xpert
mtb
rif
sputum
interferon
gamma
releas
assay
igra
quantiferron
test
ltbi
defin
igra
test
posit
test
neg
three
subject
exclud
due
lack
tool
perform
igra
result
bacillu
calmett
guerin
bcg
vaccin
subject
present
tbrelat
symptom
proven
non
tb
moment
four
subject
without
past
present
tb
histori
exhibit
posit
igra
result
show
tbrelat
radiolog
result
subject
show
neg
xpert
mtb
rif
sputum
examin
limit
studi
unabl
differenti
ltbi
contact
dormitori
contact
conclus
contact
investig
dormitori
abl
indic
subject
whose
suggest
ltbi
recommend
studi
explor
environ
nutrit
educ
infect
control
background
aim
serial
test
interferongamma
releas
assay
igra
show
convers
revers
health
care
worker
limit
studi
varianc
igra
result
close
contact
infecti
tuberculosi
tb
patient
studi
aim
know
varianc
igra
respons
serial
test
method
prospect
follow
famili
school
contact
infecti
tb
case
year
exposur
quantiferon
gold
intub
assay
qftgit
chest
xray
follow
initi
month
year
year
last
exposur
prevent
treatment
recommend
igra
posit
respond
result
total
close
contact
mean
age
ae
year
old
recruit
index
case
initi
igra
posit
contact
complet
follow
examin
without
prevent
treatment
among
initi
posit
respond
contact
revert
howev
eight
convert
five
contact
revert
overal
posit
among
initi
posit
respond
among
initi
neg
respond
contact
convert
howev
contact
revert
five
contact
convert
follow
igra
test
poorli
conduct
contact
start
prevent
treatment
three
among
contact
start
prevent
treatment
initi
posit
convers
revert
conclus
close
contact
infecti
tb
case
show
variou
convers
revers
rate
serial
test
igra
studi
suggest
simpl
dichotom
definit
igra
neg
posit
may
suitabl
diagnost
cutoff
valu
serial
test
background
aim
given
advanc
detect
tool
mycobacterium
tuberculosi
mtb
expect
patient
confirm
tubercul
pleurisi
microbiolog
evid
past
studi
investig
clinic
featur
accord
cultur
tb
patient
tb
pleurisi
method
jan
dec
medic
record
adult
patient
diagnos
treat
tb
pleurisi
review
retrospect
seoul
st
mari
hospit
bucheon
st
mari
hospit
result
among
patient
tb
pleurisi
patient
confirm
posit
cultur
mtb
posit
group
mtb
cultur
show
young
age
frequent
autoimmun
diseas
compar
neg
group
regardless
presenc
mtb
pleural
specimen
sputum
studi
mtb
infect
stain
acid
fast
bacilli
cultur
pcr
mtb
reveal
posit
result
half
patient
group
case
vs
case
analysi
pleural
effus
posit
group
mtb
significantli
lower
level
percentag
lymphocyt
glucos
neg
group
cure
complet
rate
diseas
positivecultur
group
negativecultur
group
littl
differ
treatment
respons
includ
relaps
surviv
two
group
conclus
find
prove
improv
diagnost
technolog
mtb
patient
tb
pleurisi
show
frequent
microbiolog
evid
unlik
past
addit
studi
confirm
posit
cultur
mtb
associ
lower
lymphocytosi
glucos
pleural
fluid
howev
exist
cultur
mtb
influenc
treatment
outcom
report
whole
proport
new
tb
case
world
multidrug
resist
current
indonesia
place
second
rank
number
tb
case
world
establish
diagnosi
sputum
cultur
tuberculosi
resist
test
take
least
week
result
delay
mdr
tb
treatment
commenc
increas
risk
infect
spread
assess
tool
produc
quicker
diagnost
result
greatli
need
elev
level
interleukin
mdr
tb
patient
could
one
measur
new
assess
tool
earli
detect
mdr
tb
method
studi
design
cross
section
sixti
mdr
tb
suffer
seek
treatment
mdr
tb
polyclin
dr
hasan
sadikin
hospit
bandung
period
julydecemb
result
result
level
rang
pgml
median
valu
pgml
averag
level
mdr
tb
group
pgml
nonmdr
tb
patient
pgml
signific
differ
two
group
p
conclus
conclus
studi
signific
differ
level
mdr
tb
group
nonmdr
tb
group
background
aim
aim
paper
present
case
came
due
difficulti
breath
cough
fluctuant
mass
right
thigh
diagnos
septicem
melioidosisbas
blood
sputum
wound
cultur
also
diagnos
pulmonari
tuberculosi
coinfect
manag
accordingli
addit
paper
also
strive
creat
awar
among
local
healthcar
profession
melioidosi
possibl
coinfect
pulmonari
tuberculosi
high
risk
patient
method
report
case
oldmal
live
bulacan
philippin
poultri
raiser
veget
farmer
week
histori
right
thigh
abscess
also
complain
cough
fever
dyspnea
weight
loss
result
patient
initi
diagnos
right
thigh
abscess
commun
acquir
pneumonia
moder
risk
consider
concomit
pulmonari
tuberculosi
also
thought
b
pseudomallei
isol
cultur
blood
sputum
wound
diagnosi
septicemicmelioidosi
entertain
therapi
melioidosi
start
patient
despit
antibiot
patient
still
observ
low
grade
fever
although
patient
sputum
afb
result
neg
given
follow
risk
factor
poorli
control
diabet
high
index
suspicion
pulmonari
tuberculosi
coinfect
consid
sinc
patient
diagnos
treat
tuberculosi
earlier
empir
treat
quadrupl
fix
dose
combin
antikoch
medic
conclus
patient
present
clinic
featur
tuberculosi
must
investig
work
rule
melioidosi
possibl
coinfect
tuberculosi
earli
diagnosi
treatment
reduc
risk
death
caus
melioidosi
melioidosi
pulmonari
tuberculosi
coinfect
extrem
rare
awar
possibl
exist
occurr
deter
clinician
treat
diseas
entiti
background
aim
childhood
tuberculosi
increas
incid
worldwid
occurr
repres
import
event
indic
recent
transmiss
identif
surrog
biomark
treatment
respons
risk
poor
outcom
tuberculosi
benefici
tool
patient
manag
thu
biomark
like
high
sensit
creactiv
protein
hscrp
propos
prognost
marker
method
children
diagnos
tuberculosi
base
philippin
pediatr
societi
nation
tuberculosi
program
guidelin
includ
clinic
data
review
record
blood
sampl
collect
serum
hscrp
determin
treatment
intens
phase
data
analysi
done
use
stata
se
version
mean
standard
deviat
frequenc
percent
distribut
pair
test
scatter
plot
use
level
signific
set
result
subject
pulmonari
tuberculosi
particip
twentythre
male
femal
age
rang
year
mean
age
particip
complet
studi
analysi
data
show
level
serum
hscrp
intens
phase
treatment
significantli
lower
compar
level
treatment
p
valu
hand
bodi
mass
index
use
one
object
paramet
treatment
respons
children
demonstr
statist
signific
differ
intens
phase
p
valu
hscrp
bmi
indirectli
correl
howev
statist
insignific
conclus
studi
shown
statist
signific
lower
serum
hscrp
level
intens
phase
treatment
among
pediatr
patient
tuberculosi
therefor
conclud
hscrp
addit
paramet
evalu
treatment
respons
earli
month
treatment
background
aim
ada
pleural
effus
known
use
tool
make
diagnosi
tubercul
pleurisi
hospit
tuberculosi
control
unit
littl
chanc
see
patient
tubercul
infect
howev
still
experi
patient
high
level
ada
pleural
effus
without
tubercul
infect
aim
studi
examin
background
patient
high
ada
pleural
effus
characterist
natur
pleural
effus
method
patient
receiv
pleurocentesi
hospit
enrol
clinic
chart
patient
whose
ada
pleural
effus
iul
review
result
patient
patient
receiv
pleurocentesi
iul
ada
pleural
effus
sampl
met
light
criteria
exud
pleural
effus
averag
age
year
old
men
includ
patient
underli
diseas
tuberculosi
pleurisi
malign
diseas
pneumonia
associ
pleural
effus
rheumatoid
arthriti
undiagnos
seem
differ
natur
pleural
effus
among
underli
diseas
except
pneumonia
associ
pleural
effus
effus
show
high
ldh
high
polynuclear
leukocyt
cell
low
ph
low
glucos
conclus
percentag
tuberculosi
pleurisi
varieti
underli
diseas
caus
high
ada
pleural
effus
ada
pleural
effus
use
tool
diagnosi
tuberculosi
pleurisi
detail
evalu
necessari
accur
diagnosi
background
aim
tuberculosi
tb
remain
major
public
health
problem
georgia
estim
incid
preval
per
popul
respect
littl
evid
exist
global
burden
hospit
acquir
tb
infect
among
health
care
worker
hcw
impact
differ
infect
control
ic
measur
reduc
risk
nosocomi
acquir
tuberculosi
method
evalu
perform
commerci
avail
equip
plasma
cluster
ion
gener
sharp
corpor
reduct
latent
tuberculosi
infect
ltbi
risk
among
hcw
special
tb
hospit
nation
center
tuberculosi
lung
diseas
nctld
plasma
cluster
unit
place
per
manufactur
recommend
two
four
therapeut
depart
ident
administr
engin
person
protect
ic
measur
baselin
six
month
apart
two
followup
test
quantiferontb
gold
intub
qftg
quest
diagnost
perform
compar
risk
tuberculosi
infect
among
plasma
cluster
expos
nonexpos
group
result
total
hcw
screen
ltbi
baselin
expos
nonexpos
mix
place
work
exclud
analysi
group
qft
neg
baselin
hcw
remain
neg
becam
posit
expos
group
remain
neg
becam
posit
nonexpos
group
qft
followup
tast
base
qft
convers
data
subject
within
plasma
cluster
set
show
time
greater
risk
acquir
tuberculosi
infect
compar
subject
within
plasma
cluster
set
ci
fisher
exact
pvalu
conclus
plasma
cluster
ion
gener
technolog
shown
good
perform
feasibl
use
tuberculosi
hospit
substanti
decreas
risk
tuberculosi
infect
among
hcw
background
aim
advanc
lung
cancer
usual
metastas
adren
gland
bone
liver
brain
upper
gastrointestin
haemorrhag
ugih
result
gastrointestin
metastas
rare
initi
present
present
two
patient
initi
present
malaena
secondari
duoden
metastasi
primari
lung
cancer
method
first
patient
man
smoker
present
melaena
hemoptysi
lethargi
lost
weight
two
month
durat
oesophagogastroduodenoscopi
ogd
show
multipl
polypoid
mass
forrest
iiciii
ulcer
duodenum
histopatholog
examin
immunohistochem
stain
confirm
primari
lung
adenocarcinoma
computertomographi
thorax
reveal
right
upper
lobe
mass
measur
cm
liver
mesenter
contralater
lung
metastas
second
patient
ladi
nonsmok
came
recurr
episod
melaena
symptom
anemia
weight
loss
three
month
durat
ogd
show
presenc
larg
circumferenti
mass
measur
cm
ulcer
base
third
part
duodenum
histopatholog
examin
confirm
duoden
metastasi
secondari
poorli
differenti
adenocarcinoma
subsequ
computertomographi
thorax
guid
biopsi
confirm
primari
lung
adenocarcinoma
result
lung
adenocarcinoma
upper
gastrointestin
haemorrhag
due
duoden
metastasi
uncommon
treatment
modal
avail
includ
combin
surgeri
endoscop
resect
neoadjuv
chemotherapi
conclus
upper
gastrointestin
haemorrhag
initi
present
distant
metastasi
lung
adenocarcinoma
uncommon
consid
clinician
manag
group
patient
background
aim
synovi
sarcoma
ss
destruct
atyp
tumour
origin
mesenchym
tissu
account
approxim
soft
tissu
sarcoma
infrequ
lung
primari
well
younger
patient
report
rare
case
primari
endotrach
synovi
sarcoma
man
present
asthmalik
symptom
respond
well
radiotherapi
method
man
present
histori
intermitt
short
breath
signific
famili
histori
asthma
atopi
minim
crepit
lung
auscult
evid
airway
obstruct
spirometri
fev
l
fvc
l
revers
highresolut
comput
tomographi
hrct
thorax
howev
reveal
peduncul
endotrach
mass
confirm
bronchoscopi
histopatholog
examin
show
epithelioid
morpholog
immunohistochem
studi
show
tumour
cell
diffus
posit
focal
posit
cytokeratin
consist
diagnosi
synovi
sarcoma
patient
underw
radiotherapi
treatment
total
week
repeat
bronchoscopi
ct
thorax
show
reduct
tumour
size
repeat
spirometri
also
show
improv
level
airway
obstruct
fev
l
fvc
l
fev
fvc
post
treatment
current
well
clinic
followup
month
conclus
knowledg
report
case
synovi
sarcoma
endobronchi
tree
mainstay
treatment
soft
tissu
sarcoma
surgic
remov
tumour
patient
show
mark
improv
symptom
size
lesion
radiotherapi
treatment
background
aim
relationship
pharmacokinet
effect
gefitinib
patient
epiderm
growth
factor
receptor
egfr
mutat
nonsmal
cell
lung
cancer
nsclc
unknown
studi
examin
correl
gefitinib
plasma
concentr
progressionfre
surviv
pf
patient
two
common
type
egfr
mutat
delet
exon
point
mutat
exon
method
retrospect
analysi
examin
patient
administ
mg
gefitinib
daili
patient
diagnos
treat
advanc
clinic
stage
iiib
v
nonsmal
cell
lung
carcinoma
sensit
egfr
mutat
januari
novemb
akita
univers
hospit
akita
japan
day
treatment
initi
plasma
sampl
collect
prior
first
administr
gefitinib
plasma
concentr
gefitinib
measur
highperform
liquid
chromatographi
hplc
patient
divid
four
group
trough
plasma
concentr
high
low
mutat
type
exon
delet
exon
point
mutat
pf
respons
rate
toxic
effect
analyz
four
group
result
exclud
patient
remain
success
analyz
signific
differ
pf
exon
delet
exon
point
mutat
group
median
surviv
v
month
p
patient
exon
delet
signific
differ
pf
high
low
plasma
concentr
group
median
surviv
vs
month
p
contrast
pf
significantli
prolong
patient
exon
point
mutat
high
vs
low
concentr
gefitinib
median
surviv
vs
month
p
conclus
result
suggest
high
plasma
concentr
gefitinib
patient
egfr
exon
point
mutat
compar
low
plasma
concentr
pf
prolong
background
aim
malign
peripher
nerv
sheath
tumour
mpnst
rare
soft
tissu
malign
occur
variou
anatom
site
intrapulmonari
case
extrem
rare
case
poor
prognosi
often
need
aggress
surgic
intervent
method
case
nonsmok
woman
giant
intrapulmonari
mpnst
patient
came
right
chest
pain
dyspepsia
syndrom
diagnos
tuberculosi
abdomin
ultrasonographi
ct
scan
contrast
show
larg
spaceoccupi
lesion
open
biopsi
patholog
anatomi
examin
reveal
tip
mass
thorax
low
grade
sarcomampnst
grade
examin
thorac
ct
contrast
suggest
surgic
debulk
thoracotomi
refus
year
later
patient
came
sever
right
chest
pain
thorac
ct
scan
reveal
giant
solid
mass
x
x
cm
level
th
th
th
th
right
lung
segment
surgic
debulk
thoracotomi
main
treatment
histopathologyc
immunohistochem
examin
confirm
patient
giant
intrapulmonari
mpnst
low
prolifer
rate
almost
year
surgeri
patient
get
better
result
mpnst
less
sensit
radiotherapi
chemotherapi
surgic
debulk
thoracotomi
main
treatment
appropri
diagnosi
treatment
provid
earlier
better
outcom
background
aim
cancer
cachexia
affect
patient
advanc
cancer
account
nearli
cancerrel
death
despit
recent
advanc
understand
patholog
mechan
cancer
cachexia
therapeut
option
current
avail
ghrelin
endogen
ligand
growth
hormon
secretagogu
receptor
ghsr
produc
stomach
suppress
inflamm
prevent
muscl
catabol
stimul
food
intak
activ
npi
agrp
signal
hypothalamu
investig
express
energi
homeostasi
relat
molecul
stomach
hypothalamu
pharmacolog
potenti
ghrelin
treatment
cancer
cachexia
method
gener
postnat
bronchioalveol
epitheliumspecif
ptendelet
mous
strain
ptenko
administ
urethan
intraperiton
ptenko
wild
type
mice
ptenwt
ghrelin
pb
given
mice
daili
four
week
begin
five
month
urethan
inject
correspond
time
point
lung
adenocarcinoma
format
measur
ghrelin
level
mice
lung
cancer
patient
analyz
elisa
express
level
energi
homeostasi
relat
molecul
hypothalamu
examin
quantit
realtim
pcr
result
ptenko
mice
develop
lung
adenocarcinoma
plasma
ghrelin
level
ptenko
mice
lung
cancer
patient
undergo
chemotherapi
significantli
lower
ptenwt
mice
healthi
volunt
respect
ghrelintr
ptenko
mice
smaller
reduct
food
intak
bodi
weight
skelet
muscl
mass
intraabdomin
fat
weight
pbstreat
ptenko
mice
ghrelin
treatment
increas
express
level
npi
agrp
mrna
addit
ghrelin
restor
increas
level
proopiomelanocortin
pomc
cocain
amphetamin
regul
transcript
cart
mrna
hypothalamu
ptenko
mice
conclus
pleiotrop
effect
ghrelin
activ
npyagrp
signal
suppress
cytokin
level
hypothalamu
may
attract
therapeut
target
patient
cancer
cachexia
background
aim
smoke
lead
caus
lung
cancer
spontan
pneumothorax
smoker
surgic
hospit
like
good
motiv
quit
smoke
method
data
collect
respiratori
surgeri
patient
april
june
primari
lung
cancer
pgroup
case
metastat
lung
cancer
mgroup
case
spontan
pneumothorax
sgroup
case
smoke
histori
smokernonsmok
neversmok
number
cigarett
smoke
per
day
number
year
smoke
brinkman
index
bi
nicotin
depend
test
td
enforc
case
check
case
hospit
hospit
main
outcom
set
smoke
statu
prehospit
discharg
one
month
discharg
three
month
discharg
patient
smoke
oper
specif
given
attent
see
whether
postop
nonsmok
instruct
becom
motiv
quit
result
patient
smoke
histori
case
pgroup
case
mgroup
case
sgroup
pgroup
bi
averag
td
averag
patient
smoke
oper
case
pgroup
case
mgroup
case
sgroup
nonsmok
achiev
rate
postop
instruct
postop
three
month
pgroup
mgroup
sgroup
conclus
patient
achiev
nonsmok
statu
undergo
surgeri
given
postop
nonsmok
instruct
suggest
hospit
respiratori
surgeri
becom
motiv
smoker
quit
habit
introduct
herein
report
case
penil
mondor
diseas
rare
present
lung
adenocarcinoma
complic
trousseau
syndrom
case
present
man
present
hospit
nonproduct
cough
rash
lower
leg
one
month
two
month
recogn
funicular
palpabl
indur
penil
dorsal
surfac
color
doppler
sonographi
show
blood
flow
signal
superfici
dorsal
penil
vein
also
superfici
leg
vein
comput
tomographi
ffdg
pet
reveal
solitari
pulmonari
nodul
left
upper
lobe
multipl
lymphadenopathi
multipl
hepat
mass
transbronchi
biopsi
pulmonari
nodul
reveal
adenocarcinoma
epiderm
growth
factor
receptor
egfr
gene
mutat
delet
exon
final
patient
diagnos
stage
iv
adenocarcinoma
complic
trousseau
syndrom
afatinib
edoxaban
start
temporarili
effect
howev
multipl
cerebr
infarct
nonbacteri
thrombot
endocard
occur
edoxaban
chang
heparin
administr
heparin
recurr
thrombosi
discuss
penil
mondor
diseas
superfici
thrombophleb
dorsal
vein
peni
rare
clinic
diagnosi
knowledg
first
case
report
condit
associ
lung
cancer
risk
venou
thrombosi
lung
cancer
patient
increas
compar
gener
popul
retrospect
studi
report
preval
nonsmal
cell
lung
cancer
patient
migratori
superfici
thrombophleb
heparin
consid
firstchoic
agent
control
thrombosi
associ
trousseau
syndrom
conclus
patient
present
uniqu
trousseau
syndrom
caus
penil
mondor
diseas
primari
present
case
highlight
import
includ
trousseau
syndrom
etiolog
penil
mondor
diseas
background
aim
lung
cancer
patient
diagnos
advanc
stage
reason
delay
diagnosi
might
patient
andor
health
system
current
indonesia
nation
health
insur
system
jaminan
kesehatan
nasion
situat
made
increas
number
patient
come
referr
hospit
persahabatan
hospitalth
nation
referr
respiratori
diseas
maximum
time
interv
lung
cancer
diagnosi
set
two
week
howev
sever
case
delay
conduct
studi
evalu
time
diagnosi
time
lung
cancer
method
perform
simpl
observ
studi
persahabatan
hospit
jakarta
januari
fifti
new
patient
recruit
studi
evalu
long
time
need
first
visit
initi
diagnosi
histopatolog
obtain
also
evalu
factor
correl
procedur
diagnosi
result
fifti
patient
enrol
studi
thirti
five
fifti
male
femal
median
age
year
old
rang
year
old
data
shown
patient
diagnos
target
time
week
diagnost
time
week
diagnost
delay
correl
earli
stage
diseas
poor
perform
statu
respiratori
distress
conclus
stage
perform
statu
initi
present
respiratori
distress
associ
diagnosi
delay
lung
cancer
hospit
background
aim
new
target
therapi
egfrtki
recommend
firstlin
therapi
patient
nsclcc
nonsquam
mutat
egfr
data
efficaci
toxic
new
target
therapi
egfrtki
nsclc
nonsquam
patient
mutat
egfr
compar
chemotradiotherapi
wild
type
patient
persahabatan
hospit
jakarta
method
design
studi
retrospect
cohort
medic
record
nsclc
nonsquam
patient
depart
pulmonolog
respiratori
persahabatan
hospit
januari
juli
sampl
techniqu
consecut
patient
consist
patient
nsclc
nonsquam
mutat
egfr
treat
new
target
therapi
egfrtki
patient
egfr
wild
type
treat
chemoradiotherapi
result
characterist
nsclc
nonsquam
patient
mutat
egfr
mostli
nonsmok
equal
proport
exon
insertiondelet
exon
codon
mutat
surviv
mean
time
progress
ttp
day
patient
wildtyp
egfr
domin
male
smoker
surviv
mean
ttp
day
overal
surviv
day
independ
test
show
signific
relationship
new
target
therapi
egfrtki
ttp
p
common
advers
event
egfrtki
group
nausea
vomitu
diarrhea
alopecia
rash
chemotherapi
group
anemia
leucopenia
thrombocytopenia
conclus
efgrtki
treatment
patient
preselect
basi
egfr
mutat
improv
ttp
accept
toxic
background
aim
manag
lung
cancer
multimod
therapi
surgeri
chemotherapi
radiotherapi
target
therapi
tyrosin
kinas
inhibitor
indic
lung
adenocarcinoma
egfr
mutat
evalu
efficaci
timetoprogress
ttp
surviv
combin
gefitinib
radiotherapi
lung
adenocarcinoma
egfr
mutat
method
eight
patient
evalu
ongo
studi
male
femal
femal
patient
nonsmok
mutat
exon
delet
exon
point
mutat
result
gefitinib
given
rang
week
dose
radiat
given
rang
gy
data
shown
median
ttp
week
rang
week
median
overal
surviv
rang
week
one
femal
still
aliv
treat
chemotherapi
progres
diseas
other
hand
find
sever
toxic
gefitinib
conclus
efficaci
combin
gefitinib
radiaotherapi
similiar
median
surviv
advanc
stage
lung
cancer
background
aim
lung
cancer
third
common
cancer
report
malaysia
howev
pauciti
data
look
novel
profil
egfr
posit
mutat
lung
adenocarcinoma
patient
analysi
sought
look
specif
paramet
use
profil
egfr
posit
mutat
lung
adenocarcinoma
patient
malaysian
popul
method
dualcentr
prospect
analysi
baselin
subsequ
visit
patient
attend
uitm
selayang
uitm
sungai
buloh
respiratori
clinic
till
besid
clinic
assess
patient
given
appropri
treatment
patient
inform
clinic
data
obtain
uitm
clinic
onlin
system
analys
via
statist
packag
social
scienc
spss
softwar
statist
analysi
result
total
egfr
posit
lung
adenocarcinoma
ac
patient
male
femal
recruit
age
yo
n
malay
n
nonsmok
n
diagnos
via
ct
guid
biopsi
n
mutat
detect
delet
exon
patient
present
stage
iv
diseas
ecog
comorbid
cough
normal
bmi
famili
histori
cancer
normal
albumin
level
posit
ihc
opt
chemotherapi
conclus
find
inlin
previou
find
major
egfr
posit
lung
ac
patient
femal
nonsmok
new
find
patient
get
younger
normal
bmi
good
ecog
good
nutrit
statu
cachect
malnourish
find
explain
advanc
technolog
abl
detect
cancer
earlier
patient
progress
malnourish
state
becom
sever
symptomat
studi
still
earli
phase
statist
signific
data
yield
moment
signific
data
anticip
follow
futur
background
aim
epiderm
growth
factor
receptor
egfr
mutat
predict
marker
egfrtyrosin
kinas
inhibitor
tki
therapi
compar
sensit
egfr
mutat
detect
techniqu
match
tumor
tissu
peripher
blood
sampl
patient
lung
adenocarcinoma
method
collect
pair
sampl
plasma
paraffinembed
tumor
tissu
patient
egfrtki
dna
extract
perform
use
qiaamp
minelut
viru
spin
kit
egfr
mutat
analysi
done
two
detect
method
one
pnaclamp
tm
pnabas
pcr
clamp
select
amplifi
mutat
target
dna
sequenc
minor
portion
mixtur
major
wild
type
dna
sequenc
panamutyp
tm
egfr
kit
use
pna
clampingassist
fluoresc
melt
curv
analysi
perform
mutat
detect
genotyp
background
aim
failur
epiderm
growth
factor
receptortyrosin
kinas
inhibitor
egfrtki
rebiopsi
may
help
understand
resist
mechan
guid
treatment
decis
howev
rebiopsi
still
challeng
due
sever
hurdl
tissu
avail
procedur
feasibl
limit
new
drug
aim
studi
assess
feasibl
rebiopsi
advanc
nonsmal
cell
lung
cancer
nsclc
realworld
set
method
retrospect
review
clinic
patholog
data
advanc
nsclc
patient
diseas
progress
previou
egfrtki
singl
institut
januari
februari
result
nineti
one
patient
diseas
progress
use
egfrtki
among
thirti
three
patient
underw
rebiopsi
histolog
sampl
obtain
surgeri
case
bronchoscopi
case
ctguid
transthorac
needl
biopsi
case
lymph
node
excis
biopsi
case
cytolog
sampl
obtain
thoracentesi
case
pericardiocentesi
case
spinal
tap
case
one
patient
nt
get
malign
cell
three
patient
experienc
pneumothorax
howev
one
patient
requir
close
thoracostomi
rebiopsi
patient
perform
egfr
mutat
test
among
patient
activ
mutat
initi
mutat
found
case
mutat
found
case
case
initi
egfr
mutat
longer
found
patient
rebiopsi
younger
ae
vs
ae
p
longer
respons
durat
ae
vs
ae
p
patient
nt
conclus
rebiopsi
advanc
nsclc
feasibl
real
practic
especi
younger
patient
patient
longer
respons
durat
egfrtki
background
aim
determin
surviv
prognosi
defin
appropri
therapi
patient
lung
cancer
challeng
major
patient
diagnos
later
cancer
stage
object
studi
investig
effect
differ
treatment
group
surviv
malaysian
patient
live
end
stage
nonsmal
cell
lung
cancer
nsclc
method
retrospect
studi
medic
record
nsclc
patient
nsclc
patient
review
hospit
kuala
lumpur
malaysia
data
extract
relev
inform
selfdesign
data
abstract
form
result
treatment
group
case
case
chemotherapi
case
radiotherapi
review
wherea
case
includ
treatment
group
review
case
censor
case
ie
aliv
found
chemotherapi
convers
none
aliv
case
found
radiotherapi
treatment
group
estim
mean
time
event
death
occur
day
chemotherapi
day
radiotherapi
day
treatment
groupth
overal
mean
surviv
time
day
standard
error
day
median
surviv
time
treatment
death
day
chemotherapi
radiotherapi
treatment
group
respect
comparison
test
result
surviv
time
statist
signific
chisquar
p
among
differ
group
find
multivari
analysi
keep
treatment
group
refer
suggest
death
proport
hazard
patient
undergo
chemotherapi
time
lower
undergo
radiotherapi
time
lower
patient
treatment
group
conclus
result
indic
improv
surviv
patient
undergo
chemotherapi
radiotherapi
compar
patient
treatment
end
stage
diseas
background
aim
subclin
activ
coagul
fibrinolysi
system
lung
cancer
alter
hemostat
system
seen
frequent
lung
cancer
correl
prognosi
diseas
oncolog
practic
use
tumor
marker
may
help
diagnosi
patholog
classif
tumor
tumor
marker
may
reflect
stage
diseas
prognosi
aim
research
see
relationship
paramet
chemoterapi
patient
lung
cancer
method
rectropect
studi
lung
cancer
patient
underw
chemotherapi
haji
adam
malik
gener
hospit
januari
march
measur
serum
level
hemostat
paramet
pt
inr
aptt
tt
control
ddimer
ngml
tumor
marker
cea
ngml
ngml
nse
ngml
st
cycl
chemotherapi
th
th
cycl
chemotherapi
result
patient
found
serum
level
hemostat
paramet
significantli
correl
serum
level
tumor
marker
pt
r
inr
r
aptt
r
tt
r
ddimer
r
sig
f
chang
signific
conclus
signific
correl
hemostat
paramet
tumor
marker
patient
underw
chemotherapi
studi
longer
followup
period
need
make
better
conclus
method
man
without
past
medic
histori
present
dri
cough
occasion
wheez
year
treat
allerg
rhiniti
gastroesophag
reflux
diseas
symptom
improv
came
siriraj
hospit
due
persist
cough
non
massiv
hemoptysi
day
physic
examin
reveal
rhonchi
lower
part
left
lung
chest
radiograph
demonstr
abnorm
comput
tomographi
chest
show
enhanc
mass
protrud
left
main
bronchu
cm
size
bronchoscop
find
demonstr
endobronchi
mass
left
main
bronchu
tissu
biopsi
compat
mec
patient
underw
left
lower
lung
sleev
lobectomi
histopatholog
examin
reveal
intermediategrad
mec
tumorfre
margin
lymph
node
metastas
postop
cours
good
without
sign
tumor
recurr
adjuv
treatment
given
result
mec
lung
rare
malign
usual
aris
mainstem
bronchi
lowgrad
tumor
long
natur
histori
rare
metastas
highgrad
tumor
aggress
prone
local
invas
earli
metastasi
radic
surgeri
lymph
node
dissect
treatment
choic
mec
patient
low
intermedi
grade
tumor
expect
cure
follow
complet
resect
patient
adjuv
therapi
indic
object
compar
clinic
characterist
consequ
uncommon
common
egfr
mutat
advanc
stage
adenocarcinoma
lung
method
histor
cohort
studi
conduct
songklanagarind
hospit
june
decemb
patient
patholog
confirm
advanc
stage
lung
adenocarcinoma
posit
egfr
mutat
treat
songklanagarind
hospit
includ
clinic
characterist
outcom
followup
data
includ
overal
surviv
respons
firstlin
treatment
analyz
compar
purpos
two
group
uncommon
common
egfr
mutat
result
nineti
patient
elig
analysi
common
uncommon
mutat
confirm
patient
respect
baselin
clinic
characterist
ie
mean
age
gender
smoke
histori
perform
statu
differ
group
patient
uncommon
egfr
mutat
associ
significantli
shorter
surviv
month
patient
common
egfr
mutat
month
p
moreov
respons
firstlin
treatment
patient
uncommon
egfr
mutat
significantli
less
common
egfr
mutat
versu
p
conclus
differ
clinic
characterist
uncommon
versu
common
egfr
mutat
note
advanc
stage
adenocarcinoma
lung
patient
howev
patient
uncommon
egfr
mutat
associ
significantli
shorter
surviv
decreas
respons
firstlin
treatment
compar
common
egfr
mutat
background
aim
ppnet
smallblueroundcel
malign
neuroectoderm
origin
consid
member
ewingpnet
famili
tumor
predominantli
aris
soft
tissu
bone
thorac
region
tumor
commonli
seen
origin
chest
wall
askintumor
pulmonari
ppnet
highli
malign
poor
prognosi
extrem
rare
case
describ
english
literatur
literatur
review
show
male
predomin
mean
age
year
tumor
describ
larg
aris
peripher
parenchyma
cough
fever
dyspnea
chest
pain
present
symptom
differenti
diagnosi
thorac
ppnet
includ
small
cell
carcinoma
small
roundcel
tumor
histochem
immunohistochem
studi
perform
confirm
diagnosi
posit
suggest
ppnet
ppnet
also
character
presenc
reciproc
transloc
cytogenet
studi
treatment
choic
combin
radic
surgic
resect
neoadjuv
adjuv
chemotherapi
irradi
casereport
describ
ppnet
lung
girl
rapid
progress
diseas
lethal
outcom
method
case
femal
child
refer
dyspnea
fever
cough
chest
radiograph
show
right
hemithorax
opac
computedtomograph
scan
show
welldefin
heterogen
enhanc
mass
lesion
measur
cm
lymphadenopathi
effus
histochem
studi
follow
ultrasound
guid
transthorac
biopsi
show
small
round
tumor
cell
arrang
sheet
high
nucleocytoplasm
ratio
background
necrot
debri
suggest
malign
round
cell
tumor
result
immunohistochemistri
show
vimentin
posit
confirm
diagnosi
ppnet
lung
surgeri
along
chemoradiootherapi
plan
patient
die
initi
conclus
normal
fals
fals
fals
enu
ja
xnone
immunohistochemistri
help
tremend
differenti
diagnosi
small
round
cell
tumor
lung
facilit
earli
manag
pulmonari
pnet
aggress
neoplasm
high
mortal
rate
treatment
choic
earli
surgic
remov
intens
chemoradiotherapi
prognosi
remain
dismal
background
aim
epiderm
growth
factor
receptor
egfr
mutat
common
mechan
acquir
resist
egfrtyrosin
kinas
inhibitor
tki
studi
analyz
statu
clinic
cours
patient
underw
rebiopsi
acquir
resist
egfrtki
method
investig
patient
harbor
egfrsensit
mutat
examin
emerg
tki
failur
peptid
nucleic
acidlock
nucleic
acid
polymeras
chain
reaction
clamp
method
use
egfr
mutat
analys
patient
characterist
age
gender
histolog
clinic
stage
egfr
mutat
site
progressionfre
surviv
initi
tki
rebiopsi
site
genet
chang
analyz
result
patient
male
femal
median
age
year
patient
activ
egfr
mutat
six
exon
delet
mutat
exon
point
mutat
develop
resist
egfrtki
identifi
six
lesion
lung
tissu
pleural
effus
pericardi
effus
detect
central
nervou
system
cerebrospin
fluid
patient
underw
anoth
biopsi
failur
system
chemotherapi
statu
chang
posit
neg
result
abl
select
egfrtki
rechalleng
treatment
patient
although
invas
biopsi
associ
risk
encount
signific
complic
seri
patient
conclus
tumor
rebiopsi
perform
develop
resist
egfrtki
identifi
best
treatment
option
patient
background
aim
prospect
evalu
efficaci
toxic
nonplatinum
triplet
regimen
consist
paclitaxel
irinotecan
bevacizumab
patient
advanc
nonsmal
cell
lung
cancer
nsclc
expect
platinum
resist
method
patient
diagnos
nsclc
use
endobronchi
ultrasonographi
guid
sheath
ebusg
system
defin
ebusg
core
biopsi
rna
immedi
isol
unfix
biopsi
specimen
quantit
realtim
revers
transcriptas
pcr
assay
perform
determin
excis
repair
crosscompl
mrna
express
patient
advanc
untreat
nsclc
show
high
level
enter
phase
ii
trial
nonplatinum
triplet
regimen
paclitaxel
mg
day
irinotecan
day
bevacizumab
mgkg
day
administ
everi
week
primari
end
point
object
respons
rate
orr
assum
standard
therapi
target
therapi
estim
requir
total
number
patient
simon
optim
twostag
design
result
total
untreat
patient
receiv
ebusg
evalu
express
patient
enter
trial
orr
median
progressionfre
surviv
day
grade
thrombosi
occur
one
patient
toxic
mild
fiftythre
patient
treat
platinumcontain
regimen
patient
respond
orr
ci
twentythre
patient
high
level
patient
respond
patient
low
level
patient
respond
p
fisher
exact
test
conclus
triplet
combin
paclitaxel
irinotecan
bevacizumab
might
effect
patient
advanc
untreat
nsclc
overexpress
mrna
level
extract
unfix
lung
biopsi
specimen
obtain
ebusg
also
might
predict
factor
platinumcontain
regimen
background
aim
larg
scale
health
data
collect
attract
much
recent
interest
administr
databas
provid
sourc
data
studi
lung
cancer
surviv
practic
pattern
multidisciplinari
care
adher
guidelin
australia
routin
collect
data
goe
governmentrun
repositori
gener
avail
clinician
data
often
sever
year
old
tailor
need
clinician
rational
descript
studi
three
main
object
character
relev
lung
cancer
data
repositori
australia
natur
data
collect
pattern
data
flow
linkag
repositori
barrier
access
ii
identifi
particular
gap
inconsist
includ
rang
data
collect
miss
crucial
data
item
tnm
stage
comorbid
populationbas
dataset
age
inform
collect
time
delay
access
failur
link
data
individu
case
separ
dataset
iii
identifi
potenti
innov
data
strategi
clinician
includ
routin
collect
small
prospect
realtim
dataset
highli
relev
readili
avail
feedback
clinic
practic
set
method
exist
databas
registri
australia
canvass
publicli
avail
sourc
includ
databas
websit
registri
websit
public
research
output
posit
paper
relev
data
custodian
contact
question
content
remit
linkag
databas
test
data
question
develop
applic
current
set
identifi
key
data
gap
clinic
practic
exampl
proport
stage
iiia
lung
cancer
patient
australia
treatment
includ
curativeint
surgeri
result
conclus
result
studi
help
clinician
understand
strength
limit
current
avail
dataset
relev
lung
cancer
help
build
strategi
improv
access
relev
data
lung
cancer
clinic
care
australia
background
aim
efficaci
fdg
petct
controversi
region
endem
granulomat
diseas
accuraci
specif
fdg
pet
substanti
reduc
fals
increas
fdg
uptak
inflammatori
node
aim
studi
evalu
qualit
interpret
fdgpetct
evalu
mediastin
node
distinguish
malign
benign
lesion
compar
qualit
fdgpetct
paramet
method
sixtyf
patient
patholog
document
nonsmal
cell
lung
carcinoma
show
bilater
fdg
avid
mediastin
lymph
node
pretreat
stage
fdg
petct
imag
includ
prospect
cohort
studi
seventynin
mediastin
node
patholog
analyz
endobronchi
ultrasound
transbronchi
needl
aspir
lymph
node
dissect
suvmax
suvmaxliv
suvmax
blood
pool
suvmaxcontra
suvmax
significantli
hypermetabol
lymph
node
adjust
suvmax
contralater
interlobar
hilar
lymph
node
increas
glucos
metabol
obtain
quantit
paramet
identifi
metastat
mediastin
node
result
qualit
evalu
show
sensit
specif
posit
predict
valu
neg
predict
valu
separ
metastat
lymph
node
benign
reactiv
hyperplasia
suvmax
normal
suvmax
liver
blood
pool
significantli
differenti
benign
metastat
lesion
howev
suvmaxcontra
significantli
higher
metastat
lesion
benign
lesion
p
recieveroperatingcharacterist
deriv
suvmax
contra
cutoff
area
curv
sensit
specif
conclus
qualit
interpret
fdg
petct
superior
quantit
paramet
discrimin
metastat
lymph
node
benign
reactiv
hyperplasia
patient
bilater
fdg
avid
mediastin
lymph
node
suvmaxcontra
better
sensit
specif
suvmax
suvmaxliv
suvmaxblood
pool
background
aim
lung
cancer
second
highest
case
tb
incid
preval
pulmonolog
depart
dr
soetomo
gener
hospit
sinc
lung
cancer
uniqu
dynam
chang
type
cell
sex
age
object
understand
lung
cancer
distribut
pattern
base
gender
age
patient
histopatholog
type
lung
cancer
method
descript
analyt
studi
use
crosssect
design
data
retriev
medic
record
among
patient
admit
lung
ward
dr
soetomo
gener
hospit
januari
may
result
research
reveal
preval
lung
cancer
januarimay
period
patient
lung
cancer
frequent
male
femal
male
vs
femal
base
age
span
lung
cancer
patient
admit
lung
ward
group
year
old
patient
base
cell
type
common
cellfind
histopatholog
diagnost
adenocarcinoma
patient
follow
squamou
cell
carcinoma
patient
larg
cell
lung
carcinoma
patient
least
small
cell
lung
carcinoma
patient
conclus
lung
cancer
three
time
frequent
men
women
women
lung
cancer
younger
men
smoke
less
intens
overrepresent
adenocarcinoma
observ
women
squamou
cell
carcinoma
often
found
men
women
lung
cancer
better
prognosi
men
background
aim
ectop
thymoma
account
less
thymoma
occur
neck
posterior
middl
mediastinum
lung
pleura
rare
present
huge
pulmonari
mass
method
rare
case
giant
intrathorac
ectop
thymoma
signific
respons
chemoradiotherapi
describ
yearold
male
consult
hospit
two
giant
lesion
left
hemi
thorax
detect
chest
comput
tomographi
ct
histori
histori
cough
dyspnea
chest
pain
fatigu
chest
ct
show
paramediastin
welldefin
soft
tissu
mass
cm
anterior
left
upper
lobe
anoth
mass
cm
cm
superior
segment
left
lower
lobe
extend
hilum
level
hemi
diaphragm
cm
sub
pleural
nodul
posterior
segment
left
upper
lobe
definit
diagnosi
could
made
two
transthorac
needl
biopsi
local
hospit
progress
lesion
thoracotomi
perform
multipl
biopsi
center
thoracotomi
lesion
found
unresect
due
invas
chest
wall
mediastinum
major
vascular
structur
histolog
mass
consist
type
type
thymoma
larg
volum
lesion
first
treat
chemotherapi
cours
etoposid
cisplatin
respons
chemotherapi
partial
receiv
extern
radiotherapi
dose
fraction
good
partial
respons
obtain
ct
scan
thorax
four
month
radiotherapi
conclus
patient
present
intrathorac
giant
mass
ectop
thymoma
consid
differenti
diagnosi
akita
univers
graduat
school
medicin
cardiovascular
respiratori
medicin
akita
japan
akita
univers
graduat
school
health
scienc
physic
therapi
akita
japan
background
aim
tumor
angiogenesi
import
relat
growth
metastasi
lung
cancer
number
endotheli
progenitor
cell
epc
angiogenesi
marker
differenti
tumor
vessel
high
concentr
epc
associ
acceler
angiogenesi
evalu
relationship
number
epc
treat
chemotherapi
combin
bevacizumab
cur
effect
nonsmal
nonsquam
lung
cancer
patient
method
untreat
patient
diagnos
nonsmal
nonsquam
lung
cancer
enrol
epc
defin
antibodi
posit
vascular
endotheli
growth
factor
antibodi
posit
flow
cytometri
use
measur
number
circul
epc
peripher
blood
chemotherapi
patient
divid
two
group
rel
level
epc
high
epc
group
low
epc
group
group
compar
tumor
reduct
ratio
progressionfre
surviv
object
respons
ratio
diseas
control
ratio
without
administ
bevacizumab
combin
result
low
epc
group
signific
differ
tumor
reduct
ratio
progressionfre
surviv
object
respons
ratio
diseas
control
ratio
presenc
absenc
bevacizumab
howev
high
epc
group
chemotherapi
combin
bevacizumab
produc
higher
tumor
reduct
ratio
longer
progressionfre
surviv
compar
absenc
bevacizumab
conclus
nonsmal
nonsquam
lung
cancer
effect
chemotherapi
may
improv
patient
high
epc
combin
bevacizumab
showa
univers
divis
respiratori
medicin
allergologydepart
intern
medicin
tokyo
japan
showa
univers
depart
medicinedivis
medic
oncolog
tokyo
japan
showa
univers
institut
molecular
oncolog
tokyo
japan
background
aim
lung
cancer
patient
diagnos
age
elderli
patient
higher
risk
treatmentrel
death
toxicityth
aim
present
studi
assess
antitumor
activ
toxic
chemotherapi
elderli
patient
previous
untreat
sclc
retrospect
method
jarnuray
decemb
patient
sclc
year
older
treat
chemotherapi
showa
univers
result
median
age
patient
year
rang
year
patient
limit
diseas
patient
extens
diseas
chemotherapi
regimen
carboplatin
etoposid
concurrenttrt
n
cisplatin
etoposid
concurrenttrt
n
carboplatin
etoposid
n
cisplatin
etoposid
n
carboplatin
irinoteecan
n
etoposid
alon
n
irinotecan
alon
n
overal
respons
rate
ci
median
surviv
time
month
median
progress
free
surviv
time
month
grade
hematolog
toxic
includ
neutropenia
patient
thrombocytopenia
anemia
grade
nonhematolog
toxic
includ
diarrhea
patient
infect
appetit
loss
treatmentrel
death
due
infect
drug
induc
pneumon
conclus
combin
chemotherapi
effect
sclc
toler
elderli
patient
background
aim
thymic
larg
cell
neuroendocrin
carcinoma
belong
subgroup
thymic
carcinoid
part
thymic
carcinoma
accord
classif
poorli
differenti
categori
thu
far
report
incid
thymic
carcinoid
male
preponder
symptomat
two
third
case
describ
first
local
encount
rare
tumour
share
experi
clinch
diagnosi
review
past
literatur
rare
case
result
man
came
tertiari
hospit
histori
hoars
voic
associ
dri
cough
first
assess
otorhinolaryngologist
laryngoscopi
reveal
paralysi
left
vocal
cord
subsequ
comput
tomographi
ct
imag
demonstr
anterior
mediastin
mass
x
x
cm
compress
recurr
laryng
nerv
left
pleural
effus
figur
succeed
ultrasound
guid
biopsi
mass
confirm
diagnosi
thymic
larg
cell
neuroendocrin
tumour
index
option
surgic
resect
follow
adjuv
chemoradi
explor
nonetheless
opt
tradit
treatment
two
month
later
present
us
acut
dyspnoea
complic
cardiac
tamponad
succumb
death
due
sever
respiratori
distress
conclus
larg
cell
neuroendocrin
thymic
carcinoma
subcategori
carri
worst
prognosi
italian
case
seri
tenyear
surviv
rate
document
difficult
diagnos
via
standard
needl
biopsi
due
inhomogen
natur
thymic
mass
although
thymic
carcinoid
recogn
nearli
half
centuri
ago
till
date
standardis
treatment
modal
case
highlight
aggress
natur
diseas
dismal
outcom
hope
stir
continu
search
optim
manag
strategi
type
malign
howev
addit
celecoxib
chemotherapi
clinic
trial
fail
benefit
surviv
nsclc
patient
studi
reevalu
therapeut
potenti
celecoxib
nsclc
herein
attempt
examin
cellular
impact
celecoxib
nsclc
cell
particular
emt
process
method
evalu
efficaci
celecoxib
depend
amount
dose
emt
emtrel
molecular
alter
detect
western
blot
eci
addit
akt
knock
overexpress
determin
role
prevent
emt
celecoxib
result
celecoxib
high
dose
effect
prevent
emt
indic
upregul
ecadherin
downregul
mesenchym
marker
transcript
factor
hand
celecoxib
low
dose
rather
promot
emt
found
phophokinas
array
kit
differ
effect
result
two
differ
dose
celecoxib
use
relat
stat
akt
protein
addit
akt
downregul
enhanc
revers
emt
high
dose
celecoxib
contrast
akt
upregul
relev
role
emt
conclus
differ
dose
celecoxib
use
show
opposit
effect
emt
akt
pathway
show
first
time
molecular
mechan
underli
efficaci
celecoxib
nsclc
cell
background
aim
randomis
control
trial
demonstr
firstlin
pemetrex
combin
platinum
effect
firstlin
gemcitabin
combin
platinum
advanc
lung
adenocarcinoma
date
studi
malaysia
compar
efficaci
pemetrex
versu
gemcitabin
combin
platinum
firstlin
treatment
advanc
lung
adenocarcinoma
studi
aim
compar
progressionfre
surviv
pf
overal
surviv
os
object
respons
rate
orr
diseas
control
rate
dcr
malaysian
patient
advanc
lung
adenocarcinoma
receiv
firstlin
chemotherapi
pemetrexedcarboplatin
versu
gemcitabinecarboplatin
conclus
malaysian
patient
advanc
lung
adenocarcinoma
appear
similar
pf
os
orr
dcr
irrespect
whether
receiv
pemetrexedcarboplatin
gemcitabinecarboplatin
firstlin
treatment
howev
appar
lack
differ
could
due
small
sampl
size
background
aim
famili
histori
valuabl
tool
era
big
data
genom
medicin
studi
report
associ
famili
histori
lung
cancer
egfr
activ
mutat
howev
impact
surviv
lung
cancer
patient
remain
investig
method
consecut
patient
histolog
diagnos
nonsmallcel
lung
cancer
januari
januari
receiv
analysi
egfr
activ
mutat
prospect
lung
cancer
cohort
includ
studi
associ
egfr
mutat
famili
histori
lung
cancer
firstdegre
rel
evalu
multivari
logist
regress
analysi
impact
surviv
patient
famili
histori
estim
cox
proport
hazard
model
result
seventi
five
patient
famili
histori
lung
cancer
egfr
mutat
commonli
observ
patient
famili
histori
compar
without
famili
histori
v
p
famili
histori
shown
significantli
associ
egfr
mutat
aor
ci
p
patient
famili
histori
margin
longer
surviv
compar
without
famili
histori
mst
v
month
logrank
p
presenc
egfr
mutat
signific
impact
surviv
patient
without
famili
histori
ahr
ci
p
impact
observ
patient
famili
histori
ahr
ci
p
conclus
famili
histori
lung
cancer
associ
preval
egfr
mutat
may
modifi
impact
egfr
mutat
surviv
lung
cancer
patient
background
aim
epigenet
rais
hallmark
cancer
last
decad
play
key
role
function
regul
gene
without
alter
nucleotid
sequenc
object
studi
develop
detect
quantif
modif
dna
methyl
earli
cancer
diagnost
test
method
oligonucleotid
design
base
bisulfit
modif
method
use
methyl
probe
contain
methyl
cytosin
mc
unmethyl
probe
contain
thymin
instead
uracil
base
previou
studi
ref
shin
et
al
methyl
unmethyl
target
complementari
sequenc
methyl
unmethyl
probe
respect
dna
target
bind
analysi
oligonucleotid
dissolv
dnase
rnase
free
water
methyl
unmethyl
target
ad
methyl
unmethyl
probe
ratio
mixtur
incub
min
room
temperatur
hybrid
raman
spectroscopi
raman
spectra
bench
top
type
taken
use
spectroscopi
bruko
german
diod
laser
beam
excit
wavelength
nm
bench
top
raman
scatter
light
signal
collect
object
len
laser
sourc
power
mw
focus
sampl
spot
diamet
result
observ
raman
spectra
met
methyl
probe
similar
unmet
unmethyl
probe
like
raman
spectra
met
target
similar
unmet
target
consid
mixtur
shown
figur
also
differenti
other
conclus
raman
detect
system
help
develop
pointofcaretest
diagnost
chip
dna
methyl
detect
clinic
cancer
research
background
aim
atrial
fibril
common
arrhytmia
preval
increas
age
cardiac
rhythm
disturb
common
concern
among
patient
neoplast
diseas
arrhytmia
may
due
effect
tumor
extrins
compress
heart
involv
coronari
vasculatur
treatment
neoplast
process
metabol
autonom
instabl
relationship
chemotherapi
arrhytmia
well
establish
monitor
would
prudent
lung
cancer
patient
atrial
fibril
receiv
chemotherapi
balines
male
present
dyspnea
dizzi
palpit
cough
examin
reveal
mass
right
upper
chest
atrial
fibril
postur
drop
blood
pressur
ct
scan
thorax
show
hyperdens
mass
high
contrast
enhanc
right
pleural
effus
metastat
process
sternum
corpu
vertebra
thorac
biopsi
mass
chest
reveal
squamou
cell
carcinoma
treat
system
chemotherapi
use
carboplatin
vinorelbin
follow
treatment
patient
experienc
progress
atrial
fibril
discuss
treatment
lung
cancer
chemotherapi
patient
atrial
fibril
done
close
monitor
chemotherapi
agent
chosen
base
report
regard
atrial
fibril
induc
cancer
chemotherapi
incid
sever
drug
induc
atrial
fibril
depend
drug
use
dose
schedul
employ
particularli
combin
therapi
age
patient
presenc
arrhythmogen
substrat
creat
cancer
andor
chemotherapi
regimen
chosen
combin
carboplatin
vinorelbin
less
atrial
fibril
side
effect
background
aim
pulmonari
embol
potenti
lifethreaten
complic
lung
cancer
surgeri
remain
difficult
challeng
thorac
surgeon
purpos
studi
assess
measur
ddimer
concentr
preoper
screen
test
venou
thromboembol
patient
nonsmal
cell
lung
cancer
method
august
decemb
preoper
ddimer
plasma
concentr
determin
patient
nonsmal
cell
lung
cancer
underw
surgeri
male
femal
patient
median
age
year
patholog
diagnosi
adenocarcinoma
patient
squamou
cell
carcinoma
patholog
stage
patient
stage
stage
ii
stage
iii
diseas
ddimer
concentr
determin
use
latex
agglutin
assay
lower
limb
venou
ultrasonographi
perform
patient
ddimer
plasma
concentr
higher
cutoff
valu
result
median
preoper
ddimer
concentr
rang
patient
ddimer
concentr
higher
cutoff
valu
posit
deep
vein
thrombosi
venou
ultrasonographi
anticoagul
therapi
administ
patient
postop
period
high
risk
pulmonari
embol
none
studi
patient
develop
postop
pulmonari
embol
conclus
preoper
measur
ddimer
concentr
lung
cancer
patient
may
use
screen
method
identifi
patient
high
risk
pulmonari
embol
background
aim
risk
malign
increas
person
live
hiv
plhiv
lung
cancer
incid
increas
twofold
plhiv
pulmonari
adenocarcinoma
repres
major
nonaid
defin
lesion
concurr
use
cytotox
chemotherapi
antiretrovir
therapi
art
may
result
addit
cytotox
drugdrug
interact
may
enhanc
immunosuppress
date
data
exist
efficaci
toxic
chemotherapi
method
report
case
lung
adenocarcinoma
plhiv
filipino
male
present
histori
product
cough
initi
treat
clinicallydiagnos
pulmonari
tuberculosi
progress
sign
symptom
diagnost
workup
reveal
hivposit
result
cellul
cell
count
also
present
rightsid
pleural
effus
cell
block
cytolog
reveal
adenocarcinoma
egfrposit
patient
present
two
major
problem
need
prompt
treatment
start
oral
chemotherapeut
agent
erlotinib
antiretrovir
therapi
regimen
zidovudinelamivudineefeverenz
result
presenc
activ
mutat
within
epiderm
growth
factor
receptor
egfr
gene
lung
cancer
cell
make
tumor
highli
sensit
egfrtarget
tyrosin
kinas
inhibitor
tki
erlotinib
gefitinib
mutat
incid
hivassoci
lung
cancer
known
data
exist
chemotherapi
ongo
antiretrovir
therapi
revers
immunosuppress
plhiv
import
median
surviv
improv
cell
count
simultan
use
arv
chemotherapeut
agent
challeng
due
signific
increas
myelosuppress
efavirenz
could
potenti
decreas
erlotinib
concentr
concurr
arv
expect
exacerb
side
effect
chemotherapi
perhap
make
cancer
therapi
intoler
conclus
import
consid
choic
chemotherapi
antiretrovir
treatment
manag
lung
adenocarcinoma
plhiv
strict
monitor
done
note
drug
interact
minim
prevent
advers
interact
therebi
provid
optim
treatment
diseas
background
aim
imbal
endogen
proteas
inhibitor
proteas
one
critic
mechan
chronic
obstruct
pulmonari
diseas
copd
cystatin
c
classic
inhibitor
endogen
cystein
proteas
associ
copd
limit
studi
aim
investig
serum
level
cystatin
c
copd
patient
discuss
potenti
clinic
signific
method
serum
sampl
collect
copd
health
control
subject
finish
standard
lung
function
test
serum
level
cystatin
c
creactiv
protein
determin
relationship
cystatin
c
concentr
lung
function
crp
indic
assess
pearson
correl
test
result
mean
serum
level
cystatin
c
significantli
higher
copd
patient
control
ae
versu
ae
mgl
p
serum
level
crp
also
significantli
higher
copd
patient
ae
versu
ae
mgl
p
serum
level
cystatin
c
copd
patient
correl
invers
predict
index
lung
function
r
p
correl
posit
creactiv
protein
level
indic
system
inflamm
r
p
copd
assess
test
score
r
p
conclus
result
suggest
serum
level
cystatin
c
increas
copd
patient
associ
lung
function
copd
assess
test
score
system
inflamm
copd
patient
futur
studi
perform
determin
cystatin
c
play
role
copd
ebihara
tokai
univers
tokyo
hospit
pulmonolog
tokyo
japan
background
aim
bronchial
asthma
patient
smoke
histori
number
patient
includ
ratio
copd
new
phenotyp
call
asthma
copd
overlap
syndrom
aco
elder
patient
year
seem
difficult
differenti
asthma
copd
studi
asthma
patient
smoke
histori
went
whether
retrospect
analysi
much
aco
includ
method
total
subject
male
femal
age
year
old
year
old
ae
sd
enrol
studi
inform
consent
obtain
juli
august
erimo
town
clinic
hokkaidoit
retrospect
studi
analysi
perform
asthma
control
statu
medic
histori
smoke
histori
result
control
state
mild
intermitt
type
mild
persist
type
moder
persist
sever
persist
medic
histori
ic
singl
agent
peopl
ic
saba
ic
laba
ic
leukotrien
antagonist
ic
saba
leukotrien
ic
laba
leukotrien
theophyllin
addit
lama
five
conclus
concept
aco
mani
case
treat
separ
asthma
copd
among
aco
expect
uncontrol
asthma
patientsin
treatment
elderli
patient
asthma
suggest
need
aggress
use
lama
consider
aco
background
aim
cigarett
smoke
cs
exposur
associ
increas
risk
copd
level
inflamm
high
lung
tissu
copd
patient
receptor
advanc
glycat
end
product
rage
multiligand
receptor
amplifi
inflammatori
respons
studi
investig
role
rage
signal
proinflammatori
respons
induc
cs
method
widetyp
balbc
wt
mice
rage
knockout
ko
mice
expos
mainstream
cs
room
air
hour
twice
daili
day
per
week
week
bronchoalveolar
lavag
fluid
balf
acquir
cell
count
measur
proinflammatori
cytokin
level
lung
tissu
collect
histolog
examin
gene
express
profil
affymetrix
mous
genom
genechip
result
compar
shamexpos
control
neutrophil
count
proinflammatori
cytokin
level
balf
significantli
increas
cs
exposur
wildtyp
mice
well
csinduc
thicken
airway
epithelium
peribronchi
inflammatori
cell
infiltr
airway
obstruct
howev
knockout
rage
significantli
attenu
csinduc
inflammatori
respons
histolog
alter
mous
airway
furthermor
compar
cs
wt
mice
total
upregul
gene
downregul
gene
cs
ko
well
time
rage
common
ligand
decreas
conclus
result
suggest
rage
signal
potenti
import
therapeut
target
contribut
significantli
cigarett
smokeinduc
lung
system
inflamm
acknowledg
studi
support
part
grant
nation
natur
scienc
foundat
china
grant
scienc
foundat
outstand
young
scholar
sichuan
univers
background
aim
irisin
one
myokin
newli
identifi
hormon
secret
skelet
muscl
irisin
propos
mediat
variou
benefici
effect
metabol
disord
diabet
mellitu
osteoporosi
cachexia
sarcopenia
loss
skelet
muscl
mass
strength
one
comorbid
chronic
obstruct
pulmonari
diseas
copd
subject
might
lead
poor
qol
prognosi
studi
design
evalu
irisin
level
copd
subject
sarcopenia
examin
relationship
irisin
level
pulmonari
function
measur
copd
subject
method
twentysix
stabl
male
copd
subject
enrol
pulmonari
function
test
perform
bodi
composit
evalu
bioimped
method
bia
sarcopenia
defin
skelet
muscl
index
smi
peripher
blood
irisin
level
measur
elisa
result
irisin
level
significantli
correl
muscl
mass
fat
free
mass
ffm
fat
free
mass
index
ffmi
bodi
mass
index
bmi
howev
differ
irisin
level
copd
subject
without
sarcopenia
reach
statist
signific
subject
stratifi
algorithm
includ
smi
grip
strength
irisin
level
significantli
correl
dlva
correl
fvc
conclus
irisin
level
relat
loss
muscl
mass
copd
subject
furthermor
irisin
level
relat
impair
pulmonari
function
copd
subject
irisin
might
biomark
musclepulmonari
vice
versa
interact
copd
subject
investig
desir
background
aim
st
georg
respiratori
questionnair
score
sgrq
develop
instrument
assess
health
statu
patient
copd
longitudin
chang
health
statu
well
describ
less
known
baselin
characterist
patient
deterior
health
statu
mild
moder
copd
studi
aim
investig
baselin
characterist
aggrav
sgrq
group
identifi
factor
associ
aggrav
chang
sgrq
score
method
st
georg
respiratori
questionnair
score
sgrq
develop
instrument
assess
health
statu
patient
copd
longitudin
chang
health
statu
well
describ
less
known
baselin
characterist
patient
deterior
health
statu
mild
moder
copd
studi
aim
investig
baselin
characterist
aggrav
sgrq
group
identifi
factor
associ
aggrav
chang
sgrq
score
result
total
patient
belong
improv
group
patient
stabl
group
aggrav
group
compar
baselin
characterist
group
deterior
group
lower
group
p
modifi
medic
research
council
mmrc
score
higher
significantli
p
use
anova
test
addit
risk
factor
deterior
sgrq
group
mmrc
p
acut
exacerb
p
logist
regress
analysi
analyz
year
chang
paramet
group
bmi
decreas
mmrc
increas
significantli
deterior
group
deterior
group
acut
exacerb
frequent
odd
ratio
confid
interv
p
conclus
predictor
sgrq
aggrav
lower
p
higher
mmrc
p
baselin
acut
exacerb
follow
period
background
aim
exacerb
common
caus
hospit
admiss
copd
vari
sever
increas
health
care
cost
lead
decreas
qualiti
life
diminish
lung
function
weak
reexacerb
rehospit
even
death
accur
prognost
tool
acut
exacerb
help
assess
appropri
manag
improv
outcom
howev
prognost
tool
exacerb
limit
bourk
etal
nafa
etal
studi
show
decaf
score
promis
tool
aecopd
simpl
effect
predictor
mortal
aim
studi
valid
decaf
score
promis
prognost
tool
aecopd
compar
accuraci
decaf
score
versu
predict
mortal
risk
among
aecopd
method
aecopd
patient
admit
august
august
invit
particip
studi
voluntarili
inform
would
keep
confidenti
particip
assess
stratifi
use
decaf
score
predict
mortal
risk
th
day
length
hospit
stay
time
next
exacerb
statist
analysi
done
use
epi
spss
pearson
chisquar
anova
analysi
result
pictur
copd
patient
csmc
similar
world
elderi
x
ae
major
men
mostli
histori
heavi
smoker
pack
year
x
ae
howev
studi
fail
affirm
previou
studi
decaf
score
promis
prognost
tool
aecopd
assess
conclus
decaf
score
probabl
superior
prognost
tool
aecopd
limit
studi
enough
sampl
size
get
valid
result
suggest
improv
studi
prolong
studi
multicent
studi
background
aim
chronic
obstruct
pulmonari
diseas
copd
heterogen
diseas
differ
clinic
manifest
structur
chang
respons
treatment
aim
identifi
subgroup
copd
cohort
studi
use
cluster
analysi
baselin
assess
clinic
outcom
subgroup
one
year
followup
method
analyz
patient
copd
dusti
area
cohort
main
factor
select
highest
load
variabl
use
princip
compon
analysi
pca
baselin
copd
patient
classifi
use
hierarch
cluster
analysi
clinic
physiolog
imag
data
base
pcatransform
data
clinic
paramet
evalu
among
subgroup
subgroup
also
evalu
clinic
outcom
one
year
followup
result
pca
show
six
independ
compon
account
varianc
three
distinct
subgroup
identifi
cluster
analysi
subgroup
includ
younger
patient
mild
stage
gold
fewer
exacerb
hospit
one
year
followup
subgroup
includ
femal
patient
milder
sever
sever
respiratori
symptom
show
progress
symptom
subgroup
includ
sever
subject
largest
declin
exacerb
one
year
conclus
cluster
analysi
use
baselin
data
copd
cohort
identifi
three
distinct
subgroup
differ
clinic
paramet
clinic
outcom
find
suggest
identifi
subgroup
may
repres
clinic
meaning
subtyp
copd
background
aim
believ
lung
function
test
indispens
diagnosi
chronic
obstruct
pulmonari
diseas
copd
howev
test
depend
inspect
procedur
patient
effort
enforc
mani
facil
herein
confirm
correl
lateralview
inspiratoryexpiratori
chest
radiographi
find
moreov
also
report
rvtlc
ictlc
ratio
associ
acut
exacerb
prognosi
copd
patient
aim
determin
lateralview
chest
radiographi
use
predict
precis
respiratori
function
copd
patient
method
fourteen
patient
diagnos
copd
base
japanes
respiratori
societi
copd
guidelin
underw
lateralview
inspiratoryexpiratori
chest
radiographi
hospit
analyz
use
clinic
imag
viewer
shadequestviewc
measur
vertic
direct
apex
diaphragm
anteroposterior
diamet
thorac
caviti
calcul
caviti
area
associ
measur
precis
breath
function
test
valu
investig
result
signific
correl
diamet
apex
diaphragm
anteroposterior
diamet
thorac
caviti
rv
rvtlc
ratio
note
particular
rvtlc
ratio
show
strong
correl
differ
vertic
size
inspiratori
expiratori
chest
radiographi
r
p
cutoff
valu
set
mm
rvtlc
could
detect
sensit
specif
area
curv
howev
signific
relationship
among
diamet
frc
tlc
ictlc
dlcova
observ
conclus
inspiratoryexpiratori
lateralview
chest
radiograph
consid
use
predict
precis
respiratori
function
copd
patient
background
aim
copd
exacerb
associ
decreas
lung
function
qualiti
life
identif
specif
factor
may
affect
prognosi
manag
outcom
exacerb
though
sever
score
system
propos
remain
subject
difficult
evalu
furthermor
clinic
laboratori
marker
deem
import
certain
studi
includ
base
previou
studi
aim
studi
determin
factor
affect
outcom
acut
exacerb
copd
method
subject
admit
due
acut
exacerb
copd
age
year
old
includ
patient
chart
retriev
specif
factor
record
outcom
inhospit
mortal
need
mechan
ventil
icu
admiss
record
logist
regress
analysi
done
determin
statist
signific
associ
increas
inhospit
mortal
acut
exacerb
copd
also
observ
need
invas
mechan
ventil
icu
admiss
addit
mrc
dyspnea
score
found
signific
need
invas
mechan
ventil
p
need
icu
admiss
p
howev
presenc
diabet
mellitu
p
found
protect
factor
inhospit
mortal
conclus
prognost
factor
older
age
malnutrit
sever
mrc
dyspnea
score
hypoalbuminemia
elev
urea
anemia
sever
acidosi
significantli
increas
inhospit
mortal
need
invas
mechan
ventil
icu
admiss
acut
exacerb
copd
hand
control
diabet
mellitu
shown
lower
risk
inhospit
mortal
batanga
philippin
quezon
citi
philippin
background
aim
chronic
obstruct
pulmonari
diseas
copd
etim
affect
popul
worldwid
import
caus
mortal
morbid
tradit
spirometr
measur
fev
correl
poorli
exercis
toler
exert
dyspnea
associ
lung
hyperinfl
measur
lung
volum
studi
research
identifi
presenc
hyperinfl
associ
even
mild
stage
among
increas
level
copd
sever
method
prospect
cohort
analyt
studi
among
copd
patient
diagnos
pulmonari
function
test
consist
airflow
obstruct
lung
volum
studi
done
among
lung
volum
studi
analysi
varianc
use
associ
tlc
rv
rvtlc
ratio
differ
level
copd
sever
base
gold
citeria
pvalu
consid
signific
result
patient
includ
studi
patient
male
femal
mean
age
studi
popul
year
old
major
patient
smoker
mean
fev
predict
postbronchodil
studi
patient
gold
patient
observ
copd
sever
increas
also
increas
rvtlc
ratio
howev
look
chang
one
categori
next
chang
rvtlc
significantli
increas
gold
pvalu
gold
pvalu
conclus
rvtlc
ratio
serv
good
object
paramet
hyperinfl
ratio
increas
direct
associ
increas
copd
sever
associ
significantli
note
copd
patient
gold
cataegori
background
aim
chronic
obstruct
pulmonari
diseas
copd
import
diseas
worldwid
highincom
lowincom
countri
year
estim
copd
rank
fifth
among
condit
high
burden
societi
third
among
import
caus
death
gender
worldwid
sweep
work
job
employ
special
thought
consid
menial
one
sweep
activ
sweeper
expos
dust
caus
variou
ill
effect
bodi
street
dust
complex
mixtur
soil
dust
plant
fragment
dust
motor
vehicl
biolog
materi
street
sweeper
expos
dust
particl
bioaerosol
variou
harm
gase
street
sweeper
usual
would
use
protect
devic
exposur
air
pollut
sweep
may
contribut
increas
preval
copd
preliminari
cross
section
studi
preval
copd
among
street
sweeper
jakarta
indonesia
approv
ethic
committe
faculti
medicin
universita
indonesia
method
research
design
crosssect
subject
street
sweeper
jakarta
sampl
collect
use
cluster
random
sampl
questionnair
copd
assess
test
cat
modifi
british
medic
research
council
mmrc
spirometri
examin
base
pneumobil
project
indonesia
bronchodil
test
inclus
criteria
male
femal
abl
perform
spirometri
sign
inform
consent
year
old
work
period
year
result
thirti
subject
particip
studi
age
year
male
femal
preval
copd
among
street
sweeper
area
conclus
preval
copd
among
street
sweeper
jakarta
nation
heart
lung
instituteimperi
colleg
london
airway
diseas
section
london
unit
kingdom
asthma
airway
centreunivers
health
networkunivers
toronto
depart
medicin
torontoon
canada
novarti
pharma
ag
respiratori
basel
switzerland
novarti
pharmaceut
corpor
respiratori
east
hanov
nj
usa
background
aim
gold
guidelin
recommend
longact
agonistinh
corticosteroid
combin
andor
longact
muscarin
antagonist
firstlin
therapi
copd
patient
high
risk
exacerb
gold
flame
studi
evalu
effect
indgli
versu
sfc
reduc
exacerb
copd
patient
high
risk
exacerb
method
multicent
random
doubleblind
parallelgroup
studi
patient
age
year
moderatetoveri
sever
copd
postbronchodil
fev
histori
exacerb
previou
year
random
indgli
daili
sfc
twice
daili
primari
endpoint
noninferior
indgli
sfc
term
rate
exacerb
test
superior
prespecifi
noninferior
establish
background
aim
longact
agonistsinh
corticosteroid
combin
labaic
andor
longact
muscarin
antagonist
lama
recommend
treatment
moderateto
sever
chronic
obstruct
pulmonari
diseas
copd
patient
high
risk
exacerb
gold
flame
studi
indacaterolglycopyrronium
indgli
labalama
show
superior
reduc
exacerb
salmeterolfluticason
sfc
labaic
copd
patient
histori
exacerb
report
effect
indgli
lung
function
healthrel
qualiti
life
hrqol
versu
sfc
studi
method
doubleblind
flame
studi
copd
patient
histori
exacerb
past
year
postbronchodil
forc
expiratori
volum
one
second
fev
predict
random
receiv
oncedaili
indgli
twicedaili
sfc
lung
function
assess
use
spirometri
predos
trough
fev
forc
vital
capac
fvc
standard
area
curv
fev
hour
fev
auc
subset
patient
use
serial
spirometri
hrqol
evalu
term
st
georg
respiratori
questionnair
copd
sgrqc
total
score
day
fev
auc
week
treatment
predos
trough
fev
fvc
fev
auc
sgrqc
result
random
patient
indgli
n
sfc
n
complet
treatment
period
indgli
show
signific
improv
predos
trough
fev
predos
trough
fvc
fev
auc
sgrqc
score
except
week
versu
sfc
treatment
period
tabl
conclus
indgli
show
signific
improv
lung
function
healthrel
qualiti
life
versu
sfc
consist
treatment
period
result
support
role
indgli
prefer
treatment
copd
patient
high
risk
exacerb
studi
fund
novarti
ag
nation
heart
lung
instituteimperi
colleg
london
airway
diseas
section
london
unit
kingdom
univers
marburg
respiratori
diseas
marburg
germani
novarti
pharma
ag
respiratori
basel
switzerland
novarti
pharmaceut
corpor
respiratori
east
hanov
nj
usa
background
aim
baselin
eosinophil
level
may
predict
efficaci
inhal
corticosteroid
prevent
copd
exacerb
analysi
flame
studi
present
posthoc
evalu
time
first
moder
sever
exacerb
indacaterolglycopyrronium
indgli
compar
salmeterolfluticason
sfc
moderatetoveri
sever
copd
patient
stratifi
baselin
blood
eosinophil
level
method
flame
multicent
doubleblind
doubledummi
parallelgroup
studi
random
patient
postbronchodil
fev
predict
histori
exacerb
previou
year
receiv
either
oncedaili
indgli
twicedaili
sfc
data
analyz
subgroup
defin
percentag
blood
eosinophil
absolut
blood
eosinophil
level
result
patient
random
indgli
n
sfc
n
patient
includ
analysi
time
first
moder
sever
exacerb
significantli
delay
indgli
compar
sfc
subgroup
patient
stratifi
percentag
blood
eosinophil
absolut
blood
eosinophil
furthermor
numer
improv
exacerb
risk
term
time
first
moder
sever
exacerb
observ
subgroup
patient
eosinophil
count
cell
tabl
conclus
studi
patient
high
risk
exacerb
indacaterolglycopyrronium
significantli
better
delay
time
first
moder
sever
exacerb
salmeterolfluticason
eosinophil
cutoff
given
eosinophil
cutoff
salmeterolfluticason
found
better
indacaterolglycopyrronium
delay
time
first
moder
sever
exacerb
studi
fund
novarti
pharma
ag
background
aim
background
estim
million
peopl
moder
sever
chronic
obstruct
pulmonari
diseas
copd
million
peopl
die
copd
correspond
death
global
known
almost
copd
death
occur
lowand
middleincom
countri
across
nation
region
level
limit
polici
need
challeng
obstacl
effect
care
need
remov
need
robust
polici
framework
allow
healthcar
profession
identifi
patient
earlier
make
necessari
intervent
tackl
diseas
effect
method
implement
effect
treatment
manag
protocol
smoke
cessat
step
wise
approach
treatment
recommend
global
initi
chronic
obstruct
lung
diseas
guidelin
diseas
progress
may
delay
result
expect
outcom
increas
number
stakehold
train
copd
advocaci
provid
copd
advocaci
train
technic
assist
patient
partner
region
andor
local
advocaci
increas
number
legisl
better
understand
copd
relat
polici
program
increas
public
fund
copd
activ
region
better
tobacco
control
clean
air
polici
local
region
level
conclus
address
escal
socioeconom
burden
copd
need
clear
implement
strategi
across
asia
apsr
local
societi
work
partnership
improv
diagnosi
manag
also
educ
copd
background
aim
chronic
obstruct
pulmonari
diseas
copd
frequent
caus
morbid
mortal
develop
countri
might
attribut
lack
knowledg
copd
patient
main
object
studi
evalu
knowledg
copd
among
malaysian
patient
live
copd
method
post
ethic
approv
written
consent
copd
patient
year
old
diagnos
respiratori
diseas
nil
cognit
disabl
attend
followup
appoint
chest
clinic
hospit
melaka
recruit
patient
sociodemograph
medic
data
record
patient
knowledg
copd
assess
use
malay
version
bristol
copd
knowledg
questionnair
mbckq
mbckq
assess
patient
knowledg
epidemiolog
physiolog
aetiolog
common
symptom
breathless
phlegm
chest
infect
exercis
smoke
immun
inhal
bronchodil
antibiot
oral
steroid
inhal
steroid
base
answer
scheme
score
given
correct
answer
wrong
answer
highest
possibl
score
result
enrol
copd
patient
n
patient
possess
poor
score
knowledg
n
patient
moder
level
score
knowledg
half
enrol
patient
respond
correctli
six
main
domain
copd
knowledg
includ
common
symptom
phlegm
aetiolog
chest
infect
breathless
oral
steroid
convers
patient
respond
poorli
domain
inhal
bronchodil
immun
conclus
none
patient
studi
sampl
possess
good
level
knowledg
copd
signific
gap
copd
patient
knowledg
ill
respect
manag
result
present
studi
alert
healthcar
polici
maker
administr
need
intervent
aim
increas
knowledg
copd
patient
thu
ensur
better
manag
copd
background
aim
recent
blood
eosinophil
emphas
candid
biomark
relat
acut
exacerb
therapeut
respons
inhal
corticosteroid
ic
copd
howev
role
blood
eosinophil
might
overestim
includ
patient
asthmacopd
overlap
syndrom
aco
investig
clinic
impact
blood
eosinophil
patient
nonaco
copd
method
korean
copd
subtyp
studi
kocoss
ongo
cohort
includ
patient
copd
exclud
patient
aco
defin
spanish
aco
criteria
analyz
blood
cell
count
epidemiolog
spirometr
data
event
copd
exacerb
nonaco
copd
clinic
outcom
includ
dyspnea
qualiti
life
qol
moder
sever
exacerb
copd
aecopd
declin
lung
function
compar
accord
quartil
blood
eosinophil
count
percent
result
exclud
patient
defin
spanish
criteria
aco
patient
nonaco
copd
final
analyz
median
valu
eosinophil
percent
count
eosinophilsul
total
white
blood
cell
count
neutrophil
percent
invers
correl
eosinophil
percent
p
sgrq
cat
score
fev
frequenc
aecopd
associ
blood
eosinophil
percent
count
p
even
multivari
logist
regress
analysi
adjust
age
sex
use
ic
eosinophil
count
percent
signific
risk
factor
declin
fev
frequenc
aecopd
p
conclus
patient
nonaco
copd
blood
eosinophil
associ
symptom
qol
fev
risk
factor
declin
fev
aecopd
role
blood
eosinophil
may
limit
overestim
biomark
patient
nonaco
copd
background
aim
year
world
copd
day
romania
run
copd
awar
campaign
offer
free
spirometri
gener
public
conduct
day
campaign
bucharest
use
case
find
approach
questionnair
plu
free
spirometri
method
questionnair
question
address
differ
issu
like
possibl
suggest
symptom
risk
factor
smoke
previou
respiratori
function
investig
spirometri
exist
respiratori
therapi
statist
analysi
done
use
microsoft
offic
excel
result
lot
person
mean
age
ae
year
screen
spirometri
lung
function
impair
mean
fev
ae
male
repres
case
year
year
old
respiratori
symptom
symptomat
one
dyspnea
indic
cough
chest
tight
wheez
accus
symptom
although
case
histori
obstruct
diseas
spirometri
last
month
questionnair
analysi
reveal
previous
undiagnos
patient
detect
lung
impair
symptomat
normal
spirometri
sever
diseas
case
experienc
exacerbationyear
least
exacerbationsyear
receiv
antibiot
treatment
present
emerg
room
case
requir
hospit
conclus
romania
due
copd
awar
campaign
address
access
spirometri
increas
year
year
howev
treat
copd
remain
deficitari
respect
patient
known
diagnos
obstruct
disord
actual
treat
copd
awar
campaign
questionnair
plu
spirometri
use
detect
new
case
alreadi
undertr
diagnos
case
kobe
univers
graduat
school
health
scienc
depart
commun
health
scienc
kobehyogo
japan
homevisit
nurs
station
wakakusa
home
visit
nurs
nagano
japan
nation
hospit
organ
higashi
nagano
hospit
depart
respiretori
medicin
nagano
japan
background
aim
chronic
obstruct
pulmonari
diseas
copd
patient
becom
malnourish
weight
loss
consid
independ
prognost
factor
provid
homevisit
nurs
intervent
program
copd
patient
complet
pulmonari
rehabilit
studi
aim
evalu
effect
longitudin
chang
percentag
ideal
bodi
weight
ibw
copd
patient
receiv
homevisit
nurs
method
subject
compris
copd
patient
follow
year
among
patient
receiv
homevisit
nurs
use
age
ibw
lung
function
arteri
blood
ga
activ
daili
live
adl
score
walk
distanc
chronic
respiratori
diseas
questionnair
crq
paramet
evalu
calcul
regress
line
ibw
year
furthermor
defin
increas
ibw
regress
line
slope
group
n
decreas
ibw
regress
line
slope
group
b
n
compar
result
measur
two
group
result
baselin
group
significantli
lower
ibw
group
b
howev
significantli
differ
measur
two
group
first
third
year
group
significantli
higher
crq
total
score
group
bin
third
year
group
significantli
lower
adl
score
baselin
group
significantli
lower
first
yearin
third
year
group
significantli
higher
crq
total
crq
emot
crq
masteri
score
baselin
conclus
function
declin
activ
restrict
occur
ill
age
howev
studi
suggest
longterm
nutrit
manag
homevisit
nurs
help
maintain
high
qualiti
life
copd
patient
fukuseikai
hospit
respiratori
medicin
fukuoka
japan
nishi
fukuoka
hospit
nurs
fukuoka
japan
hiroshima
univers
graduat
school
biomed
health
scienc
hiroshima
japan
background
aim
research
conduct
aim
clarifi
characterist
copd
patient
diseas
stage
appropri
prevent
behavior
respiratori
infect
method
subject
copd
patient
visit
depart
respiratori
medicin
three
medic
facil
includ
univers
hospit
fukuoka
citi
novemb
june
acquir
basic
inform
subject
medic
record
conduct
copd
assess
test
cat
use
selfadminist
survey
sheet
respiratori
infect
prepar
research
research
conduct
approv
clinic
research
support
committe
fukuoka
univers
hospit
result
subject
male
femal
subject
year
number
patient
stage
ii
iii
iv
respect
bodi
mass
index
bmi
averag
level
vital
capac
forc
expiratori
volum
one
second
declin
diseas
stage
progress
averag
age
across
stage
subject
averag
age
subject
stage
iv
year
time
diagnos
copd
cat
score
show
signific
differ
stage
point
stage
iv
point
signific
differ
prevent
behavior
respiratori
infect
across
stage
six
subject
stage
iv
smoke
conclus
patient
stage
iv
diagnos
copd
averag
age
therefor
durat
ill
long
necessit
lengthi
selfmanag
would
also
consid
patient
stage
iv
advanc
diseas
continu
smoke
lack
knowledg
diseas
might
also
prevent
engag
prevent
behavior
respiratori
infect
background
aim
chronic
obstruct
pulmonari
diseas
copd
great
impact
qualiti
life
qol
howev
evalu
qol
lack
northern
thailand
due
complex
questionnair
difficulti
commun
especi
minor
elderli
peopl
bode
index
use
predict
long
term
outcom
aim
studi
find
correl
bode
index
qol
method
crosssect
studi
conduct
copd
patient
chiang
dao
district
chiang
mai
thailand
patient
assess
qol
thai
version
st
georg
respiratori
questionnair
sgrq
associ
bode
index
includ
compon
sgrq
evalu
pearson
correl
bode
quartil
sgrq
evalu
spearman
correl
result
baselin
characterist
show
mean
age
year
male
mean
postbronchodil
fev
predict
bode
quartil
moder
associ
total
sgrq
score
r
p
sgrq
subscal
symptom
activ
impact
compon
bode
index
better
correl
sgrq
sum
bode
index
except
mmrc
r
p
conclus
bode
index
could
better
marker
qol
among
copd
patient
bodi
mass
index
lung
function
exercis
capac
background
aim
littl
known
effect
product
cough
outcom
patient
chronic
obstruct
pulmonari
diseas
copd
aim
assess
baselin
characterist
outcom
mortal
exacerb
cardiac
event
patient
without
product
cough
baselin
receiv
tiotropium
mainten
therapi
tiotropium
safeti
perform
respimat
tiospir
trial
method
tiospir
n
random
longterm
trial
compar
tiotropium
respimat
tiotropium
handihal
base
similar
efficaci
safeti
result
primari
analysi
treatment
arm
pool
patient
classifi
presenc
baselin
product
cough
hazard
ratio
confid
interv
calcul
time
event
use
cox
regress
model
result
overal
patient
classifi
baselin
product
cough
ye
n
baselin
characterist
concomit
medic
mostli
similar
howev
patient
product
cough
like
current
smoker
exacerb
last
year
slightli
wors
lung
function
patient
without
product
cough
tabl
product
cough
baselin
associ
higher
risk
death
figur
patient
product
cough
similar
risk
moderatetosever
exacerb
versu
without
product
cough
risk
sever
exacerb
requir
hospit
significantli
increas
figur
risk
major
advers
cardiovascular
event
mace
fatal
mace
independ
baselin
product
cough
figur
presenc
product
cough
may
indic
higher
risk
sever
exacerb
patient
copd
receiv
bronchodil
mainten
therapi
howev
product
cough
associ
increas
risk
death
moderatetosever
exacerb
cardiovascular
event
acknowledg
editori
write
support
provid
jennif
fuch
parexel
fund
boehring
ingelheim
background
aim
primit
neuro
ectoderm
tumor
pnet
lung
infrequ
case
elderli
peopl
rare
incid
tumor
caus
diagnost
pitfal
biopsi
continu
imunohistochemistri
examin
standard
test
confirm
diagnosi
method
present
case
women
chief
complain
cough
accompani
chest
pain
sinc
month
admit
hospit
thorac
ct
contrast
show
contrastenhanc
solid
mass
posterior
segment
left
lung
superior
lobe
fnab
fine
needl
aspir
biopsi
ct
guid
perform
obtain
patholog
diagnosisth
first
fnab
ct
guid
result
adenocarcinoma
lung
diagnosi
still
uncertain
second
fnab
ct
guid
perform
result
malign
round
cell
tumor
differenti
diagnosi
result
immunohistochemistri
result
posit
vimetin
antibodi
confirm
pnet
definit
diagnosi
patient
left
lung
pneumectomi
perform
adjuv
chemotherapi
plan
yet
patient
die
within
month
diagnos
due
rapid
aggress
progress
tumor
conclus
case
illustr
pnet
infrequ
case
aggress
clinic
characterist
poor
outcom
need
prompt
diagnosi
treatment
background
aim
multipl
primari
malign
make
approxim
carcinoma
case
literatur
second
primari
tumor
might
develop
treatment
first
primari
tumor
might
reflect
underli
genet
immunolog
defect
patient
treatmentrel
damag
environment
exposur
carcinogen
method
present
case
woman
malign
teratoma
anterior
mediastinum
lung
squamou
cell
carcinoma
thorac
ct
contrast
show
anterior
mediastin
mass
mass
lingular
segment
left
lung
fnab
ct
guid
result
mediastin
mass
malign
teratoma
dysgerminoma
two
cycl
bep
bleomycinetoposidecisplatin
regiment
chemotherapi
cycl
radiotherapi
done
result
complet
resolut
mediastin
mass
wedg
resect
mass
lingular
segment
done
postsurgeri
tissu
patholog
result
poorli
differenti
squamou
cell
carcinoma
lung
result
pet
scan
result
show
metastat
nodul
liver
platinumbas
chemotherapi
given
evalu
thorac
ct
show
good
result
conclus
case
illustr
multipl
primari
malign
involv
anterior
mediastin
lung
mass
earli
diagnosi
modern
chemotherapyradi
therapi
improv
surviv
rate
longterm
remiss
patient
cancer
allow
patient
neoplast
diseas
surviv
long
enough
develop
subsequ
primari
tumor
background
aim
thymoma
mediastin
primari
tumour
mediastinum
associ
varieti
autoimmun
disord
often
link
tcell
mediat
autoimmun
paraneoplast
pemphigu
pnp
immunolog
mediat
skin
diseas
character
epiderm
blister
may
occurin
associ
thymic
non
thymic
neoplasm
method
year
old
man
came
hospit
vesicl
ulcu
whole
bodi
sinc
week
patient
diagnos
pemphigu
vulgari
thymoma
sinc
year
patient
hospit
time
case
patient
underw
chemotherapi
carboplatinetoposid
seri
respons
document
patient
suggest
undergo
resect
thymoma
prevent
exacerb
pemphigu
refus
medic
given
aim
reduc
exacerb
pemphigu
result
pnp
character
product
autoantibodi
variou
target
antigen
mainli
plakin
famili
protein
desmoglein
pnp
result
antitumor
immun
respons
crossreact
normal
epitheli
protein
therebi
induc
autoimmun
molecular
mimicri
pnp
sera
bind
homolog
region
within
carboxyterminu
member
plakin
gene
familyther
also
involv
dysregul
tcell
develop
conclus
pemphigu
rare
associ
thymoma
fact
associ
thymoma
pemphigu
accord
fact
everi
patient
pemphigu
suspect
malign
especi
thymoma
rule
background
aim
observ
prolifer
lung
cancer
cell
line
rnai
order
provid
basi
treatment
lung
cancer
method
lentiviru
particl
infect
cell
order
silenc
express
interf
effici
plasmid
gene
detect
rtpcr
western
blot
method
analyz
prolifer
cell
cycl
mtt
assay
result
mrna
level
gene
could
downregul
inhibit
prolifer
cell
statist
signific
differ
mtt
assay
conclus
prolifer
cell
inhibit
silenc
gene
gene
may
play
role
develop
lung
cancer
may
benefici
cure
lung
cancer
dharmai
cancer
hospit
gener
practition
jakarta
barat
indonesia
dharmai
cancer
hospit
respiratori
medicin
jakarta
barat
indonesia
background
aim
malign
pleural
effus
mpe
sign
advanc
stage
lung
cancerth
frequenc
mpe
lung
cancer
relat
poor
prognosi
five
year
surviv
advanc
stage
lung
cancer
studi
aim
identifi
prognost
factor
surviv
time
patient
mpe
lung
cancer
method
retropect
studi
held
dharmai
nation
cancer
hospit
januari
decemb
prognost
factor
sex
age
stage
iva
ivb
therapi
analys
kaplanmei
techniqu
compar
use
logrank
test
cox
regress
method
use
determin
sever
prognost
factor
respect
surviv
time
result
threehundr
fortythre
patient
includ
studi
men
women
median
age
year
old
rang
year
old
patient
patient
die
patient
system
therapi
median
overal
surviv
patient
day
rang
day
kaplanmei
univari
analysi
show
surviv
significantli
relat
stage
hazard
ratio
hr
confid
interv
ci
p
therapi
hr
ci
p
prognost
factor
examin
appear
affect
overal
surviv
sex
p
age
p
background
aim
sleeprel
breath
disord
srbd
known
signific
underdiagnos
caus
morbid
children
clinic
present
includ
snore
nocturn
arous
restless
sleep
enuresi
daytim
sleepi
hyperact
method
help
identifi
srbd
without
expens
gold
standard
diagnosi
overnight
polysomnographi
could
greatli
facilit
clinic
epidemiolog
research
screen
tool
cultur
appropri
linguist
access
instrument
among
filipino
assess
sleep
qualiti
children
great
valu
aim
studi
cultur
valid
filipino
version
srbd
subscal
within
pediatr
sleep
questionnair
psq
method
srbd
subscal
within
psq
forward
translat
filipino
synthes
backtransl
english
version
panel
expert
review
prefin
filipino
version
pilottest
done
valid
final
version
done
result
total
parent
caregiv
children
vari
age
group
includ
studi
result
show
filipino
version
srbd
subscal
within
psq
accur
reliabl
intern
consist
reliabl
analysi
yield
overal
cronbach
confirm
questionnair
consist
cronbach
filipino
srbd
subscal
within
psq
rang
testretest
reliabl
item
robust
correct
item
kappa
statist
rang
conclus
filipino
version
srbd
subscal
within
psq
suffici
reliabl
valid
measur
sleep
disord
breath
outcom
effect
origin
english
version
background
aim
idiopath
pulmonari
fibrosi
ipf
involv
alveolar
epitheli
injuri
abnorm
collagen
product
lung
myofibroblast
produc
consider
amount
extracellular
matrix
compon
like
collagen
may
give
rise
abnorm
fibrosi
transform
growth
factor
tgf
appear
stimul
activ
fibroblast
myofibroblast
collagen
synthesi
thu
chemic
capabl
suppress
product
collagen
repres
good
candid
treat
ipf
patient
studi
screen
chemic
capabl
inhibit
collagen
product
cultur
fibroblast
medicin
alreadi
clinic
use
method
collagen
level
cultur
medium
determin
sircol
assay
sever
pulmonari
fibrosi
assess
base
histopatholog
evalu
lung
mechan
respiratori
function
result
select
felodipin
base
extent
collagen
product
inhibit
clinic
safeti
profil
pharmacolog
activ
felodipin
ca
channel
blocker
use
clinic
treat
patient
high
blood
pressur
felodipin
suppress
collagen
product
within
cell
lung
fibroblast
ipf
patient
presenc
absenc
intratrach
administr
felodipin
prevent
bleomycininduc
pulmonari
fibrosi
alter
lung
mechan
respiratori
dysfunct
felodipin
also
improv
pulmonari
fibrosi
well
lung
respiratori
function
administ
fibrosi
develop
furthermor
administr
felodipin
suppress
bleomycininduc
increas
activ
fibroblast
lung
also
found
ca
channel
blocker
nifedipin
benidipin
inhibit
collagen
product
vitro
also
prevent
bleomycininduc
pulmonari
fibrosi
alter
lung
mechan
respiratori
dysfunct
vivo
conclus
result
suggest
felodipin
inhibit
bleomycininduc
fibrosi
blockad
ca
channel
activ
propos
felodipin
may
therapeut
benefici
ipf
patient
background
aim
intermitt
hypoxia
ih
one
import
pathophysiolog
compon
sleep
apnea
report
produc
weight
loss
anim
howev
sleep
apnea
convers
induc
weight
gain
properli
treat
better
understand
appar
paradox
effect
ih
bodi
weight
intend
analyz
effect
ih
bodi
weight
exclud
influenc
food
intak
method
expos
femal
mice
n
week
old
hour
ih
altern
hypoxia
normoxia
sham
intermitt
hypoxia
sih
n
without
food
get
ih
sih
chamber
mice
given
highfat
diet
result
increas
bodi
weight
ih
group
significantli
sih
group
day
start
ih
p
unpair
ttest
month
start
ih
ih
hour
without
food
load
ih
group
statist
signific
reappear
consum
food
weight
ih
group
sih
group
conclus
ih
without
food
caus
bodi
weight
gain
mice
sih
reproduc
ih
alway
produc
weight
loss
mice
ih
may
pathophysiolog
factor
increas
bodi
weight
sleep
apnea
may
worsen
sleep
apnea
thu
caus
viciou
cycl
background
aim
previou
report
regard
sleep
disord
allerg
diseas
includ
asthma
limit
sleep
disord
known
caus
fatigu
daytim
sleepi
may
worsen
asthma
control
qualiti
life
moreov
increas
risk
variou
diseas
hypertens
diabet
cardiovascular
diseas
although
sleep
disord
consid
one
high
risk
factor
system
inflamm
associ
sleep
disord
asthma
fulli
clarifi
furthermor
asthma
obstruct
sleep
apnea
osa
common
diseas
may
coexist
howev
preval
osa
asthmat
well
document
therefor
focus
associ
asthma
osa
util
screen
questionnair
method
studi
particip
enrol
studi
consist
asthma
patient
regularli
visit
saitama
medic
univers
hospit
screen
questionnair
includ
physiqu
asthma
control
test
act
pittsburgh
sleep
qualiti
index
psqi
berlin
questionnair
epworth
sleepi
scale
ess
hospit
anxieti
depress
scale
had
sleep
studi
carri
asthma
patient
suspici
osa
questionnair
n
result
total
patient
asthma
divid
group
suspici
osa
suspici
signific
differ
act
psqi
berlin
questionnair
ess
had
group
furthermor
asthmat
suspici
osa
n
treat
cpap
sleep
studi
conclus
result
demonstr
high
preval
sleep
apnea
patient
asthma
multipl
questionnair
may
use
screen
sleep
apnea
patient
asthma
background
aim
obstruct
sleep
apnea
syndrom
osa
common
disord
associ
impair
qualiti
life
increas
risk
motor
vehicl
accid
cardiovascular
diseas
continu
posit
airway
pressur
cpap
therapi
wide
use
treatment
osa
howev
patient
discontinu
cpap
therapi
earli
stage
determin
whether
educ
system
base
cpap
adher
track
system
reduc
earli
discontinu
cpap
therapi
patient
osa
method
patient
osa
start
cpap
divid
two
group
good
adher
least
hoursnight
night
consecut
period
poor
adher
use
adher
track
system
furthermor
poor
adher
classifi
two
pattern
averag
dairi
usag
time
use
day
short
period
user
less
hoursnight
infrequentlong
period
user
hoursnight
new
educ
system
conform
pattern
poor
adher
group
start
short
period
user
use
everi
day
use
long
possibl
use
infrequentlong
period
user
increas
number
use
day
result
patient
start
cpap
therapi
lack
daytim
symptom
significantli
higher
poor
adher
monthli
averag
usag
time
cpap
similar
short
period
user
infrequentlong
period
user
wherea
dropout
rate
significantli
higher
short
period
user
new
educ
system
introduc
dropout
rate
significantli
reduc
p
conclus
short
period
usag
cpap
may
predict
factor
earli
discontinu
therapi
use
educ
content
adapt
pattern
poor
adher
may
use
improv
continu
cpap
therapi
patient
osa
background
aim
well
known
indigen
peopl
high
risk
develop
chronic
medic
condit
cardiovascular
respiratori
diabet
renal
diseas
contribut
higher
morbiditymort
popul
sleep
disord
breathingobstruct
sleep
apnoea
known
contribut
advers
health
consequ
nonindigen
popul
around
world
howev
publish
data
preval
obstruct
sleep
indigen
popul
especi
australian
aborigin
peopl
indigen
peopl
make
nation
indigen
popul
live
remot
commun
method
retrospect
studi
involv
peopl
indigen
origin
northern
territori
australia
year
period
undergon
diagnost
sleep
studi
clinic
diagnosi
obstruct
sleep
apnoea
demograph
clinic
characterist
presenc
medic
comorbid
condit
polysomnographi
psg
data
examin
sever
sleep
paramet
includ
presenc
sever
sleep
apnoea
result
result
studi
discuss
confer
data
still
analys
conclus
interim
analysi
data
suggest
may
significantli
high
preval
sleep
disord
breathingobstruct
sleep
apnoea
indigen
popul
addit
presenc
signific
medic
comorbid
condit
osa
may
contribut
advers
health
consequ
background
aim
sleep
disord
breath
sdb
report
acut
decompens
heart
failur
adhf
patient
expedit
treatment
sdb
transit
period
may
potenti
benefit
heart
failur
outcom
howev
standard
inlaboratori
polysomnographi
psg
limit
given
critic
condit
object
compar
perform
cardiopulmonari
monitor
type
unattend
psg
type
diagnosi
sdb
adhf
method
studi
design
crosssect
studi
popul
method
patient
hospit
adhf
age
year
recruit
ramathibodi
hospit
psg
type
perform
consecut
night
result
seventeen
subject
male
mean
age
bodi
mass
index
ae
year
ae
includ
left
ventricular
eject
fraction
rang
mean
ae
sd
ae
patient
sdb
cutoff
apneahypopnea
index
ahi
patient
ahi
apneahypopnea
index
lower
type
monitor
psg
type
median
iqr
versu
despit
good
correl
r
p
compar
psg
type
type
cardiopulmonari
monitor
sensit
specif
area
roc
curv
auc
diagnosi
sdb
osa
cutoff
ahi
respect
respect
conclus
sleep
disord
breath
highli
preval
adhf
patient
major
moder
sever
sever
psg
type
feasibl
adhf
even
type
monitor
show
good
perform
high
specif
screen
sdb
adhf
may
potenti
role
improv
current
heart
failur
treatment
background
aim
obstruct
sleep
apnea
syndrom
osa
relat
narrow
airway
forc
oscil
techniqu
fot
noninvas
method
evalu
resist
reactanc
airway
system
method
examin
respiratori
resist
patient
osa
awaken
sit
supin
left
later
recumb
posit
use
fot
instrument
result
observ
signific
correl
apneahypopnea
index
ahi
respiratori
resist
hz
predict
index
upper
airway
resist
sit
r
p
supin
r
p
left
later
recumb
posit
r
p
conclus
fot
might
use
techniqu
estim
pathophysiolog
sever
osa
background
aim
sleep
problem
common
caus
signific
disrupt
qualiti
life
chronic
pulmonari
diseas
copd
patient
littl
data
impact
sleep
qualiti
qualiti
life
patient
copd
korea
purpos
studi
determin
associ
obstruct
sleep
apnea
osa
sleep
qualiti
qualiti
life
copd
patient
method
two
hundr
patient
men
mild
sever
copd
enrol
prospect
patient
evalu
pulmonari
function
test
determin
sever
copd
mild
moder
sever
modifi
medic
research
council
scale
berlin
questionnair
pittsburgh
sleep
qualiti
index
psqi
st
georg
respiratori
questionnair
sgrq
employ
assess
patient
result
sixtytwo
patient
high
risk
osa
eightytwo
patient
show
poor
qualiti
sleep
patient
osa
copd
wors
qualiti
sleep
compar
copd
without
osa
psqi
ae
versu
ae
p
qualiti
life
copd
patient
significantli
correl
qualiti
sleep
r
p
postbronchodil
predict
r
p
sever
dyspnea
r
p
conclus
osa
common
patient
copd
sleep
qualiti
also
poor
among
group
qualiti
life
copd
patient
associ
sleep
qualiti
underli
lung
function
degre
dyspnea
recommend
adequ
attent
need
manag
sleep
problem
copd
patient
background
aim
investig
util
smart
phone
applic
wechat
follow
obstruct
sleep
apneahypopnea
syndrom
osah
children
method
recruit
case
osah
children
randomli
divid
wechat
group
tradit
telephon
group
follow
patient
follow
monthli
three
month
collect
lost
follow
rate
complianc
patient
satisfact
followup
work
time
complet
degre
patient
data
collect
result
wechat
group
significantli
lower
group
lost
follow
rate
higher
complianc
patient
satisfact
health
knowledg
score
decreas
follow
work
time
p
conclus
util
wechat
smart
phone
base
applic
follow
osah
children
feasibl
significantli
decreas
lost
follow
rate
increas
complianc
patient
satisfact
follow
work
effici
greatli
improv
integr
collect
medic
data
introduct
narcolepsi
character
tetrad
excess
daytim
sleepi
cataplexi
hypnogog
hallucin
sleep
paralysi
similar
symptomatolog
narcolepsi
across
differ
ethnocultur
background
howev
mean
given
narcolepsi
aetiolog
interpret
ethnocultur
determin
factor
also
influenc
patient
reaction
symptom
willing
seek
medic
attent
present
case
narcolepsi
cataplexi
experienc
clergyman
malaysia
present
debilit
sleep
attack
episod
give
sermon
religi
lectur
also
episod
continu
uninterrupt
sleep
day
attribut
episod
supernatur
event
polysomnographi
studi
multipl
sleep
latenc
test
confirm
diagnosi
narcolepsi
howev
patient
doubt
diagnosi
declin
medic
treatment
discuss
case
describ
difficulttotreat
patient
doubt
diagnosi
treatment
narcolepsi
despit
diagnosi
multipl
sleep
latenc
test
polysomnographi
studi
highlight
vital
role
understand
local
ethnocultur
background
process
narcolepsi
manag
malaysia
background
aim
sleep
discrep
differ
subject
object
measur
sleep
known
observ
patient
paradox
insomnia
theoret
obstruct
sleep
apnea
osa
patient
may
also
exhibit
sleep
discrep
due
sleep
disrupt
studi
want
determin
discrep
subject
object
sleep
paramet
osa
method
patient
diagnos
osa
juli
till
juli
excel
center
sleep
disord
king
chulalongkorn
memori
hospit
bangkok
thailand
age
year
old
includ
retrospect
studi
patient
sleep
disord
besid
osa
includ
period
limb
movement
disord
insomnia
sleep
bruxism
parasomnia
exclud
studi
result
total
patient
includ
studi
baselin
demograph
data
show
sampl
popul
male
mean
age
ae
year
mean
epworth
sleepi
scale
score
ae
mean
apnea
hypopnea
index
respiratori
disturb
index
ae
ae
respect
pair
comparison
selfreport
versu
polysomnographyreport
sleep
paramet
show
statist
signific
differ
mean
sleep
latenc
minut
ae
vs
ae
p
mean
total
sleep
time
minut
ae
vs
ae
p
mean
sleep
effici
ae
vs
ae
p
overal
patient
accur
predict
sleep
latenc
within
minut
total
sleep
time
minut
discrep
sleep
effici
least
conclus
result
show
obstruct
sleep
apnea
patient
tend
overestim
sleep
onset
latenc
underestim
total
sleep
time
underestim
sleep
effici
background
aim
investig
effect
ofinh
shortact
bronchodil
diaphragm
function
neural
respiratori
drive
patient
chronic
obstruct
pulmonari
diseas
copd
maxim
isocapn
ventil
miv
method
fortyseven
moderatetosever
copd
patient
random
four
group
placebo
group
n
salbutamol
group
n
ipratropium
group
n
combin
group
salbutamol
ipratropium
n
subject
initi
perform
miv
three
minut
baselin
repeat
miv
minut
inhal
placebo
salbutamol
ipratropium
combin
inhal
salbutamol
ipratropium
base
group
paramet
diaphragm
function
neural
respiratori
drive
monitor
continu
calcul
miv
result
miv
group
experienc
linear
increas
root
mean
squar
rm
diaphragm
electromyogram
show
gradual
decreas
intransdiaphragmat
pressur
pdi
minut
ventil
verm
inhal
bronchodil
paramet
salbutamol
group
ipratropium
group
combin
group
improv
significantli
comparison
placebo
group
valu
rm
borg
score
group
time
point
decreas
significantli
pdi
verm
increas
significantli
comparison
monotherapi
group
combin
group
greater
verm
p
significantli
correl
respect
p
conclus
inhal
shortact
bronchodil
allevi
diaphragm
fatigu
copd
patient
miv
increas
lung
ventil
reduc
neural
respiratori
drive
improv
neuroventilatori
coupl
might
underli
reduct
dyspnoea
copd
patient
moreov
combin
agonist
antimuscarin
antagonist
show
superior
efficaci
background
aim
pulmonari
crystalstor
histiocytosi
csh
rare
condit
associ
lymphoprolif
plasma
cell
disord
date
littl
inform
avail
regard
treatment
prognosi
pulmonari
csh
method
woman
present
fever
product
cough
consolid
right
lower
lobe
initi
diagnos
communityacquir
pneumonia
also
pancytopenia
acut
kidney
injuri
investig
diagnos
multipl
myeloma
made
chest
xray
show
progress
pulmonari
infiltr
despit
cours
antibiot
bronchoscopi
perform
transbronchi
lung
biopsi
show
intraalveolar
mononuclear
cell
contain
abund
eosinophil
cytoplasm
microglobul
without
organ
pulmonari
csh
diagnos
two
week
cours
dexamethason
treatment
chest
xray
almost
clear
result
multipl
myeloma
variou
form
pulmonari
involv
thorac
skelet
involv
common
site
wherea
parenchym
infiltr
found
almost
pneumonia
crystalstor
histiocytosi
rare
find
character
histiocyt
accumul
intracytoplasm
immunoglobulin
crystal
csh
underli
lymphoproliferativeplasma
cell
disord
diseas
involv
variou
site
occur
local
form
gener
form
lung
pleura
second
common
site
local
csh
case
seri
patient
pulmonari
csh
usual
present
singl
multipl
pulmonari
nodul
diagnosi
base
patholog
find
exclus
macrophagerich
condit
date
littl
inform
avail
accord
treatment
prognosi
pulmonari
csh
conclus
pulmonari
csh
one
rare
lung
parenchym
involv
multipl
myeloma
sever
manifest
mainstay
manag
condit
treatment
underli
condit
background
aim
desquam
interstiti
pneumonia
among
myriad
scarc
subcategori
idiopath
interstiti
lung
diseas
predisposit
factor
appear
relat
tobacco
case
age
onset
around
male
preponder
report
case
multipl
admiss
pneumonia
later
found
biopsyproven
desquam
interstiti
pneumon
case
descript
year
old
male
smoker
background
diabet
hypertens
chronic
kidney
diseas
ischem
heart
diseas
present
us
relaps
fever
dyspnoea
occur
period
six
month
multipl
antibiot
exposur
includ
carbapenem
group
meropenem
antifung
fluconazol
chest
radiographi
reveal
right
lower
zone
pleural
effus
exud
natur
cytolog
neg
bronchoscopi
inconclus
thorac
comput
tomographi
ct
demonstr
right
upper
lower
zone
consolid
peripher
ground
glass
opac
air
bronchogram
evid
malign
found
imag
ct
guid
lung
biopsi
consist
desquam
interstiti
pneumon
steroid
subsequ
commenc
smoke
cessat
time
submiss
good
clinic
respons
attain
well
conclus
rare
entiti
gener
consid
better
outcom
subtyp
idiopath
interstiti
pneumonia
thu
prompt
identif
treatment
initi
key
retard
progress
nevertheless
common
differenti
exclud
first
encount
patient
unrespons
antibiot
therapi
pneumonia
background
aim
pulmonari
alveolar
proteinosi
rare
entiti
interstiti
lung
diseas
could
often
mimic
common
respiratori
condit
initi
stage
report
pregnant
ladi
malaysia
chronic
dyspnoea
respond
diuret
antibiot
diagnos
later
scarc
diseas
unev
deliveri
case
descript
present
year
old
ladi
gravida
para
week
gestat
background
histori
mild
intermitt
asthma
present
clinic
threemonth
histori
short
breath
dri
cough
otherwis
afebril
symptom
variabl
daytim
night
time
associ
constitut
symptom
report
risk
factor
pulmonari
embol
identifi
clinic
respiratori
failur
lung
clear
connect
tissu
screen
neg
treat
initi
one
week
antibiot
cours
commun
acquir
pneumonia
privat
centr
trial
diuret
given
well
centr
presum
mild
pulmonari
edema
due
unrespons
antibiot
therapi
deliv
unev
via
elect
caesarean
section
one
week
visit
chest
radiographi
show
bilater
hilar
illdefin
opac
subsequ
thorac
comput
tomographi
reveal
crazi
pave
pattern
bronchoalveolar
lavag
posit
period
acid
schiff
stain
whole
lung
bronchopulmonari
lavag
done
month
postpartum
symptom
resolv
improv
lung
function
walk
test
conclus
case
highlight
anoth
case
pulmonari
alveolar
proteinosi
present
pregnanc
howev
respiratori
function
compromis
abl
undergo
lavag
postpartum
period
anoth
point
emphas
clinician
alway
first
consid
pneumonia
common
respiratori
diseas
approach
pregnant
ladi
chronic
dyspnoea
cough
think
rare
entiti
pulmonari
alveolar
proteinosi
background
aim
background
noncyst
fibrosi
bronchiectasi
character
neutrophildriven
airway
inflamm
lead
recurr
respiratori
infect
roflumilast
oral
phosphodiesteras
decreas
neutrophildriven
airway
inflamm
test
hypothesi
roflumilast
decreas
exacerb
frequenc
bronchiectasi
patient
object
primari
endpoint
rate
eventbas
exacerb
treatment
period
two
group
secondari
endpoint
chang
fev
bronchodil
use
chang
total
score
st
georg
respiratori
questionnair
sgrq
chang
distanc
period
method
particip
patient
diagnos
bronchiectasi
defin
hrct
least
one
pulmonari
exacerb
requir
antibiot
treatment
past
year
randomli
assign
patient
receiv
mg
roflumilast
placebo
daili
month
ratio
patient
investig
mask
treatment
alloc
result
roflumilast
placebo
group
patient
rate
eventbas
exacerb
per
patient
per
patient
roflumilast
placebo
group
respect
treatment
period
rate
ratio
p
prebronchodil
fev
increas
l
baselin
roflumilast
group
decreas
l
placebo
group
differ
signific
l
ci
p
signific
differ
found
chang
sgrq
total
score
roflumilast
unit
placebo
group
p
chang
distanc
differ
roflumilast
meter
placebo
group
meter
differ
meter
ci
p
conclus
signific
differ
observ
rate
eventbas
exacerb
bronchiectasi
patient
receiv
roflumilast
placebo
month
background
aim
bronchopulmonari
sequestr
uncommon
congenit
lung
malform
character
nonfunct
segment
lung
parenchyma
without
normal
connect
tracheobronchi
tree
method
report
case
intralobar
sequestr
male
present
pham
ngoc
thach
pnt
hospit
symptom
mass
haemoptysi
ml
long
histori
dri
cough
diagnos
pharyng
bronchiti
treat
antibiot
two
month
pnt
admiss
complain
sputum
product
hemoptysi
right
chest
pain
mild
dyspnea
two
week
ago
develop
mass
haemoptysi
immedi
admit
pnt
hospit
patient
unremark
physic
exam
chest
radiographi
show
welldefin
consolid
lower
lobe
chest
ct
scan
confirm
featur
identifi
chest
radiograph
show
consolid
caviti
right
lower
lobe
anomal
arteri
note
abdomin
aorta
enter
consolid
bronchoscopi
show
pu
come
right
lower
lobe
base
chest
radiographi
ct
scan
diagnos
case
intralobar
pulmonari
sequestr
right
lower
lobe
patient
refer
surgeri
depart
standard
thoracotomi
lobectomi
right
lower
lobe
resect
ligat
aberr
arteri
perform
success
without
complic
patholog
examin
resect
right
lower
lobe
show
featur
consist
intralobar
sequestr
associ
infect
actinomyc
haemorrhag
result
patient
later
discharg
good
health
th
postop
day
conclus
case
illustr
typic
present
intralobar
bronchopulmonari
sequestr
pulmonari
sequestr
consid
patient
repeat
pulmonari
infect
hemoptysi
persist
lower
lobe
abnorm
chest
radiograph
ct
scan
surgeri
mainstay
treatment
lobectomi
ligat
aberr
arteri
background
aim
hip
fractur
import
health
care
issu
older
peopl
one
year
mortal
hip
fractur
postop
pulmonari
complic
occur
patient
hip
fractur
surgeri
sever
complic
pneumonia
respiratori
failur
pulmonari
rehabilit
effect
reduc
postop
pulmonari
complic
especi
high
risk
surgic
patient
howev
pulmonari
rehabilit
focus
patient
hip
surgeri
today
present
retrospect
studi
effect
elderli
hip
fractur
patient
accept
comprehens
pulmonari
rehabilit
program
hip
surgeri
method
includ
elderli
patient
older
year
old
develop
new
hip
fractur
sinc
will
accept
postop
pulmonari
rehabilit
program
pulmonari
rehabilit
program
start
patient
refus
rehabilit
surgic
intervent
exclud
collect
age
sex
comorbid
lab
data
oper
type
oper
date
pneumonia
date
analysi
result
total
patient
women
men
case
case
characterist
age
sex
comorbid
lab
data
surgic
type
reveal
signific
differ
patient
total
patient
develop
pneumonia
patient
diagnos
pneumonia
found
older
year
old
cancer
patient
without
postop
pulmonari
rehabilit
program
higher
risk
pneumonia
develop
multivari
analysi
old
age
odd
ratio
stroke
diabet
patient
higher
probabl
pneumonia
conclus
older
patient
hip
fractur
surgeri
accept
postop
pulmonari
rehabilit
program
could
decreas
pneumonia
incid
studi
first
trial
prove
postop
pulmonari
rehabilit
program
effect
hip
surgeri
patient
background
aim
major
incapac
detect
incident
treat
conserv
surgic
intervent
seldom
requir
highlight
case
emphas
import
recogn
entiti
mimic
underli
pneumonia
method
woman
consult
orthopaed
team
right
lung
basal
consolid
initi
impress
orthostat
pneumonia
underli
hypertens
present
orthopaed
team
lumbar
epidur
abscess
drainag
done
patient
treat
six
week
intraven
tazobactampiperacillin
howev
diaphragmat
paralysi
demonstr
chest
ultrasonographydiaphragm
conclus
exact
occurr
diaphragmat
paralysi
worldwid
still
unclear
due
rariti
asymptomat
natur
case
could
mistakenli
treat
pneumonia
chest
ultrasonographi
appear
reason
diagnost
modal
identifi
condit
background
aim
home
mechan
ventil
hmv
shown
improv
surviv
qualiti
life
wide
varieti
indic
howev
pauciti
real
world
data
guid
optim
time
initi
hmv
indic
unclear
earlier
initi
lead
better
outcom
aim
review
impact
acut
versu
elect
initi
hmv
patient
outcom
method
conduct
retrospect
analysi
patient
hmv
singapor
gener
hospit
march
novemb
compar
outcom
acut
versu
elect
initi
hmv
result
patient
includ
tabl
noninvas
mask
ventil
except
tracheostom
patient
hmv
initi
acut
respiratori
failur
elect
initi
tracheostom
patient
acut
initi
hmv
indic
similar
acut
elect
group
exclud
tracheostom
patient
two
group
similar
demograph
machin
set
complianc
elect
initi
patient
better
continu
rate
figur
surviv
longer
compar
requir
acut
initi
mortal
versu
p
conclus
data
suggest
patient
elect
initi
hmv
improv
surviv
better
continu
rate
differ
could
attribut
time
hmv
initi
differ
diseas
sever
lead
time
bia
research
need
determin
optim
time
hmv
initi
changi
gener
hospit
respiratori
critic
care
medicin
singapor
singapor
st
andrew
commun
hospit
nurs
singapor
singapor
background
aim
massiv
haemoptysi
emerg
requir
prompt
recognit
time
intervent
airway
protect
measur
institut
follow
therapeut
intervent
review
literatur
show
studi
evalu
quantif
haemoptysi
healthcar
profession
aim
evalu
healthcar
profession
definit
massiv
haemoptysi
abil
quantifi
expector
blood
volum
accur
method
conduct
survey
doctor
nurs
changi
gener
hospit
respond
ask
defin
massiv
haemoptysi
estim
amount
moulag
blood
present
sputum
cup
consist
moulag
blood
figur
result
total
healthcar
profession
survey
thirteen
defin
massiv
haemoptysi
volum
expector
blood
defin
volum
expector
blood
incomplet
data
twentyf
estim
amount
moulag
blood
indic
indic
indic
indic
respond
accur
identifi
sputum
sampl
vari
quantiti
respond
none
correct
respond
correct
answer
respect
incomplet
answer
conclus
signific
dispar
definit
estim
massiv
haemoptysi
amongst
healthcar
profession
urgent
need
educ
train
improv
recognit
massiv
haemoptysi
background
aim
occult
pneumothorax
radiolog
patholog
determin
chest
xray
visual
comput
tomographi
ct
especi
case
trauma
candid
mechan
ventil
progress
even
small
lesion
tension
pneumothorax
import
lifethreaten
problem
hand
earli
diagnosi
also
import
regard
medicoleg
evalu
ct
investig
thorac
trauma
reveal
exist
patholog
howev
matter
debat
appli
ct
everi
case
regard
cost
high
level
radiat
slow
turnov
emerg
clinic
current
studi
investig
clinic
radiolog
characterist
accompani
case
occult
pneumothorax
order
determin
indic
thorac
ct
case
trauma
method
case
thorac
trauma
select
case
medicoleg
report
evalu
forens
medicin
depart
three
year
data
obtain
medic
file
medicoleg
report
patient
retrospect
case
admit
emerg
clinic
trauma
underw
thorac
ct
pneumothorax
assess
case
result
detect
four
case
chest
xray
ratio
occult
pneumothorax
calcul
blunt
trauma
presenc
head
trauma
extens
subcutan
emphysema
multipl
rib
fractur
common
characterist
case
detect
ct
conclus
case
coexist
patholog
recommend
investig
comput
tomographi
regard
presenc
pneumothorax
background
aim
congenit
tracheal
stenosi
ct
rare
disord
almost
alway
diagnos
infanc
due
respiratori
failur
often
complic
cardiopulmonari
abnorm
patient
requir
earli
surgic
intervent
extrem
rare
patient
surviv
undiagnos
experienc
adult
case
ct
undiagnos
intub
method
case
report
literatur
review
result
femal
admit
rightsid
spontan
pneumothorax
past
medic
histori
rightsid
spontan
pneumothorax
three
time
past
year
bronchial
asthma
atop
dermat
recurr
rightsid
pneumothorax
indic
possibl
catameni
pneumothorax
thoracoscopi
plan
definit
diagnosi
induct
gener
anesthesia
routin
intub
possibl
due
tracheal
stenosi
variou
trial
intub
final
success
uncuf
pediatr
endotrach
tube
intern
diamet
mm
visibl
bleb
ectop
endometrium
pleura
surgeri
postop
cours
unev
chest
xray
comput
tomographi
imag
show
bronchial
stenosi
unnot
prior
surgeri
postop
bronchoscopi
reveal
tracheal
stenosi
due
complet
tracheal
ring
find
suggest
underli
acquir
diseas
therefor
diagnos
ct
conclus
experienc
rare
case
adult
ct
english
japanes
literatur
report
case
adult
ct
four
case
diagnos
imag
studi
prior
intub
case
report
case
found
routin
intub
procedur
unsuccess
case
requir
postpon
surgeri
case
requir
adjust
intub
procedur
addit
invas
method
highlight
import
observ
bronchu
care
imag
studi
prior
intub
moreov
patient
recurr
asthmat
episod
resist
treatment
possibl
ct
kept
mind
silpakorn
univers
faculti
pharmaci
nakhon
pathom
thailand
background
aim
leicest
cough
questionnair
lcq
valid
coughspecif
qol
measur
use
assess
treatment
efficaci
cough
includ
physic
psycholog
social
aspect
thai
version
lcq
lcqt
recent
valid
aim
investig
mcid
lcqt
method
patient
week
cough
enrol
pulmonari
allergi
clinic
ramathibodi
hospit
selfcomplet
lcqt
borg
cough
scale
initi
repeat
questionnair
global
rate
chang
grc
scale
followup
followup
period
categor
base
previous
report
respons
given
treatment
specif
diseas
group
week
week
week
anchorbas
method
mcid
defin
chang
lcqt
score
correspond
smallest
improv
grc
perceiv
patient
distributionbas
method
mcid
calcul
standard
error
measur
sem
half
standard
deviat
sd
result
total
patient
mean
sd
age
year
includ
etiolog
cough
postinfecti
coughand
acut
bronchiti
n
asthma
n
rhinosinus
n
copd
n
bronchiectasi
n
anchorbas
mcid
total
physic
social
psycholog
domain
respect
distributionbas
mcid
use
sem
total
domain
use
half
sd
respect
conclus
clinic
relev
chang
lcqt
score
anchorbas
mcid
total
physic
social
psycholog
domain
mcid
could
appli
sampl
size
determin
futur
clinic
trial
background
aim
bronchiectasi
complex
chronic
inflammatori
airway
diseas
signific
morbid
mortal
fatigu
complex
disabl
symptom
measur
object
limit
studi
fatigu
bronchiectasi
relationship
qualiti
life
qol
anxieti
depress
lower
limb
muscl
strength
exacerb
rate
airflow
obstruct
unclear
aim
studi
associ
fatigu
function
outcom
airflow
obstruct
method
conduct
exploratori
studi
consecut
patient
attend
bronchiectasi
specialist
clinic
april
septemb
demograph
sputum
microbiolog
bodi
mass
index
bmi
lung
function
test
st
georg
respiratori
questionnair
sgrq
repetit
sittostand
test
modifi
medic
research
council
dyspnoea
score
mmrc
breathlesscoughsputum
score
bcss
hospit
anxieti
depress
score
had
sputum
colour
hospit
admiss
emerg
depart
ed
attend
rate
analys
fatigu
measur
function
assess
chronic
ill
therapyfatigu
facitf
score
result
patient
femal
median
iqr
age
year
studi
median
iqr
percent
predict
fev
respect
none
current
smoker
patient
signific
fatigu
facitf
anxieti
hadsa
depress
hadsd
fatigu
facitf
significantli
correl
had
anxieti
depress
r
p
r
p
respect
posit
correl
number
ed
attend
hospit
admiss
r
p
r
p
respect
correct
fatigu
bmi
sgrq
bcss
predict
fev
conclus
fatigu
anxieti
depress
common
patient
bronchiectasi
fatigu
facitf
correl
anxieti
depress
had
lower
limb
strength
posit
correl
rate
hospit
admiss
ed
attend
potenti
novel
predictor
exacerb
bronchiectasi
monitor
treatment
outcom
background
aim
solitari
pulmonari
nodul
frequent
encount
chest
xray
computer
tomographi
scan
chest
differenti
diagnosi
board
rang
benign
granulomata
malign
establish
etiolog
spn
accur
manner
assum
critic
import
sinc
surgic
resect
patient
earlystag
lung
cancer
provid
highest
chanc
cure
token
avoid
thorac
surgeri
benign
spn
whenev
possibl
obviat
signific
morbid
present
decis
serial
ct
chest
obtain
tissu
diagnosi
depend
pretest
probabl
malign
characterist
find
ct
chest
inform
obtain
foreign
countri
nt
actual
data
thailand
preval
tuberculosi
high
object
studi
associ
characterist
chest
ct
find
patholog
diagnosi
patient
spn
phramongkutklao
hospit
method
retrospect
studi
includ
patient
spn
undergon
chest
ct
obtain
patholog
diagnosi
phramongkutklao
hospit
result
ninetytwo
patient
mean
age
year
studi
fiftyfour
male
forti
patient
histori
smoke
sixteen
patient
previou
malign
mean
diamet
spn
mm
locat
upper
lobe
patient
lower
lobe
patient
patholog
find
reveal
malign
spn
patient
granuloma
patient
presenc
smooth
border
associ
benign
spn
pr
p
spicul
border
associ
increas
preval
rate
malign
spn
pr
p
satellit
nodul
associ
benign
spn
pr
p
pleural
retract
associ
increas
preval
rate
malign
spn
pr
p
conclus
spicul
border
pleural
retract
chest
ct
associ
malign
spn
wherea
smooth
border
satellit
nodul
associ
benign
spn
background
aim
mesothelioma
common
primari
malign
tumor
pleura
aris
mesotheli
surfac
pleura
predomin
caus
exposur
asbesto
approxim
patient
document
asbesto
exposur
method
male
farmer
present
right
pleurit
chest
pain
nonproduct
cough
low
grade
fever
week
also
dyspnea
exert
weight
loss
kg
physic
examin
reveal
c
rr
respiratori
system
show
dull
percuss
decreas
breath
sound
rll
chest
radiograph
demonstr
right
pleural
effusionchest
ct
show
cm
enhanc
soft
tissu
lesion
right
hilar
region
multifoc
pleural
thicken
anterior
later
posterior
right
upper
hemithorax
moder
amount
right
pleural
effus
figur
pleural
fluid
anaylsi
demonstr
yellow
color
rbc
cellscumm
wbc
cellscumm
mononuclear
pmn
pleural
fluid
protein
gdl
serum
protein
gdl
pleural
fluid
ldh
ul
serum
ldh
ul
pleural
fluid
ada
ul
pleural
fluid
acid
fast
stain
neg
pleural
fluid
cytolog
neg
malign
result
patholog
find
right
pleural
biopsi
show
sever
fibrosi
area
hyalin
diffus
infiltr
solid
sheet
small
larg
cell
contain
irregular
nuclei
fine
vesicular
chromatin
promin
nucleoli
immunohistochem
find
tumor
cell
posit
calretinin
figur
ema
conclus
infiltr
tumor
malign
mesothelioma
epitheloid
variant
poor
perform
statu
patient
receiv
palli
treatment
insert
icd
releas
pleural
fluid
associ
asbesto
exposur
develop
malign
mesothelioma
well
known
nonetheless
proport
patient
suffer
diseas
appear
document
exposur
asbesto
fiber
known
sourc
background
aim
appli
continu
posit
airway
pressur
cpap
acceler
absorpt
pleural
effus
due
sever
patholog
condit
assess
effect
cpap
fluid
absorpt
talc
pleurodesi
outcom
order
control
malign
pleural
effus
method
case
control
studi
design
compar
patient
underw
talc
pleurodesi
januari
decemb
primari
end
point
procedur
durat
chest
tube
drain
ctd
day
compar
patient
appli
cpap
pressur
hour
per
day
remov
ctd
talc
pleurodesi
control
group
convent
post
procedur
care
secondari
end
point
pleurodesi
success
rate
result
among
patient
twelv
group
procedur
durat
trend
shorter
cpap
group
day
day
control
group
median
day
day
ci
p
cpap
group
trend
higher
success
pleurodesi
control
group
ci
p
conclus
cpap
appli
talc
pleurodesi
trend
shorter
ctd
durat
less
failur
compar
convent
care
cpap
applic
addit
care
post
pleurodesi
patient
howev
addit
studi
larg
scale
patient
need
confirm
find
background
aim
hypothyroid
etiolog
bilater
pleural
effus
rare
first
case
pleural
effus
associ
hypothyroid
report
schneierson
katz
describ
year
old
male
myxedema
right
side
pleural
effus
resolv
follow
thyroid
hormon
replac
paper
report
case
year
old
filipino
femal
present
one
week
histori
dyspnea
method
examin
bradycardia
bpm
hypothermia
c
facial
edema
decreas
bibas
breath
sound
grade
biped
edema
initi
chest
radiograph
reveal
bilater
pleural
effus
chest
ultrasound
show
ml
right
ml
left
also
massiv
pericardi
effus
tamponad
underw
thoracentesi
right
pericardiostomi
provid
relief
dyspnea
result
differ
etiolog
bilater
pleural
effus
includ
heart
failur
liver
cirrhosi
hypoalbuminemia
urem
pleuriti
connect
tissu
diseas
pulmonari
tuberculosi
malign
rule
base
avail
clinic
data
laboratori
examin
request
thyroid
function
test
reveal
elev
tsh
uiuml
decreas
pmoll
decreas
pmoll
patient
diagnos
hypothyroid
myxedema
crisi
start
levothyroxin
day
patient
remain
hemodynam
stabl
eventu
disharg
improv
follow
two
month
resolut
dyspnea
biped
edema
repeat
chest
xray
reveal
clear
lung
field
repeat
thyroid
function
test
also
improv
less
elev
tsh
normal
uiuml
pmoll
pmoll
respect
conclus
hypothyroid
appear
rare
caus
pleural
effus
usual
diagnosi
exclus
therefor
clinician
care
investig
clinic
sign
symptom
along
judici
use
avail
laboratori
test
utmost
import
fulli
establish
diagnosi
background
aim
woman
present
dypsnea
chest
back
pain
suffer
progress
dyspnea
year
receiv
ltot
bronchodil
therapi
copd
respiratori
failur
method
physic
examin
bilater
fine
crackl
admit
intens
care
unit
connect
niv
respiratori
failur
result
anemia
elev
creatinin
potassium
crp
level
also
panca
posit
vascul
primarili
consid
differenti
diagnosi
system
steroid
start
dose
mgday
mgkgday
vital
sign
improv
blood
ph
arteri
blood
ga
normal
followup
transfer
regular
ward
howev
develop
cardiorespiratori
arrest
day
admiss
intub
connect
mechan
ventil
thorac
ct
demonstr
bilater
newli
develop
pleural
effus
predominantli
peribronchovascularli
peripher
locat
area
consolid
patchi
ground
glass
opac
lung
figur
followup
gener
statu
suddenli
deterior
also
develop
anemia
sign
ct
find
alveolar
hemorrhag
consid
administ
puls
steroid
mgday
therapi
alveolar
hemorrhag
secondari
microscop
polyangi
mpa
howev
die
six
hour
connect
mechan
ventil
conclus
mpa
rare
ancarel
small
vessel
vascul
unknown
etiolog
patholog
hallmark
includ
alveolar
hemorrhag
due
fibrinoid
necrosi
capillar
lung
focal
segmentari
necrot
glomerulonephr
kidney
prognosi
pulmonari
hemorrhag
quit
poor
treatment
depend
sever
includ
corticosteroid
cyclophosphamid
rituximab
mycophenol
mofetyl
plasmapheresi
mpa
shuld
consid
anca
level
determin
case
constitut
symptom
dyspnea
accompani
chronic
renal
failur
background
aim
choriocarcinoma
rare
malign
trophoblast
cell
metastas
lung
case
year
old
ladi
diagnos
choriocarcinoma
lung
metastasi
without
progress
primari
site
tumour
result
patient
initi
diagnos
molar
pregnanc
complet
cycl
methotrex
cycl
emaco
obstetr
histori
reveal
miscarriag
follow
children
deliv
via
csection
present
dysfunct
uterin
bleed
diagnos
uterin
fibroid
treat
oral
contracept
pill
march
amenorrhea
suggest
myomectomi
howev
opt
conserv
manag
start
dydrogesteron
april
rais
bhcg
iu
subsequ
total
abdomin
hysterectomi
may
confirm
trophoblast
tumour
subsequ
follow
transabdomin
ultrasound
note
recurr
diseas
serial
bhcg
persist
iu
year
later
bhcg
increas
iu
repeat
transabdomin
ultrasound
show
cystic
lesion
measur
cm
howev
remain
asymptomat
static
bhcg
level
static
size
cystic
lesion
serial
ultrasound
unfortun
august
bhcg
level
start
increas
trend
contrast
ct
tap
done
show
larg
left
lung
lesion
left
lower
lobe
cm
histopatholog
ct
guid
lung
biopsi
confirm
metastat
trophoblast
choriocarcinoma
subsequ
refer
oncolog
manag
conclus
case
highlight
lung
metastasi
occur
without
local
recurr
choriocarcinoma
suspect
earli
bhcg
increas
trend
background
aim
abnorm
find
chest
imag
patient
earli
stage
allerg
bronchopulmonari
aspergillosi
abpa
nonspecif
diagnosi
often
difficult
although
articl
show
chang
abnorm
find
chest
xray
abpa
patient
time
paper
describ
longterm
followup
chest
ct
imag
report
case
yearold
male
abpa
past
histori
bronchial
asthma
upper
pharyng
cancer
annual
chang
observ
chest
ct
year
method
chest
ct
perform
annual
followup
abnorm
find
diagnosi
abpa
made
use
greenberg
patterson
diagnost
criteria
result
initi
chest
ct
follow
radiat
therapi
radic
lymph
node
dissect
pharyng
cancer
reveal
mucoid
impact
bronchial
wall
thicken
within
year
followup
abnorm
find
repeatedli
withdrawn
exacerb
diagnosi
abpa
made
lung
abnorm
improv
initi
corticosteroid
antifung
medic
conclus
patient
misdiagnos
bronchopneumonia
year
follow
initi
ct
present
case
result
find
illustr
remind
consid
abpa
patient
bronchial
asthma
nonspecif
ct
find
background
aim
inflamm
one
serou
membran
result
pleural
periton
pericardi
effus
common
patient
sle
howev
case
chylou
ascit
chylothorax
extrem
rare
herein
report
case
chylothorax
sle
patient
case
present
yearold
malay
ladi
pariti
chief
complaint
fever
associ
cough
short
breath
associ
pleurit
chest
pain
progress
oedema
abdomin
distens
past
year
manag
centr
medic
histori
reveal
patient
diagnos
sle
bilater
pleural
effus
follow
persist
pleural
effus
physic
examin
reveal
tachypnea
reduc
breath
sound
lung
crepit
lower
zone
stoni
dull
percuss
reduc
vocal
reson
laboratori
test
show
high
twc
indic
infect
ct
thorax
reveal
worsen
seros
massiv
pleural
effus
chest
tube
insert
reveal
chylothorax
pleuroscopi
reveal
adhes
chalki
white
effus
hyperaem
pleural
whitish
patch
bilater
chest
drainag
reveal
exud
effus
liter
pleural
fluid
analysi
reveal
mgl
protein
triglycerid
mmoll
mgdl
patient
requir
prolong
chest
drainag
suitabl
candid
surgeri
view
high
risk
bleed
restart
high
dose
prednisolon
mg
od
hcq
mg
od
azathioprin
mg
od
three
month
taper
dose
prednisolon
effus
reduc
base
cxr
clinic
remain
asymptomat
discuss
conclus
chylou
ascit
chylothorax
rare
describ
patient
sle
therefor
besid
analysi
blood
sampl
detail
analysi
effus
serou
membran
carri
background
aim
neg
pressur
pulmonari
edema
nppe
secondari
post
upper
airway
obstruct
welldescrib
phenomenon
incid
rare
import
differ
diagnosi
fast
intervent
nppe
experienc
nppe
post
extub
emerg
gener
anesthesia
want
share
experi
happen
goe
healthi
man
underw
endoscop
pansinu
procedur
follow
administr
mg
lidocain
fentanyl
mg
propofol
mg
rocuronium
easili
intub
oral
endotrach
tube
anesthesia
maintain
use
sevofluran
rocuronium
follow
fentanyl
analgesia
patient
underw
unev
surgeri
last
hour
anesthesia
emerg
lot
bleed
patient
nose
oral
caviti
agit
cough
sever
time
given
inform
place
situat
patient
calm
breath
spontan
extub
adequ
breath
pulseoximetri
show
around
transfer
post
anesthesia
care
unit
pacu
immedi
arriv
pacu
check
oxygen
lmin
suppli
via
non
breath
facial
mask
rose
last
minut
decreas
patient
deni
dyspnea
start
sweat
even
though
administr
sugammadex
mg
lasix
mg
pulmonari
edema
show
postop
chest
xray
hypoxemia
aggrav
decreas
chekc
mmhg
suppli
manual
ventil
assist
administr
midazolam
mg
cisatracurium
mg
reintub
easili
transfer
surgic
intens
care
unit
mechan
ventil
begun
approxim
day
later
pulmonari
edema
complet
resolv
radiograph
clinic
patient
wean
ventil
extub
day
oper
day
transfer
gener
ward
observ
night
discharg
home
without
complic
method
amyloidosi
rare
diseas
caus
deposit
abnorm
protein
call
amyloid
fibril
caus
disrupt
normal
tissu
amyloid
fibril
confin
deposit
one
organ
mani
organ
caus
local
amyloidosi
system
amyloidosi
howev
respiratori
involv
amyloidosi
rare
seen
report
case
tracheobronchi
amyloidosi
result
thai
man
present
left
eyelid
mass
year
ophthalmologist
decid
remov
mass
preoper
investig
within
normal
limit
intub
intraop
period
unev
finish
surgeri
extub
period
anesthesiologist
found
ml
bright
red
blood
came
endotrach
tube
massiv
hemoptysi
continu
admit
icu
prior
histori
respiratori
tract
diseas
except
occasion
scanti
hemoptysi
never
mention
cbc
coagulogram
blood
chemistri
urin
analysi
normal
sign
system
bleed
chest
xray
ct
scan
show
multifoc
consolid
ground
glass
opac
scatter
lung
circumferenti
wall
thicken
along
trachea
rightleft
main
bronchi
calcifi
bronchial
wall
underw
bronchoscopi
besid
tracheobronchomalacia
found
irregular
airway
mucosa
extend
subglott
area
second
gener
bronchu
contact
bleed
lesion
tri
stop
bleed
fail
massiv
hemoptysi
continu
need
blood
transfus
everyday
patient
suffer
ventilatorassoci
pneumonia
dead
later
patholog
report
tracheal
tissu
eyelid
mass
consist
amyloidosi
conclus
case
repres
rare
clinic
manifest
tracheobronchi
amyloidosi
caus
bleed
patient
due
fragil
blood
vessel
infiltr
amyloid
protein
disabl
normal
vasoconstrict
properti
background
aim
scleros
pneumocytoma
sp
rare
primari
pulmonari
tumor
first
describ
liebow
hubbel
gener
classifi
benign
howev
occasion
metastas
organ
surgic
resect
cur
treatment
report
case
sp
present
slow
grow
lung
mass
method
case
presentationin
june
asymptomat
femal
hotelhousekeep
visit
hospit
evalu
slow
grow
lung
mass
detect
followup
chest
xray
homogen
mass
welldefin
border
first
observ
annual
screen
chest
xray
computer
tomographi
chest
reveal
cm
heterogen
enhanc
mass
without
calcif
later
basal
segment
left
lower
lobe
patient
initi
diagnos
possibl
earli
stage
lung
cancer
grow
tumor
thu
refer
cardiothorac
clinic
surgic
evalu
underw
lobectomi
left
lower
lung
gross
patholog
examin
reveal
cm
well
circumscrib
graywhit
mass
microscop
examin
show
mass
compos
numer
space
line
endotheli
ciliat
columnar
cell
papillari
arrang
remain
stroma
show
hypercellular
altern
sclerot
hyalin
edemat
area
stromal
cell
possess
rather
monoton
round
basophil
nuclei
inconspicu
nucleoli
mitot
figur
rare
seen
find
compat
benign
scleros
pneumocytoma
patient
schedul
annual
followup
year
followup
period
evid
tumor
recurr
discuss
demonstr
patient
primari
pulmonari
sp
rare
tumor
occur
predominantli
middleag
women
major
case
present
asymptomat
abnorm
thorac
imag
without
pathognomon
radiograph
find
lead
difficulti
make
correct
preoper
diagnosi
asymptomat
yearold
man
present
evalu
mediastin
mass
chest
comput
tomographi
scan
mass
demonstr
contrast
enhanc
multipl
scatter
calcif
mr
imag
reveal
heterogen
mass
low
intermedi
signal
intens
mr
imag
reveal
hyperintens
mass
lesion
flow
void
repres
enlarg
vein
drain
superior
inferior
vena
cava
svc
ivc
contrastenhanc
mr
imag
reveal
mass
multilocular
margin
enhanc
imag
find
mass
diagnos
mediastin
lvm
lvm
larg
remov
moreov
lvm
abund
blood
flow
also
direct
connect
svc
ivc
surgeri
sclerotherapi
thought
high
risk
complic
bleed
system
infarct
therefor
decid
followup
patient
without
treatment
mass
remain
stabl
ct
imag
obtain
six
month
discuss
vascular
malform
mediastinum
rare
account
mediastin
tumor
today
case
mediastin
lvm
report
biopsi
need
definit
diagnosi
howev
could
confer
risk
bleed
treatment
choic
vascular
malform
surgeri
sclerotherapi
patient
treat
surgeri
patient
lvm
larg
remov
complet
conclus
conclus
present
case
huge
lvm
mediastinum
diagnos
imag
find
condit
rare
biopsi
sometim
difficult
therefor
characterist
imag
find
import
definit
diagnosi
background
aim
introduct
spontan
pneumothorax
sp
primari
psp
secondari
ssp
base
absenc
presenc
underli
lung
diseas
respectivelyit
associ
high
recurr
rate
untreatedherein
present
uniqu
case
old
male
right
upper
lobe
mass
present
recurr
spontan
pneumothorax
case
present
male
nonasthmat
nonsmok
year
pta
sudden
chest
painno
symptomspneumothorax
left
seen
chest
xraytub
thoracostomi
left
donechest
ct
scan
unremarkableh
year
pta
sudden
rightsid
chest
pain
chest
xray
show
pneumothorax
righthighflow
therapi
givenchest
ct
scan
unremarkablepneumothorax
resolveddischarg
week
pta
sudden
rightsid
chest
pain
dyspneano
symptomspneumothorax
right
note
chest
xraytub
thoracostomi
right
donechest
ct
scan
biapic
bleb
hazi
confluent
densiti
rul
bronchiectasi
right
posterior
basal
segmentantitb
therapi
startedh
refer
institutionh
bmi
kgm
preoper
pulmonari
evalu
donedu
fail
vat
open
thoracotomi
rightblebectomi
andvwedg
resect
pulmonari
mass
done
mechan
pleurodesi
biopsi
mass
tuberculomapostop
period
unremark
discharg
daysantitb
therapi
complet
discuss
psp
develop
among
without
underli
lung
diseaseit
common
among
young
tall
thin
male
like
patient
ssp
seriou
psp
exist
pulmonari
condit
patient
type
spontan
pneumothorax
recurr
exact
pathogenesi
psp
remain
unknown
may
due
spontan
ruptur
subpleur
bleb
bulla
manag
may
surgic
nonsurg
depend
size
pneumothorax
symptomatolog
recurr
retrospect
surgic
intervent
alreadi
indic
patienthowev
vat
readili
avail
countri
conclus
exact
pathogenesi
psp
still
unknown
close
followup
episod
sp
need
spontan
pneumothorax
address
advanc
surgic
intervent
indic
background
aim
exud
pleural
effus
determin
use
light
criteriath
common
caus
exud
pleural
effus
pneumonia
tuberculosi
malignancythi
studi
done
determin
use
serum
pleural
protein
pr
lactat
dehydrogenas
ldh
ratio
diagnosi
effus
secondari
diseas
entitiesth
pilot
studi
made
talasaz
et
alit
show
signific
differ
mean
serum
pleural
prldh
among
parapneumon
malign
tuberculosi
group
method
total
adult
patient
includ
studi
admit
seen
philippin
heart
center
januari
june
patient
diagnos
exud
pleural
effus
wherein
caus
establish
base
clinic
data
pleural
fluid
analysi
andor
biopsi
need
subsequ
group
parapneumon
tubercul
malign
pleural
effus
data
summar
mean
standard
deviat
numer
variabl
frequenc
percentag
categor
variabl
homogen
characterist
three
group
test
use
analysi
varianc
anova
quantit
variabl
fisher
exact
test
qualit
variabl
comparison
mean
serum
pleural
fluid
prldh
ratio
three
group
ie
malign
tb
parapneumon
determin
test
use
anova
tukey
hsd
test
done
signific
anova
result
level
signific
alpha
set
presenc
cancer
coronari
arteri
diseas
play
role
develop
exud
pleural
effus
pvalu
respect
accordingli
signific
differ
serum
pleural
ldh
serum
pleural
protein
group
well
serum
pleural
prldh
ratio
conclus
serum
pleural
prldh
ratio
unabl
differenti
underli
caus
exud
pleural
effus
tabl
pf
adenosin
deaminas
ada
cut
iul
good
sensit
specif
posit
neg
predict
valu
ppv
npv
good
overal
valid
tpe
cut
iul
show
better
specif
virtual
exclud
chronic
pppe
low
sensit
npv
pf
lymphocytosi
sensit
detect
tbe
low
specif
neutrophil
predomin
present
among
pppe
npv
tbeboth
tbe
pppe
mean
pf
sugar
mgdl
howev
find
neither
sensitv
specif
conclus
studi
obstruct
sleep
apnoea
common
among
male
male
femal
ratio
male
femal
ratio
increas
increas
sever
osa
common
age
group
associ
co
morbid
like
diabet
hypertens
common
among
osa
patient
increas
bmi
mallampati
score
neck
circumfer
go
togeth
increas
sever
osa
therefor
demograph
pattern
osa
last
two
year
central
sri
lanka
similar
establish
demograph
descript
world
background
aim
spirometri
perform
pulmonari
laboratori
physician
offic
publish
report
qualiti
spirogram
spirometr
interpret
low
flowvolum
loop
inadequ
evalu
assur
adequ
test
qualiti
forc
expiratori
maneuv
involv
variabl
flow
volum
time
rotat
axe
one
obtain
flowvolum
volumetim
curv
spirometri
devic
commonli
recogn
short
exhal
time
usual
identifi
end
exhal
inspir
begin
regardless
breathhold
short
expir
time
truncat
forc
expir
produc
high
ratio
approach
forc
expiratori
time
approach
second
therefor
short
forc
expiratori
time
mask
airway
obstruct
inform
volumetim
curv
flowvolum
curv
complementari
aim
illustr
inadequaci
flowvolum
curv
use
isol
pft
interpret
method
use
clinic
spirogram
pulmonari
function
laboratori
intermountain
healthcar
inc
result
breath
hold
forc
expir
obviou
volumetim
curv
difficult
identifi
flowvolum
curv
red
arrow
figur
normal
spirogram
figur
mimick
short
exhalt
time
figur
appar
volumetim
curv
examin
well
figur
breath
hold
short
exhal
time
recogn
dash
red
line
figur
indic
second
breath
hold
becom
clear
exhal
time
figur
report
spriometri
devic
second
right
red
arrowhead
dash
vertic
line
wherea
true
exhal
time
second
left
arrowhead
dash
vertic
line
conclus
spirometri
interpret
includ
examin
flowvolum
volumetim
curv
qualiti
assur
achiev
flowvolum
curv
alon
univers
utah
intern
medicin
pulmonarycrit
care
divis
salt
lake
citi
usa
gleneagl
hospit
asian
american
liver
centr
singapor
singapor
background
aim
current
approach
clinic
decisionmak
base
individu
expert
consid
larg
amount
inform
individu
expert
make
variabl
decis
face
inform
much
variat
unwarr
link
good
evid
medic
care
qualiti
reduc
unwarr
variat
clinic
decis
institut
physician
major
reduct
unwarr
variat
gener
requir
effect
physician
decisionsupport
howev
decisionsupport
provid
person
instruct
match
individu
patient
needsa
goal
met
almost
current
guidelin
protocol
use
replic
clinician
decis
method
produc
consist
contextsensit
person
patient
care
instruct
detail
comput
protocol
protocol
rule
appli
prospect
time
clinician
decisionmak
produc
replic
decis
decis
differ
clinician
figur
protocol
rule
deriv
retrospect
databas
analysi
aim
describ
differ
method
guidelin
protocol
rule
gener
retrospect
data
analysi
method
develop
implement
clinic
detail
comput
protocol
manag
mechan
ventil
iv
fluid
blood
glucos
manag
pulmonari
function
interpret
past
year
export
protocol
across
cultur
includ
singapor
across
medic
disciplin
clinician
complianc
protocol
instruct
result
common
paperbas
protocol
variabl
comparison
studi
result
becom
difficult
lead
conflict
result
figur
illustr
variabl
insulin
dose
recommend
publish
protocol
gray
area
iv
insulin
infus
rate
insulin
unit
hour
van
den
bergh
protocol
dash
line
eprotocolinsulin
one
detail
contextsensit
comput
protocol
develop
intermountain
ld
hospit
conclus
detail
comput
protocol
use
feasibl
usa
singapor
implement
detail
comput
protocol
asian
pacif
region
increas
qualiti
care
scientif
credibl
clinic
research
univers
utah
intern
medicin
pulmonarycrit
care
divis
salt
lake
citi
usa
gleneagl
hospit
asian
american
liver
centr
depart
singapor
singapor
background
aim
hippocrat
expert
authoritarian
model
clinician
decisionmak
requir
clinician
manag
complex
inform
use
judgment
make
best
decis
medic
decisionmak
intend
consist
improv
clinic
outcom
individu
patient
goal
requir
decis
tightli
link
best
evid
howev
known
decad
clinician
consist
make
decis
carri
action
link
best
evid
one
contributor
failur
clinician
make
consist
decis
link
best
evid
limit
human
cognit
due
limit
shortterm
work
memori
psychologist
known
decad
shortterm
memori
limitedestim
current
limit
ae
construct
decis
becom
degrad
aim
identifi
import
barrier
clinic
use
decisionsupport
detail
comput
protocol
method
use
detail
comput
protocol
base
best
evid
standard
clinician
decisionmak
identifi
method
protocol
develop
multipl
clinician
follow
protocol
instruct
make
decis
face
patient
data
protocol
respond
chang
patient
context
gener
person
medicin
instruct
match
need
individu
patient
result
collabor
physician
follow
person
medicin
protocol
instruct
time
elimin
differ
institut
includ
nation
univers
hospit
singapor
figur
b
figur
partial
glucos
protocol
screen
imag
use
detail
comput
protocol
decad
clinician
resist
adopt
protocol
realiz
first
step
protocol
use
recognit
clinician
like
human
overestim
abil
accord
illusori
superior
principl
conclus
detail
comput
protocol
use
feasibl
use
singapor
clinician
limit
recogn
systemat
implement
detail
comput
protocol
allow
uniform
deliveri
good
medic
care
develop
develop
countri
teach
hospit
respiratori
kandi
sri
lanka
teach
hospit
respiratori
medicin
kandi
sri
lanka
background
aim
diaphragm
import
muscl
ventil
function
evalu
diaphragmat
function
undiagnos
breathless
import
diaphragmat
weak
commonli
suspect
identifi
elev
hemidiaphragm
chest
radiograph
aim
studi
describ
demograph
etiolog
patient
diaphragmat
weak
absenc
obviou
caus
abnorm
chest
xray
method
data
collect
patient
elev
hemidiaphragm
chest
radiographi
april
june
questionnair
base
interview
use
identifi
symptomatolog
collect
demograph
data
patient
clinic
assess
relev
investig
carri
ascxr
pulmonari
function
test
fluoroscop
ct
chest
nerv
conduct
studi
phrenic
nerv
emg
diaphragm
cervic
spine
xray
gener
relev
investig
result
analyz
use
microsoft
offic
excel
result
patient
male
mean
age
rang
select
fluoroscopi
reveal
non
function
normal
patient
restrict
pattern
normal
obstruct
pattern
patient
moder
impair
mvv
patient
udp
nerv
conduct
reveal
phrenic
nerv
palsi
pnp
evid
myopathi
diaphragmat
emg
patient
phrenic
nerv
conduct
normal
eventr
diaphragm
patient
pnp
past
tb
fibrosi
bronchiectasi
dm
caus
identifi
rest
patient
conclus
case
seri
reveal
one
third
appar
elev
due
diaphragmat
weak
major
patient
udp
pnp
diabet
mellitu
past
tb
fibrosi
case
could
identifi
obviou
patholog
patient
woman
suffer
refractori
pneumothorac
lung
sinc
year
old
age
underw
pleurodesi
left
chest
caviti
result
recurr
pneumothorax
left
side
famili
histori
includ
pneumothorac
brother
matern
aunt
cousin
patient
uniqu
distribut
multipl
lung
cyst
locat
lowermedi
zone
lung
field
adjac
interlobar
fissur
abut
peripher
pulmonari
vessel
find
led
strong
suspicion
secondari
pneumothorax
caus
syndrom
bhd
genet
diagnos
bhd
mean
peripher
blood
test
underw
surgic
reinforc
whole
viscer
pleura
right
lung
absorb
cellulos
mesh
surgicel
ethicon
prevent
recurr
pneumothorax
unpredict
thorac
endometriosi
detect
central
tendon
right
diaphragm
endometriosi
resect
stapl
devic
follow
surgic
reinforc
diaphragm
use
surgicel
postop
cours
unev
recurr
pneumothorax
record
followup
year
surgeri
teach
hospit
respiratori
kandi
sri
lanka
teach
hospit
respiratori
unit
kandi
sri
lanka
tuberculosi
second
lead
infecti
caus
death
world
wild
kill
million
peopl
per
year
despit
potenti
curabl
diseas
sri
lanka
consid
countri
moder
risk
tuberculosi
essenti
knowledg
healthcar
profession
regard
tuberculosi
manag
need
date
order
improv
manag
object
find
awar
tuberculosi
manag
among
nurs
stuff
attach
th
kandi
method
studi
done
teach
hospit
kandi
routin
health
educ
program
two
questionnair
consist
stem
cover
etiolog
symptom
sign
diagnosi
treatment
drug
side
effect
drug
storag
dot
spread
diseas
tuberculosispregn
lactat
given
complet
programresult
analyz
use
microsoft
xl
result
total
number
respond
femal
total
mark
obtain
respond
pre
post
program
identifi
area
question
calcul
averag
mark
obtain
pre
evalu
question
post
evalu
question
knowledg
regard
monitor
patient
treatment
tuberculosi
pregnanc
lactat
poor
pre
evalu
show
satisfactori
improv
post
evalu
puengpapat
faculti
medicin
thammasat
univers
medicin
pathumthani
thailand
background
aim
defin
undiagnos
pleural
effus
remain
undiagnos
initi
thoracocentesi
repeat
thoracocentesi
pleural
biopsi
common
caus
malign
tuberculosi
acut
pulmonari
embol
ape
pneumonia
mani
caus
consid
potenti
caus
method
thai
male
physic
activ
present
dri
cough
dyspnea
exert
month
insignific
weight
loss
physic
examin
follow
bp
mmhg
heart
rate
min
oxygen
satur
room
air
pit
edema
leg
chest
xray
reveal
pleural
effus
right
lower
lung
field
figur
right
thoracocentesi
done
week
present
serosanguin
pleural
fluid
rbc
cellsmm
wbc
cellsmm
monocyt
predomin
protein
gdl
observ
next
month
clinic
chest
xray
second
right
thoracocentesi
done
serosanguin
fluid
pleural
fluid
ada
ul
therefor
ct
chest
done
moder
amount
right
pleural
effus
passiv
atelectasi
right
lung
observ
lymphadenopathi
detect
consequ
third
right
thoracocentesi
pleural
biopsi
done
neg
cytolog
malign
patholog
granuloma
malign
final
ctpa
done
small
intralumin
fill
defect
segment
branch
pulmonari
arteri
suppli
anterior
segment
right
upper
lung
seen
figur
chest
xray
pa
upright
show
right
pleural
effus
report
case
relat
pulmonari
diseas
male
present
progress
dyspnea
signific
weight
loss
month
physic
examin
reveal
mild
pale
conjunctiva
small
subment
mass
laboratori
studi
show
mild
anemia
mild
renal
impair
increas
serum
globulin
level
serum
protein
electrophoresi
show
polyclon
gammopathi
neg
result
immunofix
test
bone
marrow
patholog
immunohistochemistri
show
lymphoplasmacyt
infiltr
normal
plasma
cell
subment
mass
dissect
also
reveal
lymphoplasmacyt
infiltr
chest
radiographi
chest
comput
tomographi
show
mediastin
adenopathi
bilater
multifoc
patchi
opac
thicken
interlobular
septa
figur
bronchoscopi
transbronchi
biopsi
perform
lung
parenchym
patholog
also
reveal
lymphoplasmacyt
infiltr
posit
test
igg
posit
cell
ratio
greater
serum
igg
subclass
also
show
level
mgdl
diagnosi
relat
pulmonari
diseas
made
patient
subsequ
treat
prednisolon
approxim
one
month
treatment
prednisolon
dyspnea
markedli
improv
background
aim
coinfect
higher
bacteria
endem
fungi
quit
rare
normal
person
report
rare
case
lung
abscess
caus
actinomyc
histoplasma
immunocompet
patient
method
man
refer
evalu
progress
pulmonari
lesion
prior
medic
histori
presenc
cough
leftsid
pleurit
chest
pain
last
year
cxr
time
show
cm
masslik
lesion
left
lower
lobe
bronchoalveolar
lavag
fluid
reveal
posit
afb
mycobacteri
tuberculosi
cultur
serolog
hiv
neg
complet
treatment
standard
antitb
drug
month
symptom
improv
cxr
show
enlarg
initi
lesion
crescent
format
result
siriraj
hospit
physic
examin
remark
digit
club
chest
ct
scan
demonstr
cm
caviti
later
basal
segment
left
lower
lobe
surround
centrilobular
nodul
repeat
bronchoscopi
perform
foul
smell
discharg
necrot
tissu
found
later
basal
segment
bronchu
histopatholog
show
squamou
cell
metaplasia
mark
chronic
inflamm
granul
tissu
thoracotomi
segmentectomi
perform
patholog
examin
demonstr
thin
filament
gramposit
branch
filament
bacteria
border
eosinophil
project
splendorehoeppli
materi
consist
actinomyc
spp
small
necrot
granulomat
nodul
contain
bud
yeast
also
found
morpholog
favor
histoplasmosi
spp
symptom
cxr
gradual
improv
treatment
coamoxyclav
itraconazol
howev
subsequ
bacteri
fungal
cultur
neg
conclus
actinomycosi
histoplasmosi
uncommon
lower
respiratori
tract
infect
manifest
local
consolid
lung
nodul
mass
even
cavitari
lesion
case
report
superimpos
infect
agent
preexist
destroy
lung
lesion
pulmonari
tb
report
patient
present
nonlifethreaten
hemoptysi
durat
week
year
three
also
pleurit
chest
pain
two
complain
decreas
appetit
weight
loss
initi
diagnosi
pulmonari
tuberculosi
neg
sputum
smear
impress
patient
howev
subsequ
histori
ingest
raw
crab
crayfish
nearbi
waterfal
establish
two
three
patient
cbc
result
reveal
eosinophilia
absolut
eosinophil
count
mm
conclus
pulmonari
paragonimiasi
may
mimic
pulmonari
tuberculosi
other
acut
chronic
lung
diseas
thorough
histori
take
identifi
egg
clinic
specimen
ravel
definit
diagnosi
ebvassoci
smooth
muscl
cell
tumor
rare
subset
smooth
muscl
tumor
occur
immunosuppress
individu
herein
report
yearold
male
live
hiv
infect
take
antiretrovir
agent
zidovudin
lamivudin
lopinavirritronavir
year
recent
present
chronic
cough
signific
weight
loss
month
physic
examin
show
reson
percuss
decreas
breath
sound
left
lower
lobe
area
chest
xray
demonstr
atelectasi
left
lower
lobe
consist
comput
tomographi
ct
chest
reveal
collaps
left
lower
lobe
attribut
endobronchi
mass
left
main
bronchu
cbc
blood
chemistri
normal
fiberopt
bronchoscop
perform
discov
endobronchi
mass
left
main
bronchu
caus
nearli
complet
obstruct
lesion
biopsi
done
patholog
show
smooth
muscl
cell
tumor
immunohistochemistri
strain
posit
desmin
smooth
muscl
actin
muscl
actin
wherea
neg
alk
request
ebv
situ
hybrid
demonstr
posit
subsequ
schedul
rigid
bronchoscopi
argon
coagul
tumor
remov
uneven
advis
continu
antiretrovir
therapi
close
followup
without
locoregion
recurr
conclus
report
rare
case
hivrel
ebvassoci
endobronchi
smooth
muscl
cell
tumor
success
treatment
tumor
resect
antiretrovir
therapi
background
aim
order
observ
effect
tanreq
combin
antibiot
treatment
pneumonia
children
method
children
pneumonia
patient
randomli
divid
treatment
group
control
group
tanreq
given
treatment
group
combin
antibiot
therapi
antibiot
given
patient
control
group
result
recoveri
time
bodi
temperatur
treatment
group
shorter
time
cough
significantli
shorter
control
group
signific
differ
averag
length
hospit
time
p
effect
treatment
group
better
control
group
background
aim
posit
lightwand
midlin
oral
caviti
quit
challeng
patient
cervic
immobil
direct
laryngoscopi
allow
lightwand
tip
easili
access
glottic
open
test
hypothesi
laryngoscopeassist
lightwand
intub
allow
success
endotrach
intub
convent
lightwand
intub
method
patient
requir
cervic
immobil
intub
cervic
spine
surgeri
randomli
alloc
two
group
convent
lightwand
techniqu
use
endotrach
intub
control
group
group
c
n
wherea
laryngoscopeassist
lightwand
intub
techniqu
laryngoscopeassist
group
group
l
n
group
l
macintosh
laryngoscop
insert
oral
caviti
advanc
past
tongu
epiglotti
tip
visibl
lightwand
tip
place
epiglotti
direct
view
epiglotti
tip
success
rate
intub
first
attempt
intub
time
hemodynam
chang
postop
airway
complic
evalu
result
success
rate
intub
first
attempt
significantli
higher
vs
p
number
scoop
movement
significantli
lower
median
iqr
vs
p
group
l
group
c
intub
time
postop
sore
throat
score
incid
hypertens
tachycardia
postop
oral
mucos
bleed
hoars
compar
two
group
conclus
laryngoscopeassist
lightwand
intub
allow
success
intub
first
attempt
without
increas
intub
time
compar
tradit
lightwand
intub
patient
requir
cervic
immobil
intub
cervic
spine
surgeri
background
aim
pneumonia
main
caus
death
among
patient
pneumoconiosi
however
studi
concern
associ
factor
pneumoconiosi
pneumonia
therefor
aim
studi
evalu
factor
associ
increas
risk
mortal
pneumonia
among
patient
pneumoconiosi
method
medic
record
pneumoconiosi
patient
hospit
pneumonia
investig
exclud
specif
condit
lung
cancer
malign
insuffici
medic
record
femal
patient
exclud
final
elig
popul
subject
divid
two
group
byclin
outcom
pneumonia
deceas
group
surviv
group
two
group
compar
interm
age
smoke
histori
episod
recent
pneumonia
concomit
interstiti
fibrosi
fungal
ballinfect
extent
small
opac
grade
larg
opac
result
spirometri
multipl
logist
regressionwa
appli
determin
associ
variabl
mortal
pneumonia
deceas
group
show
frequent
histori
recent
pneumonia
p
higher
preval
ofinterstiti
fibrosi
p
longer
hospit
period
p
proport
subject
haddecreas
fvc
less
predict
valu
higher
deceas
group
p
multipl
logisticregress
adjust
age
smoke
histori
recent
pneumonia
fungal
ball
larg
opac
profus
fvc
less
predict
valu
histori
recent
pneumonia
concomit
interstiti
fibrosi
type
ofpneumoconiosi
fungal
ball
present
statist
signific
associ
mortal
pneumonia
conclus
concomit
fungal
ball
interstiti
fibrosi
histori
recent
pneumonia
within
day
type
pneumoconiosi
fvc
less
predict
valu
less
predict
valuepres
statist
signific
associ
mortal
pneumonia
attent
given
topati
factor
treat
pneumonia
pneumoconiosi
background
aim
postop
pulmonari
complic
common
among
patient
undergo
major
surgeri
perpetu
succour
hospit
one
major
tertiari
hospit
cebu
citi
philippin
sinc
data
avail
author
therefor
decid
determin
incid
outcom
postop
complic
patient
method
paper
observationalanalyt
prospect
studi
patient
underw
major
surgeri
perpetu
succour
hospit
patient
check
prior
oper
followedup
postop
note
develop
postop
pulmonari
complic
identifi
risk
factor
type
complic
develop
well
subsequ
outcom
result
overal
incid
low
studi
patient
undergo
major
surgeri
perpetu
succour
hospit
among
complic
pneumonia
atelectasi
pleural
effus
document
seen
aris
hour
postop
background
aim
effici
profession
activ
primari
care
physician
depend
number
factor
determin
condit
work
mechan
degre
achiev
aim
aim
studi
evalu
factor
determin
level
profession
motiv
physician
ensur
qualiti
effect
respiratori
care
method
sociolog
survey
among
primari
care
physician
n
amur
yaroslavl
region
russian
feder
conduct
special
develop
questionnair
question
among
respond
women
men
method
spearman
rank
correl
coeffici
conjugaci
coeffici
associ
coeffici
conting
use
statist
analysi
result
question
interest
provid
highqual
care
patient
answer
ae
respond
posit
ae
neg
ae
know
answer
degre
posit
motiv
provid
highqual
effect
medic
care
determin
work
experi
level
profession
qualif
found
correl
r
work
experi
specif
weight
posit
neg
repli
question
posit
respons
given
ae
physician
whose
work
experi
less
year
ae
physician
whose
work
experi
year
p
depend
found
degre
motiv
physician
highqual
product
work
level
profession
qualif
experienc
highqualifi
physician
decreas
degre
motiv
work
effect
conclus
motiv
physician
focus
effici
qualiti
health
care
respiratori
patient
depend
work
experi
level
profession
qualif
studi
undertaken
assess
lung
function
spirometri
asymptomat
popul
resid
delhincr
least
two
year
age
year
method
volunt
popul
fulfil
studi
criteria
age
length
stay
lo
delhincr
taken
studi
inform
consent
proforma
note
demograph
biometr
histori
smoke
exercis
asthma
lung
problem
record
spirometri
perform
portabl
sstandardis
spiromet
experienc
technician
evalu
pulmonologist
result
total
volunt
student
fulfil
criteria
elig
studi
exclud
smoker
asthmat
lung
diseas
femal
male
averag
age
year
averag
lo
year
ncr
found
perfectli
normal
spirometri
anoth
normal
fvc
ratio
either
abnorm
pefr
fef
restrict
defect
seen
obstruct
defect
mix
defect
conclus
evid
earli
lung
damag
advanc
lung
damag
among
asymptomat
young
popul
expos
high
level
environment
pollut
background
aim
exposur
air
pollut
combust
fuel
signific
hazard
public
health
petroleum
detriment
effect
respiratori
function
constantli
expos
worker
recent
lpg
altern
fuel
sourc
advantag
lesser
cost
better
safeti
profil
studi
aim
measur
lung
function
among
taxi
driver
gasolinebas
lpgconvert
taxi
unit
method
one
hundr
six
taxi
driver
recruit
period
patient
demograph
comorbid
ill
smoke
histori
drive
histori
obtain
questionnair
simpl
spirometri
measur
lung
function
associ
drive
histori
lung
function
analyz
background
aim
indic
popul
diseas
incid
one
import
indic
public
health
well
level
organ
avail
medic
care
aim
studi
evalu
region
featur
respiratori
diseas
rd
incid
territori
fareast
russia
method
primari
diseas
incid
spread
rd
applic
materi
state
statist
monitor
rd
territori
russian
feder
rf
studi
result
structur
primari
diseas
incid
rd
amount
territori
region
conclus
statist
analysi
main
indic
level
dynam
rd
show
region
differ
caus
natur
climat
featur
differ
level
avail
medic
servic
form
low
motiv
popul
appli
medicalprophylact
institut
rd
background
aim
wheat
flour
dust
caus
occup
asthma
oa
bakeri
worker
studi
design
assess
relationship
wheat
flour
dust
exposur
factor
age
histori
atopi
nutrit
statu
occup
person
protect
equip
ppe
smoke
habit
method
cross
section
studi
analityc
descript
conduct
bakeri
worker
work
product
warehous
administras
market
divis
year
randomli
sampl
examin
interview
use
questionnair
physic
examin
chest
xray
spirometri
daili
peak
flow
time
peak
flow
meter
week
wheat
flour
enzym
examin
total
sampl
subject
subject
follow
within
weeak
result
eighti
nine
subject
year
old
five
subject
indic
oa
spirometri
result
subject
mild
obstruct
subject
moder
obstruct
p
pef
result
subject
p
support
clinic
symptom
oa
three
subject
work
moder
dust
concentr
subject
work
mild
dust
concentr
spt
found
posit
subject
oa
five
subject
experi
asthma
symptom
enzym
result
spectrophotometri
show
noamylas
enzym
activ
cellulos
enzym
activ
proteas
enzym
activ
ug
thiol
pmg
found
conclus
relationship
age
histori
atopi
nutrit
statu
occup
use
ppe
smoke
habit
oa
incid
worker
product
warehous
divis
like
experi
oa
worker
market
administr
divis
posit
spt
result
found
oa
subject
product
area
n
yusril
ad
susanto
j
zaini
univers
indonesia
pulmonolog
respiratori
medicinefaculti
medicineuniversita
indonesiapersahabatan
hospitaljakarta
east
jakarta
indonesia
background
aim
benzopyren
polycycl
aromat
carcinogen
agent
found
cigarett
smoke
benzopyren
metabolit
bpde
one
benzopyren
metabolit
kretek
cigarett
smoker
person
smoke
least
cigarett
per
day
least
year
less
amount
time
white
cigarett
smoke
investig
level
serum
bpde
kretek
cigarett
smoker
compar
nonsmok
method
cross
section
studi
healthi
kretek
cigarett
smoker
healthi
nonsmok
enrol
studi
collect
blood
sampl
analyz
bpde
level
also
exhal
carbonmonoxid
co
level
expir
serum
bpde
level
assay
use
elisa
kit
background
aim
smoke
forest
fire
becom
one
natur
disast
occur
annual
riau
especi
kampar
august
kampar
hotspot
district
riau
aim
studi
evalu
expir
level
carbon
monoxid
popul
peopl
expos
smoke
forest
fire
kampar
riau
asscoci
respiratori
complaint
cough
cough
sputum
short
breath
wheez
smoke
habit
method
expir
level
carbon
monoxid
measur
use
co
analyz
sampl
within
criteria
age
year
old
smoke
cigarett
last
hour
domicil
villag
rimbo
panjang
kampar
januari
everi
c
rise
risk
prematur
death
among
respiratori
patient
time
higher
rest
popul
air
pollut
exposur
trigger
new
case
copd
asthma
increas
exposur
allergen
result
global
warm
combin
exposur
pollut
act
synergist
intensifi
allerg
respons
could
point
increas
respiratori
problem
futur
extrem
heat
drought
flood
increas
morbid
respiratori
infect
mortal
chronic
respiratori
diseas
influenza
greatli
affect
temperatur
chang
warm
winter
tend
follow
sever
earlyonset
influenza
incid
follow
season
epidemiolog
studi
mozambiqu
bengal
document
increas
incid
respiratori
infect
flood
respiratori
infect
caus
mortal
rate
follow
bangladesh
flood
climat
chang
result
flood
acut
respiratori
infect
may
increas
conclus
health
effect
climat
chang
includ
increas
preval
allerg
respiratori
diseas
exacerb
copd
respiratori
infect
prematur
mortal
method
studi
use
transgen
mice
carri
luciferas
gene
control
investig
hypothesi
oral
administr
lf
could
attenu
system
inflammatori
respons
organ
damag
hyperoxia
fio
hour
activ
hyperoxia
luciferas
protein
would
express
could
observ
analyz
luminesc
excit
noninvas
vivo
imag
system
ivi
inject
luciferin
transgen
mice
assign
four
group
treat
water
room
air
background
aim
ard
associ
variabl
mortal
depend
diseas
sever
etiolog
ventil
manag
method
conduct
retrospect
studi
determin
mortal
hospit
length
stay
lo
durat
mechan
ventil
mv
ardspati
admit
medicalicu
king
chulalongkorn
memori
hospit
addit
routin
clinic
practic
factor
associ
poor
outcom
evalu
result
ardspati
admit
icu
fulfil
mild
moder
sever
ardscriteria
respect
main
caus
ard
pneumonia
mortal
respect
mean
apach
iiscor
median
lo
day
median
durat
mv
pressur
control
mode
favorit
mode
use
patient
averag
tidal
volum
mlkg
ibw
plateau
pressur
peep
recruit
maneuv
frequent
use
adjunct
intervent
wherea
proneposit
appli
patient
onethird
patient
receiv
neuromuscularblockad
median
fluid
balanc
ml
ard
sever
associ
p
mortal
p
mv
durat
p
multivari
analysi
show
mortal
associ
tidal
volum
p
mortal
associ
apach
iiscor
p
posit
fluid
balanc
day
p
conclus
mortal
ard
high
associ
diseas
sever
howev
averag
tidal
volum
plateau
pressur
fluid
balanc
greater
protect
limit
find
indic
potenti
improv
ard
outcom
hospit
statist
differ
mortal
retriev
nonretriev
case
conclus
cohort
patient
ard
support
ecmo
major
sever
pneumonia
mortal
differ
base
site
initi
ecmo
associ
lower
predict
mortal
patient
higher
sofa
score
n
yuangtrakul
p
wongsurakiat
bangkok
thailand
mahidol
univers
pulmonari
medicin
tuberculosi
bangkok
thailand
background
aim
evid
patient
acut
respiratori
distress
syndrom
ard
still
ventil
induc
lung
injuri
vili
despit
keep
ppl
less
stress
index
obtain
mechan
ventil
comput
program
might
abl
identifi
overdistent
mani
report
stress
index
calcul
shape
pressuretim
pawt
curv
hypothes
could
estim
visual
inspect
bedsid
compar
stress
index
valu
obtain
physician
visual
inspect
bedsid
valu
obtain
use
comput
softwar
method
two
physician
would
ask
inspect
pawt
curv
patient
volum
control
constant
flow
wave
form
bedsid
waveform
data
collect
use
datalogg
via
hamilton
cabl
connect
comput
stress
index
calcul
use
iculab
softwar
categor
group
includ
repres
slope
pattern
inspect
downward
concav
straight
upward
concav
respect
agreement
method
determin
use
weight
kappa
analysi
furthermor
analys
stress
index
agreement
differ
flow
rate
litermin
result
eighti
eight
stress
index
valu
obtain
comput
analysi
valu
visual
inspect
moder
agreement
stress
index
visual
inspect
comput
softwar
kappa
valu
p
sensit
specif
stress
index
visual
inspect
identifi
overdistent
respect
inspiratori
flow
rate
litermin
shown
best
agreement
kappa
valu
p
suspect
high
inspiratori
flow
rate
caus
short
inspiratori
time
lead
inadequ
inflat
respiratori
system
mask
overdistent
group
conclus
stress
index
visual
inspect
moder
correl
comput
analysi
could
reliabl
identifi
overdistent
patient
acut
respiratori
distress
syndrom
result
eight
studi
involv
final
analyz
total
number
blm
blf
group
respect
although
total
mortal
blm
group
seem
lower
blf
group
vs
statist
signific
could
demonstr
risk
ratio
ci
p
also
mortal
icu
mortal
patient
signific
differ
two
group
blm
therapi
reduc
length
total
hospit
stay
compar
blf
therapi
mean
differ
day
ci
p
howev
signific
differ
length
icu
stay
two
group
mean
differ
day
ci
p
review
reveal
none
welldesign
random
control
studi
larg
sampl
size
conclus
blm
therapi
tend
reduc
total
mortal
length
total
hospit
stay
compar
blf
therapi
patient
sever
cap
largescal
studi
might
need
reassess
whether
guidelineconcord
combin
therapi
patient
adequ
background
aim
intern
survey
demonstr
variabl
practic
respons
mechan
ventil
wean
differ
countri
aim
evalu
aspect
thailand
method
questionnair
sent
thai
physician
graduat
chulalongkorn
univers
via
electron
mail
survey
current
practic
clinic
respons
mechan
ventil
wean
hospit
includ
primari
secondari
tertiari
univers
hospit
analyz
data
number
percentag
proport
result
one
hundr
thirtyeight
physician
answer
questionnair
internist
subspecialist
work
secondari
tertiari
hospit
approxim
respond
take
care
mechanicallyventil
patient
gener
ward
around
hospit
respond
work
nurs
author
initi
set
adjust
mechan
ventil
onefourth
hospit
nurs
play
import
role
wean
name
make
decis
wean
hospit
wean
termin
hospit
extub
hospit
interestingli
physician
perspect
nurs
moder
high
respons
set
mechan
ventil
wean
wean
practic
physician
use
wean
protocol
other
use
spontan
breath
trialt
piec
low
level
pressur
support
simv
close
loop
mode
wean
rapid
shallow
breath
index
popular
paramet
use
predict
wean
outcom
approxim
physician
evalu
cuff
leak
test
extub
noninvas
ventil
one
strategi
appli
prophylaxi
reintub
hospit
conclus
due
limit
icu
resourc
thai
physician
provid
ventilatori
care
gener
ward
addit
thai
nurs
signific
respons
ventil
manag
wean
result
total
patient
includ
patient
exclud
appropri
antibiot
prior
mortal
among
pathogen
detect
signific
differ
found
among
group
percentag
patient
follow
acinetobact
speci
distribut
longer
tsfaa
group
p
percentag
polymicrobi
infect
multidrugresist
organ
infect
sourc
higher
tsfaa
h
group
compar
group
shorter
time
period
p
percentag
patient
prior
antibiot
use
higher
tsfaa
h
tsfaa
shorter
durat
multivari
analys
multidrugresist
organ
mdro
total
day
previou
antibiot
charlson
comorbid
score
mechan
ventil
septic
shock
signific
characterist
factor
tsfaa
p
conclus
previou
antibiot
use
mdro
comorbid
mechan
ventil
septic
shock
may
prolong
delay
time
onset
sepsi
first
appropri
antibiot
earli
inquiri
risk
factor
may
help
select
appropri
soon
possibl
background
aim
although
particip
inflamm
ventilatorinduc
lung
injuri
whether
play
import
role
pseudomona
aeruginosa
pa
induc
ali
mechan
remain
unclear
therefor
compar
respons
genedefici
mice
wildtyp
mice
vivo
model
painduc
ali
vitro
model
mous
macrophag
cell
method
cell
cultur
preincub
presenc
absenc
sirna
exposur
pa
hr
pa
intranas
administ
knockout
mice
lung
inflammatori
injuri
underli
mechan
regul
painduc
ali
subsequ
determin
result
level
increas
cell
lung
tissu
obtain
mous
model
painduc
ali
painduc
lung
inflamm
neutrophil
infiltr
lung
tissu
tumor
necrosi
factor
interleukin
lung
permeabl
lung
wetdri
weight
ratio
bronchoalveolar
lavag
fluid
balf
protein
concentr
mortal
rate
attenu
knockout
mice
inflammatori
reaction
tumor
necrosi
factor
interleukin
apoptosi
rate
reduc
sirnatr
cell
moreov
role
painduc
ali
partial
restor
bind
lipopolysaccharid
bind
protein
lbp
confirm
coimmunoprecipit
conclus
find
suggest
protect
painduc
ali
via
bind
lbp
background
aim
protect
lung
ventil
strategi
onelung
ventil
provid
benefici
effect
postop
pulmonari
complic
howev
effect
high
risk
patient
undergo
lung
surgeri
known
aim
studi
compar
effect
protect
lung
ventil
high
risk
group
low
risk
group
method
fifti
two
patient
schedul
elect
thoracoscop
lung
surgeri
enrol
particip
categor
accord
ariscat
score
score
high
risk
group
score
low
risk
group
onelung
ventil
use
doublelumen
endobronchi
tube
ventil
strategi
compos
fio
tidal
volum
mlkg
peep
cm
h
peak
inspiratori
pressur
plateau
airway
pressur
lung
complianc
check
prior
begin
onelung
ventil
tlv
interv
onelung
ventil
arteri
blood
ga
analysi
perform
point
time
tlv
postop
pulmonari
complic
observ
use
chest
xray
medic
record
within
postop
hour
result
arteri
oxygen
tension
significantli
decreas
high
risk
group
ae
mmhg
compar
low
risk
group
ae
mmhg
p
howev
differ
peak
inspiratori
pressur
plateau
airway
pressur
tlv
two
group
static
lung
complianc
decreas
high
risk
group
tlv
differ
incid
postop
pulmonari
complic
two
group
conclus
protect
lung
ventil
strategi
compos
fio
tidal
volum
mlkg
peep
cm
h
applic
onelung
ventil
without
increas
plateau
airway
pressur
high
risk
patient
background
aim
respiratori
dynam
exhibit
complex
pattern
variat
also
evid
suggest
rate
volum
respir
alter
airway
resist
respons
stimul
sinc
airway
hyperrespons
cardin
featur
asthma
suppos
ventil
variabl
tidal
volum
respiratori
rate
improv
airway
respons
asthmat
rat
method
initi
record
respir
control
rat
variabl
respiratori
pattern
use
bodi
box
plethysmographi
anim
sensit
ovalbumin
accord
pattern
allerg
asthma
ventil
variabl
constant
breath
pattern
min
use
harvard
inspira
ventil
variabl
breath
pattern
appli
ventil
mean
interfac
command
matlab
final
airway
respons
methacholin
compar
asthmat
anim
ventil
two
differ
breath
pattern
result
normal
rat
breath
exhibit
complex
variabl
respiratori
rhythm
volum
compar
ventil
asthmat
rat
constant
tidal
volum
respiratori
rate
variabl
ventil
equival
breathbreath
minut
volum
decreas
airway
respons
methacholin
f
p
breath
pattern
variabl
natur
ventil
variabl
pattern
decreas
airway
respons
asthmat
condit
therefor
suggest
variabl
ventil
novel
mode
may
improv
prognosi
asthmat
patient
need
longterm
ventil
background
aim
hypercapn
acidosi
report
protect
ventilatorinduc
lung
injuri
vili
far
underli
mechan
fulli
investig
heme
funderment
endogen
adapt
mechan
protect
cellular
injuri
variou
stress
condit
previous
establish
play
remark
protect
role
vili
virtu
antiinflammatori
antioxid
action
present
studi
aim
investig
whether
protect
effect
hypercapn
acidosi
vili
associ
method
rabbit
anesthet
tracheotom
receiv
hour
volumecontrol
ventil
randomli
alloc
one
four
follow
group
low
tidal
volum
lvt
group
high
tidal
volum
normocapnia
hvt
nc
group
high
tidal
volum
hypercapnia
hvt
hc
group
high
tidal
volum
hypercapnia
inhibitor
znpp
hvt
hc
znpp
group
ga
mixtur
carbon
dioxid
oxygen
fico
fico
fio
balanc
n
administerd
maintain
paco
nc
mmhg
hc
mmhg
end
experi
protein
express
enzymat
activ
measur
lung
injuri
assess
histopatholog
bronchoalveolar
lavag
bal
fluid
protein
content
neutrophil
infiltr
lung
wettodri
ratio
level
inflammatori
cytokin
pulmonari
oxid
reaction
result
injuri
hvt
caus
signific
lung
injuri
includ
increas
histolog
injuri
score
bronchoalveolar
lavag
fluid
protein
content
neutrophil
infiltr
lung
wettodri
ratio
well
elev
inflammatori
cytokin
oxid
reaction
hypercapn
acidosi
enhanc
express
activ
markedli
reduc
hvtinduc
alter
treatment
znpp
decreas
activ
partial
revers
protect
effect
hypercapn
acidosi
conclus
protect
effect
hypercapn
acidosi
vili
partial
mediat
antiinflammatori
antioxid
properti
conclus
studi
prove
use
rsbi
rate
dynam
measur
lung
mechan
accur
predictor
wean
outcom
even
reliabl
wean
paramet
lung
static
dynam
complianc
singl
rsbi
determin
background
aim
alveolar
recruit
maneuv
rm
report
improv
oxygen
acut
respiratori
distress
syndrom
ard
may
relat
reduc
extravascular
lung
water
evlw
anim
studi
design
investig
effect
rm
evlw
patient
ard
method
open
label
prospect
random
control
trial
ard
patient
conduct
two
hospit
north
taiwan
patient
divid
two
group
without
rm
clinic
valu
includ
arteri
oxygen
tensionfract
inspir
oxygen
ratio
pao
fio
evlw
index
durat
ventil
support
mortal
rate
compar
group
result
twentyfour
ard
patient
mechan
ventil
support
random
receiv
ventil
treatment
rm
rm
group
n
without
nonrm
group
n
baselin
demograph
characterist
similar
group
background
aim
ventil
associ
pneumonia
vap
one
common
fatal
complic
mechanicallyventil
patient
hospit
close
monitor
incid
vap
regularli
launch
prevent
strategi
reduc
occurr
infect
howev
vap
rate
still
high
especi
medic
intens
care
unit
icu
method
retrospect
review
incid
vap
patient
admit
medic
icu
king
chulalongkorn
memmori
hospit
modifi
ventil
care
bundl
vcb
implement
icu
april
bundl
includ
follow
issu
hand
wash
hob
elev
maintain
cuff
pressur
oral
decontamin
nursedriven
wean
protocol
ventil
circuit
care
promot
multidisciplinari
team
coordin
vcb
compar
vap
rate
modifi
vcb
applic
evalu
factor
contribut
outcomechang
result
vap
rate
modifi
vcb
implement
high
shown
bundl
help
decreas
vap
rate
occurr
ventilatorday
lowest
rate
period
major
factor
associ
improv
protocolcompli
multidisciplinari
team
approach
frequent
cuffpressur
check
nevertheless
nursedriven
protocol
play
minim
role
wean
figur
vap
rate
implement
background
aim
mechan
ventil
one
commonli
appli
intervent
icu
adapt
support
ventil
asv
posit
pressur
mode
mechan
ventil
closedloop
control
automat
adjust
base
patient
requir
addit
latest
version
intelliv
asv
autom
sbt
modul
quick
wean
perform
sbt
accord
predefin
criteria
soon
level
assist
patient
low
enough
intelliv
asv
alreadi
use
safe
mechan
ventil
passiv
activ
patient
healthi
lung
cardiac
surgeri
ard
andor
copd
articl
report
case
depart
treat
mechan
ventil
use
intelliv
asv
case
present
patient
femal
sever
asthma
attack
accompani
hypercapnia
patient
femal
acut
exacerb
interstiti
pneumonia
patient
femal
chronic
lower
respiratori
tract
infect
due
ntm
case
requir
mechan
ventil
two
patient
sever
hypoxem
one
patient
sever
hypercapnia
patient
receiv
initi
treatment
primari
diseas
mechan
ventil
adjust
respiratori
condit
treatment
radiolog
find
oxygen
laboratori
find
gradual
improv
case
surviv
without
sever
complic
two
case
immedi
success
wean
use
asv
one
case
success
wean
use
asv
case
requir
addit
mechan
support
muscl
weak
conclus
intelliv
asv
safe
use
mainten
wean
phase
mechan
ventil
differ
lung
condit
therefor
use
may
consid
divis
howev
sever
respiratori
failur
due
chronic
respiratori
diseas
muscl
weak
chronic
type
respiratori
failur
need
particular
attent
introduct
beest
caus
variou
reaction
acut
respiratori
distress
syndrom
ard
cardiac
dysfunct
follow
beest
rel
uncommon
report
case
anaphylact
shock
ard
stressinduc
cardiomyopathi
multipl
beest
case
present
woman
admit
intens
care
unit
icu
due
beeanaphylaxi
patient
unluckili
got
beest
minut
admiss
walk
park
swarm
bee
attack
honeycomb
fell
tree
head
stung
immedi
sent
hospit
emerg
depart
develop
hypotens
facial
angioedema
expiratori
wheez
lung
oxygen
desatur
addit
skin
reveal
uncount
stingmark
diagnos
sever
anaphylact
reaction
receiv
inject
antihistamin
steroid
epinephrin
plu
nebul
bronchodil
besid
sting
skin
remov
much
possibl
despit
provid
treatment
still
difficulti
breath
becam
respiratori
failur
chest
radiographi
show
bilater
diffus
alveolar
opac
mild
cardiomegali
shown
figur
consequ
assist
invas
mechan
ventil
transfer
icu
icu
addit
investig
perform
evalu
caus
pulmonari
edema
electrocardiographi
reveal
sinu
tachycardia
earli
repolar
minim
stelev
lead
avl
echocardiographi
demonstr
mildli
impair
systol
function
lvef
apic
balloon
nevertheless
inferior
vena
cava
ivc
dilat
ivc
distens
index
less
serum
tryptas
high
find
compat
anaphylaxi
complic
noncardiogen
pulmonari
edema
stressinduc
cardiomyopathi
result
lung
protect
strategi
standard
treatment
anaphylaxi
appli
final
recov
unev
extub
day
admiss
result
conclus
case
demonstr
uncommon
sever
reaction
anaphylaxi
massiv
beeenvenom
background
aim
teratoma
aris
entir
within
lung
extrem
rare
entiti
less
report
case
worldwid
sinc
first
describ
present
case
old
femal
diagnos
intrapulmonari
teratoma
present
hemoptysi
case
highlight
import
combin
diagnost
tool
arriv
correct
diagnosi
time
treatment
potenti
curabl
benign
intrapulmonari
mass
prevent
fatal
complic
morbid
method
old
femal
came
year
histori
chronic
cough
recurr
hemoptysi
imag
studi
show
heterogen
mass
locat
right
upper
lobe
nodular
calcif
bronchoscopi
done
reveal
strand
hair
aris
right
upper
lobe
lobectomi
perform
show
entir
right
upper
lobe
convert
larg
mix
solidcyst
mass
sebum
teeth
hair
strand
histopatholog
confirm
matur
teratoma
lung
result
matur
teratoma
often
abdomin
locat
may
occasion
seen
thorac
area
usual
anterior
mediastinum
pure
intrapulmonari
teratoma
extrem
rare
entiti
case
may
largest
intrapulmonari
matur
teratoma
measur
x
x
cm
conclus
case
highlight
import
combin
imag
bronchoscop
modal
diagnos
benign
lung
neoplasm
good
chanc
success
cure
background
aim
technic
develop
field
pediatr
bronchoscopi
expand
diagnost
possibl
procedur
time
make
less
invas
today
almost
examin
carri
outpati
basi
flexibl
fiberopt
instrument
use
children
reach
school
age
analgesia
sedat
technic
innov
includ
endoscop
laser
surgeri
exampl
treat
subglot
hemangioma
even
young
infant
bronchial
balloon
dilat
airway
stenos
develop
improv
render
less
stress
diagnosi
treatment
airway
pulmonari
problem
children
method
retrospect
studi
one
year
period
total
children
male
femal
respiratori
diseas
age
day
year
examin
andor
treat
bronchoscopi
includ
bronchoscop
intervent
sedat
local
anesthesia
result
flexibl
fiberopt
bronchoscopi
use
tool
evalu
patient
noisi
breath
stridor
persist
wheez
persist
atelectasi
nonresolv
pneumonia
mucos
deplug
suspect
foreign
bodi
aspir
bronchial
stenosi
patient
tracheostomi
conclus
high
diagnost
therapeut
yield
low
complic
strongli
support
use
flexibl
fibropt
bronchoscop
diagnost
evalu
infant
children
varieti
pulmonari
problem
background
aim
flexibl
bronchoscopi
increas
risk
hypoxemia
patient
baselin
impair
lung
function
oxygen
cannula
routin
use
procedur
howev
desatur
occasion
occur
highflow
nasal
cannula
hfnc
deliv
higher
fio
provid
benefit
altern
convent
oxygen
cannula
object
aim
studi
compar
pao
bronchoscopi
use
hfnc
convent
oxygen
cannula
method
patient
assign
receiv
either
hfnc
hfnc
group
convent
cannula
control
group
abg
collect
separ
time
bronchoscop
bronchoscop
insert
vocal
cord
end
procedur
post
procedur
period
continu
oxygen
therapi
result
among
patient
patient
hfnc
group
pao
shown
nonsignific
differ
group
paco
control
group
shown
tend
increas
signific
hfnc
group
final
hfnc
group
shown
signific
control
group
conclus
applic
hfnc
bronchoscopi
may
use
select
patient
especi
sever
hypoxemia
hypercapn
risk
background
aim
fibreropt
bronchoscopi
fob
common
invas
investig
field
respiratori
medicin
patient
undergo
fob
report
vari
experi
regard
anxieti
level
awar
investig
comfort
level
procedur
studi
aim
determin
live
experi
patient
undergo
fob
method
qualit
research
design
use
patient
year
age
undergon
fob
first
time
includ
depth
interview
taken
languag
comfort
data
satur
achiev
new
inform
idea
deriv
patient
understood
adequ
sampl
size
reach
focus
group
discuss
fgd
held
select
patient
purpos
sampl
health
care
provid
investig
conduct
discuss
script
question
answer
particip
investig
guid
fgd
depth
interview
held
conveni
place
particip
provid
snack
drink
later
data
analysi
done
nvivo
softwar
main
theme
identifi
categor
result
sinc
ongo
studi
result
analys
discuss
confer
later
conclus
analysi
experi
patient
undergo
fob
awar
summar
background
aim
case
foreign
bodi
lodg
airway
uncommon
especi
children
remov
foreign
bodi
usual
success
done
use
flexibl
bronchoscop
variou
extract
devic
rigid
bronchoscopi
reserv
challeng
case
result
present
case
dislodg
tooth
result
motorvehicl
accid
involv
man
initi
attempt
remov
tooth
flexibl
bronchoscop
cryoextract
futil
tooth
success
remov
rigid
biopsi
forcep
introduc
via
rigid
bronchoscopi
cyroreduct
done
surround
granul
tissu
embed
tooth
within
airway
lumen
conclus
flexibl
bronchoscopi
remain
procedur
choic
foreign
bodi
remov
owe
wide
avail
howev
rigid
bronchoscopi
provid
addit
option
challeng
case
institut
facil
avail
background
aim
aim
evalu
use
safeti
ebustbna
patient
undergo
procedur
differenti
sarcoidosi
diseas
method
method
investig
retrospect
use
safeti
ebustbna
patient
undergo
bronchoscopi
suspect
sarcoidosi
sinc
introduct
ebustbna
hospit
result
result
patient
underw
bronchoscopi
needl
laryng
patient
receiv
bf
due
suspect
sarcoidosi
patient
underw
bal
tblb
patient
receiv
addit
ebustbna
ebustbna
conduct
patient
without
evid
accident
symptom
although
maximum
shortaxi
diamet
lymph
node
patient
mm
tend
smaller
previou
report
diagnos
sarcoidosi
underw
ebustbna
diagnos
diseas
unknown
obtain
find
case
bal
tblb
ebustbna
among
procedur
conduct
tblb
posit
tend
higher
lymphocyt
count
bal
fluid
tblb
posit
ae
versu
tblb
neg
ae
p
signific
differ
also
definit
differ
pulmonari
lesion
conclus
conclus
ebustbna
use
differenti
sarcoidosi
diseas
compar
tblb
studi
find
indic
procedur
conduct
safe
without
accident
symptom
even
rel
small
lymph
node
publish
detail
studi
result
congress
apsr
background
aim
quantit
bacteriolog
method
increas
reliabl
sputum
specimen
diagnosi
lower
respiratori
tract
infect
studi
design
compar
diagnost
yield
deep
tracheal
aspir
bal
sampl
patient
pneumonia
tertiari
care
hospit
analys
whether
deep
endotrach
aspir
use
substitut
bal
less
expens
less
invas
mean
obtain
specimen
cultur
diagnos
pneumonia
method
conduct
prospect
compar
studi
patient
icu
hdu
intub
tracheostomis
show
sign
pneumonia
patient
two
sampl
collect
et
aspir
bronchoscop
bal
sampl
suction
cathet
introduc
et
advanc
beyond
carina
collect
lower
respiratori
tract
secret
mucu
trap
fiberopt
bronchoscop
introduc
advanc
bronchial
orific
select
base
radiograph
locat
new
pulmonari
infiltr
bal
perform
instil
ml
steril
normal
salin
quantit
cultur
balendotrach
aspir
done
accord
standard
protocol
result
et
cultur
show
frequenc
growth
wherea
bal
show
frequenc
variou
organ
isol
acinetobact
seen
frequent
method
frequenc
via
et
via
bal
klebsiella
et
bal
second
common
organ
isol
follow
pseudomona
et
bal
howev
comparison
overal
frequenc
differ
isol
p
valu
found
statist
signific
conclus
result
demonstr
eta
balf
gram
stain
cultur
interchang
eta
accept
altern
bronchoscopi
evalu
suspect
pneumonia
background
aim
describ
uniqu
case
inhal
foreign
bodi
piec
chopstick
overlook
year
method
woman
admit
hospit
refractori
pneumonia
hospit
repeatedli
recurr
pneumonia
left
lower
lung
histori
hemoptysi
chest
comput
tomographi
ct
show
parenchym
consolid
posterior
segment
segment
right
upper
lobe
patient
opt
surgic
treatment
rather
intervent
refractori
pneumonia
result
right
upper
lobectomi
perform
resect
specimen
reveal
obstruct
posterior
segment
bronchu
right
upper
lobe
foreign
bodi
found
embed
granul
tissu
foreign
bodi
piec
chopstick
question
patient
rememb
aspir
chopstick
eat
sever
year
earlier
difficult
remov
longstand
intrabronchi
foreign
bodi
recommend
surgic
treatment
conclus
knowledg
first
case
present
english
literatur
foreign
bodi
piec
chopstick
undetect
year
background
aim
tracheobronchopathia
osteochondroplastica
tpo
rare
benign
disord
character
multipl
submucos
osseou
cartilagin
nodul
aris
trachea
major
bronchi
spare
posterior
membran
part
condit
usual
asymptomat
andor
nonspecif
respiratori
symptom
chronic
cough
wheez
recurr
respiratori
tract
infect
occasion
hemoptysi
studi
first
case
tpo
complic
fungal
tuberculosi
coinfect
thailand
thoroughli
describ
result
case
present
femal
present
chronic
product
cough
signific
weight
two
month
chest
radiograph
show
reticulonodular
opac
rul
rll
sputum
acidfast
bacilli
neg
consecut
day
chest
ct
scan
demonstr
multipl
small
submucos
nodul
calcif
tracheal
wall
bronchial
wall
tree
bud
appear
small
area
peribronchovascular
consolid
scatter
lung
evalu
natur
lesion
flexibl
bronchoscopi
perform
multipl
irregular
nodul
protrud
tracheal
lumen
visual
nodul
distribut
along
anterolater
wall
trachea
main
bronchi
histopatholog
exam
reveal
inflam
bronchial
tissu
presenc
fragment
osseou
tissu
bronchial
submucosa
evid
point
toward
diagnosi
tpo
howev
clinic
symptom
possibl
superimpos
infect
fungal
hypha
detect
special
stain
bronchial
wash
fluid
aspergillu
fumigatu
identifi
subsequ
furthermor
bronchial
wash
fluid
gene
xpert
posit
patient
treat
antifung
antituberculosi
regimen
month
followup
patient
report
relief
symptom
chest
radiograph
show
slight
improv
conclus
tpo
rare
condit
present
nonspecif
symptom
patient
chronic
cough
given
presumpt
diagnosi
common
diseas
investig
definit
diagnosi
consid
show
util
lowdos
ct
screen
detect
rate
diagnos
nonsolid
lesion
nsl
increas
although
previous
report
effect
diagnost
bronchoscopi
nsl
predict
factor
investig
method
consecut
patient
underw
diagnost
bronchoscopi
nsl
institut
septemb
januari
enrol
among
case
perform
radial
endobronchi
ultrasound
radial
ebu
final
diagnos
lung
cancer
includ
retrospect
studi
review
analyz
examin
associ
diagnost
yield
clinic
factor
follow
locat
central
intern
peripher
consolidationtotumor
ct
ratio
size
mm
biopsi
time
use
guid
sheath
use
visibl
chest
xray
fine
use
virtual
bronchoscopi
vb
use
bronchu
sign
thinsect
ct
posit
neg
result
enrol
case
diagnos
procedur
diagnost
yield
univari
analysi
posit
bronchu
sign
signific
factor
higher
diagnost
yield
vs
p
use
vb
tend
higher
yield
signific
differ
vs
p
convers
multivari
analysi
posit
bronchu
sign
use
vb
signific
relationship
higher
diagnost
yield
p
odd
ratio
p
odd
ratio
respect
posit
bronchu
sign
thinsect
ct
use
vb
posit
predict
factor
diagnost
bronchoscopi
nsl
background
aim
foreign
bodi
aspir
uncommon
among
adult
popul
estim
incid
bronchoscopi
perform
howev
life
threaten
common
caus
death
unexpect
accid
japan
method
healthi
man
caus
pulmonari
arrest
drink
larg
amount
alcohol
patient
brought
hospit
underw
cardiopulmonari
resuscit
emerg
medic
servic
fortun
patient
revert
sinu
rhythm
good
cardiac
output
perform
endotrach
intub
patient
hospit
immedi
intens
care
unit
could
maintain
oxygen
satur
although
artifici
ventil
suspect
exist
lodg
foreign
bodi
accord
abnorm
find
close
left
main
bronchu
chest
ct
scan
imag
tri
dislodg
use
flexibl
bronchoscopi
wait
increas
oxygen
satur
result
obviou
find
right
main
bronchu
contrast
piec
meatlik
matter
complet
lodg
left
main
stem
bronchu
remov
foreign
bodi
patient
underw
bronchoscopi
use
grasp
basket
forcep
remov
complet
procedur
patient
wean
artifici
ventil
markedli
improv
oxygen
level
conscious
day
hospit
patient
went
excel
clinic
recoveri
despit
exist
atelectasi
aspir
pneumonia
discharg
hospit
day
report
case
abl
rescu
rapid
remov
foreign
bodi
background
aim
scleros
pneumocytoma
hemangioma
rare
benign
epitheli
tumor
lung
possibl
relat
pulmonari
epithelium
type
ii
pneumocyt
thoracotomi
usual
indic
definit
diagnosi
treatment
rare
diagnosi
made
use
tbna
present
case
diagnos
via
use
radial
probe
endobronchi
ultrasound
rebu
transbronchi
needl
aspir
tbna
method
woman
refer
asymptomat
right
upper
lung
nodul
chest
radiogram
thorax
comput
tomographi
reveal
contrast
enhanc
wellcircumscrib
round
mass
upper
lobe
right
lung
fig
radial
probe
endobronchi
ultrasound
rebu
transbronchi
nodal
aspir
tbna
perform
result
patholog
examin
reveal
atyp
cell
suspici
scleros
pneumocytoma
immunohistochemistri
stain
show
reactiv
cytokeratin
ema
express
lumin
cell
fig
neg
synaptophysin
pulmonari
scleros
pneumocytoma
diagnos
conclus
conclus
present
case
diagnos
via
use
endobronchi
ultrasound
tbna
although
data
limit
endobronchi
ultrasound
tbna
altern
method
diagnosi
rare
lung
tumor
background
aim
asthma
consid
major
health
problem
sri
lanka
well
global
burden
asthma
overwhelm
asthma
control
formal
evalu
sri
lanka
studi
compar
evalu
diseas
control
asthma
control
test
act
peak
expiratori
flow
rate
pefr
method
asthma
control
examin
crosssect
asthmat
year
age
use
act
pefr
predict
score
act
pefr
predict
indic
uncontrol
asthma
simultan
patient
clinic
evalu
whether
asthma
control
uncontrol
asthmat
evalu
fortnight
treatment
accord
global
initi
asthma
gina
guidelin
two
primari
care
clinic
sri
lanka
background
aim
asthma
common
chronic
respiratori
diseas
approxim
million
asthmat
person
worldwid
death
annual
due
asthma
mostli
prevent
world
health
organis
estim
million
increas
asthmat
patient
vietnam
crosssect
studi
asthma
adult
show
incid
asthma
control
situat
report
physician
control
asthma
case
sever
citi
asiapacif
countri
airiap
insight
realiti
asiapacif
includ
vietnam
hanoi
ho
chi
minh
citi
show
result
poor
control
asthma
three
major
concern
import
caus
poor
control
asthma
includ
treatment
noncompli
difficult
approach
essenti
drug
exposur
trigger
agent
purpos
work
perform
practic
approach
relat
diagnosi
assess
treatment
asthma
method
expert
opinion
evidencebas
guidanc
result
case
asthma
easili
diagnos
base
histori
clinic
present
treatment
respons
asthma
treatment
basic
depend
antiinflammatori
inhal
corticosteroid
bronchodil
effect
asthma
manag
asthma
control
mostli
relat
treatment
adher
patient
appropri
drug
use
thu
import
physician
especi
work
primari
health
care
center
monitor
assess
level
control
consult
patient
asthmat
case
control
routin
therapi
case
respond
treatment
due
patholog
character
uncommon
inflammatori
basi
nonatopi
tendenc
chronic
chang
lung
structur
comorbid
case
refer
respiratori
special
center
examin
diagnos
assess
asthma
sever
build
treatment
plan
background
aim
studi
aim
investig
effect
tradinterol
spff
prolifer
ca
elev
induc
platelet
deriv
growth
factor
pdgf
rat
airway
smooth
muscl
asm
cell
method
pdgf
expos
rat
asm
cell
h
pretreat
spff
cell
cycl
determin
flow
cytometri
evalu
effect
spff
prolifer
cell
suppress
effect
spff
elev
ca
induc
pdgf
detect
flow
cytometri
soc
inhibitor
nicl
respect
use
pharmacolog
tool
investig
possibl
mechan
gene
express
cell
measur
realtim
pcr
expos
pdgf
pretreat
spff
result
show
drug
suppress
increas
ca
cell
induc
pdgf
dosedepend
manner
spff
mm
significantli
decreas
increas
ca
induc
pdgf
similar
effect
soc
inhibitor
suppress
combin
spff
specif
soc
inhibitor
almost
soc
inhibitor
use
alon
indic
spff
soc
inhibitor
mayb
similar
mechan
action
moreov
determin
flow
cytometri
illustr
prolifer
asm
cell
promot
pdgf
inhibit
spff
concentr
maxim
efficaci
spff
found
suppress
significantli
increas
mrna
express
cell
stimul
ngml
pdgf
find
suggest
spff
could
inhibit
prolifer
rat
asm
cell
induc
pdgf
mechan
might
associ
ca
signal
pathway
background
aim
asthma
wellknownchron
inflammatori
diseas
extens
studi
mani
year
complet
cure
asthma
still
big
challeng
protein
acetyl
especi
histon
acetyl
play
signific
role
antiasthma
process
histon
deacetyl
inhibitor
hdaci
also
ideal
cur
effect
asthma
clinic
practic
order
reveal
molecular
level
relationship
protein
acetyl
antiasthma
process
provid
novel
molecular
target
asthma
treat
studi
proteom
acetylproteom
chang
healthi
asthmat
cell
mous
lung
method
balbc
mice
divid
two
group
control
group
asthmat
model
group
twentyfour
hour
ova
nebul
lung
tissu
group
taken
extract
protein
acetylpeptid
sampl
enrich
stabl
isotop
label
hplc
fraction
peptid
sent
lcmsm
last
quantif
inform
acquir
bioinformat
analysi
perform
result
total
protein
acetyl
site
identifi
among
protein
acetyl
peptid
significantli
chang
respect
mani
activ
deactiv
process
pathway
protein
group
identifi
bioinformat
analysi
associ
network
identifi
respons
antiasthma
process
sequenc
motif
prefer
asthma
condit
reveal
novel
kac
relat
core
histon
motif
identifi
key
regul
unit
data
comparison
conclus
acetyl
modif
play
import
role
pathogenesi
asthma
especi
kac
pattern
may
play
fatal
role
ova
induc
asthma
find
contribut
discoveri
selfrecoveri
mechan
asthma
young
kid
also
use
adult
asthma
treat
background
aim
asthma
chronic
obstruct
diseas
character
recur
airway
inflamm
revers
airway
obstruct
airway
hyperrespons
airway
remodel
thymoquinon
tq
activ
ingredi
isol
nigella
sativa
report
exhibit
antiinflamm
antiprolifer
variou
cancer
cell
well
epitheli
cell
aim
studi
evalu
effect
tq
inflamm
neoangiogenesi
remodel
airway
blood
vessel
induc
ovalbumin
ova
asthma
mice
method
wildtyp
balbc
mice
divid
five
group
control
ova
group
asthma
ova
tq
group
tq
group
ova
dexamethason
dex
group
airway
inflamm
assess
stain
abpa
stain
elisa
neoangiogenesi
remodel
airway
blood
vessel
assess
western
blot
rtpcr
immunohistochemistri
immunofluoresc
result
result
reveal
tq
inhibit
product
inflammatori
factor
immunohistochemistri
analysi
show
increas
express
asthma
mice
challeng
ova
suppress
tq
moreov
western
blot
immunohistochemistri
analysi
also
show
pathway
downregul
downregul
increas
tq
meanwhil
immunofluoresc
analysi
show
coexpress
tq
treatment
ovachalleng
asthma
mice
conclus
studi
demonstr
tq
attenu
inflammatori
reaction
antagon
antineoangiogenesi
effect
tq
mediat
inhibit
vegf
express
akt
signal
pathway
support
potenti
role
tq
amelior
asthma
mice
background
aim
worthi
hold
steadi
patient
asthma
remiss
avoid
relaps
astragalosid
iv
asiv
import
deriv
chines
herb
astragalu
membranaceu
demonstr
antiasthmat
effect
howev
remain
unclear
whether
asiv
use
asthma
remiss
could
allevi
airway
inflamm
acut
episod
studi
aim
investig
prevent
effect
mechan
asiv
compar
rapamycin
asthma
remiss
airway
inflamm
vivo
method
balbc
mice
sensit
ovalbumin
three
ip
inject
challeng
ovalbumin
week
week
restrecoveri
mice
reexpos
ovalbumin
week
mice
treat
asiv
rapamycin
last
week
characterist
featur
allerg
asthma
includ
airway
hyperreact
ahr
airway
histopatholog
cytokin
treg
cell
bronchoalveolar
lavag
fluid
balf
examin
downstream
protein
signal
pathway
also
assess
result
rapamycin
asiv
markedli
decreas
inflammatori
infiltr
lung
tissu
rapamycin
also
cell
treg
cell
balf
although
augment
effect
ahr
observ
asiv
also
reduc
level
limit
effect
ahr
treg
cell
drug
inhabit
phosphoryl
ribosom
protein
downstream
howev
effect
akt
phosphoryl
downstream
observ
conclus
conclud
antiasthmat
effect
least
partial
modul
signal
pathway
treatment
asiv
asthma
remiss
may
prevent
effect
diseas
control
outpati
meet
follow
criteria
recruit
age
year
resid
studi
citi
least
year
asthma
diagnosi
least
month
accord
gina
criteria
inform
demograph
asthma
control
asthma
manag
asthma
attack
selfmanag
diseas
percept
collect
facetofac
interview
electron
questionnair
data
captur
eqdc
system
employ
data
input
continu
variabl
present
mean
ae
sd
categor
variabl
present
frequenc
result
altogeth
case
includ
women
total
asthma
control
rate
china
asthma
control
rate
citi
took
part
asthma
control
investig
hospit
rate
due
asthma
exacerb
emerg
visit
rate
patient
use
peak
flow
meter
monitor
patient
select
ic
laba
daili
regular
use
control
medic
use
leukotrien
modifi
use
ic
asthma
attack
frequenc
patient
symptom
everi
week
never
experienc
asthma
attack
past
year
patient
symptom
asthma
attack
common
symptom
cough
chest
tight
short
breath
patient
right
percept
natur
diseas
conclus
despit
improv
asthma
control
compar
investig
region
differ
disproport
obviou
still
gap
proport
asthma
control
china
goal
set
gina
background
aim
background
aim
asthma
manag
achiev
better
asthma
control
asthma
control
measur
includ
variou
clinic
function
manifest
still
debat
whether
better
control
asthma
translat
better
qualiti
life
aim
evalu
associ
asthma
control
asthma
relat
qualiti
life
method
uncontrol
partli
control
asthma
patient
attend
pulmonari
medicin
clinic
recruit
studi
physic
characterist
socio
demograph
data
lung
function
result
obtain
asthma
relat
qualiti
life
questionnair
aqlq
asthma
control
questionnair
acq
administ
studi
subject
per
prefer
languag
correl
asthma
qualiti
life
pulmonari
function
paramet
pefr
asthma
control
acq
determin
use
pearson
correl
coeffici
chisquar
test
done
categor
variabl
like
age
distribut
gender
etc
pvalu
p
consid
signific
result
among
studi
patient
femal
male
partli
control
asthmat
uncontrol
asthmat
gina
domain
mean
age
bmi
respect
nine
smoker
nine
allerg
rhiniti
patient
ge
reflux
diseas
patient
group
mean
pefr
pre
bronchodil
respect
moder
neg
correl
acq
aqlq
r
p
weak
correl
aqlq
r
p
weak
correl
also
found
number
symptom
aqlq
score
r
p
pearson
chi
squar
method
p
age
bmi
comorbid
pefr
associ
qualiti
life
aqlq
conclus
asthma
control
measur
acq
predict
asthma
relat
qualiti
life
better
variabl
background
aim
cough
one
common
symptom
outpati
depart
great
neg
impact
qualiti
life
asthma
one
common
caus
cough
howev
often
difficult
diagnos
accur
therefor
press
need
novel
tool
diagnosi
asthma
patient
cough
present
studi
evalu
origin
questionnair
laboratori
find
develop
diagnost
score
system
asthma
patient
cough
method
retrospect
analyz
medic
record
patient
attend
outpati
depart
chief
complaint
subacut
chronic
cough
answer
origin
questionnair
april
march
evalu
correl
question
item
final
diagnos
identifi
factor
contribut
final
diagnosi
asthma
result
total
patient
includ
final
analysi
median
age
year
old
femal
patient
chronic
cough
final
diagnos
follow
asthma
n
gerd
n
postinfecti
cough
n
rhinosinus
n
atop
cough
n
other
n
five
question
item
wheez
night
earli
morn
cough
past
histori
asthma
past
histori
respiratori
diseas
live
wooden
hous
predict
asthma
final
diagnosi
develop
diagnost
score
system
asthma
consist
question
item
exhal
nitric
oxid
level
area
curv
diagnost
score
system
ci
conclus
develop
diagnost
score
system
compos
six
factor
asthma
patient
subacut
chronic
cough
may
aid
improv
diagnost
yield
asthma
background
aim
control
asthma
depend
variou
factor
includ
cooper
cooper
complex
concept
includ
patient
readi
follow
doctor
recommend
complianc
carri
doctor
recommend
within
particular
treatment
drug
adher
patient
awar
diseas
opinion
diseas
charact
avail
therapi
satisfact
cooper
doctor
sincer
aim
studi
estim
relationship
asthma
control
level
cooper
depress
patient
method
patient
asthma
women
age
examin
asthma
control
questionnair
itemsselfadminist
questionnair
estim
cooper
asthma
eca
lv
bogovin
et
al
center
epidemiolog
studi
depress
scale
cesd
mm
weissman
et
al
use
studi
result
patient
control
asthma
accord
mild
asthma
moder
asthma
group
posit
cooper
eca
questionnair
patient
uncontrol
asthma
mild
moder
sever
asthma
patient
partli
complet
follow
recommend
physician
neg
cooper
p
group
patient
control
asthma
compar
uncontrol
asthma
frequent
show
absenc
depress
cesd
test
vs
p
remain
group
show
mild
depress
patient
uncontrol
asthma
often
show
presenc
depress
symptom
p
mild
sever
degre
furthermor
degre
cooper
correl
invers
level
depress
cesd
test
r
conclus
increas
asthma
sever
tendenc
hypothymia
correl
patient
cooper
reveal
asthma
control
achiev
reduc
background
aim
report
frequenc
lung
sound
reflect
degre
airway
inflamm
patient
bronchial
asthma
ba
j
allergi
clin
immunol
pract
rumbl
rhonchi
rr
denot
rumbl
sound
non
sinusoid
wave
form
timeexpand
wave
form
impli
retain
secret
bronchi
thu
aspect
airway
inflamm
allergol
int
rr
frequent
heard
patient
ba
rather
asymptomat
increas
even
mild
asthma
symptom
thu
rr
may
reflect
aspect
ariway
inflamm
frequenc
lung
sound
tri
clarifi
clinic
implic
rr
patient
wirh
ba
method
studi
sixti
three
adult
asthmat
age
ae
mf
current
smoker
acut
symptom
care
auscult
lung
sound
patient
perform
pulmonari
function
test
includ
fractionl
exhal
nitric
oxid
feno
measur
biomark
eosinophil
airway
inflamm
rr
devid
three
categori
audibl
faintli
audibl
faint
cleari
audibl
present
result
presenc
rr
reflect
presenc
airflow
limit
decreas
rr
heard
rr
clearli
heard
feno
tend
higher
rr
faintli
heard
p
background
aim
alreadi
recogn
stress
evok
asthma
exacerb
howev
mechan
shortterm
stress
get
insid
bodi
clear
hand
certain
breath
pattern
advers
effect
airway
lead
symptom
exacerb
asthma
studi
aim
observ
impact
shortterm
stress
airway
constrict
breath
pattern
patient
control
asthma
method
record
respir
heart
rate
rest
condit
shortterm
stressor
stroop
test
nois
women
asthma
healthi
control
pulmonari
function
paramet
measur
use
spiromet
stress
result
exposur
stress
significantli
decreas
fvc
p
p
pef
p
asthmat
patient
wherea
level
remain
unchang
contrast
patient
asthma
healthi
particip
show
signific
increas
respiratori
rate
respiratori
complex
heart
rate
variabl
index
autonom
balanc
stress
pulmonari
function
invers
correl
respiratori
complex
heart
rate
variabl
autonom
impair
conclus
conclud
autonom
impair
breath
pattern
might
potenti
mechan
exacerb
asthmat
peopl
shortterm
stress
background
aim
respiratori
dynam
exhibit
complex
pattern
variat
pathophysiolog
basi
respiratori
pattern
decomplexif
asthma
clear
need
determin
studi
anim
model
asthma
also
question
whether
asthmalik
chang
due
repeat
bronchoconstrict
induc
methacholin
mch
nonallergen
agent
alter
breath
pattern
expect
asthmat
guinea
pig
allerg
inflamm
method
respir
consciou
guinea
pig
record
day
salin
ovalbumin
mch
inhal
day
h
aerosol
exposur
use
wholebodi
plethysmographi
twenti
minut
data
minimum
artifact
select
interbreath
interv
analysi
use
custom
written
softwar
matlab
complex
breath
pattern
quantifi
calcul
sampl
entropi
determin
irregular
degre
timeseri
result
respiratori
dynam
show
increas
regular
anim
challeng
allergen
p
mch
p
compar
salin
group
howev
signific
differ
respiratori
dynam
asthmat
mch
group
p
conclus
complex
breath
pattern
decreas
bronchoconstrict
induc
either
allergen
mch
guinea
pig
airway
remodel
due
repeat
bronchoconstrict
may
caus
decomplexif
background
aim
copper
oxid
nanoparticl
cuonp
metal
oxid
nanoparticl
use
multipl
applic
includ
wood
preserv
antimicrobi
textil
catalyst
carbon
monoxid
oxid
heat
transfer
fluid
machin
investig
effect
cuonp
respiratori
system
balbc
mice
addit
investig
effect
cuonp
asthma
develop
use
murin
model
ovalbumin
ova
induc
asthma
method
toxicolog
experi
mice
receiv
cuonp
via
intras
instil
uder
slight
anesthesia
day
evalu
airway
hyperrespons
ahr
inflammatori
cell
count
proinflammatori
cytokin
reactiv
oxygen
speci
ro
histopatholog
asthma
model
induc
asthma
mice
senstiz
day
intraperiton
inject
ova
day
mice
receiv
ova
cuonp
dispers
pb
via
intranas
instil
result
cuonp
markedli
increas
airway
hyperrespons
ahr
inflammatori
cell
count
proinflammatori
cytokin
reactiv
oxygen
speci
ro
cuonp
induc
airway
inflamm
mucu
secret
increas
phosphoryl
mapk
erk
jnk
ovainduc
asthma
model
cuonp
aggrav
increas
ahr
inflammatori
cell
count
proinflammatori
cytokin
ro
immunoglobulin
e
induc
ova
exposur
addit
cuonp
markedli
increas
inflammatori
cell
infiltr
lung
mucu
secret
mapk
phosphoryl
elev
compar
ovainduc
asthmat
mice
conclus
cuonp
exhibit
toxic
respiratori
system
associ
mapk
phosphoryl
addit
cuonp
exposur
aggrav
develop
asthma
conclud
cuonp
exposur
potenti
toxic
human
respiratori
diseas
background
aim
mucu
act
primari
defens
system
airway
variou
stimuli
howev
excess
mucu
product
caus
reduct
lung
function
via
limit
airflow
airway
patient
suffer
asthma
chronic
obstruct
pulmonari
diseas
copd
method
studi
evalu
effect
melatonin
product
major
constitu
mucin
secret
airway
use
epiderm
growth
factor
egf
stimul
cell
human
mucoepidermoid
carcinoma
cell
line
ovalbumin
ova
induc
asthma
murin
model
result
melatonin
treatment
significantli
reduc
mrna
protein
level
reduc
interleukin
il
product
egfstimul
cell
melatonin
markedli
decreas
phosphoryl
mapk
includ
jnk
induc
egf
stimul
find
consist
result
use
mapk
inhibitor
particularli
cotreat
melatonin
mapk
inhibitor
effect
suppress
mapk
phosphoryl
treatment
mapk
inhibitor
alon
result
reduct
express
asthma
murin
model
melatonintr
mice
exhibit
mark
reduct
express
airway
compar
ovainduc
mice
reduct
accompani
reduct
proinflammatori
cytokin
product
inflammatori
cell
infiltr
conclus
find
indic
melatonin
effect
inhibit
express
effect
may
close
associ
inhibit
mapk
phosphoryl
furthermor
studi
suggest
melatonin
could
repres
potenti
therapeut
chronic
airway
diseas
asthma
copd
method
total
case
asthma
untreat
retrospect
analyz
hospit
patient
classifi
naa
group
seventytwo
aa
groupallerg
asthma
aa
object
distinguish
nonallerg
asthma
naa
skin
prick
test
immunoglobulin
e
ige
level
common
allergen
describ
differ
allerg
nonallerg
asthma
gender
bodi
mass
index
gangnam
sever
hospit
intern
medicin
seoul
republ
korea
goodmorn
hospit
gyeonggido
republ
korea
background
aim
specif
immunoglobulin
e
ige
sensit
staphylococc
enterotoxin
se
recent
consid
relat
allerg
diseas
includ
asthma
although
research
conduct
studi
concern
specif
ige
sige
se
relationship
asthma
diagnosi
sever
associ
sige
se
airway
hyperrespons
ahr
well
studi
method
enrol
asthma
patient
admit
sever
hospit
korea
march
st
februari
th
retrospect
review
electron
medic
record
enrol
subject
measur
level
sige
se
ab
serum
subject
use
immunocap
phadia
uppsala
sweden
system
defin
posit
sesig
kuml
result
sesig
level
significantli
correl
asthma
sever
fev
fev
fvc
sputum
eosinophil
serum
eosinophil
wherea
sesig
level
patient
posit
ahr
mean
ae
standard
error
mean
ae
kuml
significantli
higher
patient
neg
ahr
ae
kuml
pvalu
regress
analysi
se
sensit
sige
se
kuml
signific
risk
factor
ahr
adjust
age
sex
fev
sputum
eosinophil
odd
ratio
confid
interv
pvalu
preval
se
sensit
higher
patient
allerg
rhiniti
nonatop
asthma
patient
compar
patient
without
allerg
rhiniti
atop
asthma
patient
respect
without
statist
signific
conclus
se
sensit
significantli
associ
ahr
background
aim
difficulti
achiev
asthma
control
may
associ
shift
profil
inflammatori
bronchial
infiltr
toward
polymorphonuclear
leucocyt
aim
studi
determin
influenc
neutrophil
compon
bronchial
inflamm
asthma
control
lung
function
airway
respons
method
patient
mild
persist
asthma
assess
upon
level
asthma
control
asthma
control
test
act
lung
function
fev
spirometri
airway
respons
isocapn
hyperventil
cold
air
c
ihca
ultrasound
inhal
distil
water
idw
cell
composit
induc
sputum
also
studi
patient
divid
group
low
content
neutrophil
peopl
st
group
high
content
neutrophil
peopl
nd
group
result
content
neutrophil
st
group
ae
eosinophil
ae
nd
group
ae
p
ae
p
respect
act
data
peopl
nd
group
manag
diseas
wors
st
group
background
aim
influenc
standard
combin
therapi
control
bronchial
inflamm
asthma
patient
cold
airway
hyperrespons
cahr
studi
aim
studi
estim
effici
applic
combin
therapi
asthma
patient
cahr
indic
pattern
bronchial
inflamm
method
patient
mean
age
ae
year
old
mild
persist
asthma
cahr
studi
upon
lung
function
asthma
control
cell
composit
induc
sputum
therapi
combin
budesonideformoterol
number
inflammatori
cell
studi
mean
cytochem
coeffici
myeloperoxidas
mpo
granulocyt
calcul
pixel
intens
cell
cytolysi
assess
combin
budesonideformoterol
dose
mcgday
use
achiev
control
decreas
till
stabl
support
dose
mcgday
result
baselin
asthma
control
ae
point
act
fev
ae
number
neutrophil
ae
prevail
eosinophil
ae
level
mpo
ae
pixel
week
therapi
signific
improv
lung
function
asthma
control
increas
till
ae
point
act
p
signific
decreas
eosinophil
ae
till
ae
p
intens
eosinophil
cytolysi
decreas
ae
till
ae
p
neutrophil
ae
till
ae
p
intracellular
concentr
mpo
increas
ae
till
ae
pixel
p
number
neutrophil
remain
high
ae
p
consid
factor
stabl
initi
inflamm
oxid
stress
conclus
use
mode
standard
antiinflammatori
therapi
long
treatment
combin
drug
budesonideformoterol
asthmat
cahr
help
achiev
control
number
neutrophil
background
aim
gina
state
tiotropium
bromid
could
one
recommend
option
add
standard
step
treatment
asthmat
wellcontrol
maintain
combin
therapi
month
theoret
stepdown
start
still
precis
strategi
stepdown
therapi
well
defin
method
studi
design
random
control
trial
sever
adult
asthmat
wellcontrol
receiv
gina
treatment
step
includ
medium
high
dose
icslaba
ltra
tiotropium
month
recruit
patient
random
maintain
current
treatment
discontinu
ltra
stepdown
group
feno
act
score
spirometri
exacerb
rate
examin
everi
week
month
result
patient
enrol
stepdown
perform
patient
mean
age
year
old
fev
act
score
time
entri
suggest
rel
well
asthma
control
statu
enrol
patient
drop
week
case
pef
amount
sputum
week
case
exacerb
asthma
week
case
rhiniti
symptom
respect
discontinu
ltra
clinic
characterist
among
droppedout
patient
except
femal
receiv
high
dose
icslaba
combin
inhal
month
differ
group
time
first
exacerb
mean
number
exacerbationspersonyear
stepdown
group
vs
chang
fev
act
score
conclus
withdraw
ltra
might
safe
option
consid
stepdown
combin
therapi
icslaba
tiotropium
bromid
ltra
sever
asthmat
case
patient
receiv
high
dose
icslaba
studi
limit
small
sampl
size
short
durat
therefor
consid
preliminari
background
aim
studi
level
fungalspecif
immunoglobulin
e
sige
phenomenon
multipl
fungal
sensit
patient
suffer
respiratori
diseas
method
screen
adult
patient
suffer
asthma
adult
allerg
bronchopulmonari
aspergillosi
abpa
patient
aspergillu
fumigatessig
detect
posit
grade
equal
greater
level
three
divid
two
group
group
asthma
aspergillu
fumigatu
sensit
group
abpa
patient
serum
concentr
ige
penicillum
notatum
branch
cinerea
aspergillu
fumigatu
candida
albican
mould
alternaria
helminthosporium
detect
immunocap
fluor
euzymelink
immunosorb
system
result
result
group
abpa
patient
aspergillu
fumigatu
sige
significantli
higher
group
asthma
aspergillu
fumigatu
sensit
p
kul
vs
kul
candida
albican
sige
kul
vs
kul
penicillium
notatum
sige
kul
vs
kul
alternaria
sige
kul
vs
kul
patient
embrac
phenomenon
multipl
fungal
sensit
signific
correl
sige
level
fungu
p
moreov
optim
scale
techniqu
reflect
similar
relationship
aspergillu
fumigatu
alternaria
cronbach
alpha
conclus
nutshel
patient
sensit
aspergillu
fumigatu
often
exist
phenomenon
multipl
fungal
sensit
mayb
phenomenon
caus
sensit
protein
secret
fungu
combin
differ
fungu
sige
detect
may
regard
auxiliari
examin
fungal
allerg
asthma
background
aim
respiratori
diseas
refractori
diseas
remark
reduc
life
qualiti
patient
cost
great
amount
social
wealth
studi
reveal
correl
environment
factor
develop
progress
diseas
determin
particul
matter
concentr
air
bedroom
outdoor
hdm
allergen
concentr
bed
pillow
appli
hepa
air
purifi
evalu
effect
improv
air
qualiti
efficaci
adjuv
therapi
respiratori
allerg
diseas
method
air
purifi
set
near
bed
bedroom
month
peopl
ae
year
old
diagnos
allerg
rhiniti
adult
diagnos
bronchial
asthma
select
applic
purifi
everi
month
dust
sampl
collect
vacuum
cleaner
dust
collector
pm
valu
measur
chang
pm
valu
shown
pm
ratio
rqlq
use
access
symptom
patient
applic
air
purifi
use
data
entri
analysi
measur
data
descript
analyz
nonparametr
test
independ
test
repeat
measur
anova
use
comparison
among
group
p
consid
statist
signific
result
der
ngg
abund
allergen
air
patient
bedroom
follow
ng
g
der
concentr
ngg
bed
pillow
higher
der
ngg
der
der
concentr
slightli
decreas
applic
air
purifi
concentr
significantli
decreas
first
three
month
increas
th
month
score
activ
limit
practic
problem
declin
way
conclus
air
purifi
properli
function
effect
reduc
pm
hdm
allergen
concentr
air
therebi
improv
clinic
manifest
patient
allerg
rhiniti
asthma
background
aim
report
preval
bacteri
viral
infect
acut
exacerb
asthma
vari
region
report
studi
conduct
western
countri
recent
guidelin
manag
asthma
recommend
antibiot
routin
prescrib
acut
exacerb
asthma
investig
preval
bacteri
viral
infect
predict
marker
bacteri
infect
acut
exacerb
asthma
singl
center
south
korea
method
retrospect
analyz
medic
record
patient
acut
exacerb
asthma
admit
korea
univers
guro
hospit
januari
june
search
electron
medic
record
databas
key
word
asthma
acut
exacerb
result
episod
acut
exacerb
patient
men
women
mean
age
ae
year
number
patient
bacteri
infect
viral
infect
bacteri
viral
infect
pathogen
respect
major
bacteria
streptococcu
pneumonia
haemophilu
influenza
major
virus
rhinoviru
influenza
viru
serum
eosinophil
count
significantli
lower
bacteri
posit
group
p
serum
creactiv
protein
crp
procalcitonin
pct
level
higher
bacteri
posit
group
p
p
respect
conclus
studi
show
streptococcu
pneumonia
rhinoviru
common
isol
acut
exacerb
asthma
serum
eosinophil
count
serum
crp
pct
level
use
distinguish
bacteri
infect
acut
exacerb
asthma
find
provid
use
inform
antibiot
treatment
patient
acut
exacerb
asthma
background
aim
asthma
character
airway
hyperrespons
airflow
obstruct
bronchial
level
often
revers
either
spontan
treatment
last
decad
continu
increas
preval
asthma
observ
worldwid
complex
chronic
diseas
particularli
challeng
research
need
environment
determin
diseas
increas
asthma
incid
last
decad
strongli
suggest
role
environment
air
pollut
street
sweeper
expos
dust
particl
bioaerosol
variou
harm
gase
inhal
particul
enter
lung
may
lead
advers
respiratori
ill
effect
fact
street
sweeper
usual
would
use
protect
devic
like
face
mask
exposur
dust
gener
sweep
may
contribut
increas
preval
lung
diseas
preliminari
cross
section
studi
preval
asthma
among
street
sweeper
jakarta
indonesia
approv
ethic
committe
faculti
medicin
universita
indonesia
method
research
design
cross
section
subject
street
sweeper
jakarta
indonesia
sampl
collect
use
cluster
random
sampl
questionnair
asthma
screen
questionnair
asq
asthma
control
test
act
spirometri
examin
base
pneumobil
project
indonesia
bronchodil
test
inclus
criteria
male
femal
abl
perform
spirometri
sign
inform
consent
year
old
work
period
year
result
thirti
street
sweeper
whose
work
area
particip
studi
age
year
old
femal
male
preval
asthma
among
street
sweeper
area
subject
year
old
femal
conclus
preval
asthma
among
street
sweeper
jakarta
background
aim
measur
peak
expiratori
flow
pef
easi
inexpens
method
monitor
bronchial
asthma
mani
digit
peak
flow
meter
pfm
smart
phone
app
develop
howev
clinic
applic
limit
korea
develop
portabl
digit
pfm
asthma
monitor
system
softwar
android
mobil
devic
one
part
project
develop
portabl
digit
pfm
made
prototyp
digit
pfm
aim
studi
compar
perform
miniatur
wright
pfm
share
experi
process
project
method
prototyp
digit
pfm
compar
minwright
pfm
pair
calibr
flow
provid
two
calibr
simultan
data
digit
pfm
transmit
app
smart
phone
bluetooth
pef
valu
shown
screen
smart
devic
pef
valu
miniwright
pfm
read
analogu
scale
directli
result
pair
pef
valu
obtain
valu
pef
lmin
lmin
strong
posit
correl
shown
pef
digit
pfm
miniwright
pfm
p
digit
pfm
could
use
clinic
would
use
part
asthma
monitor
alarm
system
patient
asthma
background
aim
asthma
common
respiratori
ill
affect
almost
indian
involv
airway
inflamm
hyper
respons
signific
percentag
asthmat
show
presenc
atopi
variou
allergen
includ
food
allergen
present
studi
look
pattern
food
sensit
asthmat
india
method
total
asthmat
patient
diagnos
accord
gina
guidelin
enrol
patient
underw
skin
prick
test
food
allergen
total
allergen
commonli
consum
test
result
food
sensit
present
asthmat
patient
common
group
caus
sensit
anim
product
follow
legum
seed
cereal
grain
individu
five
common
food
prawn
fennel
red
gram
baker
yeast
bean
conclus
among
indian
patient
suffer
asthma
found
anim
product
common
offend
agent
follow
legum
individu
prawn
fennel
red
gram
baker
yeast
bean
five
commonest
sensit
food
found
food
allergen
commonest
sensit
agent
asthmat
india
background
aim
previou
studi
demonstr
mutant
genotyp
associ
poor
inhal
corticosteroid
ic
respons
asthmat
human
airway
relax
regul
circul
epinephrin
epi
enhanc
corticosteroid
unknown
whether
mutant
associ
circul
concentr
chang
epinephrin
cortisol
asthma
aim
studi
evalu
relationship
method
total
asthmat
healthi
control
recruit
studi
mildtomoder
asthmat
receiv
fluticason
propion
bid
treatment
week
genotyp
perform
iplex
massarray
genotyp
platform
plasma
concentr
cortisol
cor
epinephrin
particip
detect
elisa
kit
result
homozygot
mutant
genotyp
gg
higher
plasma
epinephrin
concentr
median
concentr
pgml
n
gg
median
concentr
pgml
n
aaag
p
cortisol
concentr
median
concentr
ngml
n
gg
median
concentr
ngml
n
aaag
p
epinephrin
concentr
cortisol
concentr
plasma
posit
correl
fev
r
r
respect
correl
mrna
express
asthmat
treat
ic
associ
plasma
epinephrin
cortisol
concentr
chang
recess
model
aa
ag
vs
gg
gg
less
improv
epinephrin
concentr
aaag
pgml
n
aaag
gg
pgml
n
gg
p
cortisol
concentr
aaag
ngml
n
aaag
gg
ngml
n
gg
p
conclus
studi
suggest
poor
ic
respons
mutant
genotyp
might
relat
less
increas
amplitud
plasma
epinephrin
cortisol
asthmat
patient
background
aim
background
long
term
respiratori
limit
live
asthma
stigma
also
identifi
social
phenomenon
among
adult
asthmat
main
object
studi
valid
newli
devis
malay
version
stigma
scale
mss
use
group
malaysian
patient
diagnos
asthma
method
crosssect
studi
adult
asthma
patient
enrol
four
respiratori
clinic
locat
selangor
malaysia
permiss
adapt
translat
questionnair
obtain
correspond
author
questionnair
translat
malay
languag
forward
backward
translat
harmon
cognit
debrief
interview
proof
read
establish
content
face
valid
extract
data
complet
questionnair
analys
construct
valid
moreov
reliabl
assess
cronbach
intraclass
correl
coeffici
icc
intern
consist
one
month
testretest
reliabl
respect
result
final
mss
found
reliabl
instrument
use
measur
intern
consist
cronbach
one
month
testretest
reliabl
icc
moreov
kaisermeyerolkin
kmo
measur
verifi
sampl
adequaci
kmo
barlett
test
spheric
x
p
indic
correl
item
suffici
larg
enough
factor
analysi
analysi
scree
plot
eigenvalu
suggest
retain
three
factor
name
discrimin
disclosur
perceiv
posit
basi
natur
item
conclus
mss
found
highli
reliabl
valid
instrument
assess
stigma
malaysian
adult
asthma
patient
questionnair
develop
iter
process
studi
suggest
test
instrument
malaysian
state
reinforc
good
psychometr
properti
background
aim
asthma
signific
health
problem
twothird
asthmat
patient
sensit
common
allergen
sensit
fungu
particularli
aspergillu
associ
increas
risk
sever
develop
abpa
sensit
tune
report
north
india
scant
data
avail
south
studi
done
assess
occurr
factor
associ
aspergillu
sensit
bangalor
result
sixti
one
patient
studi
mean
age
ae
year
f
patient
urban
rural
area
respect
eight
patient
histori
atopi
allerg
rhiniti
famili
histori
asthma
eleven
patient
smoker
cutan
sensit
aspergillu
fumigatu
seen
patient
correl
aspergillu
sensit
durat
ill
presenc
allerg
rhiniti
histori
atopi
smoke
statu
area
resid
rural
vs
urban
associ
aspergillu
sensit
asthma
sever
control
conclus
aspergillu
sensitz
seen
asthmat
cohort
associ
aspergillu
sensit
demograph
clinic
factor
asthma
sever
control
background
aim
oxid
stress
play
import
role
maintain
inflamm
respiratori
tract
loss
asthma
control
aim
studi
evalu
twoday
dynam
index
lipid
peroxidaion
blood
asthma
patient
singl
exposur
hyposmolar
stimulu
method
patient
mean
age
ae
year
fev
ae
mild
persist
partli
control
uncontrol
asthma
asthma
control
test
ae
point
involv
studi
fev
measur
spirometri
content
lipid
hydroperoxid
vitamin
e
ceruloplasmin
blood
serum
measur
colorimetr
method
measur
taken
inhal
distil
water
idw
next
day
statist
signific
differ
determin
use
mannwhitney
pair
test
result
fev
differ
first
second
day
studi
ae
ae
l
respect
p
mean
respons
idw
consist
ae
averag
content
lipid
hydroperoxid
first
day
studi
consist
ae
nmolml
slightli
increas
ae
nmolml
p
respons
idw
second
day
lipid
hydroperoxid
content
increas
ae
nmolml
p
correl
baselin
fev
r
p
vitamin
e
content
first
day
significantli
increas
ae
ae
mgml
p
idw
next
day
consist
ae
gml
p
content
ceruloplasmin
blood
serum
significantli
increas
ae
first
day
ae
ml
second
day
p
chang
ceruloplasmin
idw
statist
insignific
conclus
patient
asthma
singl
inhal
distil
water
follow
develop
oxid
stress
symptom
persist
least
day
work
support
russian
scienc
foundat
grant
result
patient
copd
male
year
sever
diseas
gold
iii
smoker
exposur
indoor
air
pollut
due
use
biomass
fuel
histori
tb
alcohol
abus
patient
bronchial
asthma
young
femal
year
mild
asthma
patient
categori
overlap
copd
asthma
sever
symptom
consum
alcohol
regularli
signific
exposur
indoor
air
pollut
conclus
tobacco
smoke
toxic
exposur
indoor
smoke
tower
burden
tb
alcohol
abus
risk
factor
converg
togeth
interfac
copd
asthma
low
incom
countri
need
reconstruct
prevail
paradigm
lung
health
lowincom
countri
like
nepal
basi
avail
evid
background
aim
histor
dri
powder
inhal
dpi
consid
provid
better
airway
distribut
easier
identif
empti
devic
easier
handl
compar
pressur
meter
dose
inhal
pmdi
prior
research
major
handl
error
inhal
devic
use
shown
error
result
compar
impair
asthma
control
dpi
pmdi
research
demonstr
patient
prescrib
similar
type
prevent
inhal
devic
reliev
better
asthma
control
patient
prescrib
pmdi
inhal
corticosteroidlong
act
beta
agonist
reliev
could
benefit
switch
dpi
pmdi
health
insur
review
assess
hira
databas
provid
coverag
medic
claim
million
peopl
korea
offer
opportun
studi
asthma
control
nation
basi
aim
studi
provid
review
possibl
korean
hira
databas
prepar
studi
investig
effect
asthma
control
patient
switch
inhal
type
method
methodolog
previou
literatur
describ
hira
databas
analys
focus
identif
asthma
patient
clinic
characterist
eg
exacerb
comorbid
reallif
medic
switch
behaviour
healthcar
resourc
use
includ
medic
associ
cost
result
patient
medic
histori
could
construct
primari
secondari
diagnosi
associ
individu
databas
entri
asthma
exacerb
could
proxi
prescript
acut
oral
corticosteroid
hospit
admiss
emerg
room
attend
associ
diagnosi
asthma
lower
respiratori
infect
respiratori
failur
patient
could
consid
switch
patient
receiv
prescript
pmdi
prescript
dpi
inhal
addit
variabl
avail
includ
medic
hospitalis
cost
conclus
hira
databas
allow
studi
analys
switch
success
inhal
type
term
persist
asthma
control
healthcar
resourc
utilis
background
aim
case
present
ovarian
cancer
sudden
dyspnea
show
dilat
right
ventricl
atrium
sign
pressur
volum
overload
sever
pulmonari
hypertens
ph
patent
ductu
arteriosu
pda
advis
pda
closur
done
present
er
bp
chest
ctangiographi
show
larg
bilater
main
pulmonari
arteri
emboli
pda
hypoxemia
high
alveolararteri
gradient
blood
ga
thrombosi
leg
duplex
scan
abdominopelv
ctangiographi
lowmolecular
weight
heparin
lmwh
start
treatment
result
improv
bp
dyspnea
howev
repeat
chest
ct
angiographi
month
lmwh
reveal
persist
emboli
still
show
sever
ph
pulmonari
endarterectomi
plan
chronic
thromboembol
pulmonari
hypertens
done
right
heart
catheter
show
signific
stepup
level
right
ventricl
main
pulmonari
arteri
predomin
left
right
shunt
qpq
confirm
pda
unfortun
irrevers
ph
make
good
candid
pda
closur
high
risk
endarterectomi
markedli
elev
suggest
ovarian
cancer
sever
ph
preclud
invas
procedur
abdomin
pigtail
insert
palli
care
case
inde
unfortun
sinc
might
alreadi
elev
pa
pressur
pda
aggrav
pte
presum
underli
malign
combin
three
diseas
significantli
worsen
prognosi
closur
lesion
onset
irrevers
ph
treatment
pda
surgic
remov
emboli
constitut
manag
persist
pte
howev
irrevers
ph
document
right
heart
catheter
coupl
high
risk
natur
diseas
preclud
invas
procedur
done
resort
palli
measur
background
aim
data
bronchial
leukocyt
activ
cytokin
asthmat
osmot
ahr
aim
studi
assess
activ
mpo
cytolysi
bronchial
leukocyt
hyperosmolar
ahr
depend
method
asthma
patient
group
airway
hyperrespons
inhal
ultrasound
nebul
hyperton
nacl
solut
ih
patient
without
respons
group
examin
healthi
person
control
group
leukocyt
induc
sputum
mean
cytochem
coeffici
mcc
pixel
mpo
intens
cell
cytolysi
icc
au
determin
concentr
pgml
exhal
breath
condens
measur
elisa
result
icc
neutrophil
group
ae
au
group
ae
au
p
control
group
ae
au
p
icc
eosinophil
ae
ae
ae
au
p
respect
activ
neutrophil
cytolysi
group
associ
increas
activ
mpo
mcc
background
aim
corticosteroid
cs
wide
use
variou
inflammatori
diseas
includ
bronchial
asthma
efficaci
advers
effect
cs
heterogen
individu
patient
may
partli
caus
genet
variat
inflammatori
cytokin
transcript
factor
cs
act
singl
nucleotid
polymorph
snp
glucocorticoidinduc
transcript
report
associ
clinic
effect
inhal
corticosteroid
asthma
present
studi
intend
analyz
relationship
gene
polymorph
inhibitori
effect
cytokin
product
methylprednisolon
mpsl
method
peripher
blood
mononuclear
cell
purifi
healthi
volunt
incub
cultur
plate
coat
antibodi
presenc
antibodi
hr
variou
concentr
mpsl
add
cultur
concentr
cytokin
ilb
tnfa
tnfb
infg
cultur
supernat
measur
bead
method
use
flow
cytomet
genotyp
taqman
probe
analyz
relationship
gene
polymorph
inhibitori
concentr
mpsl
individu
cytokin
result
genotyp
frequenc
gg
n
ga
aa
similar
healthi
japanes
upload
nbdc
japan
site
significantli
associ
mpsl
product
howev
allel
weak
respons
high
g
inconsist
one
previous
publish
conclus
given
lack
strong
consist
associ
inhibitori
effect
mpsl
vitro
studi
need
establish
clinic
signific
snp
background
aim
prostaglandin
e
pge
major
eicosanoid
multipl
often
opposit
effect
human
bodi
protect
effect
respiratori
system
condit
includ
bronchoconstrict
induc
ultrason
nebul
distil
water
undw
known
long
time
cours
research
eicosanoid
involv
osmot
airway
hyperrespons
oah
aim
studi
estim
pge
exhal
breath
condens
ebc
serum
asthmat
differ
respons
hypoand
hyperosmolar
stimuli
method
ebc
collect
asthmat
provoc
undw
serum
collect
patient
provoc
undw
ultrason
nebul
hyperton
solut
unhr
nacl
content
pge
measur
ebc
freezedri
serum
without
preliminari
purif
eia
commerci
kit
r
system
usa
result
pge
detect
ebc
patient
sampl
undw
among
patient
found
pge
ebc
provoc
patient
detect
pge
ebc
belong
group
hyperrespons
undw
pge
pgml
without
pge
pgml
pge
content
serum
rang
pgml
statist
differ
group
asthmat
differ
airway
respons
osmot
stimuli
undw
unhr
howev
found
signific
correl
pge
content
serum
lung
function
indic
patient
oah
unhr
conclus
content
pge
ebc
low
involv
oah
least
undw
pge
content
serum
associ
lung
function
asthmat
oah
hyperton
solut
research
support
russian
scientif
foundat
grant
dvtfather
day
admiss
patient
develop
cough
hemoptysi
bilater
pleurit
chest
pain
consult
er
yield
normal
chest
xray
sent
home
day
consult
outpati
depart
persist
symptom
plain
chest
ct
scan
reveal
lower
lobe
nonhomogen
opac
left
basal
area
smaller
one
right
cavitari
ptb
vs
pneumonia
consid
admit
given
moxifloxacin
daili
sputum
afb
tb
gene
expert
neg
patient
complain
progress
symptom
despit
antibiot
nd
hospit
day
chest
xray
show
leftsid
pleural
effus
atelectasi
fluid
left
seen
ultrasound
antibiot
shift
piperacillintazobactam
bronchoscopi
rd
day
show
blood
clot
left
basal
segment
bronchial
wash
tb
gene
expert
cultur
includ
legionella
mycoplasma
pcp
autoimmunehiv
test
neg
patient
underw
chest
ct
angiogram
th
hospit
day
show
fill
defect
repres
thrombu
impress
pulmonari
thromboembol
lower
lung
complet
occlus
left
basal
trunk
branch
low
molecular
weight
heparin
lmwh
start
everi
hour
venou
duplex
scan
lower
extrem
unremark
th
hospit
day
less
hemoptysi
develop
fever
tmax
c
total
episod
th
hospit
day
patient
claim
feel
lot
better
complain
vagu
pain
left
upper
inner
arm
venou
duplex
scan
upper
extrem
reveal
heterogen
hypoecho
intralumin
densiti
repres
acutesubacut
superfici
vein
thrombosi
partial
occlud
left
cephal
basilica
vein
lmwh
shift
rivaroxiban
bid
patient
sent
home
result
eightynin
surgeri
perform
patient
mean
pulmonari
embol
sever
index
pesi
ae
class
class
class
class
class
patient
receiv
anticoagul
therapi
use
heparin
case
low
molecular
weight
heparin
case
howev
anticoagul
therapi
prescrib
case
pte
mean
period
surgeri
diagnosi
pte
ae
day
mean
anesthesia
time
ae
minut
surgeri
patient
admit
icu
close
observ
although
almost
immedi
postop
complic
identifi
recurr
pte
confirm
patient
next
day
surgeri
discharg
aliv
day
surgeri
two
patient
die
uncontrol
infect
patient
cardiac
tamponad
within
day
caus
death
unrel
pte
conclus
orthoped
surgeri
within
month
patient
acut
pte
feasibl
background
aim
patholog
featur
highaltitud
pulmonari
edema
hape
character
mark
diffus
alveolar
edema
alveolar
hyalin
membran
dilat
pulmonari
capillari
pulmonari
arteri
thrombosi
secondari
bronchopneumonia
maintain
alveolar
structur
light
microscop
date
rapid
collect
fluid
lung
hape
yet
suffici
explain
contemporarili
demonstr
mechan
result
pulmonari
hypertens
misdistribut
perfus
increas
pulmonari
capillari
permeabl
method
order
refresh
pathogenesi
hape
regard
pulmonari
capillari
permeabl
report
novel
find
ultrastructur
pulmonari
alveolarcapillari
wall
two
case
hape
observ
electron
microscop
result
found
neutrophil
trap
pulmonari
capillari
part
neutrophil
protrud
adher
basement
membran
capillari
endothelium
activ
degranul
neutrophil
wall
endotheli
cell
pulmonari
capillari
deform
thick
swell
degener
side
alveolar
space
infiltr
neutrophil
macrophag
prolifer
type
ii
pneumocyt
also
observ
electron
microscop
observ
confid
provid
evid
structur
pulmonari
alveolarcapillari
wall
impair
deform
thick
probabl
due
adher
neutrophil
activ
degranul
stimulu
hypoxia
structur
injuri
might
fundament
precondit
solut
fluid
penetr
speedili
capillari
side
alveolar
side
eventu
fluid
collect
alveolar
space
occur
hape
background
aim
allerg
rhiniti
ar
impair
patient
qualiti
life
bring
heavi
economicburden
societi
grow
evid
suggest
air
poluut
correl
occurr
allergi
symptom
air
pollut
mostli
suspend
factor
includ
ozon
nitrogen
oxid
may
facilit
allergen
assess
immunoregulatori
cell
promot
develop
allerg
symptom
howev
whether
level
directli
correl
symptom
ar
patient
unclear
would
possibl
improv
qualiti
life
ar
patient
reduc
level
studi
aim
improv
correl
qualiti
life
ar
patient
level
surround
enviro
evalu
efficaci
air
purifi
improv
qualiti
life
ar
patient
method
clinicali
confirm
ar
patient
enrol
studi
includ
male
femalesss
age
year
subject
ask
fill
rhiniti
qualiti
life
questionnair
rqlq
evryday
month
correspond
level
live
enviro
record
simultan
patient
ask
fill
rqlq
everi
month
monitor
symptom
ar
patient
use
air
purifi
data
collect
consid
statisc
signific
result
among
sub
score
rqlq
nasal
symptom
r
p
correl
show
signific
correl
p
daili
activ
r
p
sleep
qualiti
r
p
nonnas
symptom
r
p
emot
problem
r
p
significantli
correl
level
conclus
level
correl
nasal
symptom
ar
patient
air
purfier
effect
lower
level
allevi
certain
symptom
ar
patient
improv
qualiti
life
background
aim
bilater
giant
pulmonari
arteri
aneurysm
rare
patholog
entiti
thorac
caviti
deterl
clagett
report
eight
case
post
mortem
examin
present
case
year
old
filipina
previous
diagnos
atrial
septal
defect
incident
find
bilater
pulmonari
arteri
aneurysm
aneurysm
dilat
main
pulmonari
arteri
peripher
wall
fill
defect
also
note
right
left
pulmonari
arteri
intens
medic
treatment
propos
patient
clinic
improv
sign
symptom
method
bilater
giant
pulmonari
arteri
aneurysm
paa
rare
patholog
entiti
thorac
caviti
specif
report
regard
preval
paa
defin
dilat
pulmonari
arteri
barbour
mention
cutoff
diamet
pulmonari
arteri
paa
would
present
nonspecif
symptom
like
dyspnea
chest
heavi
pain
would
present
hemoptysi
case
report
would
present
case
year
old
filipina
incident
find
giant
paa
result
ct
angiogram
pulmonari
arteri
reveal
aneurysm
dilat
main
pulmonari
arteri
right
left
pulmonari
arteri
peripher
wall
fill
defect
seen
right
left
pulmonari
arteri
interlobar
arteri
might
repres
chronic
thrombu
format
conclus
paa
rare
diagnosi
bilater
giant
pulmonari
arteri
aneurysm
rare
patholog
entiti
thorac
caviti
deterl
clagett
report
eight
case
post
mortem
examin
sever
surgic
techniqu
offer
patient
howev
due
presenc
probabl
eisenmengeris
definit
treatment
patient
cardiac
lung
transplant
howev
patient
rel
refus
undergo
surgic
procedur
henc
arrang
regular
close
followup
visit
discharg
stabl
improv
background
aim
studi
conduct
evalu
associ
ar
mental
health
statu
gener
korean
adult
popul
investig
rel
burden
ar
mental
health
use
allerg
rhiniti
impact
asthma
aria
classif
method
survey
univari
analysi
conduct
healthi
ar
group
weight
preval
demograph
characterist
socioeconom
statu
comorbid
diseas
subanalysi
classifi
ar
sever
accord
aria
classif
carri
evalu
relationship
ar
sever
mental
health
odd
ratio
or
compon
repres
mental
health
statu
estim
multipl
logist
regress
analysi
confound
adjust
result
univari
analysi
chisquar
test
adjust
age
sex
bodi
mass
index
smoke
statu
alcohol
use
statu
exercis
statu
compon
repres
mental
health
statu
show
linear
relationship
sever
ar
accord
aria
classif
stress
depress
mood
suicid
thought
psycholog
consult
factor
correl
ar
adjust
demograph
characterist
socioeconom
statu
even
adjust
comorbid
allerg
diseas
correl
remain
signific
stress
depress
mood
psycholog
consult
factor
conclus
patient
ar
appear
higher
risk
mental
disord
gener
korean
adult
popul
moreov
persist
sever
ar
correl
poor
mental
health
therefor
better
control
ar
may
conduc
better
mental
health
attent
paid
psycholog
statu
ar
patient
background
aim
introduct
mycot
pulmonari
pseudoaneurysm
uncommon
complic
cavitatori
pneumonia
associ
organ
like
mycobacterium
tuberculosi
staphylococcu
aureu
mucormycosi
vaishali
et
al
carri
high
mortal
risk
report
interest
case
sever
pneumonia
mycot
pulmonari
pseudoaneurysm
fail
bronchial
arteri
embol
therapi
method
case
present
year
old
indian
male
smoker
pack
year
previou
histori
stroke
hypertens
peripher
vascular
diseas
present
sudden
onset
hemoptysi
report
cough
millilit
fresh
blood
prior
hospit
deni
chest
pain
fever
night
sweat
weight
loss
prior
pulmonari
tuberculosi
recurr
chest
infect
clinic
examin
reveal
tachypnea
coars
crepit
right
lung
base
deterior
worsen
type
respiratori
failur
intub
stabilis
icu
ct
thorax
fig
reveal
bilater
lower
lobe
consolid
cavit
right
lower
lobe
mycot
pseudoaneurysm
along
posteromedi
wall
cystic
lesion
result
antibiot
therapi
initi
blood
sputum
neg
organ
cultur
smear
pulmonari
tuberculosi
neg
underw
success
bronchial
arteri
embol
blood
product
transfus
close
follow
massiv
hemoptysi
recur
repeat
ct
show
obviou
focu
activ
bleed
decis
made
surgic
intervent
henc
underw
right
lower
lobectomi
right
lower
lobe
pseudoaneurysm
invad
right
diaphragm
note
intraop
histolog
resect
lung
neg
malign
thereaft
made
progress
recoveri
discharg
well
conclus
mycot
pseudoaneurysm
present
hemoptysi
requir
emerg
manag
multidisciplinari
approach
bronchial
arteri
embol
prefer
initi
treatment
hemostasi
case
illustr
need
vigil
follow
even
success
embol
prompt
earli
decis
surgeri
embol
fail
background
aim
femor
head
avascular
necrosi
common
disord
among
lupu
patient
caus
lot
neg
effect
qualiti
patient
life
aim
explor
clinic
paraclin
characterist
femor
head
avascular
necrosi
among
system
lupu
erythemat
patient
method
cross
section
studi
carri
system
lupu
erythemat
patient
also
femor
head
avascular
necrosi
studi
conduct
center
allergi
clinic
immunolog
bachmai
hospit
patient
fulfil
slicc
criteria
classif
sle
patient
femor
head
avascular
necrosi
symptomat
diagnosi
femor
head
avascular
necrosi
made
plain
radiographi
bone
scan
andor
mri
scan
result
mean
age
time
studi
year
rang
highest
age
group
year
old
patient
femor
head
avascular
necrosi
iv
xray
mri
renal
disord
common
seen
pain
symptom
correl
level
necrosi
femor
head
dyslipidemia
low
bone
densiti
risk
factor
femor
head
avascular
necrosi
conclus
half
sle
patient
sever
femor
head
avascular
necrosi
level
iv
among
nearli
renal
disord
femor
head
avascular
necrosi
common
among
young
patient
late
recogn
background
aim
respiratori
diseas
asthma
chronic
obstruct
pulmonari
diseas
copd
lung
infect
critic
consequ
mortal
morbid
human
aim
present
studi
examin
mechan
affect
transcript
airway
inflamm
depend
activ
gprotein
signal
ag
identifi
specif
molecul
suppress
airway
inflamm
act
gproteincoupl
receptor
method
charri
western
blot
anlaysi
detect
specif
gene
express
use
mous
lung
result
herein
suppress
upregul
regul
found
gprotein
regulatori
gpr
motif
peptid
bind
downregul
express
contrast
motif
upregul
express
mutat
gpr
peptid
increas
express
decreas
express
moreov
dendrit
extens
matrix
cultur
inhibit
gpr
peptid
compar
wildtyp
gpr
peptid
gpr
peptid
also
inhibit
morpholog
chang
inflammatori
cell
infiltr
mous
lung
product
inflammatori
cytokin
bronchoalveolar
lavag
bal
fluid
lung
conclus
data
indic
gpr
motif
critic
regul
express
cytokin
product
inflammatori
microenviron
w
hirofumi
yokosuka
citi
hospit
intern
medicin
yokosuka
japan
report
case
femal
asymptomat
isol
unilater
absenc
proxim
pulmonari
main
arteri
uapa
refer
hospit
abnorm
show
chest
xray
year
age
diagnosi
confirm
pulmonari
angiographi
show
absenc
right
pulmonari
arteri
collater
circul
ipsilater
lung
evid
pulmonari
hypertens
upon
cardiac
cathet
examin
safe
deliv
twice
care
manag
use
swanganz
cathet
remain
asymptomat
healthi
without
medic
uapa
rare
congenit
lesion
kept
mind
differenti
diagnosi
patient
abnorm
chest
xray
uapa
may
caus
varieti
symptom
although
patient
isol
uapa
complet
asymptomat
other
may
sever
pulmonari
hypertens
congest
heart
failur
report
case
consid
mechan
symptomat
variat
literatur
review
background
aim
repeatedli
hospit
patient
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
often
expos
antibiot
distribut
pathogen
bacteria
patient
poorli
understood
object
studi
analyz
distribut
pathogen
bacteria
risk
factor
associ
multidrugresist
mdr
bacteria
infect
earli
readmiss
patient
aecopd
method
retrospect
review
chart
patient
aecopd
admit
hospit
januari
novemb
earli
readmiss
group
nonearli
readmiss
group
determin
whether
patient
readmit
within
day
discharg
detect
potenti
pathogen
microorgan
ppm
mdr
bacteria
analyz
logist
regress
analysi
perform
identifi
independ
risk
factor
mdr
bacteria
infect
background
aim
cycl
ergomet
train
cet
shown
improv
exercis
perform
quadricep
muscl
patient
chronic
obstruct
pulmonari
diseas
copd
inspiratori
muscl
train
imt
could
improv
pressuregener
capac
inspiratori
muscl
purpos
studi
determin
whether
combin
cet
imt
would
lead
addit
benefit
compar
cet
alon
patient
copd
addit
effect
combin
train
compar
patient
without
respiratori
muscl
weak
method
patient
copd
randomli
divid
three
group
patient
receiv
combin
cet
imt
combin
group
receiv
cet
alon
cet
group
patient
receiv
intervent
control
group
pulmonari
function
exercis
capac
dyspnea
qualiti
life
respiratori
muscl
strength
emot
nutrit
statu
bode
index
measur
pulmonari
rehabilit
program
result
pulmonari
rehabilit
exercis
capac
dyspnea
qualiti
life
respiratori
muscl
strength
depress
anxieti
nutrit
statu
improv
combin
group
cet
group
compar
control
group
p
inspiratori
muscl
strength
significantli
increas
combin
group
compar
cet
group
ae
vs
ae
respect
p
howev
signific
differ
indic
two
group
p
combin
group
cet
group
patient
weaken
respiratori
muscl
greater
benefit
without
weaken
respiratori
muscl
p
conclus
combin
train
effect
increas
inspiratori
muscl
strength
compar
cet
alon
exercis
perform
dyspnea
depress
symptom
nutrit
statu
imt
may
use
ad
cet
patient
weaken
inspiratori
muscl
background
aim
age
known
predictor
mortal
admiss
exacerb
subject
copd
frailti
geriatr
syndrom
origin
defin
fri
meet
three
five
criteria
consist
low
unintent
weight
loss
selfreport
exhaust
low
grip
strength
slow
walk
speed
low
physic
activ
howev
altern
tool
report
one
kihon
checklist
kcl
questionnair
wide
use
japan
identifi
frail
individu
compos
item
yesno
respons
investig
relationship
kcl
clinic
indic
includ
patientreport
outcom
pro
stabl
copd
patient
method
examin
consecut
outpati
stabl
copd
particip
complet
st
georg
respiratori
questionnair
sgrq
copd
assess
test
cat
hyland
scale
kcl
pulmonari
function
test
kcl
rang
high
score
indic
frailti
syndrom
categor
particip
robust
prefrail
frail
respect
result
classifi
particip
robust
prefrail
frail
accord
kcl
statist
signific
differ
sqrq
total
score
cat
score
hyland
scale
score
score
among
three
group
kcl
score
significantli
correl
sgrq
total
score
r
p
cat
score
r
p
hyland
scale
score
r
p
score
r
p
contrarili
found
neither
signific
betweengroup
differ
pulmonari
function
measur
includ
fev
fev
fvc
tlc
rvtlc
ic
dl
co
dl
co
v
noteworthi
associ
kcl
score
spirometr
measur
conclus
frailti
screen
kcl
may
relev
healthrel
qualiti
life
breathless
stabl
copd
patient
background
aim
chronic
obstruct
pulmonari
diseas
copd
high
morbid
mortal
world
copd
exacerb
crucial
event
patient
aim
studi
investig
factor
affect
inhospit
mortal
patient
copd
exacerb
creat
tool
predict
individu
outcom
patient
statu
admiss
use
nationwid
inpati
databas
japan
method
retrospect
collect
data
patient
admit
due
copd
exacerb
discharg
juli
march
multivari
logist
regress
analysi
perform
examin
factor
associ
inhospit
mortal
result
total
elig
patient
inhospit
death
occur
patient
higher
mortal
associ
advanc
age
male
lower
bmi
disturb
conscious
sever
dyspnea
histori
mechan
ventil
pneumonia
asthma
admiss
base
result
multivari
logist
regress
analysi
develop
nomogram
predict
inhospit
mortal
concord
index
nomogram
intern
valid
perform
bootstrap
method
resampl
calibr
plot
well
fit
predict
inhospit
mortal
conclus
nomogram
predict
inhospit
prognosi
may
help
clinician
determin
appropri
treatment
min
session
respiratori
condit
breath
retrain
walk
stretch
train
mainli
conduct
one
one
decreas
patient
exert
dyspnea
session
behavior
modif
intervent
ad
encourag
patient
increas
physic
activ
use
copd
diari
pedomet
individu
activ
action
plan
given
interv
patient
visit
month
class
group
patient
educ
minsess
time
start
patient
copd
attend
last
three
year
result
number
copdrel
hospit
decreas
signific
reduct
age
group
seventi
eighti
p
dpc
diagnosi
procedur
combin
copd
hospit
tokyo
rank
releas
ministri
highest
howev
forth
ninth
respect
also
reduct
number
hospit
due
pneumonia
respect
conclus
suggest
outpati
pulmonari
rehabilit
selfmanag
educ
potenti
prevent
hospit
admiss
copd
patient
laborsav
respiratori
condit
enhanc
program
help
spread
pulmonari
rehabilit
background
aim
patient
prefer
satisfact
inhal
may
impact
adher
treatment
henc
outcom
advantag
studi
compar
prefer
feedback
mechan
breezhal
ellipta
inhal
comfort
devic
mouth
piec
copd
patient
dri
powder
inhal
use
method
openlabel
crossov
studi
random
patient
year
copd
sever
per
gold
smoke
histori
packyear
use
breezhal
ellipta
devic
differ
sequenc
separ
minut
devic
inhal
patient
complet
questionnair
contain
question
captur
patient
percept
feedback
mechan
comfort
mouth
piec
question
answer
scale
lower
prefer
higher
prefer
includ
percept
feedback
mechan
mean
first
three
question
comfort
mouth
piec
fourth
question
wilcoxon
sign
rank
test
use
level
signific
safeti
assess
includ
advers
event
physic
examin
vital
sign
height
weight
result
one
hundr
patient
men
women
mean
sd
age
year
random
patient
current
smoker
mean
sd
durat
copd
year
overal
patient
report
breezhal
devic
offer
greater
confid
dose
deliveri
better
comfort
mouth
piec
mean
score
attribut
vs
ellipta
mean
score
respect
figur
safeti
signal
identifi
studi
background
aim
dyspnea
main
symptom
chronic
obstruct
pulmonari
diseas
copd
restrict
activ
daili
live
adl
assess
motor
process
skill
amp
standard
measur
adl
howev
associ
amp
copd
remain
unclear
purpos
studi
evalu
amp
inhom
copd
patient
associ
breath
function
dyspnea
qualiti
life
diseasespecif
adl
standard
method
observ
studi
includ
outpati
stabl
copd
without
longterm
oxygen
therapi
conclus
amp
correl
diseasespecif
adl
scale
suggest
amp
reflect
adl
abil
stabl
copd
patient
kobe
univers
graduat
school
health
scienc
commun
health
scienc
kobe
japan
homevisit
nurs
station
wakakusa
homevisit
nurs
nagano
japan
nation
hospit
organ
higashi
nagano
hospit
intern
medicin
nagano
japan
background
aim
long
term
oxygen
therapi
ltot
improv
mortal
patient
chronic
obstruct
pulmonari
diseas
copd
adapt
standard
ltot
rest
howev
mani
copd
patient
hypoxia
movement
rest
sinc
provid
homenurs
intervent
program
copd
patient
complet
pulmonari
rehabilit
patient
routin
taken
care
home
homenurs
intervent
receiv
continu
inhospit
evalu
aim
present
studi
examin
effect
ltot
copd
patient
method
copd
patient
particip
program
year
includ
studi
patient
drop
period
exclud
measur
includ
pulmonari
function
arteri
blood
ga
walk
test
activ
daili
live
adl
score
healthrel
qualiti
life
qol
score
first
measur
result
surviv
rate
compar
patient
without
ltot
second
compar
ltot
without
desatur
group
walk
ltot
desatur
group
b
desatur
walk
defin
result
fortythre
subject
includ
analysi
subject
ltot
significantli
lower
bodi
mass
index
bmi
adl
score
subject
without
ltot
surviv
rate
ltot
lower
without
ltot
six
subject
classifi
group
subject
group
b
group
significantli
higher
group
b
lower
surviv
rate
respect
conclus
ltot
improv
hypoxia
howev
improv
surviv
rate
copd
patient
although
efficaci
bronchodil
administr
establish
treatment
effect
compromis
patient
prefer
skill
requir
use
inhal
devic
import
inhal
devic
easi
use
correct
dosag
administ
studi
compar
satisfact
error
occurr
three
type
dpi
name
breezhal
ellipta
genuair
method
healthi
subject
age
without
experi
use
dpi
recruit
n
subject
learn
use
dpi
read
product
instruct
follow
watch
demonstr
audio
explan
dpi
provid
subject
random
order
type
number
error
commit
subject
evalu
subject
ask
complet
questionnair
indic
satisfact
prefer
variou
aspect
dpi
result
subject
rate
significantli
greater
satisfact
indic
correct
dose
prepar
genuair
ellipta
vs
p
genuair
also
score
significantli
higher
ellipta
breezhal
vs
vs
p
subject
ask
confid
inhal
assign
dose
term
conveni
number
subject
prefer
breezhal
higher
genuair
ellipta
subject
prefer
ellipta
eas
dose
prepar
overal
satisfact
score
genuair
significantli
higher
breezhal
ellipta
vs
vs
p
conclus
use
genuair
dpi
associ
greater
user
satisfact
healthi
volunt
import
satisfact
would
improv
patient
complianc
inhal
therapi
week
p
indgli
show
signific
improv
sgrqc
total
score
unit
p
numer
reduct
rescu
medic
use
treatment
differ
puffsday
p
versu
sfc
pneumonia
incid
indgli
sfc
incid
oral
candidiasi
indgli
sfc
advers
event
ae
rate
gener
compar
indgli
sfc
sever
ae
numer
higher
sfc
group
conclus
indgli
better
sfc
term
moderatesever
exacerb
patientreport
outcom
safeti
asian
patient
flame
studi
studi
fund
novarti
pharma
ag
background
aim
concentr
cytokin
increas
lung
patient
stabl
chronic
obstruct
pulmonari
diseas
copd
augment
airway
exacerb
nacetylcystein
nac
seem
abl
reduc
copd
exacerb
addit
wellknown
mucolyt
activ
pharmacolog
mechan
effect
still
unclear
aim
pharmacolog
character
antiinflammatori
effect
nac
ex
vivo
model
copd
exacerb
method
influenc
nac
assess
contractil
respons
antiinflammatori
profil
human
isol
bronchi
incub
overnight
krebshenseleit
buffer
solut
control
lipopolysaccharid
lp
ngml
result
nac
prevent
desensit
induc
lp
incub
contractil
tone
linear
concentrationrespons
manner
pec
ae
ae
concentr
nac
inhibit
inflammatori
respons
human
airway
overal
ae
p
vs
lp
induc
overnight
stimul
lp
wherea
lower
concentr
nac
suffici
reduc
releas
ae
p
vs
lp
elicit
lp
conclus
result
studi
demonstr
concentr
nac
need
restor
normal
contractil
respons
human
bronchi
challeng
lp
concentr
nac
essenti
obtain
antiinflammatori
respons
ex
vivo
model
copd
exacerb
background
aim
background
cigarett
smoke
major
risk
factor
develop
cardiovascular
diseas
atherosclerosi
chronic
obstruct
pulmonari
diseas
copd
extens
research
gone
identifi
attempt
valid
relev
diagnost
biomark
diseas
activ
therapeut
respons
chronic
obstruct
pulmonari
diseas
creactiv
protein
crp
may
easili
sensit
measur
varieti
clinic
situat
monitor
diseas
progress
studi
attempt
identifi
relationship
smoke
behavior
level
crp
focus
use
crp
measur
predict
longterm
health
smoker
aim
compar
crp
level
asymptomat
smoker
nonsmok
compar
lung
function
spirometr
valu
asymptomat
smoker
nonsmok
correl
crp
level
lung
function
valu
method
hospit
base
prospect
studi
smoker
non
smoker
year
age
tertiari
care
hospit
recruit
mean
crp
smoker
sd
mean
crp
nonsmok
sd
comparison
done
use
ttest
independ
sampl
signific
differ
averag
crp
valu
smoker
nonsmok
p
nonsignific
neg
correl
mmefr
crp
p
smoker
nonsignific
neg
correl
mmefr
crp
p
nonsmok
signific
differ
averag
mmef
valu
smoker
nonsmok
p
conclus
studi
demonstr
signific
reduct
crp
smoker
non
smokersthu
crp
cheaper
altern
biomark
prognosi
drug
develop
predict
outcom
copd
high
sensit
crp
sensit
may
use
biomark
background
aim
chronic
obstruct
pulmonari
diseas
copd
may
extrapulmonari
manifest
includ
balanc
control
function
physic
incapac
balanc
impair
risk
fall
impact
clinic
outcom
activitylimit
daili
live
depress
qualiti
life
copd
patient
determin
risk
factor
balanc
impair
copd
method
crosssect
studi
conduct
singl
visit
involv
stabl
copd
patient
age
year
old
balanc
test
measur
use
berg
balanc
scale
bb
score
indic
balanc
impair
clinic
relev
data
age
sex
bmi
educ
comorbid
pft
sever
copd
longterm
oxygen
therapi
histori
fall
histori
acut
exacerb
sgrq
score
cat
score
mmrc
score
visual
deficit
time
go
test
tug
sixminut
walk
distanc
hospit
anxieti
depress
scale
had
compar
impair
nonimpair
balanc
patient
logist
regress
analysi
conclus
regardless
bodi
weight
presenc
sarcopenia
associ
time
increas
risk
decreas
bmd
copd
baselin
characterist
number
exacerb
pulmonari
function
test
mmrc
dyspnea
scale
mwd
cat
score
ccq
score
pulmonari
rehabilit
program
assess
result
patient
male
median
age
year
mean
forc
expiratori
volum
one
second
ae
predict
pulmonari
rehabilit
mmrc
dyspnea
scale
cat
score
statist
signific
differ
compar
pulmonari
rehabilit
mean
chang
ae
p
ae
p
respect
cat
score
met
minim
clinic
import
differ
mcid
ccq
mwd
improv
statist
signific
pulmonari
function
paramet
number
exacerb
differ
pulmonari
rehabilit
program
conclus
outpati
hospitalbas
pulmonari
rehabilit
program
copd
patient
improv
qualiti
life
term
cat
score
muang
thailand
maharat
nakhonratsima
hospit
medicin
nakhonratsima
thailand
background
acut
exacerb
chronic
obstruct
pulmonari
diseas
copd
lead
caus
hospit
econom
burden
frequent
exacerb
impair
qualiti
life
effect
declin
lung
function
object
evalu
characterist
copd
patient
acut
exacerb
readmit
within
day
discharg
hospit
precipit
caus
acut
manag
hospit
stay
outcom
cost
admiss
also
determin
method
studi
popul
includ
copd
patient
acut
exacerb
readmit
within
day
discharg
maharat
nakornratchasima
hospit
octob
june
retrospect
descript
studi
appli
result
patient
readmit
within
day
discharg
due
acut
exacerb
mean
age
year
male
femal
ration
admiss
describ
previou
readmiss
mean
durat
symptom
day
respect
patient
previou
admiss
patient
readmiss
respiratori
failur
requir
mechan
ventil
common
precipit
caus
pneumonia
occur
respect
organ
pneumonia
identifi
patient
previou
admiss
pseudomona
aeruginosa
promin
readmiss
common
organ
acinetobact
baumannii
background
aim
conflict
report
role
inflammasom
inflamm
copd
cigarett
smokeinduc
injuri
hypothes
would
activ
nlrp
andor
altern
inflammasom
type
includ
absent
melanoma
airway
copd
patient
respons
cigarett
smoke
method
human
cell
line
primari
alveolar
macrophag
analys
releas
elisa
cleavageactiv
express
local
asc
cleav
immunofluorescenceconfoc
microscopi
western
blot
effect
inhibitor
zyvadfmk
antagonist
glyburid
treatment
receptor
regul
without
exposur
cigarett
smoke
extract
investig
result
cigarett
smoke
induc
human
primari
alveolar
macrophag
increas
intracellular
express
level
fold
cell
two
differ
donor
p
particl
size
brightli
stain
cleav
insid
outsid
cell
fold
p
particl
partial
coloc
particul
shown
sharpli
increas
cigarett
smoketr
cell
cigarett
smoke
also
induc
activ
monocytederiv
macrophag
particul
activ
seen
mostli
intracellularli
releas
cigarett
smoketr
cell
block
zyvadfmk
glyburid
significantli
protect
macrophag
cigarett
smokeinduc
activ
p
conclus
inflamm
copd
could
initi
inflammasom
regul
sphingolipid
signal
suggest
novel
therapeut
target
copd
background
aim
incid
chronic
obstruct
pulmonari
diseas
copd
obes
rise
malaysia
date
studi
report
spirometri
airflow
limit
includ
restrict
obstruct
pattern
nonselect
popul
malaysia
purpos
studi
estim
preval
risk
factor
airflow
limit
screen
copd
use
new
handheld
devic
airsmart
spirometri
copd
popul
screener
copdp
questionnair
method
crosssect
studi
perform
screen
nonselect
popul
two
tertiari
medic
institut
malaysia
nation
univers
malaysia
medic
centr
univers
technolog
mara
hospit
selayang
campu
use
valid
fiveitem
questionnair
copdo
new
airsmart
spirometri
devic
patient
demograph
obtain
use
standard
questionnair
facetofac
interview
conduct
result
subject
recruit
screen
popul
observ
restrict
obstruct
pattern
respect
screen
popul
copdp
score
subject
obstruct
pattern
activ
exsmok
p
p
whilst
subject
restrict
pattern
like
bodi
mass
index
ci
p
use
spearman
correl
analys
neg
correl
forc
vital
capac
bodi
mass
index
rs
p
onefifth
subject
airflow
limit
return
formal
assess
conclus
studi
report
high
preval
airflow
limit
includ
restrict
lung
diseas
new
airsmart
spiromet
studi
highlight
high
preval
undiagnos
copd
high
bmi
caus
airflow
limit
popul
background
aim
proper
spirometr
method
defin
airflow
limit
longdeb
particularli
elderli
popul
suspect
uncertain
optim
current
threshold
may
contribut
controversi
herein
therefor
optim
current
threshold
investig
fix
ratio
fr
zscore
zs
also
prefer
spirometr
method
elderli
popul
assess
use
thresholdfre
measur
area
receiv
oper
characterist
curv
auroc
method
data
collect
third
unit
state
nation
health
nutrit
examin
survey
data
nonhispan
white
whose
age
analyz
roc
curv
fr
zs
plot
allcaus
respiratori
copd
mortal
optim
threshold
assess
compar
current
one
roc
curv
prefer
spirometr
method
assess
compar
auroc
method
result
subject
mean
age
ae
male
optim
threshold
fr
allcaus
respiratori
copd
mortal
respect
lower
current
one
contrast
zs
respect
higher
current
one
signific
differ
auroc
observ
spirometr
method
respiratori
copd
mortal
fr
vs
zs
p
fr
vs
zs
p
respect
figur
comparison
auroc
respiratori
mortal
conclus
current
threshold
fr
zs
seem
bias
may
contribut
overand
underdiagnosi
airflow
limit
elderli
popul
method
show
compar
predict
respiratori
copd
mortal
believ
conveni
fr
may
prefer
clinician
object
assess
efficaci
practic
pr
sever
copd
limit
resourc
set
method
new
clinic
attend
last
six
month
gold
stage
iii
iv
copd
enrol
studi
patient
recent
ischaem
heart
diseas
cardiomyopathi
sever
pulmonari
hypertens
exclud
underw
six
week
cours
pr
consist
anterior
chest
wall
upper
chest
wall
diaphragmat
muscl
strengthen
exercis
purs
lip
breath
supervis
train
physiotherapist
avail
simpl
tool
graduat
tension
band
free
weight
treadmil
ergomet
avail
spirometri
use
vitalograph
alpha
touch
softwar
version
six
minut
walk
test
perform
onset
end
pr
result
patient
age
year
male
studi
initi
mean
forc
expiratori
volum
first
second
predict
age
sex
individu
studi
show
improv
end
pr
initi
mean
sixminut
walk
distanc
studi
group
meter
end
six
week
mean
increas
meter
p
conclus
short
cours
pr
sever
sever
copd
result
improv
studi
effect
low
cost
pr
program
could
easili
set
minimum
resourc
appropri
clinic
set
sanglah
gener
hospit
radiolog
denpasarbali
indonesia
background
aim
idiopath
pulmonari
fibrosi
ipf
diseas
unknown
etiolog
consider
morbid
mortal
character
profound
chang
lung
morpholog
includ
excess
extracellular
matrix
deposit
myofibroblast
foci
alveolar
epitheli
cell
hyperplasia
extens
remodel
one
difficulti
convent
imag
msct
hsct
ipf
radiolog
pattern
look
like
usual
interstiti
pneumonia
due
limit
convent
imag
thu
paper
would
like
introduc
acoust
radiat
forc
impuls
arfi
elastographi
elasticitybas
imag
usual
biomark
liver
fibrosi
use
novel
biomark
lung
fibrosi
method
eightyon
patient
diagnos
idiopath
lung
fibrosi
recruit
stage
fibrosi
determin
biopsi
diagnost
accuraci
fi
fibroscan
arfi
well
combin
method
evalu
base
conform
result
test
biopsi
result
lung
phenotyp
ipf
character
patchi
predominantli
peripher
subpleur
bibas
reticular
abnorm
peripher
reticular
opac
furthermor
use
lung
biopsi
find
thicken
lung
parenchym
excess
growth
factor
fibroblast
reason
make
patient
lung
look
stiff
rigid
use
ultason
wave
propag
produc
arfi
imag
calcif
fibrosi
level
measur
shear
wave
veloc
smv
swv
correl
fibrosi
r
p
necroinflammatori
activ
lung
r
p
use
criteria
arfi
imag
strongli
compar
lung
biopsi
diagnost
accuraci
predict
sever
fibrosi
ipf
conclus
swv
indic
caus
ultrason
wave
propag
lung
tissu
use
quantifi
shear
modulu
lung
tissu
base
lung
elast
level
fibrosiscalcif
arfi
modal
studi
noninvas
diagnost
tool
ipf
without
necess
lung
biopsi
background
aim
naval
diver
uniqu
adapt
hypoxem
term
pulmonari
vasculatur
pulmonari
vascular
endotheli
epitheli
nitric
oxid
impair
increas
pulmonari
arteri
pressur
pap
lead
pulmonari
hypertens
previou
studi
effect
hyperbar
oxygen
therapi
hbo
select
diver
suffer
pulmonari
hypertens
remain
controversi
aim
studi
assess
use
hbo
secondari
prevent
pulmonari
hypertens
among
naval
diver
method
consecut
naval
diver
pulmonari
hypertens
mpap
mmhg
met
inclus
criteria
enter
nonrandom
control
clinic
trial
patient
random
two
group
follow
experiment
receiv
ata
hyperbar
chamber
oxygen
suppli
via
oxygen
hood
sodium
beraprost
control
receiv
sodium
beraprost
pulmonari
arteri
pressur
measur
echocardiographi
hbo
session
everi
week
followup
result
first
treatment
session
hbo
averag
systol
spap
diastol
dpap
mean
mpap
arteri
pressur
similar
group
averag
mpap
significantli
lower
experiment
group
least
treatment
durat
pvalu
follow
pvalu
follow
valu
spap
vs
mmhg
dpap
vs
mmhg
mpap
vs
mmhg
mark
lower
significantli
compar
control
group
conclus
result
demonstr
hbo
reduc
pulmonari
arteri
pressur
significantli
pilot
studi
effect
hbo
pulmonari
hypertens
need
caution
interpret
background
aim
decad
resurg
much
technolog
advanc
field
radiolog
enabl
play
indispens
role
aid
diagnosi
follow
mani
respiratori
disord
high
resolut
comput
tomographi
hrct
vital
tool
arsen
investig
avail
physician
evalu
lung
interstitium
ground
glass
opac
gco
radiolog
descript
term
use
rather
commonli
occasion
indiscrimin
clinician
defin
hazi
area
increas
lung
attenu
without
obscur
underli
vasculatur
non
specif
find
result
abnorm
involv
alveolar
space
interstitium
combin
howev
signific
lie
indic
presenc
activ
potenti
treatabl
patholog
result
highlight
sever
interest
case
ground
glass
opac
mimick
elabor
addit
ancillari
featur
propos
practic
algorithm
approach
gco
conclus
earli
recognit
ground
glass
opac
etiolog
enabl
earli
intervent
group
patient
background
aim
sirolimu
first
approv
japan
drug
treatment
lymphangioleiomyomatosi
lam
treat
case
lam
use
sirolimu
april
april
retrospect
review
patient
order
clarifi
incid
clinic
featur
sirolimusassoci
interstiti
lung
diseas
sild
method
review
clinic
cours
highresolut
comput
tomographi
hrct
sirolimu
concentr
patient
experienc
sild
medic
record
also
evalu
serum
biomark
includ
kreb
von
den
surfact
protein
sp
spa
result
experienc
patient
sild
patient
femal
sporad
lam
median
age
yearold
rang
median
period
start
sirolimu
onset
sild
month
rang
one
symptomat
patient
fever
dyspnea
exert
diffus
ground
glass
opac
ggo
hrct
effect
treat
high
dose
corticosteroid
receiv
treatment
low
dose
sirolimu
one
year
onset
sild
one
asymptomat
patient
mild
ggo
improv
stop
sirolimu
worsen
restart
sirolimu
three
patient
local
consolid
hrct
spontan
remiss
remain
treat
sirolimu
despit
ineffici
antibiot
median
concentr
sirolimu
ngml
rang
median
concentr
serum
spd
spawer
iul
rang
ngml
rang
ngml
rang
respect
symptom
opac
hrct
complet
improv
patient
within
month
conclus
experienc
patient
asymptomat
local
consolid
grade
continu
sirolimu
patient
ggo
stop
sirolimu
includ
sever
sild
grade
corticosteroid
patient
sild
could
receiv
readministr
sirolimu
background
aim
studi
perform
evalu
cardiomyopathi
patient
collagen
vascular
diseaseassoci
interstiti
pneumonia
cvdip
myocardi
scintigraphi
pentadecano
acid
scintigraphi
method
myocardi
scintigraphi
pentadecano
acid
scintigraphi
carri
patient
diagnos
cvdip
result
perform
patient
granulomatosi
polyangi
rheumatoid
patient
cardiomyopathi
conclus
necessari
collect
case
asses
evalu
cardiomyopathi
patient
cvdip
background
aim
pulmonari
langerhan
cell
histiocytosi
plch
rare
diseas
character
accumul
inflammatori
langerhan
cell
bronchiol
alveolar
interstitium
result
format
nodular
inflammatori
lesion
paper
report
case
year
old
filipino
male
present
recurr
bilater
pneumothorax
method
patient
previous
admit
anoth
hospit
due
recurr
pneumothorax
bilater
novemb
rightsid
decemb
advis
undergo
lung
biopsi
lost
followup
januari
consult
institut
due
recurr
bilater
pneumothorax
bilater
chest
tube
place
result
chest
xray
show
extens
bilater
cystic
lucenc
lung
field
chest
tomographi
reveal
coars
reticular
lesion
lung
interspers
cystic
lesion
chronic
volum
loss
traction
bronchiectasi
intermix
area
ground
glass
opac
pulmonari
function
test
show
sever
restrict
ventilatori
defect
sever
reduct
dlco
due
histori
recurr
pneumothorax
underw
videoassist
thorac
surgeri
lung
biopsi
histopatholog
immunohistochemistri
stain
protein
show
acut
eosinophil
interstiti
pneumon
granuloma
format
consist
pulmonari
langerhan
cell
histiocytosi
start
prednison
discharg
improv
stabl
two
month
discharg
develop
progress
dyspnea
cough
recurr
pneumothorax
chest
tube
place
eventu
underw
pleurodesi
possibl
lung
transplant
also
discuss
patient
famili
howev
despit
medic
manag
persist
progress
dyspnea
eventu
succumb
death
due
develop
acut
respiratori
failur
tension
pneumothorax
conclus
plch
rare
lung
diseas
cours
unpredict
quiescent
spontan
progress
inevit
caus
complic
includ
death
background
aim
radiat
pneumon
pulmonari
fibrosi
sever
complic
larg
administ
activ
herein
present
patient
papillari
thyroid
carcinoma
develop
interstiti
pneumonia
follow
lowdos
radioiodin
therapi
method
man
receiv
neartot
thyroidectomi
function
lymph
node
resect
februari
papillari
thyroid
carcinoma
metastas
anoth
hospit
mci
initi
given
june
ten
day
later
patient
mild
short
breath
accept
oral
antibiot
therapi
sever
day
juli
treatment
repeat
period
everi
month
unfortun
develop
dyspnea
exert
chest
comput
tomographi
ct
scan
describ
mesh
like
shadow
stripe
patch
lung
furthermor
accept
intraven
methylprednisolon
mgd
antibiot
ten
day
short
breath
progress
increas
could
walk
addit
chest
ct
scan
also
demonstr
diffus
interstiti
pneumonia
came
clinic
hypoxia
continu
deterior
could
nt
toler
pulmonari
function
test
blood
ga
analysi
demonstr
po
mmhg
oxygen
therapi
relev
laboratori
test
exclud
tuberculosi
viral
infect
cardiac
diseas
connect
tissu
diseas
higher
dose
methylprednisolon
anti
inflammatori
therapi
mgd
mgd
mgd
condit
improv
could
walk
independ
methylprednisolon
adjust
oral
administr
gradual
reduc
result
three
month
later
chest
ct
scan
demonstr
diffus
interstiti
pneumonia
significantli
reduc
could
walk
upstair
conclus
interstiti
pneumonia
realli
happen
indic
low
dose
possibl
induc
sever
side
effect
papillari
thyroid
carcinoma
patient
doctor
pay
attent
pulmonari
complic
nation
univers
health
system
univers
medicin
clusterdivis
respiratori
critic
care
medicin
singapor
singapor
nation
univers
health
system
depart
diagnost
imag
singapor
singapor
nation
univers
health
system
depart
patholog
singapor
singapor
background
aim
earli
accur
diagnosi
interstiti
lung
diseas
ild
essenti
initi
diseasespecif
therapi
optimis
patient
manag
current
guidelin
recommend
multidisciplinari
team
mdt
approach
involv
experienc
pulmonologist
radiologist
pathologist
improv
diagnost
confid
variou
ild
aim
review
ild
case
outcom
present
mdt
meet
determin
discuss
result
consensu
diagnosi
recommend
subsequ
patient
manag
method
report
retrospect
review
patient
medic
record
mdt
meet
discuss
outcom
april
june
mdt
consist
pulmonologist
radiologist
pathologist
result
total
patient
refer
mdt
discuss
april
june
patient
histolog
specimen
avail
discuss
mdt
discuss
led
consensu
diagnosi
case
patient
usual
interstiti
pneumonia
idiopath
pulmonari
fibrosi
nonspecif
interstiti
pneumonia
ild
relat
underli
connect
tissu
diseas
combin
pulmonari
fibrosi
emphysema
undefin
ild
addit
provid
consensu
diagnosi
guid
conditionspecif
treatment
undefin
ild
recommend
possibl
differenti
diagnos
investig
deriv
diagnosi
conclus
mdt
discuss
result
consensu
diagnosi
major
case
refer
signific
proport
patient
undefin
ild
requir
addit
clinic
inform
followup
studi
need
impact
mdt
subsequ
manag
patientrel
outcom
background
aim
report
methotrexateassoci
lymphoprolif
mtxlpd
disord
increas
although
mtx
withdraw
known
moder
effect
tumor
regress
appropri
treatment
predict
factor
tumor
regress
yet
establish
mtxlpd
lung
lesion
method
retrospect
evalu
case
mtxlpd
lung
lesion
result
median
age
year
rang
maletofemal
ratio
preced
autoimmun
diseas
rheumatoid
arthriti
case
median
period
diagnosi
rheumatoid
arthriti
onset
mtxlpd
year
median
period
mtxadministr
year
median
cumul
mtx
dosag
mg
multipl
pulmonari
nodul
case
solitari
pulmonari
nodul
case
hilar
mediastin
lymph
node
enlarg
one
caseth
histolog
type
lymphoma
diffus
larg
bcell
lymphoma
case
cell
rich
bcell
lymphoma
one
case
atyp
lymphocyt
case
case
could
diagnos
bronchoscopi
four
case
ebvposit
case
unknown
mtx
stop
case
tumor
shrinkag
occur
case
one
case
die
week
lymphocyt
recoveri
two
week
mtx
withdraw
higher
case
tumor
regress
median
increas
without
tumor
regress
lactat
dehydrogenas
serum
solubl
receptor
higher
case
without
tumor
regress
tumor
regress
conclus
although
studi
small
result
indic
poor
lymphocyt
recoveri
mtx
cessat
might
associ
tumor
progress
studi
warrant
determin
mtx
discontinu
subsequ
chemotherapi
fibrot
chang
cpfe
commonli
attribut
cigarett
smoke
definit
could
includ
pulmonari
fibrosi
varieti
diseas
collagen
diseas
hypersensit
pneumon
pigeon
igg
antibodi
known
diagnost
tool
birdrel
hypersensit
pneumonia
brhp
assess
signific
serum
pigeon
igg
antibodi
level
cpfe
patient
method
singlecent
retrospect
cohort
studi
conduct
diagnos
interstiti
pneumonia
patient
hospit
extract
case
ct
find
characterist
cpfe
serum
pigeon
igg
antibodi
measur
may
june
subsequ
investig
relationship
serum
pigeon
igg
antibodi
level
day
first
cpfe
exacerb
result
total
cpfe
case
male
femal
includ
final
analysi
median
age
year
seventyon
patient
current
former
histori
smoke
median
amount
packyear
eight
patient
experienc
exacerb
followup
measur
pigeon
igg
antibodi
secondli
classifi
cpfe
popul
three
group
accord
pigeon
igg
antibodi
level
low
n
medium
n
high
n
median
pigeon
igg
antibodi
level
group
mgal
mgal
mgal
respect
kaplanmei
curv
show
significantli
earlier
exacerb
highpigeon
igg
antibodi
group
compar
low
middl
group
conclus
cpfe
patient
high
serum
pigeon
igg
antibodi
risk
factor
exacerb
cpfe
popul
could
consist
variou
patient
includ
brhp
could
respond
remov
antigen
background
aim
target
diagnosi
treatment
acut
lung
injuri
inhibitor
urokinas
plasminogen
activ
receptor
upar
complement
factor
cfd
compon
altern
complement
pathway
best
known
role
humor
suppress
infecti
agent
object
present
studi
detect
express
upar
cfd
ischemiareperfus
lung
injuri
irli
investig
potenti
role
method
human
pulmonari
microvascular
endotheli
cell
hpmec
cellml
within
passag
use
present
studi
vitro
firstli
divid
cell
normal
irli
group
construct
irli
model
hpmec
normal
group
cultur
carbon
dioxid
incub
use
complet
medium
hand
cell
irli
group
place
incub
without
oxygen
use
medium
without
glucos
next
cell
reperfus
complet
medium
carbon
dioxid
incub
observ
cell
optic
microscop
final
express
upar
cfd
examin
use
rtpcr
western
blot
method
result
irli
model
hpmec
success
construct
ischemia
reperfus
furthermor
compar
normal
group
express
upar
cfd
irli
hpmec
significantli
decreas
p
addit
decreas
mrna
level
line
chang
protein
express
conclus
irli
express
upar
cfd
significantli
decreas
compar
normal
group
indic
decreas
upar
cfd
may
induc
inflamm
irli
therefor
upar
cfd
potenti
use
earli
diagnosi
treatment
lung
injuri
background
aim
mizoribin
mzr
immunosuppress
drug
proven
effect
patient
nephrot
syndrom
rheumatoid
arthriti
sinc
mzr
give
less
seriou
advers
event
oftenus
immunosuppres
calcineurin
inhibitor
mzr
could
administ
patient
interstiti
pneumonia
ip
altern
littl
known
mzr
work
behav
patient
ip
therefor
investig
efficaci
safeti
mzr
patient
ip
method
twentyfour
patient
ip
treat
mzr
januari
decemb
institut
evalu
retrospect
twelv
patient
idiopath
ip
patient
connect
tissu
diseas
relat
ip
dmpm
ra
ssc
sj
sle
background
administ
mzr
effect
mzr
frequenc
side
effect
investig
result
mzr
ad
steroid
monotherapi
n
steroid
plu
immunosuppres
n
patient
mzr
substitut
prior
immunosuppres
cyclosporin
cya
azathioprin
side
effect
physician
avoid
possibl
futur
risk
regard
efficaci
mzr
improv
prevent
worsen
patient
three
patient
present
progress
ip
spite
ad
mzr
one
patient
unabl
continu
mzr
sever
rash
conclus
patient
ip
mzr
administ
effect
safe
mzr
could
altern
oftenus
immunosuppres
manag
ip
background
aim
report
power
spectrum
ps
lung
sound
interstiti
pneumonia
ip
reflect
intens
fine
crackl
typic
ps
fine
crackl
show
sound
peak
around
hz
dip
around
hz
jr
jr
tri
clarifi
chang
ps
acut
exacerb
ae
ip
method
examin
case
ip
experienc
ae
among
ten
patient
improv
two
stay
condit
five
patient
deterior
clinic
clinic
improv
deterior
judg
subject
symptom
vital
sign
xray
find
analyz
lung
sound
ten
second
record
bilater
lung
base
soundspectromet
kenzmedico
measur
sound
power
three
frequenc
rang
ie
low
middl
mfp
high
hfp
compar
mfp
hfp
dbm
treatment
includ
steroid
immunosuppress
agent
result
improv
patient
mfp
treatment
dbm
hfp
treatment
stabl
patient
mfp
treatment
hfp
treatment
deterior
patient
mfp
treatment
hfp
treatment
decreas
mfp
hfp
improv
patient
increas
mfp
hfp
deterior
patient
conclus
conclud
ps
especi
mfp
hfp
patient
ip
use
paramet
detect
improv
deterior
result
suggest
listen
lung
sound
patient
ip
patient
improv
lung
sound
becom
softer
deterior
lung
sound
becom
louder
background
aim
detail
bodi
composit
fatfre
mass
examin
idiopath
pulmonari
fibrosi
ipf
investig
whether
fatfre
mass
index
ffmi
index
lean
bodi
mass
predict
surviv
method
fortyfour
patient
ipf
enrol
studi
bodi
composit
assess
use
direct
segment
multifrequ
bioelectr
imped
analysi
degre
correl
variabl
bodi
composit
variabl
physiolog
surviv
examin
result
signific
posit
correl
ffmi
fvc
dlco
walk
distanc
signific
neg
correl
age
howev
signific
correl
ffmi
either
percentag
predict
fvc
dlco
degre
correl
similar
observ
bodi
mass
index
bmi
bmi
ffmi
show
signific
correl
patientcentr
outcom
includ
dyspnoea
healthrel
qualiti
life
anxieti
depress
score
univari
cox
proport
hazard
model
show
sever
variabl
bmi
associ
significantli
surviv
ffmi
hr
ci
p
fvc
percentag
predict
hr
ci
p
signific
factor
multivari
model
conclus
conclud
ffmi
signific
predictor
surviv
patient
ipf
background
aim
fine
crackl
brief
discontinu
highpitch
lung
sound
heard
patient
interstiti
pneumonia
ip
coars
crackl
loud
lowpitch
heard
patient
wtih
bacteri
pneumonia
bp
descript
subject
auscultatori
find
need
defin
lung
sound
analysi
tri
clarifi
differ
fine
coars
crackl
analyz
adventit
lung
sound
sound
spectrogram
especi
power
spectrum
distribut
method
seventeen
subject
ip
honeycomb
chest
ct
four
subject
acut
pneumonia
examin
record
analyz
lung
sound
bilater
lung
base
patient
ip
affect
area
patient
bp
analyz
breath
sound
sound
spectromet
kenz
medico
lsa
examin
frequencypow
distribut
power
spectrum
ps
result
ten
patient
ip
power
peak
around
hz
power
dip
around
show
revers
shape
figur
graphic
seven
patient
ip
show
hz
peak
without
dip
thu
revers
shape
patient
ip
show
strong
sound
power
higher
frequenc
rang
ie
hz
hz
four
patient
bp
show
ps
gradual
taper
sound
power
hz
conclus
fine
crackl
patient
ip
show
strong
sound
intens
coars
crackl
patient
bp
show
sound
attenu
ps
lung
sound
analysi
use
tool
differenci
fine
crackl
coars
crackl
object
background
aim
patient
interstiti
pneumonia
ip
report
poor
sleep
qualiti
howev
far
believ
reduc
caudal
traction
upper
airway
due
decreas
lung
volum
enhanc
collaps
less
understood
associ
impair
pulmonari
function
interstiti
pneumonia
sleep
breath
disord
sbd
studi
clarifi
relat
apneahypoxia
index
ahi
pulmonari
function
patient
ip
method
assess
pulmonari
function
test
ahi
use
overnight
portabl
monitor
devic
nihon
kohden
inc
tokyo
japan
equip
heart
rate
airflow
sensor
snore
bodi
posit
respiratori
effort
percutan
satur
spo
day
correl
ahi
fev
fvc
vc
dlco
dlcova
pulmonari
function
test
evalu
result
enrol
patient
male
mean
age
ae
year
diagnos
ip
accord
highresolut
comput
tomographi
restrict
impair
vc
ip
patient
restrict
impair
despit
correl
ahi
vc
significantli
neg
correl
ahi
dlcova
r
p
ci
p
independ
associ
extens
pulmonaryles
involv
four
lobe
decreas
cholesterol
level
decreas
ratio
viscer
fat
volum
percentag
subject
chang
low
ina
high
ina
higher
ntm
patient
diseas
progress
stabl
diseas
cours
p
valu
multivari
analysi
decreas
cholesterol
concentr
mgdl
predict
factor
diseas
progress
ci
p
conclus
find
suggest
chang
cholesterol
level
may
marker
diseas
progress
patient
pntm
diseas
background
aim
organ
pneumonia
op
secondari
mycobacterium
tuberculosi
tb
infect
recent
report
acceler
sever
origin
infecti
diseas
case
seri
studi
aim
studi
examin
effect
system
steroid
therapi
sever
pulmonari
tb
infect
secondari
organ
pneumonia
method
case
seri
studi
case
tb
infect
secondari
op
treat
steroid
hospit
enrol
secondari
op
diagnos
chest
xray
ct
serum
spd
result
case
yo
male
tb
past
histori
admit
intens
care
unit
icu
sever
respiratori
failur
bilater
consolid
chest
ct
steroid
mgbodi
start
admiss
day
lung
infiltr
disappear
day
case
yo
femal
sever
respiratori
failur
bilater
infiltr
chest
xray
steroid
mgbodi
start
admiss
day
lung
infiltr
disappear
day
case
yo
femal
miliari
tb
consolid
chest
xray
steroid
mgbodi
start
day
admiss
die
day
later
case
yo
male
miliari
tb
admit
icu
respiratori
ventil
control
bilater
lung
consolid
steroid
mgbodi
start
day
admiss
effect
die
day
abl
perform
bronchoscop
evalu
tblb
bal
patient
severitytwo
case
treat
steroid
admiss
day
recov
soon
howev
two
miliari
tb
case
treat
steroid
day
day
admiss
abl
benefit
steroid
eventu
die
conclus
earli
diagnosi
earli
treatment
seem
import
sever
tb
infect
secondari
op
background
aim
pf
deadli
diseas
human
health
current
effect
treatment
therapi
eagerli
need
improv
anim
model
drug
evalu
drug
evalu
rhesu
pf
model
drug
evalu
rhesu
simultan
bind
vegf
strong
affin
call
tri
find
slow
progress
pf
method
inject
blm
trachea
atom
injector
establish
rhesu
pf
model
month
blm
inject
placebo
given
model
monkey
time
week
intraven
inject
monitor
fibrosi
progress
hrct
level
biomark
sp
mmp
sao
also
take
activ
level
supplement
month
later
monkey
sacrif
arteri
blood
ga
analysi
sacrif
masson
stain
patholog
chang
perform
protein
level
investig
result
nt
see
signific
differ
patholog
chang
group
placebo
group
stain
hrct
arteri
blood
averag
po
group
better
placebo
group
statist
signific
signific
differ
serum
sp
level
group
month
begin
inject
blood
level
spa
lower
placebo
group
found
pathway
partli
block
conclus
current
studi
show
might
littl
use
rhesu
pf
model
research
rhesu
pf
model
focus
lncrna
chang
proteom
new
drug
evalu
come
soon
enough
time
background
aim
tuberculosi
tb
global
health
problem
million
bacteriolog
confirm
pulmonari
tb
case
million
pulmonari
tb
case
world
low
middleincom
countri
like
indonesia
still
use
acidfast
bacilli
afb
assay
help
diagnos
tb
simpl
fast
low
cost
procedur
nevertheless
diagnosi
tb
neg
sputum
afb
result
smearneg
difficult
held
unspecif
clinic
manifest
caus
late
diagnosi
therapi
increas
morbid
mortal
transmiss
rate
mani
case
world
case
indonesia
report
smear
neg
tb
case
particularli
immunocompromis
patient
xpert
mtbrif
assay
rapid
molecular
assay
detect
mycobacterium
tuberculosi
mtb
hour
equival
sensit
mtb
cultur
purpos
preliminari
studi
evalu
role
xpert
mtbrif
assay
mtb
detect
new
presumpt
tuberculosi
patient
neg
sputum
afb
method
subject
n
presumpt
tuberculosi
patient
new
case
base
clinic
indic
afb
neg
sputum
result
persahabatan
hospit
jakarta
indonesia
subject
test
xpert
mtbrif
assay
mtb
cultur
use
sputum
sampl
result
xpert
mtbrif
final
result
among
subject
subject
mtb
detect
mtb
detect
low
mtb
detect
low
mtb
detect
medium
subject
mtb
detect
rifampicin
resist
detect
hand
among
subject
subject
neg
cultur
posit
cultur
one
subject
posit
cultur
mtb
detect
low
xpert
mtbrif
assay
conclus
conclus
xpert
mtbrif
assay
increas
detect
rate
mtb
even
patient
neg
sputum
afb
background
aim
activ
tuberculosi
patient
often
deterior
even
induct
antitubercul
medic
problemat
patient
need
longterm
hospit
although
factor
associ
vulner
tuberculosi
infect
pathogenesi
elucid
report
show
factor
involv
deterior
activ
tuberculosi
patient
studi
design
elucid
factor
deterior
activ
tuberculosi
patient
method
april
may
inpati
activ
tuberculosi
infect
ryukyu
univers
hospit
includ
retrospect
studi
diagnos
confirm
cultur
andor
polymeras
chain
reaction
tuberculosi
medic
record
review
extract
relat
clinic
featur
ibm
spss
statist
window
version
armonk
ny
ibm
corp
use
statist
analysi
result
total
tb
case
collect
male
mean
age
patient
year
old
patient
acut
respiratori
failur
univari
analysi
show
daili
steroid
p
daili
nonsteroid
immunosuppress
p
sputum
smearposit
p
higher
age
p
lower
serum
albumin
p
relat
acut
respiratori
failur
multivari
analysi
reveal
daili
steroid
p
lower
serum
albumin
p
relat
acut
respiratori
failur
number
survivor
nonsurvivor
respect
univari
analysi
show
mainten
dialysi
histori
month
p
acut
respiratori
failur
p
miliari
tuberculosi
p
lower
serum
albumin
p
relat
death
conclus
studi
show
lower
serum
albumin
relat
risk
factor
acut
respiratori
failur
death
multivari
analysi
reveal
daili
steroid
lower
serum
albumin
relat
acut
respiratori
failur
background
aim
rayong
provinc
thailand
tuberculosi
still
major
public
health
problem
local
nation
level
highest
number
per
popul
mdr
case
countri
therefor
fast
accur
diagnosi
mdrtb
import
patient
care
reduc
spread
infect
commun
xpert
mtb
rif
thu
role
help
diagnos
tuberculosi
multidrugresist
object
aim
evalu
diagnost
perform
xpert
mtb
rif
sensit
specif
accuraci
posit
predict
valu
ppv
neg
predict
valu
npv
posttest
probabl
actual
user
experi
noncentr
part
thailand
method
studi
retrospect
studi
august
octob
result
xpert
mtb
rif
test
sputum
clinic
suspect
mdr
tuberculosi
includ
studi
studi
use
tuberculosi
cultur
gold
standard
diagnosi
result
total
sampl
includ
studi
smear
posit
sampl
number
hiv
sampl
reason
xpert
mtb
rif
test
retreat
failur
sputum
convers
third
month
prison
respect
total
sampl
specimen
cultur
confirm
studi
show
sensit
xpert
mtb
rif
mdrtb
diagnost
specif
accuraci
test
neg
predict
valu
found
posit
predict
valu
ppv
posttest
probabl
good
abil
detect
afb
stain
patient
hiv
xpert
mtb
rif
use
group
abil
detect
tuberculosi
conclus
xpert
mtb
rif
diagnosi
mdrtb
effect
better
fasterhowev
cultur
also
requir
confirm
diagnosi
background
aim
propylthiouracil
ptu
use
hyperthyroid
number
ptu
induc
advers
reaction
leukopenia
rash
arthriti
vascul
lupuslik
syndrom
ptu
observ
associ
antineutrophil
cytoplasm
antibodi
anca
posit
small
vessel
vasculitid
describ
patient
ptuinduc
ancaposit
vascul
caus
alveolar
hemorrhag
rapidli
improv
cessat
ptu
administr
corticosteroid
method
woman
admit
hospit
evalu
dyspnea
two
week
five
month
admiss
complain
cough
nonmass
haemoptysi
weight
loss
diagnos
hyperthyroid
age
therapi
ptu
initi
dose
mgday
decreas
mgday
six
month
maintain
admiss
physic
examin
reveal
tachycardia
tachypnea
room
air
bibasilar
crackl
laboratori
show
anemia
hb
gl
microscop
heamaturia
proteinuria
panca
posit
titer
antimyeloperoxidas
mpo
posit
ana
posit
low
toter
chest
xray
ct
chest
show
alveolar
opac
middl
lower
lobe
lung
bronchoscop
find
show
sequenti
bal
establish
consist
alveolar
hemorrhag
lung
biopsi
perform
exclud
infect
bal
report
indic
benign
cytolog
bal
cultur
organ
diagnosi
ptuinduc
alveolar
hemorrhag
ptu
discontinu
prednisolon
mgday
start
treatment
gradual
improv
within
week
result
present
patient
develop
ptuinduc
ancaassoci
vascul
result
pulmonari
hemorrhag
without
kidney
involv
bronchoscop
find
histopatholog
could
inconclus
detect
anca
help
diagnosi
dramat
improv
discontinu
ptu
start
treatment
high
dose
steroid
conclus
ptuinduc
ancaassoci
vascul
import
continu
use
ptu
lead
lifethreaten
alveolar
hemorrhag
background
aim
idiopath
pulmonari
fibrosi
ipf
incur
lung
diseas
lung
tissu
becam
thick
stiff
scar
although
great
achiev
made
term
molecular
diagnost
pathobiolog
underli
pathogenesi
associ
ipf
still
unclear
need
well
defin
method
present
studi
chang
microrna
mirna
mrna
ipf
investig
use
integr
network
approach
origin
mirna
mrna
express
profil
dataset
download
gene
express
omnibu
geo
differ
express
mirnamrna
identifi
use
signific
analysi
microarray
sam
algorithm
molecular
target
associ
mirna
expand
use
cytargetlink
cytoscap
final
valid
use
mrna
array
express
profil
result
integr
mirnamrna
network
encompass
gene
mirna
associ
ipf
initi
function
enrich
analysi
indic
cytokinecytokin
receptor
interact
glycin
serin
threonin
metabol
signal
pathway
highli
associ
ipf
progress
integr
network
demonstr
interact
mirna
gene
particular
highlight
target
gene
osm
may
shed
new
light
ipf
initi
develop
conclus
use
public
avail
dataset
geo
databas
establish
mirna
mrna
interact
network
ipf
screen
mirna
candidatesand
gene
ipf
initi
develop
may
serv
potenti
target
ipf
diagnosi
therapeut
yearold
femal
present
eight
month
histori
progress
dyspnea
product
cough
signific
weight
loss
heavi
alcohol
drink
packyear
smoke
note
receiv
treatment
nearbi
hospit
left
upper
lobe
consolid
periaort
radioluc
reveal
initi
chest
radiographi
decreas
lung
volum
juxtraphren
peak
sign
also
note
find
consist
luftsichel
sign
sputum
afb
stain
posit
mycobacterium
tuberculosi
complex
confirm
cultiv
standard
regimen
antitb
given
isoniazid
rifampicin
pyrazinamid
ethambutol
riboflavin
prescrib
initi
treatment
month
treatment
symptom
subsid
still
ongo
weight
loss
kg
kg
despit
neg
sputum
afb
improv
chest
radiographi
isoniazid
rifampicin
given
mainten
therapi
comput
tomographi
chest
done
persist
left
upper
lobe
consolid
atelectasi
detect
lung
mass
endobronchi
obstruct
suspect
refer
investig
concern
primari
lung
cancer
despit
medic
adher
treatment
poor
flexibl
bronchoscopi
perform
narrow
left
upper
lobe
bronchu
open
without
endobronchi
mass
lesion
demonstr
bronchoscopi
histopatholog
transbronchi
biopsi
left
upper
lobe
consist
chronic
granulomat
inflamm
addit
polymeras
chain
reaction
mycobacterium
tuberculosi
posit
neither
malign
fungi
detect
treatment
antitb
continu
conclus
rare
caus
luftsichel
sign
chest
radiographi
confirm
pulmonari
tuberculosi
howev
malign
diseas
must
taken
account
prove
otherwis
background
aim
plch
kind
rare
diseas
particularli
multipl
organ
involv
review
diagnosi
differenti
diagnosi
plch
special
case
plch
associ
posit
anca
asthma
method
one
male
admiss
second
hospit
jilin
univers
chief
complaint
paroxysm
wheez
year
seriou
dyspnea
cough
expector
week
month
ago
central
diabet
insipidu
diagnos
patient
appear
polyuria
mild
osteolyt
destruct
upper
jaw
left
acetabular
bone
multipl
small
pulmonari
nodul
patient
smoke
packsyear
without
quit
meaning
result
auxiliari
examin
follow
multipl
small
pulmonari
centrilobular
nodul
mm
accompani
small
amount
small
cystic
chang
found
lung
ct
bronchial
dilat
test
posit
lung
diffus
function
dlco
anca
test
posit
eosinophil
peripher
blood
langerhanscel
seen
intra
alveolar
exud
cell
small
amount
eosinophil
cell
shown
biopsi
lung
tissu
fibrobronchoscopi
result
diagnosi
patient
plch
involv
multipl
organ
also
call
eosinophil
granulomadiseas
signific
improv
found
clinic
manifest
lung
ct
month
treatment
prednison
mg
day
quit
smoke
allerg
granulomatosi
churgstrauss
syndrom
css
consid
differenti
diagnosi
case
associ
asthma
increas
eosinophil
blood
lung
tissu
posit
anca
plch
diagnos
case
final
accompan
central
diabet
insipidu
osteolyt
destruct
patholog
chang
langerhanscel
alveoli
special
rare
report
plch
accompani
asthma
posit
anca
measur
possibl
plch
combin
css
also
consid
follow
instruct
given
continu
background
aim
diagnosi
tuberculosi
difficult
nonspecif
clinic
present
report
two
case
diagnosi
delay
due
cognit
bia
method
case
japanes
man
diabet
nephropathi
present
severalweek
histori
fever
back
pain
admiss
enter
shock
antibiot
administ
blood
pressur
immedi
improv
fever
continu
needl
biopsi
fifth
lumbar
vertebra
compress
fractur
perform
suspicion
pyogen
spondyl
organ
cultur
incub
week
one
month
biopsi
acidfast
bacteria
grew
specimen
cultur
reveal
tuberculosi
chest
comput
tomographi
show
diffus
small
pulmonari
nodul
acidfast
stain
sputum
show
posit
result
day
start
symptom
miliari
tuberculosi
tubercul
spondyl
diagnos
case
japanes
woman
suffer
rheumatoid
arthriti
interstiti
pneumonia
take
prednisolon
salazosulfapyridin
display
moder
arthralgia
slight
fever
loss
appetit
start
biolog
reduc
symptom
chest
comput
tomographi
perform
check
interstiti
pneumonia
comput
tomographi
reveal
nodular
shadow
right
middl
left
upper
lobe
final
tuberculosi
confirm
bronchoscopi
result
case
tuberculosi
list
differenti
diagnos
antibiot
state
shock
appear
effect
kept
suspect
common
bacteri
infect
due
anchor
bia
awar
insidi
progress
could
detect
tuberculosi
need
airborn
isol
case
regard
fever
appetit
loss
symptom
uncontrol
rheumatoid
arthriti
due
avail
bia
overconfid
bia
despit
cellular
immun
defici
juntendo
univers
graduat
school
medicin
depart
respiratori
medicin
bunkyoku
japan
juntendo
univers
urayasu
hospit
depart
respiratori
medicin
urayasuc
japan
background
aim
one
chines
tradit
medicin
nijutsuto
use
patient
osteoarthr
oa
sever
case
report
develop
interstiti
pneumonia
acut
lung
injuri
induc
herbal
medicin
especi
bofutsushosan
syosaikoto
goshajinkigan
howev
unknown
nijutsuto
induc
pulmonari
toxic
method
retrospect
review
two
case
acut
respiratori
failur
initi
nijutsuto
result
two
japanes
men
oa
receiv
nijutsuto
patient
develop
acut
respiratori
failur
sever
week
initi
nijutsuto
cough
dyspnea
time
develop
acut
respiratori
failur
chest
comput
tomographi
find
show
diffus
ground
glass
opac
traction
bronchiectasi
serum
surfact
proteind
level
increas
patient
clinic
diagnos
find
diffus
alveolar
damag
dad
therefor
one
patient
receiv
steroid
puls
therapi
cyclophosphamid
treat
steroid
puls
therapi
howev
symptom
chest
radiolog
find
desatur
acut
progress
although
two
patient
receiv
mechan
ventil
die
sever
week
develop
acut
respiratori
failur
one
patient
famili
consent
autopsi
patholog
find
autopsi
demonstr
capillari
congest
hyalin
membran
interstitialintraalveolar
edema
observ
earli
exud
dad
phase
elastica
van
gieson
evg
stain
organ
exud
prolifer
fibroblast
evg
stain
observ
late
organ
fibrot
dad
phase
find
honeycomb
conclus
report
acut
respiratori
failur
develop
interstiti
pneumonia
probabl
induc
radix
scutellaria
contain
herbal
medicin
includ
nijutsuto
chines
tradit
medicin
contain
radix
scutellaria
care
use
potenti
role
develop
dad
background
aim
widespread
use
molecular
suscept
test
drug
mycobacterium
tuberculosi
mtb
found
result
test
ident
convent
phenotyp
suscept
test
method
aug
jan
tb
patient
perform
two
drug
suscept
test
dst
mtbie
molecular
test
mtbdrplu
isoniazid
inh
rifampicin
rfp
genexpert
rfp
phenotyp
testwer
collect
medic
record
review
retrospect
tertiari
hospit
result
among
tb
patient
patient
enrol
mean
age
yearold
thirti
male
underli
diseas
follow
diabet
case
copd
lung
cancer
malign
case
mdror
xdrtb
discord
pattern
dst
result
inh
show
inconsist
rfp
two
test
wherea
case
inh
suscept
mtbdrplu
inh
resist
r
phenotyp
test
case
inh
r
former
inh
latter
rfp
case
r
mtbdrplu
convent
dst
two
case
invers
among
case
recogn
final
result
two
type
dst
patient
treat
phenotyp
result
clinic
respons
tb
control
treatment
success
case
failur
followup
loss
death
ongo
treatment
conclus
might
happen
situat
inconsist
data
two
type
dst
mtb
especi
mdr
inh
drug
result
convent
dst
consid
import
molecular
dst
real
practic
studi
clinic
impact
inconsist
requir
confirm
better
dst
background
aim
airway
complic
heartlung
transplant
usual
relat
anastomosi
ischemia
infect
report
incid
vari
among
center
tracheal
anastomot
infect
lead
major
airway
complic
necrosi
dehisc
bacteri
infect
common
howev
aspergillu
infect
report
caus
subsequ
airway
complic
report
case
woman
undergon
heartlung
transplant
year
patient
present
nonmass
hemoptysi
acut
diarrhea
fever
later
develop
acut
respiratori
failur
requir
mechan
ventil
initi
investig
reveal
pulmonari
mycobacterium
avium
complex
mac
aspergillu
sppinfect
patient
treat
antibiot
antifung
agent
admiss
patient
complain
chest
discomfort
recurr
right
pneumothoraxbronchoscopi
perform
extub
tracheal
ulcer
found
tracheal
anastomosi
tracheal
biopsi
done
tissu
patholog
reveal
intracellular
organ
morpholog
compat
histoplasma
spp
antifung
agent
chang
amphotericin
b
follow
bronchoscopywa
done
one
month
later
demonstr
improv
tracheal
ulcer
conclus
histoplasmosi
rare
caus
tracheal
infect
consid
immunosuppress
patient
background
aim
vitamin
enhanc
host
protect
immun
respons
mycobacterium
tuberculosi
reduc
diseas
associ
inflamm
host
aim
studi
compar
vitamin
group
pulmonari
tuberculosi
patient
placebo
group
term
sputum
convers
radiolog
improv
method
sixti
four
pulmonari
tuberculosi
patient
visit
sever
clinic
public
health
medan
april
june
includ
studi
subject
randomis
receiv
vitamin
oral
placebo
singl
blind
method
baselin
day
start
standard
tuberculosi
treatment
primari
endpoint
time
initi
antimicrobi
treatment
sputum
cultur
convers
rate
sputum
convers
radiolog
examin
evalu
result
patient
includ
primari
efficaci
analysi
assign
intervent
assign
placebo
median
time
sputum
cultur
convers
day
intervent
group
day
theplacebo
group
vitamin
group
placebo
group
sputum
conversionthi
differ
statist
signific
p
improv
radiograph
find
group
vitamin
also
higher
second
month
p
conclus
vitamin
support
effect
pulmonari
tuberculosi
patient
improv
heal
process
indic
faster
improv
sputum
convers
radiograph
background
aim
leptospirosi
widespread
zoonot
diseas
world
diseas
often
multisystem
wide
varieti
clinic
sign
symptom
diagnosi
difficult
may
confus
diseas
present
leptospirosi
case
caus
polyseros
unusu
find
second
case
world
report
first
case
report
istanbul
unfortun
patient
succumb
method
report
case
year
old
malay
male
present
week
product
cough
pleurit
chest
pain
fever
examin
tachypn
auscult
lung
show
reduc
breath
sound
bilater
later
develop
septic
shock
acut
kidney
injuri
confus
respiratori
distress
requir
intub
mechan
ventil
derang
coagul
profil
leucocytosi
bicytopenia
transamin
cxr
ct
thorax
show
bilater
pleural
effus
echocardiogram
show
massiv
pericardi
effus
correspond
pericardi
tamponad
pleural
fluid
pericardi
fluid
analysi
consist
exud
pictur
cultur
yield
growth
atyp
pneumonia
screen
tb
work
connect
tissu
diseas
screen
viral
screen
thyroid
function
test
neg
leptospirosi
ig
microscop
agglutin
test
mat
strongli
posit
titr
given
iv
tazocin
still
spike
temperatur
thu
antibiot
escal
iv
meropenam
condit
improv
ward
stay
discharg
penicillin
v
show
improv
clinic
follow
leptospirosi
igm
postiv
patient
posit
microagglutin
test
patient
pleural
pericardi
effus
conclus
exud
polyseros
may
real
though
uncommon
manifest
leptospirosi
seen
patient
henc
high
degre
suspicion
test
leptospirosi
earli
diagnosi
made
prompt
manag
institut
prevent
mortal
morbid
background
aim
introduct
dissemin
tuberculosi
tb
compris
two
noncontigu
site
result
lymphohematogen
dissemin
mycobacterium
tuberculosi
case
report
present
case
year
old
malay
ladi
known
case
diabet
mellitu
hypertens
bronchial
asthma
end
stage
renal
failur
regular
dialysi
present
cough
month
loss
weight
appetit
admit
medic
ward
treat
pneumonia
chest
xray
show
bilater
reticulonodular
opac
broad
spectrum
antibiot
administ
escal
tazosin
patient
spike
temperatur
dyspnea
note
vagu
central
abdomin
mass
systol
murmur
mitral
region
case
refer
surgic
team
proced
ultrasonographi
abdomen
comput
tomographi
abdomen
show
oment
mass
locul
ascit
oesophagoduedenoscop
show
antral
gastriti
colonoscop
surgic
team
unabl
advanc
scope
beyond
cm
due
extern
compress
plan
ct
guid
biopsi
abandon
due
high
risk
procedur
echo
show
right
atrial
mass
pericardi
effus
posterior
wall
possibl
diagnosi
atrial
myxoma
given
sputum
afb
neg
patient
refer
pulmonolog
team
bronchoscop
gene
expert
test
upon
review
pulmonolgi
team
patient
treat
empir
dissemin
tuberculosi
schedul
bronchoscopi
patient
show
remark
improv
day
antitb
medic
fever
subsid
appear
less
tachypno
gene
expert
studi
came
back
posit
ct
abdomen
echo
repeat
week
antitb
medic
show
reduct
mass
respect
conclus
case
illustr
import
intervent
pulmonolog
high
index
suspicion
treat
dissemin
tuberculosi
mimic
diseas
background
aim
investig
clinic
signific
hypersensit
creactiv
protein
fribriogen
ddimmer
patient
connect
tissu
diseas
relat
interstiti
lung
diseas
ctdild
method
patient
interstiti
lung
diseas
admit
april
zhujiang
hospit
southen
medic
univers
includ
research
patient
classifi
ctdild
group
patient
classifi
nonconnectivetissuediseaserel
intersiti
lung
diseas
nctdild
group
also
healthi
peopl
includ
control
group
hypersensit
creactiv
protein
hscrp
fribriogen
fg
ddimmer
ddi
analyz
result
level
hscrp
fg
ddi
ctdild
nctdild
group
significantli
higher
control
group
level
hscrp
ctdild
group
significantli
higher
nctdild
group
differ
fg
ddi
level
group
signific
conclus
hscrp
fg
ddi
show
great
valu
clinic
diagnosi
ctd
obvious
high
level
hscrp
correl
ctd
background
aim
mycobacterium
tuberculosi
infect
influenc
genet
environment
factor
vitamin
defici
genet
variant
vitamin
receptor
vdr
gene
report
associ
pulmonari
tuberculosi
tb
studi
investig
interact
vitamin
serum
concentr
vitamin
receptor
gene
bsmi
polymorph
pulmonari
tb
method
conduct
casecontrol
studi
use
pulmonari
tb
patien
case
healthi
control
vitamin
level
measur
particip
vitamin
receptor
gene
bsmi
polymorph
perfom
pcrrflp
corel
vitamin
level
vitamin
receptor
gene
bsmi
polymorph
pulmonari
tb
statist
analyz
result
frequenc
vitamin
level
suffici
insuffici
defici
pulmonari
tb
patient
suffici
insuffici
defici
healthi
control
signific
associ
vitamin
level
pulmonari
tb
ci
defici
vs
suffici
associ
vitamin
level
pulmonari
tb
ci
defici
vs
insuffici
frequenc
bsmi
genotyp
bb
bb
bb
pulmonari
tb
patient
bb
bb
bb
healthi
control
signific
associ
vitamin
receptor
gene
bsmi
polymorph
pulmonari
tb
ci
bb
vs
bb
also
signific
associ
vitamin
receptor
gene
bsmi
polymorph
pulmonari
tb
ci
bb
vs
bb
conclus
signific
associ
vitamin
level
pulmonari
tb
signific
associ
vitamin
receptor
gene
bsmi
polymorph
pulmonari
tb
background
aim
prosthet
joint
infect
seriou
complic
prosthet
arthroplasti
common
etiolog
agent
coagulas
neg
staphylococcu
staphylococcu
aureu
gram
neg
bacilli
anaerob
mycobacterium
tuberculosi
mtb
infect
prosthet
joint
rare
atyp
manifest
may
delay
diagnosi
result
poor
clinic
outcom
method
man
refer
siriraj
hospit
fever
along
left
knee
pain
swell
month
underli
diseas
nasopharyng
carcinoma
treat
concurr
chemoradi
papillari
thyroid
carcinoma
statu
post
total
thyroidectomi
ablat
bilater
osteoarthr
knee
total
knee
arthroplasti
year
ago
result
physic
examin
reveal
erythemat
swell
warmth
left
knee
limit
rang
motion
laboratori
find
show
peripher
wbc
count
pmn
cxr
reveal
militari
nodul
correspond
prior
followup
chest
ct
scan
month
earlier
monitor
thyroid
cancer
arthrocentesi
left
knee
yield
turbid
joint
fluid
wbc
pmn
lymphocyt
gram
stain
demonstr
organ
stain
afb
posit
subsequ
molecular
studi
reveal
mtb
dna
without
mutat
confer
rifampicin
resist
subsequ
cultur
posit
mtb
week
later
antituberculosi
drug
consist
isoniazid
rifampicin
pyrazinamid
moxifloxacin
prescrib
along
prosthet
joint
remov
patient
remain
well
followup
visit
conclus
tubercul
infect
prosthet
joint
uncommon
complic
medium
high
tb
burden
countri
thailand
clinic
present
mimic
usual
septic
arthriti
confus
physician
definit
diagnosi
usual
verifi
joint
fluid
andor
synovi
joint
tissu
cultur
tissu
histopatholog
patient
also
concomit
pulmonari
tuberculosi
primari
sourc
hematogen
spread
joint
background
aim
tuberculosi
tb
infecti
diseas
caus
mycobacterium
tuberculosi
mtb
becom
primari
caus
death
cytokin
tubercul
pleural
effus
ietnfa
produc
cell
act
primari
inflammatori
mediat
local
reaction
form
granuloma
pleura
mycobacteri
antigen
interact
previous
sensit
cell
pleura
process
stimul
delay
type
hypersensit
reaction
caus
caseat
necrosi
granuloma
affect
pleural
capillari
permeabl
toward
protein
lead
pleural
effus
goal
research
compar
level
pleural
fluid
tnfa
tubercul
non
tubercul
pleural
effus
method
experiment
research
observ
analysi
cross
section
design
held
drsoetomo
gener
hospit
surabaya
inpati
unit
subject
tubercul
non
tubercul
pleural
effus
patient
meet
inclus
exclus
criteria
total
subject
patient
tubercul
pleural
effus
group
patient
non
tubercul
pleural
effus
group
result
result
research
show
level
pleural
fluid
tnfa
tubercul
pleural
effus
higher
compar
non
tubercul
pleural
effus
ae
pgml
vs
ae
pgml
p
valu
conclus
level
pleural
fluid
tnfa
tubercul
pleural
effus
higher
compar
non
tubercul
pleural
effus
background
aim
nowaday
tuberculosi
smoke
becom
major
health
problem
world
indonesia
rank
second
highest
countri
term
tb
case
rank
th
countri
highest
cigarett
consumpt
world
exposur
smoke
increas
risk
infect
diseas
recurr
even
death
tb
secret
cell
import
cytokin
bodi
immun
respons
intracellular
bacteria
eg
mycobacterium
tuberculosi
variou
studi
mention
exposur
cigarett
smoke
reduc
product
inhibit
macrophag
cell
function
studi
aim
determin
relationship
smoke
degre
assess
brinkman
index
sputum
level
smearposit
pulmonari
tb
patient
method
conduct
cross
section
observ
analysi
studi
design
outpati
smearposit
pulmonari
tb
dr
soetomo
hospit
earli
morn
spontan
sputum
obtain
sampl
determin
level
smoke
degre
calcul
multipli
number
cigarett
smoke
per
day
smoke
durat
year
relationship
sputum
level
smoke
degre
subject
analyz
pearson
spearman
correl
test
accord
scale
data
exist
result
signific
relationship
sputum
level
smoke
degre
smear
posit
pulmonari
tb
patient
p
obtain
mean
level
sputum
ae
pgml
mean
brinkman
index
amount
ae
conclus
signific
correl
sputum
level
smoke
degre
smear
posit
pulmonari
tb
patient
background
aim
background
chronic
obstruct
pulmonari
diseas
copd
asthma
import
lower
obstruct
airway
diseas
spirometri
gold
standard
diagnosi
copd
support
diagnosi
asthma
howev
patient
physic
mental
limit
may
meet
accept
criteria
fvc
maneuv
impuls
oscillometri
io
measur
resist
r
reactanc
x
respiratori
system
requir
minim
patient
effort
may
altern
spirometri
diagnosi
categori
obstruct
pulmonari
disord
aim
determin
correl
io
paramet
ax
fre
patient
lower
airway
obstruct
method
crosssect
studi
conduct
evalu
correl
io
spirometri
patient
diagnos
either
copd
asthma
patient
patient
copd
patient
asthma
perform
spirometri
io
enrol
studi
result
ax
fre
except
significantli
associ
p
patient
lower
obstruct
airway
diseas
highest
correl
fre
fvc
r
howev
degre
airway
obstruct
express
predict
correl
fevfvc
highest
correl
ax
predict
r
conclus
area
reactanc
ax
impuls
oscillometri
system
io
correl
predict
patient
lower
airway
obstruct
background
aim
although
cryotherapi
shown
effect
manag
advanc
malign
bronchial
tumour
adult
littl
literatur
describ
use
pediatr
airway
diseas
observ
short
term
effect
cryotherapi
via
flexibl
bronchoscopi
treatment
variou
bronchial
problem
children
method
perform
flexibl
bronchoscop
use
nitrou
oxidedriven
cryoprob
manag
airway
diseas
foreign
bodi
granul
tissu
bronchial
mass
remov
repair
subglott
stenosi
transebronchi
lung
biopsi
tblb
children
rang
age
month
year
analyz
outcom
complic
result
period
month
cryotherapi
perform
light
sedat
inhal
lidocain
low
dose
propofol
use
fibropt
bronchoscopeth
indic
cryotherapi
foreign
bodi
case
granul
tissu
case
bronchial
mass
remov
case
repair
subglott
stenosi
case
transebronchi
lung
biopsi
case
complic
regard
cryotherapi
mild
bleed
case
manag
use
local
epinephrin
balloon
dilat
conclus
cryotherapi
via
flexibl
bronchoscop
effect
method
treat
trachobronchi
diseas
children
background
aim
larg
scale
epidemiolog
data
pleural
fluid
characterist
lack
establish
pleural
centr
high
rate
pleural
malign
north
east
england
aim
follow
british
thorac
guidelin
sought
add
bodi
evid
method
pleural
aspir
done
januari
st
decemb
st
analys
fluid
biochemistri
microbiolog
cytolog
final
diagnos
classifi
exud
fluid
protein
gl
fluid
ldh
iul
utilis
light
criteria
serum
characterist
collect
data
result
includ
patient
studi
averag
age
year
final
diagnosi
primari
lung
cancer
patient
cytolog
analys
patient
posit
pleural
fluid
cytolog
first
aspir
patient
aspir
diagnost
benefit
addit
patient
transud
pleural
effus
review
patient
empyema
n
posit
microbiolog
ph
two
patient
ph
sent
patient
exud
regard
follow
bt
guidelin
pleural
aspir
meet
current
bt
guidelin
everi
pleural
aspir
sent
ph
microbiolog
cytolog
protein
ldh
glucos
commonli
miss
investig
glucos
occas
conclus
find
consist
current
literatur
regard
transud
lung
cancer
trust
improv
microbiolog
yield
suspect
empyema
encourag
contemporan
blood
ldh
protein
patient
suggest
use
blood
cultur
bottl
addit
univers
contain
background
aim
thoracoscop
biopsi
local
anesthesia
report
effect
method
diagnosi
pleural
diseas
fullthick
biopsi
specimen
requir
especi
mesothelioma
insulatedtip
diatherm
knife
knife
propos
use
devic
devis
new
simplifi
techniqu
precut
method
use
inject
needl
obtain
sufficientlys
tissu
specimen
pleural
biopsi
method
thoracoscop
pleural
biopsi
perform
local
anesthesia
undiagnos
exud
pleural
effus
precut
method
use
inject
needl
appli
two
patient
procedur
perform
follow
inject
needl
mm
length
insert
pleura
around
lesion
semiflex
thoracoscop
ltf
type
olympu
inject
lidocain
epinephrin
lift
pleura
fascia
needl
posit
make
incis
pleura
three
precut
incis
line
arrang
triangl
close
biopsi
forcep
insert
precut
incis
line
forcep
open
peel
pleura
fascia
replic
maneuv
along
triangular
incis
one
side
triangl
grasp
forcep
specimen
peel
pariet
pleura
result
case
male
right
pleural
thicken
effus
precut
method
permit
diagnosi
biphas
mesotheliomacas
male
left
pleural
effus
acidfast
stain
polymeras
chain
reaction
analysi
pleural
effus
neg
acidfast
bacilli
use
histopatholog
tissu
cultur
find
precut
method
permit
diagnosi
tuberculosi
conclus
precut
method
use
inject
needl
effect
techniqu
obtain
sufficientlys
specimen
pleural
biopsi
without
special
apparatu
background
aim
nasotrach
intub
use
techniqu
dental
orofaci
surgeri
anatom
variat
nasal
caviti
common
patient
sometim
nasotrach
intub
without
thorough
understand
anatomi
nasal
caviti
difficult
approach
creat
sever
complic
case
present
nasotrach
tube
obstruct
due
total
middl
turbinectomi
nasotrach
intub
method
male
schedul
left
mandibular
angl
orbit
wall
fractur
nasotrach
intub
need
surgeri
induct
anesthesiologist
ask
nostril
comfort
breath
occlud
felt
comfort
right
nostril
anesthesiologist
decid
put
tube
right
nostril
induct
perform
bolu
inject
propofol
rocuronium
continu
infus
remifentanil
mask
ventil
anesthesiologist
intub
patient
intub
patient
ventil
well
decreas
breath
sound
abrupt
increas
inspiratori
pressur
observ
anesthesiologist
extub
tube
immedi
found
nasotrach
tube
obstruct
turbin
nasotrach
intub
perform
right
nostril
stop
epistaxi
compress
effect
surgeri
perform
problem
surgeri
consult
otolaryngologist
facial
ct
examin
found
patient
sever
nasal
septal
deviat
right
side
total
middl
turbinectomi
done
nasotrach
intub
patient
got
discharg
complic
conclus
care
assess
perform
nasotrach
intub
avoid
complic
sever
method
perform
decid
nostril
use
perform
intub
breath
one
nostril
one
method
perfect
avoid
complic
septal
deviat
clinic
symptom
ca
nt
get
match
suggest
anterior
rhinoscopi
nasotrach
intub
patient
fulli
evalu
facial
ct
background
aim
epithelioma
uncommon
report
occur
soft
tissu
salivari
gland
fort
lung
howev
occurr
bone
rare
case
report
worldwid
moreov
case
report
pediatr
rib
method
report
case
femal
epithelioma
rib
refer
hospit
pain
left
side
chest
particularli
pain
play
saxophon
xray
show
abnorm
shadow
rib
mri
show
contrast
lesion
rib
ct
show
bone
destruct
sclerosi
insid
lesion
difficult
determin
whether
lesion
malign
benign
incision
biopsi
perform
result
patholog
result
show
cytokeratin
sma
desmin
posit
suggest
epithelioma
therefor
costal
segment
en
bloc
resect
perform
remov
tumor
oper
patient
sharp
pain
reliev
conclus
rib
tumor
make
approxim
bone
tumor
rel
rare
repres
benign
case
includ
osteochondroma
enchondroma
fibrou
bone
dysplasia
acidophilerel
granulomat
diseas
malign
case
includ
bone
metastasi
chondrosarcoma
osteosarcoma
isol
plasma
cell
tumor
ewe
sarcoma
frequent
misdiagnos
surgeri
suggest
wide
local
excis
perform
costal
tumor
case
patient
epithelioma
occur
bone
show
import
consid
rib
lesion
patient
present
chest
pain
background
aim
tunnel
indwel
pleural
cathet
tipc
utilis
effect
altern
palli
manag
malign
pleural
effus
applic
benign
refractori
pleural
effus
rapidli
grow
expand
evid
condit
hepat
hydrothorax
cardiac
failur
benign
chylothorax
anoth
condit
tipc
may
offer
effect
symptom
manag
particularli
surgic
intervent
radiolog
procedur
suitabl
nevertheless
repeat
drainag
proteinrich
chyle
rais
concern
sever
nutrit
defici
caution
must
exercis
method
report
case
benign
chylothorax
manag
success
safe
tipc
result
previouslyindepend
caucasian
femal
present
month
worsen
dyspnoea
found
leftsid
unilater
pleural
effus
background
comorbid
includ
ischaem
cardiomyopathi
benign
multinodular
goitr
atrial
fibril
type
diabet
dyslipidaemia
gout
histori
malign
neversmok
drink
alcohol
echocardiogram
confirm
stabl
left
ventricular
function
thoracocentesi
reveal
chylothorax
triglycerid
mmoll
signific
symptomat
improv
note
pleural
fluid
examin
exclud
malign
infect
caus
ct
chest
demonstr
larg
multinodular
goitr
signific
mass
effect
superior
thorac
outlet
left
intern
jugular
subclavian
vein
displac
thorac
duct
like
compress
thyroid
function
normal
surgeri
recommend
prefer
manag
radioact
iodin
therapi
altern
howev
refus
patient
tipc
insert
due
rapid
reaccumul
chylothorax
patient
report
stabl
effect
symptom
relief
month
insert
intermitt
drainag
regim
develop
protein
defici
good
dietician
liaison
supplement
conclus
tipc
offer
safe
effect
option
palli
manag
benign
chylothorax
though
attent
monitor
nutrit
statu
essenti
background
aim
chronic
obstruct
pulmonari
diseas
known
chronic
inflammatori
diseas
occur
local
lung
also
system
effect
includ
peripher
muscl
weak
increas
lactic
acid
ubiquinon
contain
mitochondria
play
import
role
aerob
energi
product
also
antioxid
effect
give
ubiquinon
expect
improv
mwt
lower
lactic
acid
level
patient
copd
method
studi
experiment
studi
doubleblind
random
control
subject
studi
patient
stabl
copd
categori
b
outpati
pulmonari
clinic
dr
soetomo
hospit
meet
inclus
exclus
criteria
patient
meet
select
criteria
divid
group
ubiquinon
placebo
week
patient
continu
use
drug
regularli
patient
measur
blood
level
lactic
acid
walk
test
spirometri
administr
ubiquinon
placebo
total
subject
divid
patient
ubiquinon
group
patient
control
group
result
signific
differ
two
group
gender
degre
copd
bmi
lactic
acid
level
treatment
group
decreas
significantli
compar
control
ae
ae
ubiquinon
group
ae
ae
control
group
p
pulmonari
function
test
statist
signific
group
walk
distanc
increas
treatment
group
compar
control
group
ae
ae
ubiquinon
group
ae
ae
control
group
p
conclus
ubiquinon
administr
favor
effect
energi
product
muscl
lower
lactic
acid
level
patient
stabl
copd
categori
b
background
aim
cigarett
smoke
caus
small
airway
obstruct
sao
harbing
develop
chronic
obstruct
pulmonari
diseas
copd
reduct
fef
associ
chronic
cigarett
smoke
explain
loss
lung
elast
recoil
pressur
reduc
forc
drive
air
lung
therefor
earli
detect
pulmonari
function
test
prevent
risk
airway
diseas
aim
present
studi
analyz
pulmonari
function
chang
fef
smoke
compar
healthi
non
smoker
method
studi
healthi
male
femal
subject
age
rang
year
smoker
nonsmok
assess
pulmonari
function
test
use
spiromet
result
studi
show
impact
cigarett
smoke
pulmonari
function
smoker
significantli
greater
percentag
declin
fef
ratio
nonsmok
p
suggest
smoker
develop
chang
pulmonari
function
indic
earli
peripher
airway
narrow
signific
correl
smoke
durat
rate
valu
fef
found
doserespons
relat
smoke
fef
durat
amount
smoke
associ
reduct
fef
conclus
smoker
significantli
greater
percentag
declin
fef
nonsmok
signific
correl
smoke
durat
rate
valu
fef
deterior
lung
function
relat
number
cigarett
smoke
per
day
smoker
background
aim
loss
airway
epitheli
integr
contribut
significantli
asthma
pathogenesi
recent
report
reveal
thymic
stromal
lymphopoietin
tslp
may
dual
immunoregulatori
role
tslp
present
isoform
includ
short
long
tslp
inflammatori
disord
bowel
longform
tslp
ltslp
promot
inflamm
short
form
tslp
sftslp
inhibit
inflamm
hypothes
synthet
sftslp
preventsairway
epitheli
barrier
disrupt
induc
hous
dust
mite
hdm
method
normal
human
bronchial
epitheli
cell
stimul
hdm
evalu
express
tslp
quantit
realtim
pcr
western
blot
meanwhil
transepitheli
electr
resist
teer
fluorescentdextran
fitcdextran
permeabl
distribut
ecadherin
assess
evalu
airway
epitheli
barrier
function
vivo
balbc
mice
expos
hdm
nasal
inhal
set
asthma
model
consecut
day
per
week
sftslp
inhal
hour
hdm
inhal
week
latter
util
anim
lung
function
test
patholog
stain
evalu
asthma
situat
result
vitro
upregul
sftslp
express
inhibit
hdmdepend
upregul
ltslp
use
sftslp
could
prevent
hdminduc
airway
epitheli
barrier
disrupt
asthmat
mice
model
success
establish
inflammatori
factor
like
ltslp
balf
unregul
consist
serum
ige
except
airway
epitheli
junction
protein
partial
lost
disloc
moreov
synthet
sftslp
amelior
hdminduc
asthma
mice
conclus
two
isoform
short
long
tslp
differ
express
differ
biolog
properti
emphas
import
analyz
two
tslp
isoform
separ
moreov
result
indic
sftslp
may
novel
therapeut
strategi
individu
treatment
asthma
background
aim
accident
inhal
organ
nonorgan
foreign
bodi
continu
lead
caus
childhood
morbid
mortal
requir
prompt
diagnosi
earli
manag
minim
risk
seriou
sometim
fatal
consequ
case
foreign
bodi
aspir
differ
face
variabl
involv
includ
type
object
reaction
aspir
locat
physic
characterist
object
clinic
present
expertis
bronchoscopist
frequent
determin
ultim
outcom
method
patient
underw
flexibl
fibropt
bronchoscopi
procedur
done
pediatr
bronchoscopi
suit
introduc
light
sedat
low
dose
propofol
extract
done
mani
type
forcep
basket
balloon
electrocuteri
knife
cryoprob
result
flexibl
fibropt
bronchoscopi
new
method
hundr
case
aspir
foreign
bodi
cover
rang
month
year
success
rate
major
complic
conclus
expert
hand
well
equip
facil
flexibl
fibropt
bronchoscopi
gold
standard
diagnosi
pediatr
airway
foreign
bodi
prefer
instrument
manag
background
aim
discuss
valu
medic
thoracoscopi
pleural
diseas
diagnosi
treatment
children
method
retrospect
analyz
clinic
characterist
outcom
children
case
refractori
pleural
lesion
diagnos
treat
medic
thoracoscopi
hospit
januari
februari
result
averag
age
case
male
case
femal
case
year
old
rang
lesion
case
locat
left
pleural
caviti
right
case
acut
phase
within
week
perform
medic
thoracoscopi
case
consid
streptococcu
pneumonia
consid
staphylococcu
aureu
infect
consid
tubercul
pleurisi
case
unknown
medic
thoracoscopi
made
conculs
caus
case
streptococcu
pneumonia
staphylococcu
aureu
infect
tubercul
pleurisi
mycoplasma
infect
chest
foreign
bodi
pathogen
anoth
still
unknown
medic
thoracoscopi
locul
pleural
effus
atelectasi
compress
still
case
even
thorac
drainag
pleural
lavag
salin
urokinas
medic
thoracoscopi
lung
recruit
found
case
conclus
medic
thoracoscopi
minim
invas
surgic
treament
pediatr
pyothorax
promot
lung
recruit
drainag
lavag
direct
vision
clear
pu
moss
parcel
adhes
time
children
pleurisi
unknown
caus
confirm
diagnosi
pleural
wooden
bronchu
foreign
bodi
move
distal
airway
even
wear
pleura
pleural
caviti
breath
convent
treatment
solv
problem
medic
thoracoscopi
may
effect
background
aim
report
rare
case
foreign
bodi
thorac
caviti
method
retrospect
analyz
clinic
characterist
process
case
foreign
bodi
thorac
caviti
result
twoyearold
male
admit
hospit
fever
cough
day
histori
foreign
bodi
inhal
unev
computer
tomographi
ct
scan
show
right
lower
lung
infect
right
pleural
effus
subsequ
treat
antibiot
temperatur
return
normal
frequenc
cough
increas
perform
bronchoscopi
reveal
wooden
foreign
bodi
right
side
basal
segment
fail
remov
whole
foreign
bodi
appear
repeatedli
high
fever
postop
hyperpyrexia
tachypnea
rate
mild
inspir
three
concav
bad
spirit
immedi
cpap
machin
auxiliari
ventil
eighth
day
admiss
perform
flexibl
bronchoscop
use
thoracoscop
gener
anesthesia
bronchoscop
found
foreign
bodi
punctur
lung
pleura
chest
figur
henc
foreign
bodi
dog
tail
grass
cm
directli
taken
boy
inhal
high
oxygen
flow
remov
foreign
bodi
continu
complet
thorac
caviti
close
drainag
blood
oxygen
satur
remain
temperatur
return
normal
day
ct
scan
show
lung
compress
tissu
less
compar
previou
improv
significantli
boy
continu
antiinfect
treatment
discharg
hospit
growth
develop
good
followup
telephon
call
computer
tomographi
scan
reveal
lesion
fundament
absorpt
conclus
wooden
foreign
bodi
mayb
move
thorac
caviti
thoracoscopi
consid
earli
patient
case
refractori
pleural
effus
pneumothorax
result
compar
direct
immunefluoresc
assay
sampl
inconsist
result
two
method
verifi
rtpcr
result
result
indic
influenza
viru
antigen
detect
sofia
influenza
b
fia
highli
consist
result
direct
immunefluoresc
assayth
sensit
specif
detect
influenza
viru
specif
rais
verifi
rtpcr
inconsist
sampl
posit
rtpcr
influenza
b
sensit
specif
rais
verifi
rtpcr
inconsist
sampl
posit
rtpcr
compar
influenza
viru
b
children
infect
influenza
viru
cours
seriou
clinic
symptom
conclus
influenza
signific
caus
children
respiratori
infectionssofia
influenza
b
fia
rapid
easi
antigendetect
assay
influenza
viru
b
high
concord
rate
direct
immunefluoresc
assay
use
screen
diagnosi
influenza
viru
b
background
aim
chrysin
member
flavonoid
famili
shown
capac
antiinflamm
properti
autophagi
consid
key
role
inflammatori
respons
tri
investig
effect
novel
chrysin
lpsinduc
ard
determin
whether
autophagi
invovl
method
balbc
mice
age
week
randomli
divid
group
control
group
receiv
salin
chrysin
lp
group
receiv
chrysin
chrysin
follow
lp
group
receiv
autophagi
antagonist
group
receiv
chrysin
final
lp
lp
salin
inject
intratrach
chrysin
inject
intraperiton
min
lp
inject
intraperiton
min
chrysin
mice
kill
h
sampl
balf
lung
tissu
collect
analysi
result
time
point
group
receiv
either
dose
chrysin
follow
lp
significantli
lower
total
cell
count
level
balf
group
given
lp
h
western
blot
show
level
chrysin
group
high
lp
group
passway
significantli
restrain
chrysin
activ
autophagi
increas
level
dosedepend
manner
autophagi
inhibitor
partial
revers
chrysininduc
elev
passway
suppress
conclus
result
suggest
chrysin
may
attenu
lung
inflamm
lpsinduc
ard
activ
autophagi
autophagi
may
deepli
involv
ard
inflammatori
respons
